{ "druges" : [{
  "title": "Faslodex (fulvestrant)  Injection ",
  "date_of_approval": "April 25, 2002",
  "company": " AstraZeneca",
  "treatment": " Breast Cancer",
  "drug_description": "Faslodex (fulvestrant) is an estrogen receptor antagonist  indicated for the treatment of hormone receptor positive metastatic breast cancer.",
  "previous application": "AstraZeneca Receives FDA Approval for Faslodex (fulvestrant):\tA New Type of Breast Cancer Treatment Effective In Tamoxifen-Resistant Breast Cancer Faslodex (fulvestrant) FDA Approval History"
},{
  "title": "Lexapro (escitalopram oxalate)  Tablets and Oral Solution ",
  "date_of_approval": "August 14, 2002",
  "company": " Allergan, Inc.",
  "treatment": " Depression, Generalized Anxiety Disorder",
  "drug_description": "Lexapro (escitalopram oxalate) is a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of major depressive disorder and for the treatment of generalized anxiety disorder (GAD).",
  "previous application": "Lexapro, The Single-Isomer of Celexa, Receives FDA Approval For the Treatment of Major Depression"
},{
  "title": "Pegasys (peginterferon alfa-2a)  Injection ",
  "date_of_approval": "October 16, 2002",
  "company": " Hoffmann-La Roche",
  "treatment": " Chronic Hepatitis C",
  "drug_description": "Pegasys (peginterferon alfa-2a) is a covalent conjugate of recombinant alfa-2a interferon indicated for the combination\r treatment of adults with chronic hepatitis C.",
  "previous application": "Pegasys Hoffmann-La Roche - Treatment for Chronic Hepatitis C"
},{
  "title": "Humira (adalimumab)  Injection ",
  "date_of_approval": "December 31, 2002",
  "company": " Abbvie, Inc.",
  "treatment": " Rheumatoid Arthritis, Psoriatic Arthritis, Crohn's Disease -- Acute, Crohn's Disease -- Maintenance, Psoriasis, Juvenile Idiopathic Arthritis, Ulcerative Colitis, Hidradenitis Suppurativa, Uveitis",
  "drug_description": "Humira (adalimumab) is a recombinant human IgGl monoclonal antibody specific for human tumor necrosis factor (TNF) indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, juvenile idiopathic arthritis, ulcerative colitis, hidradenitis suppurativa, and certain types of uveitis.",
  "previous application": "FDA Approves Humira (adalimumab) for Rheumatoid Arthritis Humira (adalimumab) FDA Approval History"
},{
  "title": "Amevive (alefacept) ",
  "date_of_approval": "January 30, 2003",
  "company": " Biogen, Inc",
  "treatment": " Psoriasis",
  "drug_description": "Amevive (alefacept) is a selective immunomodulating antipsoriatic agent used to treat moderate to severe chronic plaque psoriasis.",
  "previous application": "Amevive Biogen, Inc - Treatment for Psoriasis"
},{
  "title": "Cardizem LA (diltiazem hydrochloride)  Extended-Release Tablets ",
  "date_of_approval": "February 6, 2003",
  "company": " Biovail Laboratories Incorporated",
  "treatment": " Hypertension, Angina Pectoris",
  "drug_description": "Cardizem LA is an extended-release formulation of diltiazem for indicated for the once-daily treatment of hypertension and for the management of chronic stable angina.",
  "previous application": "Cardizem LA Biovail Laboratories Incorporated - Treatment for Hypertension"
},{
  "title": "Oxytrol (oxybutynin)  Transdermal System ",
  "date_of_approval": "February 26, 2003",
  "company": " Allergan, Inc.",
  "treatment": " Overactive Bladder",
  "drug_description": "Oxytrol (oxybutynin) is a transdermal therapy used to treat overactive bladder\r (OAB), with symptoms of urge urinary incontinence, urgency and\r frequency.",
  "previous application": "Oxytrol Watson Labs - Treatment for Overactive Bladder"
},{
  "title": "Fuzeon (enfuvirtide) ",
  "date_of_approval": "March 13, 2003",
  "company": " Roche",
  "treatment": " HIV Infection",
  "drug_description": "Fuzeon (enfuvirtide) is a fusion inhibitor used in combination with other\r medicines to treat HIV infection.",
  "previous application": "Fuzeon Roche - Treatment for HIV Infection"
},{
  "title": "Femring (estradiol acetate)  Vaginal Ring ",
  "date_of_approval": "March 20, 2003",
  "company": " Galen Ltd",
  "treatment": " Postmenopausal Symptoms",
  "drug_description": "Femring (estradiol acetate) is a vaginal estrogen product in the form of a flexible,\r self-inserted ring. Femring is indicated to treat both the hot flushes and vaginal symptoms associated with menopause.",
  "previous application": "Femring Galen Ltd - Treatment for Menopausal Vasomotor Symptoms"
},{
  "title": "Somavert (pegvisomant)  for Injection ",
  "date_of_approval": "March 25, 2003",
  "company": " Pharmacia and Upjohn",
  "treatment": " Acromegaly",
  "drug_description": "Somavert (pegvisomant) is a growth hormone receptor antagonist indicated for the\r treatment of acromegaly.",
  "previous application": "Somavert Pharmacia and Upjohn - Treatment for Acromegaly"
},{
  "title": "Emend (aprepitant)  Capsules ",
  "date_of_approval": "March 27, 2003",
  "company": " Merck",
  "treatment": " Nausea/Vomiting -- Chemotherapy Induced",
  "drug_description": "Emend (aprepitant) is a substance P/neurokinin 1 (NK1) receptor antagonist used in combination with other antiemetic agents to prevent and control acute and delayed nausea and vomiting associated with chemotherapy.",
  "previous application": "Emend Merck - Treatment for Chemotherapy-Induced Nausea and Vomiting (CINV)"
},{
  "title": "Iprivask (desirudin)  Injection ",
  "date_of_approval": "April 4, 2003",
  "company": " Aventis Pharmaceuticals, Inc",
  "treatment": " Deep Vein Thrombosis -- Prophylaxis",
  "drug_description": "Iprivask (desirudin) is a specific inhibitor of human thrombin indicated for the prophylaxis of deep vein thrombosis, which may lead to pulmonary\r embolism, in patients undergoing elective hip replacement surgery.",
  "previous application": "Iprivask Aventis Pharmaceuticals, Inc - Treatment for Prophylaxis of Deep Vein Thrombosis"
},{
  "title": "Factive (gemifloxacin)  Tablets ",
  "date_of_approval": "April 4, 2003",
  "company": " LG Life Sciences, Ltd",
  "treatment": " Bacterial Infection",
  "drug_description": "Factive (gemifloxacin) is a fluoroquinolone  antibiotics indicated\r for the treatment of community-acquired pneumonia and acute\r bacterial exacerbation of chronic bronchitis.",
  "previous application": "Factive LG Life Sciences, Ltd - Treatment for Bacterial Infections"
},{
  "title": "Vigamox (moxifloxacin)  Ophthalmic Solution ",
  "date_of_approval": "April 15, 2003",
  "company": " Alcon",
  "treatment": " Bacterial Conjunctivitis",
  "drug_description": "Vigamox (moxifloxacin) is a fourth generation fluoroquinilone antibiotic indicated for the treatment of bacterial conjunctivitis caused by susceptible\r strains of bacteria.",
  "previous application": "Vigamox Alcon - Treatment for Bacterial Conjunctivitis"
},{
  "title": "Fabrazyme (agalsidase beta) ",
  "date_of_approval": "April 24, 2003",
  "company": " Genzyme Corp",
  "treatment": " Fabry Disease",
  "drug_description": "Fabrazyme (agalsidase beta) is a recombinant form of human alpha-galactosidase A,\r administered intravenously for the treatment of Fabry Disease.",
  "previous application": "Fabrazyme Genzyme Corp - Treatment for Fabry Disease"
},{
  "title": "Aldurazyme (laronidase) ",
  "date_of_approval": "April 30, 2003",
  "company": " Biomarin Pharmaceutical",
  "treatment": " Mucopolysaccharidosis Type I",
  "drug_description": "Aldurazyme (laronidase) is recombinant human alpha-L-iduronidaseis indicated for the treatment of mucopolysaccharidosis I (MPS I).",
  "previous application": "Aldurazyme Biomarin Pharmaceutical - Treatment for Mucopolysaccharidosis I (MPS-I)"
},{
  "title": "Iressa (gefitinib)  Tablets ",
  "date_of_approval": "May 5, 2003",
  "company": " AstraZeneca",
  "treatment": " Non-Small Cell Lung Cancer",
  "drug_description": "Iressa (gefitinib) is a tyrosine kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have specific epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.",
  "previous application": "Astrazeneca Receives FDA Approval for New Cancer Drug Iressa (gefitinib, ZD1839) Iressa (gefitinib) FDA Approval History"
},{
  "title": "Velcade (bortezomib)  for Injection ",
  "date_of_approval": "May 13, 2003",
  "company": " Millennium Pharmaceuticals",
  "treatment": " Multiple Myeloma",
  "drug_description": "Velcade is an antineoplastic agent indicated for the treatment of multiple myeloma and mantle cell lymphoma.",
  "previous application": "FDA Approves Velcade (bortezomib) for Injection for the Treatment of Relapsed and Refractory Multiple Myeloma Velcade (bortezomib) FDA Approval History"
},{
  "title": "Uroxatral (alfuzosin)  Extended-Release Tablets ",
  "date_of_approval": "June 12, 2003",
  "company": " Sanofi Synthelabo",
  "treatment": " Benign Prostatic Hyperplasia",
  "drug_description": "Uroxatral (alfuzosin) an alpha-1-adrenergic receptor antagonist, is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia.",
  "previous application": "Uroxatral Sanofi Synthelabo - Treatment for Benign Prostatic Hyperplasia (BPH)"
},{
  "title": "FluMist (Influenza Virus Vaccine, Live, Intranasal) ",
  "date_of_approval": "June 17, 2003",
  "company": " MedImmune Vaccines, Inc",
  "treatment": " Influenza Prophylaxis",
  "drug_description": "FluMist is a live trivalent nasally administered vaccine intended\r for active immunization for the prevention of influenza.",
  "previous application": "FluMist MedImmune Vaccines, Inc - Treatment for Prevention of Influenza"
},{
  "title": "Reyataz (atazanavir sulfate)  Capsules ",
  "date_of_approval": "June 20, 2003",
  "company": " Bristol Myers Squibb",
  "treatment": " HIV Infection",
  "drug_description": "Reyataz is a protease inhibitor indicated for use in combination with other\r antiretroviral agents for the treatment of HIV-1 infection.",
  "previous application": "Reyataz Bristol Myers Squibb - Treatment for HIV Infection"
},{
  "title": "Xolair (omalizumab)  Subcutaneous Injection ",
  "date_of_approval": "June 20, 2003",
  "company": " Genentech, Inc.",
  "treatment": " Asthma -- Maintenance, Urticaria, Nasal Polyps",
  "drug_description": "",
  "previous application": "FDA Approves Xolair (omalizumab) for Moderate-to-Severe Asthma Xolair (omalizumab) FDA Approval History"
},{
  "title": "Bexxar (Tositumomab and Iodine I 131 Tositumomab) ",
  "date_of_approval": "June 27, 2003",
  "company": " Corixa Corporation",
  "treatment": " non-Hodgkin's Lymphoma",
  "drug_description": "Bexxar is a dual-action therapy that combines the tumor-targeting\r ability of a cytotoxic monoclonal antibody and the therapeutic\r potential of radiation. Bexxar is indicated for the treatment of\r Non-Hodgkin\u2019s lymphoma.",
  "previous application": "Bexxar Corixa Corporation - Treatment for Non-Hodgkin\u2019s Lymphoma"
},{
  "title": "Emtriva (emtricitabine)  Capsules ",
  "date_of_approval": "July 2, 2003",
  "company": " Gilead Sciences, Inc.",
  "treatment": " HIV Infection",
  "drug_description": "Emtriva (emtricitabine) is a nucleoside reverse transcriptase inhibitor (NRTI) used\r with other anti-HIV medicines to treat people with HIV infection.",
  "previous application": "Emtriva Gilead Sciences, Inc. - Treatment for HIV Infection"
},{
  "title": "Ciprodex (ciprofloxacin 0.3% and dexamethasone 0.1%)  Otic Suspension ",
  "date_of_approval": "July 18, 2003",
  "company": " Alcon Research, Ltd.",
  "treatment": " Acute Otitis Externa, Otitis Media",
  "drug_description": "Ciprodex (ciprofloxacin/dexamethasone) is an antibiotic / anti-inflammatory combination used for the treatment of acute otitis media and acute otitis externa.",
  "previous application": "Ciprodex Alcon Research, Ltd. - Treatment for Ear Infections"
},{
  "title": "Clobex (clobetasol propionate)  Lotion ",
  "date_of_approval": "July 24, 2003",
  "company": " Galderma Laboratories",
  "treatment": " Atopic Dermatitis, Psoriasis",
  "drug_description": "Clobex (clobetasol) is a topical corticosteroid used to treat steroid-responsive dermatoses including moderate-to-severe\r atopic dermatitis and moderate-to-severe psoriasis.",
  "previous application": "Clobex Galderma Laboratories - Treatment for Inflammatory Skin Conditions"
},{
  "title": "Advate (antihemophilic factor [recombinant]) ",
  "date_of_approval": "July 25, 2003",
  "company": " Baxter Healthcare Corp",
  "treatment": " Hemophilia A",
  "drug_description": "Advate (antihemophilic factor [recombinant]) is indicated for use in hemophilia A (classical hemophilia) for the prevention and control of bleeding episodes, and also indicated in the perioperative management of patients with hemophilia A.",
  "previous application": "Advate Baxter Healthcare Corp - Treatment for Hemophilia A"
},{
  "title": "Aloxi (palonosetron)  Injection ",
  "date_of_approval": "July 25, 2003",
  "company": " Helsinn Healthcare",
  "treatment": " Nausea/Vomiting -- Chemotherapy Induced",
  "drug_description": "Aloxi (palonosetron) is a 5-HT3 receptor antagonist indicated for the prevention of nausea and vomiting associated with chemotherapy.",
  "previous application": "FDA Approves Aloxi for Chemotherapy-Induced Nausea and Vomiting (CINV)"
},{
  "title": "Zavesca (miglustat)  Capsules ",
  "date_of_approval": "July 31, 2003",
  "company": " Actelion Pharmaceuticals",
  "treatment": " Gaucher Disease",
  "drug_description": "Zavesca (miglustat) is a glucosylceramide synthase inhibitor indicated for the treatment of adult patients with mild to moderate type 1 Gaucher disease.",
  "previous application": "Zavesca Actelion Pharmaceuticals - Treatment for Type 1 Gaucher Disease"
},{
  "title": "Clobex (clobetasol propionate)  Lotion ",
  "date_of_approval": "July 24, 2003",
  "company": " Galderma Laboratories",
  "treatment": " Atopic Dermatitis, Psoriasis",
  "drug_description": "Clobex (clobetasol) is a topical corticosteroid used to treat steroid-responsive dermatoses including moderate-to-severe\r atopic dermatitis and moderate-to-severe psoriasis.",
  "previous application": "Clobex Galderma Laboratories - Treatment for Scalp Psoriasis"
},{
  "title": "Crestor (rosuvastatin calcium)  Tablets ",
  "date_of_approval": "August 12, 2003",
  "company": " AstraZeneca",
  "treatment": " Heterozygous Familial Hypercholesterolemia, Homozygous Familial Hypercholesterolemia, Hypertriglyceridemia, Dyslipidemia, Prevention of Cardiovascular Disease",
  "drug_description": "Crestor is an HMG-CoA reductase inhibitor approved as an adjunct to\r diet for the treatment of various lipid disorders including primary\r hypercholesterolemia, mixed dyslipidemia and isolated hypertriglyceridemia. Crestor is also indicated for the primary prevention of cardiovascular disease.",
  "previous application": "Crestor AstraZeneca - Treatment for Hypercholesterolemia"
},{
  "title": "Levitra (vardenafil hydrochloride)  Tablets ",
  "date_of_approval": "August 19, 2003",
  "company": " Bayer Corporation",
  "treatment": " Erectile Dysfunction",
  "drug_description": "Levitra is a phosphodiesterase type 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction.",
  "previous application": "Levitra Bayer Corporation - Treatment for Erectile Dysfunction"
},{
  "title": "Gamunex (immune globulin intravenous (human))  Injection ",
  "date_of_approval": "August 27, 2003",
  "company": " Bayer Corporation",
  "treatment": " Primary Immunodeficiency Syndrome, Idiopathic (Immune) Thrombocytopenic Purpura, Chronic Inflammatory Demyelinating Polyradiculoneuropathy",
  "drug_description": "Gamunex (immune globulin intravenous (human)) is indicated for the treatment of primary humoral immunodeficiency, idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy (CIDP).",
  "previous application": "FDA Approves Gamunex for Primary Humoral\r Immunodeficiency and Idiopathic Thrombocytopenic Purpura\r "
},{
  "title": "Seasonale (ethinyl estradiol and levonorgestrel)  Tablets ",
  "date_of_approval": "September 5, 2003",
  "company": " Barr Laboratories",
  "treatment": " Contraception",
  "drug_description": "Seasonale (ethinyl estradiol and levonorgestrel) is an extended-cycle oral\r contraceptive.",
  "previous application": "Seasonale Barr Laboratories - Treatment for Prevention of Pregnancy"
},{
  "title": "Riomet (metformin hydrochloride)  Oral Solution ",
  "date_of_approval": "September 11, 2003",
  "company": " Ranbaxy Pharmaceuticals Inc.",
  "treatment": " Diabetes Type 2",
  "drug_description": "Riomet is an oral solution formulation of the antihyperglycemic drug metformin indicated for the treatment of type 2 diabetes.",
  "previous application": "Riomet Ranbaxy Pharmaceuticals Inc. - Treatment for Type 2 Diabetes"
},{
  "title": "Cubicin (daptomycin )  Injection ",
  "date_of_approval": "September 12, 2003",
  "company": " Cubist Pharmaceuticals",
  "treatment": " Skin and Structure Infection, Bacteremia",
  "drug_description": "Cubicin (daptomycin) is a lipopeptide antibacterial indicated for the treatment of complicated skin and skin structure infections (cSSSI) and staphylococcus aureus bloodstream infections (bacteremia).",
  "previous application": "Cubicin Cubist Pharmaceuticals - Treatment for Skin Infections"
},{
  "title": "Jantoven (warfarin sodium)  Tablets ",
  "date_of_approval": "October 2, 2003",
  "company": " Upsher-Smith",
  "treatment": " Thromboembolic Stroke Prophylaxis",
  "drug_description": "Jantoven (warfarin) is an anticoagulant used to prevent heart attacks, strokes, and blood clots in veins and arteries. Jantoven is therapeutically equivalent to Coumadin.",
  "previous application": "Jantoven Upsher-Smith - Treatment for Anticoagulant Therapy"
},{
  "title": "Radiogardase (prussian blue insoluble)  Capsules ",
  "date_of_approval": "October 2, 2003",
  "company": " HEYL Chemisch-pharmazeutische Fabrik GmbH",
  "treatment": " Radiation Emergency",
  "drug_description": "Radiogardase (prussian blue) is used to treat people who have been contaminated with radioactive cesium or thallium, or non-radioactive thallium.",
  "previous application": "Radiogardase HEYL Chemisch-pharmazeutische Fabrik GmbH - Treatment for Radiation Exposure"
},{
  "title": "Estrasorb (estradiol topical )  Emulsion ",
  "date_of_approval": "October 9, 2003",
  "company": " Novovax",
  "treatment": " Postmenopausal Symptoms",
  "drug_description": "Estrasorb is a topical estradiol emulsion approved for short-term\r use to reduce moderate to severe vasomotor symptoms (commonly known\r as \"hot flashes\") in menopausal women.",
  "previous application": "Estrasorb Novovax - Treatment for Menopausal Vasomotor Symptoms"
},{
  "title": "Namenda (memantine hydrochloride) ",
  "date_of_approval": "October 16, 2003",
  "company": " Allergan, Inc.",
  "treatment": " Alzheimer's Disease",
  "drug_description": "Namenda is a low to moderate\r affinity NMDA (N-methyl-D-aspartate) receptor antagonist indicated for treatment of moderate to severe dementia of the Alzheimer\u2019s type.",
  "previous application": "Namenda Forest Laboratories Inc. - Treatment for Alzheimer\u2019s Disease"
},{
  "title": "Elestat (epinastine hydrochloride)  Ophthalmic Solution, 0.05% ",
  "date_of_approval": "October 16, 2003",
  "company": " Allergan, Inc.",
  "treatment": " Allergic Conjunctivitis",
  "drug_description": "Elestat (epinastine) is topical H1-receptor antagonist used for the prevention of itching associated with\r allergic conjunctivitis.",
  "previous application": "Elestat Allergan, Inc. - Treatment for Prevention of Itching associated with Allergic Conjunctivitis"
},{
  "title": "Lexiva (fosamprenavir calcium) ",
  "date_of_approval": "October 20, 2003",
  "company": " ViiV Healthcare",
  "treatment": " HIV Infection",
  "drug_description": "Lexiva (fosamprenavir) is a protease inhibitor (PI) for the treatment of HIV\r infection in adults in combination with other antiretroviral\r medications. Lexiva offers flexible dosing with no food or water restrictions.",
  "previous application": "Lexiva GlaxoSmithKline - Treatment for HIV Infection"
},{
  "title": "Raptiva (efalizumab)  Injection ",
  "date_of_approval": "October 27, 2003",
  "company": " Genentech Inc.",
  "treatment": " Psoriasis",
  "drug_description": "Raptiva (efalizumab) is a monoclonal antibody indicated for the treatment of adult patients with chronic moderate to severe plaque psoriasis.",
  "previous application": "Raptiva Genentech Inc. - Treatment for Psoriasis"
},{
  "title": "Climara Pro (estradiol and levonorgestrel )  Transdermal System ",
  "date_of_approval": "November 21, 2003",
  "company": " Berlex Laboratories",
  "treatment": " Postmenopausal Symptoms",
  "drug_description": "Climara Pro (estradiol and levonorgestrel) is a transdermal combined hormone therapy for the relief of moderate to severe\r vasomotor symptoms associated with menopause, such as hot flashes\r and night sweats.",
  "previous application": "Climara Pro Berlex Laboratories - Treatment for Menopausal Vasomotor Symptoms"
},{
  "title": "Cialis (tadalafil)  Tablets ",
  "date_of_approval": "November 21, 2003",
  "company": " Eli Lilly and Co.",
  "treatment": " Erectile Dysfunction, Benign Prostatic Hyperplasia",
  "drug_description": "Cialis is a phosphodiesterase 5 (PDE5) inhibitor indicated for erectile dysfunction, and to treat the signs and symptoms of benign prostatic hyperplasia.",
  "previous application": "Lilly ICOS Announces FDA Approval of Cialis (tadalafil), A New Oral Treatment for Erectile Dysfunction Cialis (tadalafil) FDA Approval History"
},{
  "title": "Climara Pro (estradiol and levonorgestrel )  Transdermal System ",
  "date_of_approval": "November 21, 2003",
  "company": " Berlex Laboratories",
  "treatment": " Postmenopausal Symptoms",
  "drug_description": "Climara Pro (estradiol and levonorgestrel) is a transdermal combined hormone therapy for the relief of moderate to severe\r vasomotor symptoms associated with menopause, such as hot flashes\r and night sweats.",
  "previous application": "Climara Pro Approved for Prevention of Postmenopausal Osteoporosis"
},{
  "title": "Zorbtive (somatropin)  for Injection ",
  "date_of_approval": "December 1, 2003",
  "company": " Serono, Inc.",
  "treatment": " Short Bowel Syndrome",
  "drug_description": "Zorbtive [somatropin (rDNA origin) for injection] is recombinant human growth hormone indicated for the treatment of Short Bowel\r Syndrome in patients receiving specialized nutritional support.",
  "previous application": "Zorbtive Serono, Inc. - Treatment for Short Bowel Syndrome"
},{
  "title": "Ertaczo (sertaconazole topical)  Cream ",
  "date_of_approval": "December 11, 2003",
  "company": " Mylan Pharmaceuticals Inc.",
  "treatment": " Tinea Pedis",
  "drug_description": "Ertaczo (sertaconazole) is an imidazole derivative antifungal indicated for the treatment of tinea pedis.",
  "previous application": "Ertaczo Mylan Pharmaceuticals Inc. - Treatment for Tinea Pedis"
},{
  "title": "Restylane (dermal filler)  Injectable Gel ",
  "date_of_approval": "December 12, 2003",
  "company": " Medicis",
  "treatment": " Facial Wrinkles",
  "drug_description": "Restylane is a dermal filler made of a biodegradable non-animal\r stabilized hyaluronic acid used for the\r correction of moderate to severe facial wrinkles and folds, such as\r nasolabial folds, the lines between the nose and mouth.",
  "previous application": "Restylane Medicis - Treatment for Facial Wrinkles"
},{
  "title": "Oraqix (lidocaine and prilocaine )  Periodontal Gel ",
  "date_of_approval": "December 19, 2003",
  "company": " Dentsply Pharmaceutical",
  "treatment": " Periodontal Anesthesia",
  "drug_description": "Oraqix is a non-injectable anesthetic for periodontal applications. The anesthetic is delivered to the treatment site without the use of a needle and anesthetizes the site within 30 seconds for a period of approximately 20 minutes.",
  "previous application": "Oraqix Dentsply Pharmaceutical - Treatment for Periodontal Anesthesia"
},{
  "title": "Symbyax (fluoxetine and olanzapine)  Capsules ",
  "date_of_approval": "December 24, 2003",
  "company": " Eli Lilly",
  "treatment": " Bipolar Disorder, Depression",
  "drug_description": "Symbyax (fluoxetine/olanzapine) is a selective serotonin reuptake inhibitor and atypical antipsycotic combination indicated for the acute treatment of depressive episodes associated with bipolar I disorder and treatment resistant depression.",
  "previous application": "Symbyax Eli Lilly - Treatment for Bipolar Depression"
},{
  "title": "Acetadote (acetylcysteine)  Injection ",
  "date_of_approval": "January 23, 2004",
  "company": " Cumberland Pharmaceuticals",
  "treatment": " Acetaminophen Overdose",
  "drug_description": "Acetadote (acetylcysteine) is an injectable treatment to prevent or lessen potential liver damage resulting from acetaminophen overdose.",
  "previous application": "Acetadote Cumberland Pharmaceuticals - Treatment for Acetaminophen Overdose Acetadote (acetylcysteine) FDA Approval History"
},{
  "title": "Caduet (amlodipine and atorvastatin)  Tablets ",
  "date_of_approval": "January 30, 2004",
  "company": " Pfizer Inc.",
  "treatment": " Hypertension, Dyslipidemia, Angina Pectoris",
  "drug_description": "Caduet (amlodipine and atorvastatin) is calcium channel blocker and HMG-CoA reductase inhibitor combination used for the treatment of hypertension, angina and for the prevention of cardiovascular disease.",
  "previous application": "Caduet High Blood Pressure and High Cholesterol - Treatment for High Blood Pressure and High Cholesterol Caduet (amlodipine and atorvastatin) FDA Approval History"
},{
  "title": "Spiriva (tiotropium bromide)   Inhalation Powder ",
  "date_of_approval": "January 30, 2004",
  "company": " Boehringer Ingelheim",
  "treatment": " Chronic Obstructive Pulmonary Disease -- Maintenance",
  "drug_description": "Spiriva HandiHaler (tiotropium bromide) is an anticholinergic indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), and for reducing COPD exacerbations.",
  "previous application": "Spiriva HandiHaler Boehringer Ingelheim - Treatment for Chronic Obstructive Pulmonary Disease (COPD) Spiriva (tiotropium bromide) FDA Approval History"
},{
  "title": "Alimta (pemetrexed)  Injection ",
  "date_of_approval": "February 4, 2004",
  "company": " Eli Lilly",
  "treatment": " Malignant Pleural Mesothelioma, Non-Small Cell Lung Cancer",
  "drug_description": "Alimta (pemetrexed) is an antifolate antineoplastic agent indicated for the treatment of malignant pleural mesothelioma and locally-advanced and metastatic non-small cell lung cancer (NSCLC).",
  "previous application": "FDA Approves Alimta for Malignant Pleural Mesothelioma Alimta (pemetrexed) FDA Approval History"
},{
  "title": "Orthovisc (sodium hyaluronate)  Injection ",
  "date_of_approval": "February 4, 2004",
  "company": " Anika Therapeutics, Inc.",
  "treatment": " Osteoarthritis",
  "drug_description": "Orthovisc is a highly purified, high molecular weight form of\r hyaluronic acid used for treating pain in patients suffering from\r osteoarthritis (OA) of the knee who have failed to respond\r adequately to conservative non-pharmacologic therapy and to simple\r analgesics.",
  "previous application": "Orthovisc Anika Therapeutics, Inc. - Treatment for Osteoarthritis of the Knee Orthovisc (sodium hyaluronate) FDA Approval History"
},{
  "title": "Fazaclo (clozapine)  Orally Disintegrating Tablets ",
  "date_of_approval": "February 9, 2004",
  "company": " Alamo Pharmaceuticals",
  "treatment": " Schizophrenia",
  "drug_description": "Fazaclo is an orally disintegrating atypical antipsychotic indicated for the treatment of schizophrenia.",
  "previous application": "Fazaclo Alamo Pharmaceuticals - Treatment for Schizophrenia Fazaclo (clozapine) FDA Approval History"
},{
  "title": "EstroGel (estradiol topical)  Gel ",
  "date_of_approval": "February 9, 2004",
  "company": " Solvay Pharmaceuticals",
  "treatment": " Postmenopausal Symptoms",
  "drug_description": "EstroGel (estradiol) is transdermal gel estrogen therapy for the treatment of\r moderate to severe vasomotor symptoms, as well as vulvar and\r vaginal atrophy associated with the menopause.",
  "previous application": "EstroGel Solvay Pharmaceuticals - Treatment for Menopausal Vasomotor Symptoms EstroGel (estradiol topical) FDA Approval History"
},{
  "title": "Rhophylac (Rh0(D) immune globulin intravenous (human))  Injection ",
  "date_of_approval": "February 12, 2004",
  "company": " ZLB Bioplasma AG, Switzerland",
  "treatment": " Prevention of Rho(D) Sensitization",
  "drug_description": "Rhophylac (Rh0(D) immune globulin intravenous (human)) is indicated for the suppression of rhesus (Rh) isoimmunization in\r pregnancy, obstetric conditions and incompatible transfusions, and the treatment of immune thrombocytopenic purpura.",
  "previous application": "Rhophylac ZLB Bioplasma AG, Switzerland - Treatment for Prevention of Rho(D) Sensitization Rhophylac (Rh0(D) immune globulin intravenous (human)) FDA Approval History"
},{
  "title": "Erbitux (cetuximab)  Injection ",
  "date_of_approval": "February 12, 2004",
  "company": " ImClone",
  "treatment": " Colorectal Cancer, Head and Neck Cancer",
  "drug_description": "Erbitux is epidermal growth factor receptor (EGFR) antagonist indicated for the treatment of colorectal cancer and Head and Neck Cancer.",
  "previous application": "Erbitux ImClone - Treatment for Advanced Colorectal Cancer Erbitux (cetuximab) FDA Approval History"
},{
  "title": "Avastin (bevacizumab)  Injection ",
  "date_of_approval": "February 26, 2004",
  "company": " Genentech, Inc.",
  "treatment": " Colorectal Cancer, Non-Small Cell Lung Cancer, Glioblastoma Multiforme, Renal Cell Carcinoma, Cervical Cancer, Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer",
  "drug_description": "Avastin (bevacizumab) is a recombinant humanized monoclonal IgG1 antibody for the treatment of colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical cancer, ovarian cancer, fallopian tube cancer, and peritoneal cancer.",
  "previous application": "Avastin Approved for treatment for Metastatic Colorectal Cancer Avastin (bevacizumab) FDA Approval History"
},{
  "title": "Myfortic (mycophenolic acid)  Tablets ",
  "date_of_approval": "February 27, 2004",
  "company": " Novartis Pharma AG",
  "treatment": " Organ Transplant -- Rejection Prophylaxis",
  "drug_description": "Myfortic is an enteric-coated formulation of mycophenolic acid\r for use in combination with cyclosporine and corticosteroids to\r prevent organ rejection in kidney transplant patients.",
  "previous application": "Myfortic Novartis Pharma AG - Treatment for Prevention of Organ Rejection Myfortic (mycophenolic acid) FDA Approval History"
},{
  "title": "Iquix (levofloxacin ophthalmic)  Ophthalmic Solution ",
  "date_of_approval": "March 1, 2004",
  "company": " Santen",
  "treatment": " Corneal Ulcers",
  "drug_description": "",
  "previous application": "Iquix Santen - Treatment for Bacterial Corneal Ulcers Iquix (levofloxacin ophthalmic) FDA Approval History"
},{
  "title": "Sensipar (cinacalcet)  Tablets ",
  "date_of_approval": "March 8, 2004",
  "company": " Amgen Inc.",
  "treatment": " Secondary Hyperparathyroidism, Hypercalcemia of Malignancy",
  "drug_description": "Sensipar (cinacalcet) is a calcimimetic agent indicated for the treatment of secondary hyperparathyroidism in dialysis patients and for the treatment of hypercalcemia in patients with parathyroid\r carcinoma.",
  "previous application": "Sensipar Amgen Inc. - Treatment for Secondary Hyperparathyroidism in dialysis patients Sensipar (cinacalcet) FDA Approval History"
},{
  "title": "Follistim AQ (follitropin beta)  Injection ",
  "date_of_approval": "March 24, 2004",
  "company": " Organon USA Inc.",
  "treatment": " Female Infertility, Hypogonadism -- Male, Ovulation Induction",
  "drug_description": "Follistim AQ (follitropin beta) is human follicle-stimulating hormone \r prescribed for women undergoing assisted reproductive treatments\r (ART) such as in vitro fertilization (IVF), and for the induction\r of ovulation to achieve pregnancy, and for men with hypogonadism.",
  "previous application": "Follistim AQ Organon USA Inc. - Treatment for Infertility Follistim AQ (follitropin beta) FDA Approval History"
},{
  "title": "Ribasphere (ribavirin)  Capsules ",
  "date_of_approval": "April 6, 2004",
  "company": " Three Rivers Pharmaceuticals, LLC",
  "treatment": " Chronic Hepatitis C",
  "drug_description": "Ribasphere (ribavirin) is a nucleoside analogue indicated in combination with peginterferon alfa-2a for the\r treatment of adults with chronic hepatitis C virus infection.",
  "previous application": "Ribasphere Three Rivers Pharmaceuticals - Treatment for Hepatitis C (\"HCV\") Ribasphere (ribavirin) FDA Approval History"
},{
  "title": "ChiRhoStim (secretin synthetic human)  - formerly Human Secretin",
  "date_of_approval": "April 9, 2004",
  "company": " ChiRhoClin, Inc.",
  "treatment": " Diagnostic",
  "drug_description": "ChiRhoStim is indicated for use in diagnostic procedures.",
  "previous application": "Human Secretin ChiRhoClin, Inc. - Treatment for Secretin Stimulation Testing ChiRhoStim (secretin synthetic human) FDA Approval History"
},{
  "title": "Apidra (insulin glulisine)  Injection ",
  "date_of_approval": "April 16, 2004",
  "company": " Aventis Pharmaceuticals Inc.",
  "treatment": " Diabetes Type 1, Diabetes Type 2",
  "drug_description": "Apidra (insulin glulisine) is a rapid-acting recombinant DNA human insulin analogue used for the control of hyperglycemia in patients with diabetes mellitus.",
  "previous application": "Apidra Aventis Pharmaceuticals Inc. - Treatment for Diabetes Mellitus Apidra (insulin glulisine) FDA Approval History"
},{
  "title": "Apokyn (apomorphine)  Injection ",
  "date_of_approval": "April 20, 2004",
  "company": " Bertek Pharmaceuticals",
  "treatment": " Parkinson's Disease",
  "drug_description": "Apokyn (apomorphine) is a non-ergoline dopamine agonist indicated for the acute, intermittent treatment of hypomobility, \"off\" episodes (\"end-of-dose wearing\r off\" and unpredictable \"on/off\" episodes) associated with advanced\r Parkinson\u2019s disease.",
  "previous application": "Apokyn Bertek Pharmaceuticals - Treatment for Parkinson\u2019s Disease Apokyn (apomorphine) FDA Approval History"
},{
  "title": "Fortamet (metformin)  Extended-Release Tablets ",
  "date_of_approval": "April 28, 2004",
  "company": " Andrx Corporation",
  "treatment": " Diabetes Type 2",
  "drug_description": "",
  "previous application": "FDA Approves Fortamet (metformin HCl) Extended-Release Tablets for Type 2 Diabetes Fortamet (metformin) FDA Approval History"
},{
  "title": "Vitrase (hyaluronidase)  for Injection ",
  "date_of_approval": "May 5, 2004",
  "company": " ISTA Pharmaceuticals, Inc.",
  "treatment": " Hypodermoclysis, Subcutaneous Urography",
  "drug_description": "Vitrase is a preparation of purified ovine testicular hyaluronidase indicated as an adjuvant to increase the absorption and\r dispersion of other injected drugs; for hypodermoclysis; and as an adjunct in subcutaneous urography for improving resorption of radiopaque agents.",
  "previous application": "Vitrase ISTA Pharmaceuticals, Inc. - Treatment for Spreading Agent Vitrase (hyaluronidase) FDA Approval History"
},{
  "title": "HalfLytely and Bisacodyl  Tablets (bisacodyl and polyethylene glycol (PEG) 3350 with electrolytes)  Bowel Prep Kit ",
  "date_of_approval": "May 10, 2004",
  "company": " Braintree Laboratories, Inc.",
  "treatment": " Bowel Preparation",
  "drug_description": "",
  "previous application": "HalfLytely Braintree Laboratories, Inc. - Treatment for Colonoscopy Preparation HalfLytely and Bisacodyl  Tablets (bisacodyl and polyethylene glycol (PEG) 3350 with electrolytes) FDA Approval History"
},{
  "title": "LidoSite (lidocaine and Epinephrine )  Topical System ",
  "date_of_approval": "May 10, 2004",
  "company": " Vyteris, Inc.",
  "treatment": " Local Anesthesia",
  "drug_description": "LidoSite (lidocaine and epinephrine) is an iontophoretic delivery system providing local analgesia prior to the administration of superficial dermatological\r procedures.",
  "previous application": "LidoSite Vyteris, Inc. - Treatment for Localized Pain LidoSite (lidocaine and Epinephrine ) FDA Approval History"
},{
  "title": "Enjuvia (synthetic conjugated estrogens, B)  Tablets ",
  "date_of_approval": "May 10, 2004",
  "company": " Duramed Pharmaceuticals",
  "treatment": " Postmenopausal Symptoms, Atrophic Vaginitis",
  "drug_description": "",
  "previous application": "Enjuvia Duramed Pharmaceuticals - Treatment for Menopausal Vasomotor Symptoms Enjuvia (synthetic conjugated estrogens, B) FDA Approval History"
},{
  "title": "Tindamax (tinidazole)  Tablets ",
  "date_of_approval": "May 17, 2004",
  "company": " Presutti Laboratories",
  "treatment": " Trichomoniasis, Giardiasis, Bacterial Vaginosis",
  "drug_description": "Tindamax (tinidazole) is a synthetic nitroimidazole antiprotozoal agent for the treatment of trichomoniasis, giardiasis, amebiasis, and bacterial vaginosis in nonpregnant women.",
  "previous application": "Tindamax Presutti Laboratories - Treatment for Infections Tindamax (tinidazole) FDA Approval History"
},{
  "title": "DepoDur (morphine sulfate)  extended-release liposome Injection ",
  "date_of_approval": "May 18, 2004",
  "company": " SkyePharma PLC and Endo Pharmaceuticals",
  "treatment": " Pain",
  "drug_description": "",
  "previous application": "DepoDur SkyePharma PLC and Endo Pharmaceuticals - Treatment for Post-Surgical Pain Relief DepoDur (morphine sulfate) FDA Approval History"
},{
  "title": "Vidaza (azacitidine)   for Injectable Suspension ",
  "date_of_approval": "May 19, 2004",
  "company": " Pharmion Corporation",
  "treatment": " Myelodysplastic Disease",
  "drug_description": "Vidaza (azacitidine) is an antineoplastic agent for the treatment of patients with myelodysplastic syndromes.",
  "previous application": "FDA Approves Vidaza for Myelodysplastic Syndromes (MDS) Vidaza (azacitidine) FDA Approval History"
},{
  "title": "Octagam (immune globulin intravenous (human))   Injection ",
  "date_of_approval": "May 21, 2004",
  "company": " Octapharma AG",
  "treatment": " Primary Immunodeficiency Syndrome",
  "drug_description": "Octagam (immune globulin intravenous (human)) is a ready-to-use immunoglobulin intravenous (IGIV) product indicated for the treatment of primary immunodeficiency diseases.",
  "previous application": "Octagam Octapharma AG - Treatment for Primary Immunodeficiency Diseases Octagam (immune globulin intravenous (human)) FDA Approval History"
},{
  "title": "Xifaxan (rifaximin)  Tablets ",
  "date_of_approval": "May 25, 2004",
  "company": " Salix Pharmaceuticals, Ltd",
  "treatment": " Traveler's Diarrhea, Hepatic Encephalopathy, Irritable Bowel Syndrome",
  "drug_description": "Xifaxan (rifaximin) is a nonsystemic antibiotic indicated for the treatment of patients with traveler's diarrhea caused by noninvasive strains of Escherichia coli, to reduce the risk of recurrence of hepatic encephalopathy in patients with advanced liver disease, and for the treatment of irritable bowel syndrome with diarrhea (IBS-D).",
  "previous application": "Xifaxan Salix Pharmaceuticals, Ltd - Treatment for Travelers\u2019 Diarrhea Xifaxan (rifaximin) FDA Approval History"
},{
  "title": "Sanctura (trospium chloride)  Tablets ",
  "date_of_approval": "May 28, 2004",
  "company": " Allergan, Inc.",
  "treatment": " Overactive Bladder Syndrome, Urinary Frequency, Urinary Incontinence",
  "drug_description": "",
  "previous application": "Sanctura Indevus Pharmaceuticals, Inc. - Treatment for Overactive Bladder Sanctura (trospium chloride) FDA Approval History"
},{
  "title": "Istalol (timolol maleate ophthalmic)  Solution ",
  "date_of_approval": "June 4, 2004",
  "company": " ISTA Pharmaceuticals, Inc.",
  "treatment": " Glaucoma",
  "drug_description": "Istalol (timolol maleate ophthalmic solution) is a beta-blocking agent for the treatment of glaucoma.",
  "previous application": "Istalol ISTA Pharmaceuticals, Inc. - Treatment for Glaucoma Istalol (timolol maleate ophthalmic) FDA Approval History"
},{
  "title": "Menostar (estradiol transdermal system) ",
  "date_of_approval": "June 8, 2004",
  "company": " Berlex",
  "treatment": " Prevention of Osteoporosis",
  "drug_description": "Menostar (estradiol transdermal system) is an estrogen patch for the prevention of postmenopausal osteoporosis.",
  "previous application": "Menostar Berlex - Treatment for Osteoporosis Prevention Menostar (estradiol transdermal system) FDA Approval History"
},{
  "title": "Zegerid (omeprazole and sodium bicarbonate)  - formerly Rapinex",
  "date_of_approval": "June 15, 2004",
  "company": " Santarus, Inc.",
  "treatment": " Duodenal Ulcer, Gastroesophageal Reflux Disease, Gastric Ulcer, Erosive Esophagitis",
  "drug_description": "Zegerid (omeprazole and sodium bicarbonate)  is proton-pump inhibitor and antacid combination for the treatment of duodenal ulcer, heartburn and other symptoms associated with gastroesophageal reflux disease (GERD), and erosive esophagitis.",
  "previous application": "Zegerid Santarus, Inc. - Treatment for Heartburn/GERD, Erosive Esophagitis, Duodenal Ulcers Zegerid (omeprazole and sodium bicarbonate) FDA Approval History"
},{
  "title": "Codeprex (chlorpheniramine polistirex and codeine polistirex)  Extended Release Suspension ",
  "date_of_approval": "June 21, 2004",
  "company": " Lannett Company, Inc.",
  "treatment": " Cough",
  "drug_description": "",
  "previous application": "Codeprex Celltech Group plc - Treatment for Cough Codeprex (chlorpheniramine polistirex and codeine polistirex) FDA Approval History"
},{
  "title": "Mucinex D (guaifenesin and pseudoephedrine)  Extended-Release Tablets ",
  "date_of_approval": "June 22, 2004",
  "company": " Adams Respiratory Therapeutics",
  "treatment": " Cough and Nasal Congestion",
  "drug_description": "Mucinex D (guaifenesin and pseudoephedrine) is an expectorant and decongestant combination used for the relief of coughs and congestion associated with colds and allergies.",
  "previous application": "Mucinex D Adams Respiratory Therapeutics - Treatment for Cough and Congestion Mucinex D (guaifenesin and pseudoephedrine) FDA Approval History"
},{
  "title": "Alinia (nitazoxanide)  Tablets ",
  "date_of_approval": "July 21, 2004",
  "company": " Romark Laboratories",
  "treatment": " Traveler's Diarrhea",
  "drug_description": "Alinia (nitazoxanide) is an antiprotozoal agent indicated for the treatment of diarrhea caused by Giardia lamblia in patients 12 years of age and older.",
  "previous application": "Alinia Romark Laboratories - Treatment for Diarrhea Alinia (nitazoxanide) FDA Approval History"
},{
  "title": "Vytorin (ezetimibe/simvastatin)  Tablets ",
  "date_of_approval": "July 23, 2004",
  "company": " Merck/Schering-Plough Pharmaceuticals",
  "treatment": " Heterozygous Familial Hypercholesterolemia, Homozygous Familial Hypercholesterolemia",
  "drug_description": "Vytorin (ezetimibe/simvastatin) is a combination of ezetimibe (a lipid-lowering compound) and simvastatin (an HMG-CoA reductase inhibitor) for the treatment of high LDL cholesterol (LDL-C) in patients with primary hypercholesterolemia or mixed hyperlipidemia as adjunctive therapy to diet when diet alone is not enough.",
  "previous application": "Vytorin Merck/Schering-Plough Pharmaceuticals - Treatment for Cholesterol Reduction Vytorin (ezetimibe/simvastatin) FDA Approval History"
},{
  "title": "Metvixia (methyl aminolevulinate hydrochloride)  Cream ",
  "date_of_approval": "July 27, 2004",
  "company": " PhotoCure ASA",
  "treatment": " Keratosis",
  "drug_description": "",
  "previous application": "FDA Approves Metvixia for Actinic Keratosis Metvixia (methyl aminolevulinate hydrochloride) FDA Approval History"
},{
  "title": "Campral (acamprosate calcium)  Delayed-Release Tablets ",
  "date_of_approval": "July 29, 2004",
  "company": " Allergan, Inc.",
  "treatment": " Alcohol Dependence",
  "drug_description": "",
  "previous application": "Campral Forest Laboratories, Inc. and Merck - Treatment for Alcoholism Campral (acamprosate calcium) FDA Approval History"
},{
  "title": "Epzicom (abacavir and lamivudine)  Tablets ",
  "date_of_approval": "August 2, 2004",
  "company": " ViiV Healthcare",
  "treatment": " HIV Infection",
  "drug_description": "Epzicom (abacavir and lamivudine) is a combination of two nucleoside reverse transcriptase inhibitors (NRTIs) indicated for use with other antiretroviral drugs\r for the treatment of HIV-1 infection in adults.",
  "previous application": "Epzicom GlaxoSmithKline - Treatment for HIV Infection Epzicom (abacavir and lamivudine) FDA Approval History"
},{
  "title": "Truvada (emtricitabine and tenofovir)  Tablets ",
  "date_of_approval": "August 2, 2004",
  "company": " Gilead Sciences, Inc.",
  "treatment": " HIV Infection, Pre-Exposure Prophylaxis",
  "drug_description": "Truvada (emtricitabine and tenofovir disoproxil fumarate) is a combination of nucleoside analog HIV-1 reverse transcriptase inhibitors indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection, and for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in people at high risk.",
  "previous application": "Truvada Gilead Sciences, Inc. - Treatment for HIV Infection Truvada (emtricitabine and tenofovir) FDA Approval History"
},{
  "title": "Sculptra (injectable poly-L-lactic acid) ",
  "date_of_approval": "August 3, 2004",
  "company": " Sanofi-aventis U.S.",
  "treatment": " Facial Lipoatrophy; Facial Wrinkles",
  "drug_description": "Sculptra (injectable poly-L-lactic acid) is a dermal filler indicated for the restoration and/or correction of the signs of facial fat loss (lipoatrophy) in people with human immunodeficiency virus. Sculptra Aesthetic is indicated for the correction of shallow to deep nasolabial fold (smile lines) contour deficiencies and other facial\r wrinkles in healthy patients.",
  "previous application": "Sculptra Dermik Laboratories - Treatment for Facial Lipoatrophy in HIV Patients Sculptra (injectable poly-L-lactic acid) FDA Approval History"
},{
  "title": "Cymbalta (duloxetine)  Delayed-Release Capsules ",
  "date_of_approval": "August 3, 2004",
  "company": " Eli Lilly and Company",
  "treatment": " Neuropathic Pain, Pain, Osteoarthritis, Generalized Anxiety Disorder, Depression, Fibromyalgia, Diabetic Nephropathy",
  "drug_description": "Cymbalta is a selective serotonin and norepinephrine reuptake inhibitor (SSNRI) indicated for the treatment of major depressive disorder, neuropathic pain associated with diabetic peripheral neuropathy, generalized anxiety disorder, fibromyalgia and chronic musculoskeletal pain.",
  "previous application": "FDA Approves Cymbalta for the Treatment of Depression  Cymbalta (duloxetine) FDA Approval History"
},{
  "title": "Femtrace (estradiol acetate)  Tablets ",
  "date_of_approval": "August 20, 2004",
  "company": " Warner Chilcott",
  "treatment": " Postmenopausal Symptoms",
  "drug_description": "",
  "previous application": "Femtrace Warner Chilcott - Treatment for Menopausal Vasomotor Symptoms Femtrace (estradiol acetate) FDA Approval History"
},{
  "title": "Fluxid (famotidine)  Orally Disintegrating Tablets ",
  "date_of_approval": "September 24, 2004",
  "company": " Schwarz Pharma, Inc.",
  "treatment": " Duodenal Ulcer, Gastric Ulcer, Gastroesophageal Reflux Disease, Zollinger-Ellison Syndrome",
  "drug_description": "",
  "previous application": "Fluxid Schwarz Pharma, Inc. - Treatment for Ulcers and other Gastrointestinal Conditions Fluxid (famotidine) FDA Approval History"
},{
  "title": "Palladone (hydromorphone hydrochloride)  Extended Release Capsules ",
  "date_of_approval": "September 24, 2004",
  "company": " Purdue Pharma L.P.",
  "treatment": " Pain",
  "drug_description": "",
  "previous application": "FDA Approves Palladone (hydromorphone HCl extended-release) Capsules (CII) For The Management Of Persistent, Moderate To Severe Pain Palladone (hydromorphone hydrochloride) FDA Approval History"
},{
  "title": "OraDisc A (amlexanox)  Mucoadhesive Patch ",
  "date_of_approval": "September 29, 2004",
  "company": " Access Pharmaceuticals, Inc.",
  "treatment": " Aphthous Ulcers",
  "drug_description": "OraDisc A is a mucoadhesive patch which gradually erodes and releases the active drug amlexanox when applied to the inside of the mouth. OraDisc A is approved for the treatment of aphthous ulcers in adults and adolescents 12 years of age and older with a normal immune system.",
  "previous application": "OraDisc A Access Pharmaceuticals, Inc. - Treatment for Aphthous Ulcers OraDisc A (amlexanox) FDA Approval History"
},{
  "title": "Luveris (lutropin alfa)  for Injection ",
  "date_of_approval": "October 8, 2004",
  "company": " Serono, Inc.",
  "treatment": " Female Infertility",
  "drug_description": "",
  "previous application": "Luveris Serono, Inc. - Treatment for Infertility Luveris (lutropin alfa) FDA Approval History"
},{
  "title": "Vantas (histrelin)  Implant ",
  "date_of_approval": "October 12, 2004",
  "company": " Valera Pharmaceuticals",
  "treatment": " Prostate Cancer",
  "drug_description": "Vantas (histrelin) implant is an LHRH agonist administered once-yearly for the palliative treatment of advanced prostate cancer.",
  "previous application": "Vantas Valera Pharmaceuticals - Treatment for Prostate Cancer Vantas (histrelin) FDA Approval History"
},{
  "title": "Hylaform Plus (dermal filler) ",
  "date_of_approval": "October 13, 2004",
  "company": " Inamed Corporation and Genzyme Corporation",
  "treatment": " Wrinkle Correction",
  "drug_description": "Hylaform Plus is a large particle size hyaluronic acid-based dermal\r filler that is indicated for the correction of moderate to severe\r facial wrinkles and folds.",
  "previous application": "Hylaform Plus Inamed Corporation and Genzyme Corporation - Treatment for Wrinkle Correction Hylaform Plus (dermal filler) FDA Approval History"
},{
  "title": "Allegra-D 24 Hour (fexofenadine and pseudoephedrine) ",
  "date_of_approval": "October 19, 2004",
  "company": " Sanofi Aventis US",
  "treatment": " Allergic Rhinitis, Nasal Congestion",
  "drug_description": "Allegra-D 24 Hour (fexofenadine and pseudoephedrine) is a once daily prescription antihistamine and decongestant formulation approved for the treatment of seasonal allergy symptoms with nasal congestion in adults and children 12 years of age and older.",
  "previous application": "Allegra-D 24 Hour Aventis Pharmaceuticals Inc. - Treatment for Seasonal Allergy Symptoms with Nasal Congestion Allegra-D 24 Hour (fexofenadine and pseudoephedrine) FDA Approval History"
},{
  "title": "Evoclin (clindamycin phosphate)  Foam  - formerly Actiza",
  "date_of_approval": "October 22, 2004",
  "company": " Connetics Corporation",
  "treatment": " Acne",
  "drug_description": "Evoclin (clindamycin) is a topical antibiotic  indicated for the treatment of acne vulgaris.",
  "previous application": "Evoclin Connetics Corporation - Treatment for Acne Evoclin (clindamycin phosphate) FDA Approval History"
},{
  "title": "Amphadase (hyaluronidase)  Injection ",
  "date_of_approval": "October 26, 2004",
  "company": " Amphastar Pharmaceuticals, Inc",
  "treatment": " Adjuvant to increase the absorption and dispersion of other injected drugs",
  "drug_description": "Amphadase (hyaluronidase) used as an adjunctive agent to facilitate the dispersion and absorption of other drugs.",
  "previous application": "Amphadase Amphastar Pharmaceuticals, Inc - Treatment for Adjunctive Agent Amphadase (hyaluronidase) FDA Approval History"
},{
  "title": "Fosrenol (lanthanum carbonate)  Chewable Tablets ",
  "date_of_approval": "October 26, 2004",
  "company": " Shire Pharmaceuticals Group plc",
  "treatment": " Hyperphosphatemia of Renal Failure",
  "drug_description": "Fosrenol is a phosphate binder used to reduce high phosphorus levels in end-stage renal disease (ESRD) patients.",
  "previous application": "Fosrenol Shire Pharmaceuticals Group plc - Treatment for Hyperphosphataemia in ESRD Patients Fosrenol (lanthanum carbonate) FDA Approval History"
},{
  "title": "TriCor (fenofibrate)  Tablets ",
  "date_of_approval": "November 5, 2004",
  "company": " Abbott Laboratories",
  "treatment": " Hyperlipoproteinemia Type IIa (Elevated LDL), Hyperlipoproteinemia Type IIb (Elevated LDL + VLDL), Hyperlipoproteinemia, Hyperlipoproteinemia Type IV (Elevated VLDL), Hyperlipoproteinemia Type V (Elevated Chylomicrons + VLDL), Hypertriglyceridemia",
  "drug_description": "TriCor (fenofibrate tablets) is a lipid regulating agent indicated for the treatment of hypercholesterolemia and hypertriglyceridemia.",
  "previous application": "TriCor Abbott Laboratories - Treatment for Lipid Disorders TriCor (fenofibrate) FDA Approval History"
},{
  "title": "Omacor (omega-3-acid ethyl esters)  Capsules ",
  "date_of_approval": "November 10, 2004",
  "company": " Reliant Pharmaceuticals, Inc.",
  "treatment": " Hypertriglyceridemia",
  "drug_description": "Omacor (omega-3 polyunsaturated fatty acids)  is indicated as an adjunct to diet for the reduction of triglycerides in adult patients with very high triglyceride levels.",
  "previous application": "Omacor Reliant Pharmaceuticals, Inc. - Treatment for Hypertriglyceridemia Omacor (omega-3-acid ethyl esters) FDA Approval History"
},{
  "title": "Tarceva (erlotinib)  Tablets ",
  "date_of_approval": "November 18, 2004",
  "company": " OSI/Genentech",
  "treatment": " Non-Small Cell Lung Cancer, Pancreatic Cancer",
  "drug_description": "Tarceva (erlotinib) is a kinase inhibitor indicated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) and for the treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine.",
  "previous application": "FDA Approves Tarceva (erlotinib) for Non-Small Cell Lung Cancer (NSCLC) Tarceva (erlotinib) FDA Approval History"
},{
  "title": "VESIcare (solifenacin succinate)  Tablets ",
  "date_of_approval": "November 19, 2004",
  "company": " Astellas Pharma Inc.",
  "treatment": " Overactive Bladder Syndrome",
  "drug_description": "VESIcare (solifenacin) is a muscarinic receptor antagonist for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults. VESIcare LS is an oral suspension formulation of solifenacin for the treatment of\r neurogenic detrusor overactivity in pediatric patients aged 2 years and older.",
  "previous application": "FDA Approves Vesicare (solifenacin succinate) for the Treatment of Overactive Bladder VESIcare (solifenacin succinate) FDA Approval History"
},{
  "title": "Tysabri (natalizumab)  Injection  - formerly Antegren",
  "date_of_approval": "November 23, 2004",
  "company": " Biogen Idec / Elan Corporation, plc",
  "treatment": " Multiple Sclerosis, Crohn's Disease -- Maintenance",
  "drug_description": "Tysabri (natalizumab) is a recombinant humanized IgG4\u03ba monoclonal antibody for the treatment of multiple sclerosis and Crohn's disease.",
  "previous application": "Tysabri Approved for Multiple Sclerosis Tysabri (natalizumab) FDA Approval History"
},{
  "title": "Combunox (ibuprofen and oxycodone hydrochloride)  Tablets ",
  "date_of_approval": "November 26, 2004",
  "company": " Forest Laboratories, Inc.",
  "treatment": " Pain",
  "drug_description": "",
  "previous application": "Combunox Forest Laboratories, Inc. - Treatment for Moderate to Severe Pain Combunox (ibuprofen and oxycodone hydrochloride) FDA Approval History"
},{
  "title": "Antara (fenofibrate)  Capsules ",
  "date_of_approval": "November 30, 2004",
  "company": " Reliant Pharmaceuticals, Inc.",
  "treatment": " Hypertriglyceridemia, Heterozygous Familial Hypercholesterolemia",
  "drug_description": "Antara (fenofibrate) is a lipid-lowering agent approved as adjunctive therapy to diet for the treatment of elevated levels of cholesterol and triglycerides.",
  "previous application": "Antara Reliant Pharmaceuticals, Inc. - Treatment for Hypercholesterolemia and Hypertriglyceridemia Antara (fenofibrate) FDA Approval History"
},{
  "title": "Clindesse (clindamycin phosphate)  Vaginal Cream ",
  "date_of_approval": "November 30, 2004",
  "company": " KV Pharmaceutical Company",
  "treatment": " Bacterial Vaginosis",
  "drug_description": "Clindesse (clindamycin) Vaginal Cream is a single-dose topical antibiotic\r therapy indicated to treat bacterial vaginosis.",
  "previous application": "Clindesse KV Pharmaceutical Company - Treatment for Bacterial Vaginosis Clindesse (clindamycin phosphate) FDA Approval History"
},{
  "title": "Captique (dermal filler)  Injectable Gel ",
  "date_of_approval": "November 12, 2004",
  "company": " Inamed Corp / Genzyme Corp",
  "treatment": " Wrinkle Correction",
  "drug_description": "Captique is a non-animal stabilized hyaluronic acid dermal filler\r indicated for the correction of moderate to severe facial wrinkles.",
  "previous application": "Captique Inamed Corp / Genzyme Corp - Treatment for Facial Wrinkle Correction Captique (dermal filler) FDA Approval History"
},{
  "title": "Equetro (carbamazepine)  Extended-Release Capsules ",
  "date_of_approval": "December 10, 2004",
  "company": " Shire Pharmaceuticals Group plc",
  "treatment": " Bipolar Disorder",
  "drug_description": "Equetro (carbamazepine) is an extended-release anticonvulsant indicated for the treatment of acute manic and mixed episodes associated with Bipolar I Disorder.",
  "previous application": "Equetro Shire Pharmaceuticals Group plc - Treatment for Bipolar Disorder Equetro (carbamazepine) FDA Approval History"
},{
  "title": "Zylet (loteprednol and tobramycin)  Ophthalmic Suspension ",
  "date_of_approval": "December 14, 2004",
  "company": " Bausch &amp; Lomb",
  "treatment": " Uveitis, Iritis, Bacterial Conjunctivitis, Keratitis, Cyclitis",
  "drug_description": "Zylet (loteprednol etabonate and tobramycin ophthalmic suspension) a topical\r anti-inflammatory corticosteroid and antibiotic combination for use in the treatment of inflammatory ocular conditions.",
  "previous application": "Zylet Bausch & Lomb - Treatment for Inflammatory Ocular Conditions Zylet (loteprednol and tobramycin) FDA Approval History"
},{
  "title": "Lunesta (eszopiclone)  Tablets  - formerly Estorra",
  "date_of_approval": "December 15, 2004",
  "company": " Sepracor Inc.",
  "treatment": " Insomnia",
  "drug_description": "Lunesta (eszopiclone) is a nonbenzodiazepine\r hypnotic agent indicated for the treatment of patients who\r experience difficulty falling asleep as well as for the treatment\r of patients who are unable to sleep through the night (sleep\r maintenance difficulty).",
  "previous application": "Lunesta Sepracor Inc. - Treatment for Insomnia Lunesta (eszopiclone) FDA Approval History"
},{
  "title": "Kepivance (palifermin)  Injection ",
  "date_of_approval": "December 15, 2004",
  "company": " Amgen Inc.",
  "treatment": " Mucositis",
  "drug_description": "Kepivance (palifermin) is a recombinant human keratinocyte growth factor\r indicated to decrease the incidence and duration of severe oral\r mucositis.",
  "previous application": "Kepivance Amgen Inc. - Treatment for Severe Oral Mucositis in Cancer Patients Kepivance (palifermin) FDA Approval History"
},{
  "title": "Macugen (pegaptanib)  Ophthalmic Injection ",
  "date_of_approval": "December 17, 2004",
  "company": " Eyetech / Pfizer Inc",
  "treatment": " Macular Degeneration",
  "drug_description": "Macugen (pegaptanib) is a selective vascular endothelial growth factor (VEGF)\r antagonist indicated for the treatment of neovascular (wet)\r age-related macular degeneration (AMD), an eye disease associated\r with aging that destroys central vision.",
  "previous application": "Macugen Eyetech / Pfizer Inc - Treatment for Neovascular (Wet) Age-Related Macular Degeneration Macugen (pegaptanib) FDA Approval History"
},{
  "title": "depo-subQ provera 104 (medroxyprogesterone acetate)  Injection ",
  "date_of_approval": "December 17, 2004",
  "company": " Pfizer Inc.",
  "treatment": " Contraception",
  "drug_description": "depo-subQ provera 104 (medroxyprogesterone acetate) is a lower dose,\r subcutaneous formulation of Depo Provera indicated for the\r prevention of pregnancy in women of child bearing potential.",
  "previous application": "depo-subQ provera 104 Pfizer Inc. - Treatment for Prevention of Pregnancy depo-subQ provera 104 (medroxyprogesterone acetate) FDA Approval History"
},{
  "title": "Enablex (darifenacin)  Extended-Release Tablets ",
  "date_of_approval": "December 22, 2004",
  "company": " Allergan, Inc.",
  "treatment": " Overactive Bladder",
  "drug_description": "Enablex (darifenacin) is a muscarinic receptor antagonist indicated for\r the treatment of overactive bladder.",
  "previous application": "Enablex Novartis Pharmaceuticals Corporation - Treatment for Overactive Bladder Enablex (darifenacin) FDA Approval History"
},{
  "title": "Clolar (clofarabine)  for Intravenous Infusion ",
  "date_of_approval": "December 28, 2004",
  "company": " Genzyme Corp.",
  "treatment": " Acute Lymphoblastic Leukemia",
  "drug_description": "Clolar (clofarabine) is a purine nucleoside anti-metabolite indicated for the\r treatment of children with refractory or relapsed acute\r lymphoblastic leukemia (ALL).",
  "previous application": "Clolar Genzyme Corp. - Treatment for Leukemia in Children Clolar (clofarabine) FDA Approval History"
},{
  "title": "Prialt (ziconotide)  Intrathecal Infusion ",
  "date_of_approval": "December 28, 2004",
  "company": " Elan Corporation, plc",
  "treatment": " Pain",
  "drug_description": "Prialt (ziconotide) is a non-opioid intrathecal (IT) therapy indicated for the management of severe chronic pain in patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies, or IT morphine.",
  "previous application": "Prialt Elan Corporation, plc - Treatment for Severe Chronic Pain Prialt (ziconotide) FDA Approval History"
},{
  "title": "Ventavis (iloprost)  Inhalation Solution ",
  "date_of_approval": "December 29, 2004",
  "company": " CoTherix, Inc.",
  "treatment": " Pulmonary Hypertension",
  "drug_description": "Ventavis (iloprost) inhalation solution is synthetic analogue of prostacyclin PGIB2B indicated for the treatment of pulmonary arterial hypertension.",
  "previous application": "Ventavis CoTherix, Inc. - Treatment for Pulmonary Arterial Hypertension Ventavis (iloprost) FDA Approval History"
},{
  "title": "Lyrica (pregabalin)  Capsules ",
  "date_of_approval": "December 30, 2004",
  "company": " Pfizer Inc.",
  "treatment": " Neuropathic Pain, Postherpetic Neuralgia, Fibromyalgia, Diabetic Neuropathy, Epilepsy",
  "drug_description": "Lyrica (pregabalin) is a structural derivative of the inhibitory neurotransmitter gamma aminobutyric acid indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia and spinal cord injury; as an adjunctive therapy for partial onset seizures and for the treatment of fibromyalgia.",
  "previous application": "Lyrica Pfizer Inc. - Treatment for Neuropathic Pain Lyrica (pregabalin) FDA Approval History"
},{
  "title": "Abraxane (paclitaxel protein-bound)  for Injectable Suspension ",
  "date_of_approval": "January 7, 2005",
  "company": " American Pharmaceutical Partners, Inc. / American Bioscience, Inc.",
  "treatment": " Breast Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer",
  "drug_description": "Abraxane (paclitaxel protein-bound) is an albumin-bound form of the antineoplastic agent paclitaxel indicated for the treatment of breast cancer, non-small cell lung cancer, and pancreatic cancer.",
  "previous application": "Abraxane American Pharmaceutical Partners, Inc. / American Bioscience, Inc. - Treatment for Metastatic Breast Cancer Abraxane (paclitaxel protein-bound) FDA Approval History"
},{
  "title": "ThyroShield (potassium iodide)  Oral Solution ",
  "date_of_approval": "January 12, 2005",
  "company": " Fleming &amp; Company",
  "treatment": " Radiation Emergency",
  "drug_description": "ThyroShield (potassium iodide) is used to protect the thyroid gland from the effects of radiation from inhaled or swallowed radioactive iodine.",
  "previous application": "ThyroShield Fleming & Company - Treatment for Thyroid Protection in a Radiation Emergency ThyroShield (potassium iodide) FDA Approval History"
},{
  "title": "Menactra (meningococcal conjugate vaccine) ",
  "date_of_approval": "January 14, 2005",
  "company": " Sanofi Pasteur",
  "treatment": " Meningococcal Meningitis Prophylaxis",
  "drug_description": "Menactra (meningococcal conjugate vaccine) is a quadrivalent conjugate vaccine indicated for the prevention of meningococcal disease.",
  "previous application": "Menactra Sanofi Pasteur - Treatment for Protection Against Meningococcal Disease Menactra (meningococcal conjugate vaccine) FDA Approval History"
},{
  "title": "Niravam (alprazolam)  Orally Disintegrating Tablets ",
  "date_of_approval": "January 19, 2005",
  "company": "NONE",
  "treatment": " Anxiety, Panic Disorder",
  "drug_description": "",
  "previous application": "Niravam Schwarz Pharma AG - Treatment for Anxiety Disorders Niravam (alprazolam) FDA Approval History"
},{
  "title": "Vanos (fluocinonide)  Cream ",
  "date_of_approval": "February 11, 2005",
  "company": " Medicis",
  "treatment": " Psoriasis, Atopic Dermatitis, Dermatitis",
  "drug_description": "Vanos (fluocinonide) is a corticosteroid (steroid hormone) approved to relieve the inflammation and itching caused by certain skin conditions that respond to treatment with corticosteroids in patients 12 years of age or older.",
  "previous application": "Vanos Medicis - Treatment for Plaque-Type Psoriasis Vanos (fluocinonide) FDA Approval History"
},{
  "title": "Ammonul (sodium benzoate and sodium phenylacetate)  Injection ",
  "date_of_approval": "February 17, 2005",
  "company": " Medicis",
  "treatment": " Hyperammonemia",
  "drug_description": "Ammonul (sodium benzoate and sodium phenylacetate) is indicated as an adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle.",
  "previous application": "Ammonul Medicis - Treatment for Urea Cycle Disorder Ammonul (sodium benzoate and sodium phenylacetate) FDA Approval History"
},{
  "title": "Clarinex-D 24 Hour (desloratadine and pseudoephedrine sulfate)  ER Tablets ",
  "date_of_approval": "March 3, 2005",
  "company": " Schering-Plough Corporation",
  "treatment": " Allergic Rhinitis",
  "drug_description": "Clarinex-D 24 Hour (desloratadine and pseudoephedrine sulfate) is a once-daily antihistamine and decongestant for the relief of the symptoms of seasonal allergic rhinitis.",
  "previous application": "Clarinex-D 24 Hour Schering-Plough Corporation - Treatment for Symptoms of Seasonal Allergic Rhinitis Clarinex-D 24 Hour (desloratadine and pseudoephedrine sulfate) FDA Approval History"
},{
  "title": "Mycamine (micafungin sodium)  for Injection ",
  "date_of_approval": "March 16, 2005",
  "company": " Astellas Pharma Inc.",
  "treatment": " Esophageal Candidiasis, Fungal Infection Prophylaxis, Candidemia",
  "drug_description": "Mycamine (micafungin sodium) is an echinocandin antifungal agent indicated for the treatment of candidemia, acute disseminated candidiasis, candida peritonitis and abscesses, esophageal candidiasis, and for the prevention of candida Infections in patients undergoing Hematopoietic  Stem Cell Transplantation (HSCT).",
  "previous application": "Mycamine Approved for Candida Infections Mycamine (micafungin sodium) FDA Approval History"
},{
  "title": "Symlin (pramlintide acetate)  Injection ",
  "date_of_approval": "March 16, 2005",
  "company": " Amylin Pharmaceuticals, Inc.",
  "treatment": " Diabetes Type 1, Diabetes Type 2",
  "drug_description": "Symlin (pramlintide acetate) is an antihyperglycemic drug for use in patients\r with diabetes treated with insulin.",
  "previous application": "Symlin Amylin Pharmaceuticals, Inc. - Treatment for Diabetes in conjunction with insulin Symlin (pramlintide acetate) FDA Approval History"
},{
  "title": "Xibrom (bromfenac)  Ophthalmic Solution ",
  "date_of_approval": "March 24, 2005",
  "company": " ISTA Pharmaceuticals, Inc.",
  "treatment": " Postoperative Ocular Inflammation",
  "drug_description": "",
  "previous application": "Xibrom ISTA Pharmaceuticals, Inc. - Treatment for Ocular Inflammation Following Cataract Surgery Xibrom (bromfenac) FDA Approval History"
},{
  "title": "Baraclude (entecavir)  Tablets / Oral Solution ",
  "date_of_approval": "March 29, 2005",
  "company": " Bristol-Myers Squibb Company",
  "treatment": " Chronic Hepatitis B",
  "drug_description": "Baraclude (entecavir) is a nucleoside analogue oral antiviral therapy for the treatment of chronic hepatitis B in adults.",
  "previous application": "Baraclude Bristol-Myers Squibb Company - Treatment for Chronic Hepatitis B Baraclude (entecavir) FDA Approval History"
},{
  "title": "Asmanex (mometasone furoate)  Inhalation Powder ",
  "date_of_approval": "March 30, 2005",
  "company": " Schering-Plough Corporation",
  "treatment": " Asthma",
  "drug_description": "Asmanex Twisthaler (mometasone furoate) is an inhaled corticosteroid for the treatment of asthma.",
  "previous application": "FDA Approves Asmanex Twisthaler for Asthma Asmanex (mometasone furoate) FDA Approval History"
},{
  "title": "Xibrom (bromfenac)  Ophthalmic Solution ",
  "date_of_approval": "March 24, 2005",
  "company": " ISTA Pharmaceuticals, Inc.",
  "treatment": " Postoperative Ocular Inflammation",
  "drug_description": "",
  "previous application": "Xibrom - ISTA Pharmaceuticals, Inc. - New Indication Approved Xibrom (bromfenac) FDA Approval History"
},{
  "title": "Fosamax Plus D (alendronate and cholecalciferol)  Tablets ",
  "date_of_approval": "April 7, 2005",
  "company": " Merck &amp; Co., Inc.",
  "treatment": " Osteoporosis",
  "drug_description": "Fosamax Plus D is a single once-weekly tablet containing the\r bisphosphonate drug alendronate, and seven days\u2019 worth of\r vitamin D, an essential nutrient required for calcium absorption.\r Fosamax Plus D is used to reduce the risk of hip and spinal\r fractures in postmenopausal women with osteoporosis, and to\r increase bone mass in men with osteoporosis.",
  "previous application": "Fosamax Plus D Merck & Co., Inc. - Treatment for Osteoporosis Fosamax Plus D (alendronate and cholecalciferol) FDA Approval History"
},{
  "title": "Retisert (fluocinolone acetonide)  Intravitreal Implant ",
  "date_of_approval": "April 8, 2005",
  "company": " Bausch &amp; Lomb",
  "treatment": " Uveitis",
  "drug_description": "Retisert (fluocinolone acetonide) intravitreal implant is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.",
  "previous application": "Retisert Bausch & Lomb - Treatment for Chronic Non-Infectious Uveitis Retisert (fluocinolone acetonide) FDA Approval History"
},{
  "title": "Byetta (exenatide)  Injection ",
  "date_of_approval": "April 28, 2005",
  "company": " Amylin Pharmaceuticals / Eli Lilly &amp; Co.",
  "treatment": " Diabetes Type 2",
  "drug_description": "Byetta (exenatide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type\r 2 diabetes mellitus.",
  "previous application": "Byetta Amylin Pharmaceuticals / Eli Lilly & Co. - Treatment for Type 2 Diabetes Byetta (exenatide) FDA Approval History"
},{
  "title": "Vaccinia (vaccinia immune globulin intravenous (human))  Injection ",
  "date_of_approval": "May 2, 2005",
  "company": " DynPort Vaccine Company LLC",
  "treatment": " Smallpox Vaccine Reaction",
  "drug_description": "Vaccinia Immune Globulin Intravenous (Human) (VIGIV) indicated for the treatment of complications from smallpox vaccination",
  "previous application": "Vaccinia DynPort Vaccine Company LLC - Treatment for Complications of Smallpox Vaccination Vaccinia (vaccinia immune globulin intravenous (human)) FDA Approval History"
},{
  "title": "Gammagard Liquid (immune globulin infusion (human))  Solution ",
  "date_of_approval": "May 2, 2005",
  "company": " Baxter Healthcare Corporation",
  "treatment": " Primary Immunodeficiency Syndrome",
  "drug_description": "Gammagard (immune globulin infusion (human)) is an immune globulin infusion (human) indicated as replacement therapy for primary humoral immunodeficiency (PI) in adult and \r pediatric patients two years of age or older.",
  "previous application": "Gammagard Liquid Baxter Healthcare Corporation - Treatment for Primary Immunodeficiency Disorders Gammagard Liquid (immune globulin infusion (human)) FDA Approval History"
},{
  "title": "Boostrix (tetanus, diphtheria, acellular pertussis vaccine (Tdap)) ",
  "date_of_approval": "May 3, 2005",
  "company": " GlaxoSmithKline Biologicals",
  "treatment": " Diphtheria Prophylaxis, Tetanus Prophylaxis, Pertussis Prophylaxis",
  "drug_description": "Boostrix is a combination vaccine that provides a booster immunization against pertussis (whooping cough) in combination with tetanus and diphtheria.",
  "previous application": "Boostrix GlaxoSmithKline Biologicals - Treatment for Prevention of Diphtheria, Tetanus & Pertussis in Adolescents Boostrix (tetanus, diphtheria, acellular pertussis vaccine (Tdap)) FDA Approval History"
},{
  "title": "Triglide (fenofibrate)  Tablets ",
  "date_of_approval": "May 7, 2005",
  "company": " SkyePharma PLC",
  "treatment": " Hyperlipoproteinemia, Hyperlipoproteinemia Type IIa (Elevated LDL), Hyperlipoproteinemia Type IIb (Elevated LDL + VLDL), Hyperlipoproteinemia Type IV (Elevated VLDL), Hyperlipoproteinemia Type V (Elevated Chylomicrons + VLDL), Hypertriglyceridemia",
  "drug_description": "Triglide (fenofibrate) is a lipid-regulating agent for the treatment of hypercholesterolemia and hypertriglyceridemia.",
  "previous application": "Triglide SkyePharma PLC - Treatment for Lipid Disorders Triglide (fenofibrate) FDA Approval History"
},{
  "title": "Proquin XR (ciprofloxacin)  Extended-Release Tablets ",
  "date_of_approval": "May 19, 2005",
  "company": " Depomed, Inc.",
  "treatment": " Urinary Tract Infection",
  "drug_description": "",
  "previous application": "Proquin XR Depomed, Inc. - Treatment for Uncomplicated Urinary Tract Infections Proquin XR (ciprofloxacin) FDA Approval History"
},{
  "title": "Focalin XR (dexmethylphenidate)  Extended-Release Capsules ",
  "date_of_approval": "May 26, 2005",
  "company": " Novartis Pharmaceuticals Corporation",
  "treatment": " Attention Deficit Disorder",
  "drug_description": "Focalin XR (dexmethylphenidate) is a once-daily extended-release form of Focalin\r indicated for the treatment of Attention-Deficit/Hyperactivity\r Disorder (ADHD) in adults, adolescents and children.",
  "previous application": "Focalin XR Novartis Pharmaceuticals Corporation - Treatment for Attention-Deficit/Hyperactivity Disorder (ADHD) Focalin XR (dexmethylphenidate) FDA Approval History"
},{
  "title": "Naglazyme (galsulfase)  - formerly Aryplase",
  "date_of_approval": "May 31, 2005",
  "company": " BioMarin Pharmaceutical Inc.",
  "treatment": " Mucopolysaccharidosis Type VI",
  "drug_description": "Naglazyme (galsulfase) is an enzyme-replacement therapy for\r treatment of mucopolysaccharidosis VI (MPS VI), an inherited,\r life-threatening lysosomal storage disorder caused by a deficiency\r of the lysosomal enzyme N-acetylgalactosamine 4-sulfatase (also\r known as arylsulfatase B).",
  "previous application": "Naglazyme BioMarin Pharmaceutical Inc. - Treatment for Mucopolysaccharidosis VI (MPS VI) Naglazyme (galsulfase) FDA Approval History"
},{
  "title": "Revatio (sildenafil citrate) ",
  "date_of_approval": "June 3, 2005",
  "company": " Pfizer Inc.",
  "treatment": " Pulmonary Hypertension",
  "drug_description": "Revatio (sildenafil) is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of pulmonary arterial hypertension.",
  "previous application": "Revatio Pfizer Inc. - Treatment for Pulmonary Arterial Hypertension Revatio (sildenafil citrate) FDA Approval History"
},{
  "title": "Glumetza (metformin extended release)  Tablets ",
  "date_of_approval": "June 3, 2005",
  "company": " Biovail Corporation/Depomed, Inc.",
  "treatment": " Diabetes Type 2",
  "drug_description": "Glumetza (metformin extended-release) is a once-daily oral antihyperglycemic formulation indicated for the treatment of type 2 diabetes.",
  "previous application": "FDA Approves Glumetza for Type 2 Diabetes Glumetza (metformin extended release) FDA Approval History"
},{
  "title": "Adacel (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap)) ",
  "date_of_approval": "June 10, 2005",
  "company": " Aventis Pasteur Limited",
  "treatment": " Tetanus Prophylaxis, Diphtheria Prophylaxis, Pertussis Prophylaxis",
  "drug_description": "Adacel (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap)) is indicated for active booster immunization for the prevention of tetanus, diphtheria and pertussis.",
  "previous application": "U.S. FDA Licenses sanofi pasteur\u2019s Adacel Vaccine for Combined Protection Against Tetanus, Diphtheria and Pertussis  Adacel (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap)) FDA Approval History"
},{
  "title": "Tygacil (tigecycline)  Injection ",
  "date_of_approval": "June 15, 2005",
  "company": " Wyeth Pharmaceuticals",
  "treatment": " Skin and Structure Infection, Intraabdominal Infection, Pneumonia",
  "drug_description": "Tygacil (tigecycline) is a glycylcycline antibacterial indicated for the treatment of \r complicated skin and skin structure infections, complicated intra-abdominal infections and community-acquired bacterial pneumonia in adults.",
  "previous application": "Tygacil Wyeth Pharmaceuticals - Treatment for Complicated Skin and Intra-abdominal Infections Tygacil (tigecycline) FDA Approval History"
},{
  "title": "Levemir (insulin detemir )  Injection ",
  "date_of_approval": "June 16, 2005",
  "company": " Novo Nordisk Inc.",
  "treatment": " Diabetes Type 1, Diabetes Type 2",
  "drug_description": "Levemir (insulin detemir) is a novel, long- acting form of insulin that provides up\r to a 24-hour duration of action for the treatment of diabetes\r mellitus (type 1 and type 2).",
  "previous application": "Levemir Novo Nordisk Inc. - Treatment for Diabetes Mellitus (Type 1 and Type 2) Levemir (insulin detemir ) FDA Approval History"
},{
  "title": "Aptivus (tipranavir)  Capsules ",
  "date_of_approval": "June 22, 2005",
  "company": " Boehringer Ingelheim",
  "treatment": " HIV Infection",
  "drug_description": "Aptivus (tipranavir) is a non-peptidic protease inhibitor which is co-administered with ritonavir for the treatment of HIV Infection.",
  "previous application": "FDA Approves Aptivus for HIV Infection Aptivus (tipranavir) FDA Approval History"
},{
  "title": "Synera (lidocaine and tetracaine)  Topical Patch  - formerly S-Caine Patch",
  "date_of_approval": "June 23, 2005",
  "company": " ZARS, Inc.",
  "treatment": " Local Anesthesia",
  "drug_description": "Synera (lidocaine and tetracaine) is a local anesthetic patch indicated for use on intact skin to provide local dermal\r analgesia before certain medical procedures",
  "previous application": "Synera ZARS, Inc. - Treatment for Topical Anesthesia Synera (lidocaine and tetracaine) FDA Approval History"
},{
  "title": "BiDil (isosorbide dinitrate and hydralazine)  Tablets ",
  "date_of_approval": "June 23, 2005",
  "company": " NitroMed, Inc.",
  "treatment": " Congestive Heart Failure",
  "drug_description": "BiDil is a fixed-dose combination of isosorbide dinitrate (a vasodilator) and hydralazine hydrochloride (an arterial dilator) indicated for the treatment of heart failure in black patients.",
  "previous application": "BiDil NitroMed, Inc. - Treatment for Heart Failure in Black Patients BiDil (isosorbide dinitrate and hydralazine) FDA Approval History"
},{
  "title": "Aptivus (tipranavir)  Capsules ",
  "date_of_approval": "June 22, 2005",
  "company": " Boehringer Ingelheim",
  "treatment": " HIV Infection",
  "drug_description": "Aptivus (tipranavir) is a non-peptidic protease inhibitor which is co-administered with ritonavir for the treatment of HIV Infection.",
  "previous application": "Aptivus (tipranavir) Capsules Granted Full Approval by the U.S. FDA Aptivus (tipranavir) FDA Approval History"
},{
  "title": "Adacel (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap)) ",
  "date_of_approval": "June 10, 2005",
  "company": " Aventis Pasteur Limited",
  "treatment": " Tetanus Prophylaxis, Diphtheria Prophylaxis, Pertussis Prophylaxis",
  "drug_description": "Adacel (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap)) is indicated for active booster immunization for the prevention of tetanus, diphtheria and pertussis.",
  "previous application": "Sanofi Pasteur Announces FDA Has Expanded Age Indication of Adacel Tdap Vaccine to Include Persons 10 Years of Age Adacel (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap)) FDA Approval History"
},{
  "title": "Rozerem (ramelteon)  Tablets ",
  "date_of_approval": "July 22, 2005",
  "company": " Takeda Pharmaceuticals North America, Inc.",
  "treatment": " Insomnia",
  "drug_description": "Rozerem (ramelteon) is an orally active hypnotic indicated for the treatment of insomnia characterized by difficulty with sleep onset.",
  "previous application": "Rozerem Takeda Pharmaceuticals North America, Inc. - Treatment for Insomnia Rozerem (ramelteon) FDA Approval History"
},{
  "title": "Fortical (calcitonin)  Nasal Spray ",
  "date_of_approval": "August 12, 2005",
  "company": " Unigene / Upsher-Smith Laboratories, Inc.",
  "treatment": " Osteoporosis",
  "drug_description": "",
  "previous application": "Fortical Unigene / Upsher-Smith Laboratories, Inc. - Treatment for Postmenopausal Osteoporosis Fortical (calcitonin) FDA Approval History"
},{
  "title": "Actonel with Calcium (risedronate sodium and calcium carbonate) ",
  "date_of_approval": "August 12, 2005",
  "company": " Procter &amp; Gamble Pharmaceuticals, Inc.",
  "treatment": " Osteoporosis",
  "drug_description": "",
  "previous application": "Actonel with Calcium Procter & Gamble Pharmaceuticals, Inc. - Treatment for Postmenopausal Osteoporosis Actonel with Calcium (risedronate sodium and calcium carbonate) FDA Approval History"
},{
  "title": "Nevanac (nepafenac)  Ophthalmic Suspension ",
  "date_of_approval": "August 19, 2005",
  "company": " Alcon, Inc.",
  "treatment": " Postoperative Ocular Inflammation",
  "drug_description": "Nevanac (nepafenac) is a topical nonsteroidal anti-inflammatory (NSAID) and\r analgesic prodrug indicated for the treatment of pain and\r inflammation associated with cataract surgery.",
  "previous application": "Nevanac Alcon, Inc. - Treatment for Pain and Inflammation Associated with Cataract Surgery Nevanac (nepafenac) FDA Approval History"
},{
  "title": "ACTOplus met (pioglitazone and metformin)  Tablets ",
  "date_of_approval": "August 29, 2005",
  "company": " Takeda Pharmaceuticals",
  "treatment": " Diabetes Type 2",
  "drug_description": "Actoplus met (pioglitazone and metformin) is a combination antihyperglycemic medication used in the management of type 2 diabetes.",
  "previous application": "ACTOplus met Takeda Pharmaceuticals - Treatment for Type 2 Diabetes ACTOplus met (pioglitazone and metformin) FDA Approval History"
},{
  "title": "Increlex (mecasermin)  Injection ",
  "date_of_approval": "August 30, 2005",
  "company": " Tercica, Inc.",
  "treatment": " Primary IGF-1 Deficiency",
  "drug_description": "Increlex (mecasermin)  contains human insulin-like growth factor-1 (rhIGF-1)\r produced by recombinant DNA technology. Increlex is indicated for\r the long-term treatment of growth failure in children with severe\r primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH)\r gene deletion who have developed neutralizing antibodies to growth\r hormone.",
  "previous application": "Increlex Tercica, Inc. - Treatment for Short Stature Caused by Primary IGF-1 Deficiency Increlex (mecasermin) FDA Approval History"
},{
  "title": "ProQuad (measles, mumps, rubella and varicella virus vaccine, live)  Injection ",
  "date_of_approval": "September 6, 2005",
  "company": " Merck &amp; Co., Inc.",
  "treatment": " Mumps Prophylaxis, Measles Prophylaxis, Rubella Prophylaxis, Varicella-Zoster -- Prophylaxis",
  "drug_description": "ProQuad (measles, mumps, rubella and varicella virus vaccine, live) is a vaccine indicated for active immunization for the\r prevention of measles, mumps, rubella, and varicella in children 12\r months through 12 years of age.",
  "previous application": "Proquad Merck & Co., Inc. - Treatment for Measles, Mumps, Rubella and Varicella Vaccination ProQuad (measles, mumps, rubella and varicella virus vaccine, live) FDA Approval History"
},{
  "title": "Angeliq (drospirenone and estradiol)  Tablets ",
  "date_of_approval": "September 28, 2005",
  "company": " Berlex, Inc.",
  "treatment": " Postmenopausal Symptoms",
  "drug_description": "Angeliq is a hormone replacement therapy containing estradiol and the progestin drospirenone, a hormone that counters the excess water and sodium buildup that is a side effect of estradiol. Angeliq is used to treat moderate to severe menopausal symptoms, such as hot flashes and vaginal dryness.",
  "previous application": "Angeliq Berlex, Inc. - Treatment for Menopausal Symptoms Angeliq (drospirenone and estradiol) FDA Approval History"
},{
  "title": "Flexbumin (albumin human)  Solution ",
  "date_of_approval": "October 17, 2005",
  "company": " Baxter Healthcare Corporation",
  "treatment": " Plasma Volume Expansion",
  "drug_description": "Flexbumin (albumin human) is the first human serum albumin preparation packaged in\r a flexible container (previously packaged in glass bottles).\r Flexbumin is indicated in hypovolemia, hypoalbuminemia due to\r inadequate reproduction, excessive catabolism, hemorrhage, major\r surgery or burns, and for use during cardiopulmonary bypass\r surgery.",
  "previous application": "Flexbumin Baxter Healthcare Corporation - Treatment for Plasma Volume Expansion Flexbumin (albumin human) FDA Approval History"
},{
  "title": "Arranon (nelarabine)  Injection ",
  "date_of_approval": "October 28, 2005",
  "company": " GlaxoSmithKline",
  "treatment": " Acute Lymphoblastic Leukemia, Lymphoma",
  "drug_description": "Arranon (nelarabine) is a chemotherapy agent indicated for the treatment of adults and children with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.",
  "previous application": "Arranon GlaxoSmithKline - Treatment for Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Arranon (nelarabine) FDA Approval History"
},{
  "title": "Soltamox (tamoxifen)  Oral Solution ",
  "date_of_approval": "October 29, 2005",
  "company": " Savient Pharmaceuticals, Inc.",
  "treatment": " Breast Cancer",
  "drug_description": "Soltamox is an oral liquid formulation of tamoxifen indicated for the treatment of breast cancer.",
  "previous application": "Soltamox Savient Pharmaceuticals, Inc. - Treatment for Breast Cancer Soltamox (tamoxifen) FDA Approval History"
},{
  "title": "Exjade (deferasirox)  Dispersible Tablets ",
  "date_of_approval": "November 2, 2005",
  "company": " Novartis",
  "treatment": " Hemosiderosis, Iron Overload",
  "drug_description": "Exjade (deferasirox) is a once-daily oral iron chelator approved for the\r treatment of chronic iron overload due to blood transfusions, and non-transfusion-dependent thalassemia.",
  "previous application": "Exjade Novartis - Treatment for Chronic Iron Overload Due to Blood Transfusions Exjade (deferasirox) FDA Approval History"
},{
  "title": "Hylenex (hyaluronidase)  Injection  - formerly Enhanze SC",
  "date_of_approval": "December 2, 2005",
  "company": " Halozyme Therapeutics/Baxter Healthcare Corporation",
  "treatment": " Adjuvant Agent to Enhance Drug Delivery",
  "drug_description": "Hylenex recombinant is a purified preparation of the enzyme\r recombinant human hyaluronidase, indicated for use as an adjuvant\r agent to increase the absorption and dispersion of other injected\r drugs, for hypodermoclysis, and as an adjunct in subcutaneous\r urography for improving resorption of radiopaque agents.",
  "previous application": "Hylenex Halozyme Therapeutics/Baxter Healthcare Corporation - Treatment for Adjuvant Agent to Enhance Drug Delivery Hylenex (hyaluronidase) FDA Approval History"
},{
  "title": "iPlex (mecasermin rinfabate [rDNA origin])  Injection  - formerly SomatoKine",
  "date_of_approval": "December 12, 2005",
  "company": " Insmed Incorporated",
  "treatment": " Primary IGF-1 Deficiency",
  "drug_description": "iPlex (mecasermin rinfabate) is the human recombinant of the naturally occurring protein complex of insulin-like growth factor-I (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3). iPlex is indicated for the treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH.",
  "previous application": "iPlex Insmed Incorporated - Treatment for Severe Primary IGF-1 Deficiency iPlex (mecasermin rinfabate [rDNA origin]) FDA Approval History"
},{
  "title": "Nexavar (sorafenib)  Tablets ",
  "date_of_approval": "December 20, 2005",
  "company": " Bayer Pharmaceuticals Corporation",
  "treatment": " Renal Cell Carcinoma, Hepatocellular Carcinoma, Thyroid Cancer",
  "drug_description": "Nexavar (sorafenib) is an oral multi-kinase inhibitor indicated for the\r treatment of hepatocellular carcinoma, renal cell carcinoma, and thyroid carcinoma.",
  "previous application": "FDA Approves Nexavar (sorafenib) for Advanced Renal Cell Carcinoma Nexavar (sorafenib) FDA Approval History"
},{
  "title": "Orencia (abatacept)  Injection ",
  "date_of_approval": "December 23, 2005",
  "company": " Bristol-Myers Squibb Company",
  "treatment": " Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis",
  "drug_description": "Orencia (abatacept) is a selective T cell costimulation modulator indicated for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis and psoriatic arthritis.",
  "previous application": "Orencia Bristol-Myers Squibb Company - Treatment for Rheumatoid Arthritis Orencia (abatacept) FDA Approval History"
},{
  "title": "Revlimid (lenalidomide)  Capsules ",
  "date_of_approval": "December 27, 2005",
  "company": " Celgene Corporation",
  "treatment": " Myelodysplastic Syndrome, Multiple Myeloma, Lymphoma, Follicular Lymphoma",
  "drug_description": "Revlimid (lenalidomide) is a thalidomide analogue indicated for the treatment of adult\r patients with:",
  "previous application": "FDA Grants Revlimid NDA Approval Revlimid (lenalidomide) FDA Approval History"
},{
  "title": "Vaprisol (conivaptan hydrochloride)  Injection ",
  "date_of_approval": "December 29, 2005",
  "company": " Astellas Pharma US, Inc.",
  "treatment": " Hyponatremia",
  "drug_description": "Vaprisol (conivaptan hydrochloride injection) is an arginine vasopressin antagonist for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.",
  "previous application": "Vaprisol Astellas Pharma US, Inc. - Treatment for Euvolemic Hyponatremia Vaprisol (conivaptan hydrochloride) FDA Approval History"
},{
  "title": "Revlimid (lenalidomide)  Capsules ",
  "date_of_approval": "December 27, 2005",
  "company": " Celgene Corporation",
  "treatment": " Myelodysplastic Syndrome, Multiple Myeloma, Lymphoma, Follicular Lymphoma",
  "drug_description": "Revlimid (lenalidomide) is a thalidomide analogue indicated for the treatment of adult\r patients with:",
  "previous application": "Revlimid in Combination With Dexamethasone sNDA Granted Approval By FDA for Treatment of Multiple Myeloma Revlimid (lenalidomide) FDA Approval History"
},{
  "title": "Vivaglobin (immune globulin subcutaneous (human)) ",
  "date_of_approval": "January 9, 2006",
  "company": " ZLB Behring",
  "treatment": " Primary Immunodeficiency Syndrome",
  "drug_description": "Vivaglobin is a pasteurized, polyvalent human normal immunoglobulin for subcutaneous infusion indicated for the treatment of patients with primary immune deficiency (PID).",
  "previous application": "Vivaglobin Approved - ZLB Behring - Treatment for Primary Immunodeficiencies Vivaglobin (immune globulin subcutaneous (human)) FDA Approval History"
},{
  "title": "Taclonex (calcipotriene and betamethasone dipropionate)  Ointment ",
  "date_of_approval": "January 9, 2006",
  "company": " LEO Pharma ",
  "treatment": " Psoriasis",
  "drug_description": "Taclonex is a topical ointment containing a combination of calcipotriene and betamethasone for the treatment of psoriasis vulgaris in adults.",
  "previous application": "FDA Approves Taclonex - Once Daily Therapy for Treatment of Psoriasis\r  Taclonex (calcipotriene and betamethasone dipropionate) FDA Approval History"
},{
  "title": "Sutent (sunitinib malate)  Capsules ",
  "date_of_approval": "January 26, 2006",
  "company": " Pfizer Inc.",
  "treatment": " Gastrointestinal Stromal Tumor, Renal Cell Carcinoma, Pancreatic Cancer",
  "drug_description": "Sutent (sunitinib malate) is an oral multi-kinase inhibitor indicated for the treatment of gastrointestinal stromal tumors, advanced renal cell carcinoma (RCC), adjuvant treatment of patients at high risk of recurrent RCC following nephrectomy, and the treatment of pancreatic neuroendocrine tumors.",
  "previous application": "FDA Approves Sutent for Gastrointestinal Stromal Tumors and Advanced Renal Cell Carcinoma Sutent (sunitinib malate) FDA Approval History"
},{
  "title": "Ranexa (ranolazine)  Extended-Release Tablets ",
  "date_of_approval": "January 27, 2006",
  "company": " CV Therapeutics, Inc.",
  "treatment": " Angina Pectoris",
  "drug_description": "Ranexa (ranolazine) is an antianginal and anti-ischemic agent indicated for the treatment of chronic angina.",
  "previous application": "Ranexa Approved - CV Therapeutics, Inc. - Treatment for Chronic Angina Ranexa (ranolazine) FDA Approval History"
},{
  "title": "Exubera (insulin inhalation)  Powder ",
  "date_of_approval": "January 27, 2006",
  "company": " Pfizer Inc.",
  "treatment": " Diabetes Type 1, Diabetes Type 2",
  "drug_description": "",
  "previous application": "Exubera Approved - Pfizer Inc - Treatment for Type 1 and Type 2 Diabetes in Adults Exubera (insulin inhalation) FDA Approval History"
},{
  "title": "HepaGam B (hepatitis B immune globulin) ",
  "date_of_approval": "January 30, 2006",
  "company": " Cangene",
  "treatment": " Exposure to Hepatitis B Virus",
  "drug_description": "HepaGam B is hepatitis B immune globulin (human), a purified antibody or hyperimmune that is specific for the hepatitis B virus. HepaGam B is indicated for treatment following acute exposure to hepatitis B virus.",
  "previous application": "HepaGam B - Cangene - Treatment for Exposure to Hepatitis B HepaGam B (hepatitis B immune globulin) FDA Approval History"
},{
  "title": "Amitiza (lubiprostone)  Capsules ",
  "date_of_approval": "January 31, 2006",
  "company": " Sucampo Pharmaceuticals, Inc.",
  "treatment": " Chronic Idiopathic Constipation, Opioid-Induced Constipation, Irritable Bowel Syndrome with Constipation",
  "drug_description": "Amitiza (lubiprostone) is a selective chloride channel activator for the treatment of chronic idiopathic constipation and opioid-induced constipation in adults, and irritable bowel syndrome with constipation in adult women.",
  "previous application": "Amitiza - Sucampo Pharmaceuticals, Inc. - Treatment for Constipation Amitiza (lubiprostone) FDA Approval History"
},{
  "title": "RotaTeq (rotavirus vaccine, live, oral, pentavalent) ",
  "date_of_approval": "February 3, 2006",
  "company": " Merck &amp; Co., Inc.",
  "treatment": " Rotavirus Gastroenteritis",
  "drug_description": "RotaTeq (rotavirus vaccine, live, oral, pentavalent) is an oral, three-dose vaccine given to infants between the ages of six to 32 weeks for the prevention of rotavirus gastroenteritis, a leading cause of severe diarrhea in infants and young children.",
  "previous application": "RotaTeq Approved - Merck & Co., Inc. - Treatment for Prevention of Rotavirus Gastroenteritis RotaTeq (rotavirus vaccine, live, oral, pentavalent) FDA Approval History"
},{
  "title": "Vusion (miconazole nitrate, zinc oxide and white petrolatum)  Ointment  - formerly Zimycan",
  "date_of_approval": "February 16, 2006",
  "company": " Barrier Therapeutics, Inc.",
  "treatment": " Cutaneous Candidiasis",
  "drug_description": "Vusion (miconazole nitrate, zinc oxide and white petrolatum) is a steroid-free ointment for the treatment of diaper dermatitis.",
  "previous application": "Vusion Approved - Barrier Therapeutics, Inc. - Treatment for Diaper Dermatitis Complicated by Candidiasis Vusion (miconazole nitrate, zinc oxide and white petrolatum) FDA Approval History"
},{
  "title": "Eraxis (anidulafungin)  Injection ",
  "date_of_approval": "February 17, 2006",
  "company": " Pfizer Inc.",
  "treatment": " Candidemia",
  "drug_description": "Eraxis (anidulafungin) is an antifungal medicine of the echinocandin class, indicated for the treatment of candidemia and other forms of Candida infections (intra-abdominal abscess, and peritonitis) and esophageal candidiasis.",
  "previous application": "Eraxis - Pfizer Inc - Treatment for Candidemia Eraxis (anidulafungin) FDA Approval History"
},{
  "title": "Loestrin 24 Fe (norethindrone acetate/ethinyl estradiol and ferrous fumarate)  Tablets ",
  "date_of_approval": "February 17, 2006",
  "company": " Warner Chilcott",
  "treatment": " Contraception",
  "drug_description": "Loestrin 24 Fe (norethindrone acetate/ethinyl estradiol and ferrous fumarate) is an oral contraceptive providing 24 days of active hormonal therapy with four days of iron containing placebo pills. Loestrin 24 Fe is indicated for the prevention of pregnancy.",
  "previous application": "Loestrin 24 Fe Approved - Warner Chilcott - Treatment for Prevention of Pregnancy Loestrin 24 Fe (norethindrone acetate/ethinyl estradiol and ferrous fumarate) FDA Approval History"
},{
  "title": "Emsam (selegiline)  Transdermal System ",
  "date_of_approval": "February 27, 2006",
  "company": " Somerset Pharmaceuticals, Inc.",
  "treatment": " Depression",
  "drug_description": "Emsam is a transdermal patch containing the monoamine oxidase inhibitor selegiline. Emsam is indicated for the treatment of major depressive disorder (MDD) in adults.",
  "previous application": "Emsam Approved - Bristol-Myers Squibb Company/Somerset Pharmaceuticals, Inc. - Treatment for Major Depressive Disorder Emsam (selegiline) FDA Approval History"
},{
  "title": "Yaz (drospirenone and ethinyl estradiol)  Tablets ",
  "date_of_approval": "March 16, 2006",
  "company": " Berlex, Inc.",
  "treatment": " Acne, Contraception, Premenstrual Dysphoric Disorder",
  "drug_description": "Yaz (drospirenone and ethinyl estradiol) is a combination oral contraceptive indicated for prevention of pregnancy in women who elect to use an oral contraceptive, treatment of symptoms of premenstrual dysphoric disorder and for the treatment of moderate acne vulgaris.",
  "previous application": "Yaz Berlex, Inc. - Treatment for Prevention of Pregnancy Yaz (drospirenone and ethinyl estradiol) FDA Approval History"
},{
  "title": "Yaz (drospirenone and ethinyl estradiol)  Tablets ",
  "date_of_approval": "March 16, 2006",
  "company": " Berlex, Inc.",
  "treatment": " Acne, Contraception, Premenstrual Dysphoric Disorder",
  "drug_description": "Yaz (drospirenone and ethinyl estradiol) is a combination oral contraceptive indicated for prevention of pregnancy in women who elect to use an oral contraceptive, treatment of symptoms of premenstrual dysphoric disorder and for the treatment of moderate acne vulgaris.",
  "previous application": "Yaz Acne - Treatment for Prevention of Pregnancy, Premenstrual Dysphoric Disorder Yaz (drospirenone and ethinyl estradiol) FDA Approval History"
},{
  "title": "Yaz (drospirenone and ethinyl estradiol)  Tablets ",
  "date_of_approval": "March 16, 2006",
  "company": " Berlex, Inc.",
  "treatment": " Acne, Contraception, Premenstrual Dysphoric Disorder",
  "drug_description": "Yaz (drospirenone and ethinyl estradiol) is a combination oral contraceptive indicated for prevention of pregnancy in women who elect to use an oral contraceptive, treatment of symptoms of premenstrual dysphoric disorder and for the treatment of moderate acne vulgaris.",
  "previous application": "FDA Approves New Indication for Yaz to Treat Acne Yaz (drospirenone and ethinyl estradiol) FDA Approval History"
},{
  "title": "Daytrana (methylphenidate)  Transdermal System  - formerly MTS",
  "date_of_approval": "April 6, 2006",
  "company": " Shire Pharmaceuticals Group plc / Noven Pharmaceuticals, Inc.",
  "treatment": " Attention Deficit Hyperactivity Disorder (ADHD)",
  "drug_description": "Daytrana is a once daily transdermal patch formulation of methylphenidate indicated for the treatment of attention deficit hyperactivity disorder (ADHD).",
  "previous application": "Daytrana Approved - Shire plc - Treatment for Attention Deficit Hyperactivity Disorder Daytrana (methylphenidate) FDA Approval History"
},{
  "title": "NeoProfen (ibuprofen lysine)  Injection ",
  "date_of_approval": "April 13, 2006",
  "company": " Farmacon-IL, LLC",
  "treatment": " Patent Ductus Arteriosus",
  "drug_description": "NeoProfen is an intravenous formulation of ibuprofen lysine indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants, who are no more than 32 weeks gestational age when usual medical management is ineffective.",
  "previous application": "NeoProfen Approved - Farmacon-IL, LLC - Treatment for Patent Ductus Arteriosus NeoProfen (ibuprofen lysine) FDA Approval History"
},{
  "title": "Vivitrol (naltrexone)  for Extended-Release Injectable Suspension  - formerly Vivitrex",
  "date_of_approval": "April 13, 2006",
  "company": " Alkermes, Inc.",
  "treatment": " Alcohol Dependence, Opiate Dependence",
  "drug_description": "Vivitrol (naltrexone) is is an opioid antagonist indicated for the treatment of alcohol dependence and opioid dependence.",
  "previous application": "FDA Approves Vivitrol (naltrexone) for the Treatment for Alcohol Dependence Vivitrol (naltrexone) FDA Approval History"
},{
  "title": "Myozyme (alglucosidase alfa) ",
  "date_of_approval": "April 28, 2006",
  "company": " Genzyme Corp.",
  "treatment": " Pompe disease",
  "drug_description": "Myozyme is a recombinant formulation of the human enzyme acid alpha-glucosidase (GAA) indicated for use in patients with Pompe disease (GAA deficiency), a debilitating and often fatal muscle disorder.",
  "previous application": "Myozyme Approved - Genzyme Corp. - Treatment for Pompe Disease Myozyme (alglucosidase alfa) FDA Approval History"
},{
  "title": "Oracea (doxycycline)  Capsules ",
  "date_of_approval": "May 26, 2006",
  "company": " CollaGenex Pharmaceuticals, Inc.",
  "treatment": " Acne Rosacea",
  "drug_description": "Oracea is a once-a-day capsule formulation of doxycycline, consisting a combination of immediate and delayed release beads. Oracea is indicated for the treatment of inflammatory lesions (papules and pustules) of rosacea in adult patients.",
  "previous application": "Oracea CollaGenex Pharmaceuticals, Inc. - Treatment for Rosacea Oracea (doxycycline) FDA Approval History"
},{
  "title": "Seasonique (levonorgestrel and ethinyl estradiol)  Extended-Cycle Oral Contraceptive Tablets ",
  "date_of_approval": "May 25, 2006",
  "company": " Duramed Pharmaceuticals, Inc.",
  "treatment": " Contraception",
  "drug_description": "Seasonique (levonorgestrel/ethinyl estradiol) is an extended-cycle oral contraceptive regimen designed to reduce the number of withdrawal bleeding periods from monthly to four per year. Seasonique is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of birth control.",
  "previous application": "FDA Approves Duramed's Seasonique Extended-Cycle Oral Contraceptive Seasonique (levonorgestrel and ethinyl estradiol) FDA Approval History"
},{
  "title": "Orapred ODT (prednisolone sodium phosphate)  Orally Disintegrating Tablets ",
  "date_of_approval": "June 1, 2006",
  "company": " BioMarin Pharmaceutical Inc./Alliant Pharmaceuticals, Inc.",
  "treatment": " Asthma -- Acute",
  "drug_description": "Orapred ODT is an orally disintegrating tablet formulation of prednisolone, used to treat exacerbations of asthma and other inflammatory diseases and conditions in children. Orapred ODT tablets are grape flavored and can be swallowed whole or allowed to dissolve in the mouth, with or without the assistance of water.",
  "previous application": "Orapred ODT BioMarin Pharmaceutical Inc./Alliant Pharmaceuticals, Inc. - Treatment for Asthma and other Inflammatory Conditions in Children Orapred ODT (prednisolone sodium phosphate) FDA Approval History"
},{
  "title": "Juvederm (dermal filler) ",
  "date_of_approval": "June 2, 2006",
  "company": " Allergan, Inc.",
  "treatment": " Facial Rejuvenation",
  "drug_description": "Juv\u00e9derm is a hyaluronic acid dermal filler indicated for the correction of facial wrinkles and folds.",
  "previous application": "Juvederm Allergan, Inc. - Treatment for Facial Wrinkles and Folds Juvederm (dermal filler) FDA Approval History"
},{
  "title": "Gardasil (human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant)  Injection ",
  "date_of_approval": "June 8, 2006",
  "company": " Merck &amp; Co., Inc.",
  "treatment": " Human Papillomavirus Prophylaxis",
  "drug_description": "",
  "previous application": "FDA Approves Gardasil for Prevention of Cervical Cancer other HPV-related Diseases Gardasil (human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant) FDA Approval History"
},{
  "title": "Zelapar (selegiline hydrochloride)  Orally Disintegrating Tablets ",
  "date_of_approval": "June 14, 2006",
  "company": " Valeant Pharmaceuticals International",
  "treatment": " Parkinson's Disease",
  "drug_description": "Zelapar (selegiline) is an an irreversible inhibitor of monoamine oxidase (MAO) indicated as an adjunct in the management of patients with Parkinson\u2019s disease.",
  "previous application": "Zelapar Valeant Pharmaceuticals International - Treatment for Parkinson\u2019s Disease Zelapar (selegiline hydrochloride) FDA Approval History"
},{
  "title": "Opana (oxymorphone)  Tablets and ER Tablets ",
  "date_of_approval": "June 22, 2006",
  "company": " Endo Pharmaceuticals Inc.",
  "treatment": " Pain",
  "drug_description": "",
  "previous application": "Opana ER Endo Pharmaceuticals Inc. - Treatment for Moderate-to-Severe Pain Opana (oxymorphone) FDA Approval History"
},{
  "title": "Prezista (darunavir)  Tablets  - formerly TMC114",
  "date_of_approval": "June 23, 2006",
  "company": " Janssen Therapeutics",
  "treatment": " HIV Infection",
  "drug_description": "Prezista (darunavir) is a protease inhibitor used with ritonavir in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV) infection.",
  "previous application": "Prezista Tibotec Pharmaceuticals Ltd. - Treatment for Human Immunodeficiency Virus (HIV) Prezista (darunavir) FDA Approval History"
},{
  "title": "Sprycel (dasatinib)  Tablets ",
  "date_of_approval": "June 28, 2006",
  "company": " Bristol-Myers Squibb Company",
  "treatment": " Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia",
  "drug_description": "Sprycel (dasatinib) is a kinase inhibitor indicated for the treatment of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.",
  "previous application": "Sprycel Bristol-Myers Squibb Company - Treatment for Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (Ph+ALL) Sprycel (dasatinib) FDA Approval History"
},{
  "title": "Lucentis (ranibizumab)  Injection ",
  "date_of_approval": "June 30, 2006",
  "company": " Genentech, Inc.",
  "treatment": " Macular Degeneration; Macular Edema; Diabetic Macular Edema; Diabetic Retinopathy; Myopic Choroidal Neovascularization",
  "drug_description": "Lucentis (ranibizumab) is a humanized anti-VEGF antibody fragment indicated for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization.",
  "previous application": "FDA Approves Lucentis (ranibizumab) for the Treatment of Wet Age-Related Macular Degeneration Lucentis (ranibizumab) FDA Approval History"
},{
  "title": "Sprycel (dasatinib)  Tablets ",
  "date_of_approval": "June 28, 2006",
  "company": " Bristol-Myers Squibb Company",
  "treatment": " Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia",
  "drug_description": "Sprycel (dasatinib) is a kinase inhibitor indicated for the treatment of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.",
  "previous application": "FDA Approves New Sprycel (Dasatinib) Product Labeling for Patients\r with Chronic-Phase CML Sprycel (dasatinib) FDA Approval History"
},{
  "title": "Juvederm (dermal filler) ",
  "date_of_approval": "June 2, 2006",
  "company": " Allergan, Inc.",
  "treatment": " Facial Rejuvenation",
  "drug_description": "Juv\u00e9derm is a hyaluronic acid dermal filler indicated for the correction of facial wrinkles and folds.",
  "previous application": "FDA Approves Juv\u00e9derm XC Containing Lidocaine to Correct Facial Wrinkles and Folds Juvederm (dermal filler) FDA Approval History"
},{
  "title": "Juvederm (dermal filler) ",
  "date_of_approval": "June 2, 2006",
  "company": " Allergan, Inc.",
  "treatment": " Facial Rejuvenation",
  "drug_description": "Juv\u00e9derm is a hyaluronic acid dermal filler indicated for the correction of facial wrinkles and folds.",
  "previous application": "FDA Approves Juv\u00e9derm Voluma XC to Correct Age-Related Volume Loss in the Cheek Area Juvederm (dermal filler) FDA Approval History"
},{
  "title": "Atripla (efavirenz, emtricitabine and tenofovir disoproxil fumarate)  Tablets ",
  "date_of_approval": "July 12, 2006",
  "company": " Bristol-Myers Squibb Company / Gilead Sciences, Inc.",
  "treatment": " HIV Infection",
  "drug_description": "Atripla is a once-daily single tablet regimen combining the non-nucleoside reverse transcriptase inhibitor Sustiva (efavirenz), and the nucleoside reverse transcriptase inhibitors Emtriva (emtricitabine) and Viread (tenofovir disoproxil fumarate). Atripla is indicated as a stand-alone therapy or in combination with other antiretrovirals for the treatment of HIV-1 infection in adults.",
  "previous application": "Atripla Bristol-Myers Squibb Company / Gilead Sciences, Inc. - Treatment for HIV-1 Infection Atripla (efavirenz, emtricitabine and tenofovir disoproxil fumarate) FDA Approval History"
},{
  "title": "Implanon (etonogestrel)  Implant ",
  "date_of_approval": "July 18, 2006",
  "company": " Organon",
  "treatment": " Contraception",
  "drug_description": "Implanon (etonogestrel) is a single-rod subdermal implant that continually\r releases a low, steady dose of progestin  providing contraceptive effectiveness for a period of up to three years.",
  "previous application": "Implanon Organon - Treatment for Contraception Implanon (etonogestrel) FDA Approval History"
},{
  "title": "Symbicort (budesonide and formoterol)  Inhaler ",
  "date_of_approval": "July 21, 2006",
  "company": " AstraZeneca",
  "treatment": " Asthma -- Maintenance, Chronic Obstructive Pulmonary Disease -- Maintenance",
  "drug_description": "Symbicort (budesonide and formoterol) is a combination of a corticosteroid and a long-acting bronchodilator indicated for the long-term\r maintenance treatment of asthma and the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.",
  "previous application": "AstraZeneca\u2019s Symbicort (budesonide/formoterol) Treatment For Asthma Approved By The FDA Symbicort (budesonide and formoterol) FDA Approval History"
},{
  "title": "Elaprase (idursulfase)  Injection ",
  "date_of_approval": "July 24, 2006",
  "company": " Shire plc",
  "treatment": " Mucopolysaccharidosis Type II",
  "drug_description": "Elaprase (idursulfase) is a purified form of the human lysosomal enzyme iduronate-2-sulfatase produced by recombinant DNA technology. Elaprase is indicated for the treatment of Hunter syndrome, also known as Mucopolysaccharidosis II (MPS II).",
  "previous application": "Elaprase Shire plc - Treatment for Hunter Syndrome Elaprase (idursulfase) FDA Approval History"
},{
  "title": "Xolegel (ketoconazole)  Gel  - formerly Sebazole",
  "date_of_approval": "July 28, 2006",
  "company": " Barrier Therapeutics, Inc.",
  "treatment": " Seborrheic Dermatitis",
  "drug_description": "Xolegel is a topical waterless gel formulation of the antifungal agent ketoconazole, applied once-daily for the treatment of seborrheic dermatitis in immunocompetent adults and children twelve years of age and older.",
  "previous application": "Xolegel Gel Barrier Therapeutics, Inc. - Treatment for Seborrheic Dermatitis Xolegel (ketoconazole) FDA Approval History"
},{
  "title": "Duetact (pioglitazone HCl and glimepiride)  Tablets ",
  "date_of_approval": "July 31, 2006",
  "company": " Takeda Pharmaceuticals North America, Inc.",
  "treatment": " Diabetes Type 2",
  "drug_description": "Duetact is a combination of pioglitazone, which directly targets insulin resistance, and glimepiride, a sulfonylurea that acts primarily by increasing the amount of insulin produced by the pancreas. Duetact is indicated for the treatment of type 2 diabetes.",
  "previous application": "Duetact Takeda Pharmaceuticals North America, Inc. - Treatment for Type 2 Diabetes Duetact (pioglitazone HCl and glimepiride) FDA Approval History"
},{
  "title": "MoviPrep (polyethylene glycol 3350 with electrolytes)  for Oral Solution ",
  "date_of_approval": "August 2, 2006",
  "company": " Salix Pharmaceuticals, Ltd.",
  "treatment": " Bowel Preparation",
  "drug_description": "MoviPrep is a two-liter liquid PEG bowel cleansing agent indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older.",
  "previous application": "MoviPrep Salix Pharmaceuticals, Ltd. - Treatment for Bowel Cleansing prior to Colonoscopy MoviPrep (polyethylene glycol 3350 with electrolytes) FDA Approval History"
},{
  "title": "Noxafil (posaconazole) ",
  "date_of_approval": "September 15, 2006",
  "company": " Schering-Plough Corporation",
  "treatment": " Aspergillosis -- Invasive, Candidemia, Oral Thrush",
  "drug_description": "Noxafil is a triazole antifungal agent indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients 13 years of age and older who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy.",
  "previous application": "Noxafil Schering-Plough Corporation - Treatment for Prevention of Invasive Fungal Infections Noxafil (posaconazole) FDA Approval History"
},{
  "title": "Verdeso (desonide)  Foam ",
  "date_of_approval": "September 19, 2006",
  "company": " Connetics Corporation",
  "treatment": " Dermatitis",
  "drug_description": "Verdeso (desonide) Foam is a low-potency topical steroid formulated in VersaFoam emulsion foam drug delivery vehicle for the treatment of mild-to-moderate atopic dermatitis.",
  "previous application": "Verdeso Connetics Corporation - Treatment for Mild-to-Moderate Atopic Dermatitis Verdeso (desonide) FDA Approval History"
},{
  "title": "Travatan Z (travoprost)  Ophthalmic Solution ",
  "date_of_approval": "September 21, 2006",
  "company": " Alcon, Inc.",
  "treatment": " Glaucoma",
  "drug_description": "Travatan Z (travoprost) is a new formulation of Travatan solution in which benzalkonium chloride is replaced with Sofzia, a robust ionic buffered preservative system that is gentle to the ocular surface. Travatan Z is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension, who are intolerant of or insufficiently responsive to other intraocular pressure lowering medications.",
  "previous application": "Travatan Z Alcon, Inc. - Treatment for Glaucoma and Ocular Hypertension Travatan Z (travoprost) FDA Approval History"
},{
  "title": "Fentora (fentanyl)  Buccal Tablets  - formerly OraVescent Fentanyl",
  "date_of_approval": "September 25, 2006",
  "company": " Cephalon, Inc.",
  "treatment": " Pain",
  "drug_description": "Fentora is an effervescent buccal formulation of the potent opioid analgesic fentanyl, indicated for the management of breakthrough pain in patients with cancer who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.",
  "previous application": "Fentora Cephalon, Inc. - Treatment for Breakthrough Pain in Patients with Cancer Fentora (fentanyl) FDA Approval History"
},{
  "title": "Vectibix (panitumumab)  Injection ",
  "date_of_approval": "September 27, 2006",
  "company": " Amgen",
  "treatment": " Colorectal Cancer",
  "drug_description": "Vectibix (panitumumab) is an epidermal growth factor receptor (EGFR) antagonist indicated for the treatment of wild-type RAS (defined as wild-type in both KRAS and NRAS) metastatic colorectal cancer.",
  "previous application": "FDA Approves Vectibix (panitumumab) to Treat Patients with Metastatic Colorectal Cancer Vectibix (panitumumab) FDA Approval History"
},{
  "title": "Pylera (bismuth subcitrate potassium, metronidazole and tetracycline)  Capsules  - formerly Helizide",
  "date_of_approval": "September 28, 2006",
  "company": " Allergan, Inc.",
  "treatment": " Helicobacter pylori Infection",
  "drug_description": "Pylera (bismuth subcitrate potassium, metronidazole and tetracycline) is a 3-in-1 capsule triple therapy indicated for the eradication of Helicobacter pylori, a bacterium now recognized as being the main cause of gastric and duodenal ulcers.",
  "previous application": "Pylera Axcan Pharma Inc. - Treatment for Eradication of Helicobacter pylori Pylera (bismuth subcitrate potassium, metronidazole and tetracycline) FDA Approval History"
},{
  "title": "Brovana (arformoterol tartrate)  Inhalation Solution ",
  "date_of_approval": "October 6, 2006",
  "company": " Sepracor Inc.",
  "treatment": " Chronic Obstructive Pulmonary Disease",
  "drug_description": "Brovana (arformoterol tartrate) is a long-acting beta2-agonist for inhalation via a nebulizer, used for the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.",
  "previous application": "Brovana Sepracor Inc. - Treatment for Chronic Obstructive Pulmonary Disease Brovana (arformoterol tartrate) FDA Approval History"
},{
  "title": "Zolinza (vorinostat)  Capsules ",
  "date_of_approval": "October 6, 2006",
  "company": " Merck &amp; Co., Inc.",
  "treatment": " Cutaneous T-cell Lymphoma",
  "drug_description": "Zolinza (vorinostat) is a histone deacetylase (HDAC) inhibitor for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL), a form of non-Hodgkin's lymphoma, who have progressive, persistent or recurrent disease on or following two systemic therapies.",
  "previous application": "Zolinza Merck & Co., Inc. - Treatment for Cutaneous T-cell Lymphoma Zolinza (vorinostat) FDA Approval History"
},{
  "title": "Januvia (sitagliptin phosphate)  Tablets ",
  "date_of_approval": "October 17, 2006",
  "company": " Merck &amp; Co., Inc.",
  "treatment": " Diabetes Type 2",
  "drug_description": "Januvia (sitagliptin phosphate) is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.",
  "previous application": "Januvia Merck & Co., Inc. - Treatment for Type 2 Diabetes Januvia (sitagliptin phosphate) FDA Approval History"
},{
  "title": "Desonate (desonide)  Gel ",
  "date_of_approval": "October 20, 2006",
  "company": " SkinMedica, Inc.",
  "treatment": " Dermatitis",
  "drug_description": "Desonate (desonide) is a low potency topical steroid formulated in a proprietary water- based Hydrogel vehicle indicated for the treatment of mild to moderate atopic dermatitis.",
  "previous application": "Desonate SkinMedica, Inc. - Treatment for Atopic Dermatitis Desonate (desonide) FDA Approval History"
},{
  "title": "Omnaris (ciclesonide)  Nasal Spray ",
  "date_of_approval": "October 20, 2006",
  "company": " Altana Pharma",
  "treatment": " Allergic Rhinitis",
  "drug_description": "Omnaris (ciclesonide) is an intranasal corticosteroid indicated for the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis in patients 12 years of age and older.",
  "previous application": "Omnaris Altana Pharma - Treatment for Allergic Rhinitis Omnaris (ciclesonide) FDA Approval History"
},{
  "title": "Tyzeka (telbivudine)  Tablets ",
  "date_of_approval": "October 25, 2006",
  "company": " Novartis",
  "treatment": " Chronic Hepatitis B",
  "drug_description": "",
  "previous application": "Tyzeka Novartis - Treatment for Chronic Hepatitis B Tyzeka (telbivudine) FDA Approval History"
},{
  "title": "Bellafill (dermal filler)  Injection  - formerly ArteFill",
  "date_of_approval": "October 27, 2006",
  "company": " Suneva Medical, Inc.",
  "treatment": " Facial Wrinkles; Acne Scars",
  "drug_description": "Bellafill is a dermal filler indicated for the correction of nasolabial folds (smile lines) and for the treatment of acne scars.",
  "previous application": "FDA Approves ArteFill as the First Non-Resorbable Injectable Wrinkle Filler to Correct Smile Lines Bellafill (dermal filler) FDA Approval History"
},{
  "title": "Veregen (kunecatechins)  Ointment  - formerly Polyphenon E",
  "date_of_approval": "October 31, 2006",
  "company": " MediGene AG",
  "treatment": " Condylomata Acuminata",
  "drug_description": "Veregen(kunecatechins) contains a concentrate of catechines extracted from green tea leaves. Veregen is indicated for the treatment of external genital and perianal warts.",
  "previous application": "Polyphenon E MediGene AG - Treatment for Genital and Perianal Warts Veregen (kunecatechins) FDA Approval History"
},{
  "title": "NitroMist (nitroglycerin)  Lingual Aerosol ",
  "date_of_approval": "November 2, 2006",
  "company": " NovaDel Pharma",
  "treatment": " Angina Pectoris",
  "drug_description": "NitroMist is an oral spray formulation of nitroglycerin indicated for acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease.",
  "previous application": "NitroMist NovaDel Pharma - Treatment for Angina Pectoris NitroMist (nitroglycerin) FDA Approval History"
},{
  "title": "Ziana (clindamycin phosphate and tretinoin)  Gel ",
  "date_of_approval": "November 7, 2006",
  "company": " Medicis and Dow Pharmaceutical Sciences",
  "treatment": " Acne",
  "drug_description": "Ziana Gel (clindamycin phosphate and tretinoin) is a topical antibiotic and retinoid combination indicated for the treatment of acne vulgaris in patients 12 years or older.",
  "previous application": "Ziana Medicis and Dow Pharmaceutical Sciences - Treatment for Acne Ziana (clindamycin phosphate and tretinoin) FDA Approval History"
},{
  "title": "Alaway (ketotifen ophthalmic)  Ophthalmic Solution ",
  "date_of_approval": "December 1, 2006",
  "company": " Bausch Health Companies Inc.",
  "treatment": " Eye Redness/Itching",
  "drug_description": "Alaway (ketotifen) is an over-the-counter ophthalmic antihistamine indicated for the temporary relief of itchy eyes associated with pollen, ragweed, grass, animal hair and dander.",
  "previous application": "Alaway Itchy Eyes - Treatment for Itchy Eyes Alaway (ketotifen ophthalmic) FDA Approval History"
},{
  "title": "Cyanokit (hydroxocobalamin)  Injection ",
  "date_of_approval": "December 15, 2006",
  "company": " EMD Pharmaceuticals and Dey, LP",
  "treatment": " Cyanide Poisoning",
  "drug_description": "Cyanokit contains hydroxocobalamin, an antidote indicated for the treatment of known or suspected cyanide poisoning.",
  "previous application": "Cyanokit EMD Pharmaceuticals and Dey, LP - Treatment for Cyanide Poisoning Cyanokit (hydroxocobalamin) FDA Approval History"
},{
  "title": "Elestrin (estradiol)  Gel  - formerly Bio-E-Gel",
  "date_of_approval": "December 15, 2006",
  "company": " BioSante Pharmaceuticals, Inc.",
  "treatment": " Postmenopausal Symptoms",
  "drug_description": "Elestrin is a fast-drying transdermal gel formulation of bio-identical estradiol indicated for the treatment of moderate-to-severe vasomotor symptoms (hot flashes) associated with menopause.",
  "previous application": "Elestrin BioSante Pharmaceuticals, Inc. - Treatment for Menopausal Vasomotor Symptoms Elestrin (estradiol) FDA Approval History"
},{
  "title": "Invega (paliperidone) ",
  "date_of_approval": "December 19, 2006",
  "company": " Janssen, L.P.",
  "treatment": " Schizophrenia, Schizoaffective Disorder",
  "drug_description": "Invega (paliperidone) is a once-daily oral atypical antipsychotic indicated for the acute and maintenance treatment of schizophrenia, and the acute treatment of schizoaffective disorder.Invega Sustenna is an extended-release injectable formulation of paliperidone administered once-monthly for the treatment of schizophrenia and schizoaffective disorder.",
  "previous application": "Invega Approved By FDA as New Treatment for Schizophrenia Invega (paliperidone) FDA Approval History"
},{
  "title": "Radiesse (dermal filler)  Dermal Filler ",
  "date_of_approval": "December 22, 2006",
  "company": " BioForm Medical, Inc",
  "treatment": " Wrinkle Correction",
  "drug_description": "Radiesse is a cosmetic dermal filler, for the long-lasting correction of moderate to severe facial wrinkles and folds.",
  "previous application": "Radiesse BioForm Medical, Inc - Treatment for Moderate to Severe Facial Wrinkles Radiesse (dermal filler) FDA Approval History"
},{
  "title": "Invega (paliperidone) ",
  "date_of_approval": "December 19, 2006",
  "company": " Janssen, L.P.",
  "treatment": " Schizophrenia, Schizoaffective Disorder",
  "drug_description": "Invega (paliperidone) is a once-daily oral atypical antipsychotic indicated for the acute and maintenance treatment of schizophrenia, and the acute treatment of schizoaffective disorder.Invega Sustenna is an extended-release injectable formulation of paliperidone administered once-monthly for the treatment of schizophrenia and schizoaffective disorder.",
  "previous application": "FDA Approves Invega for Long-Term Maintenance Treatment ofSchizophrenia Invega (paliperidone) FDA Approval History"
},{
  "title": "Olux-E (clobetasol propionate)  Foam ",
  "date_of_approval": "January 12, 2007",
  "company": " Stiefel Laboratories, Inc.",
  "treatment": " Psoriasis, Eczema",
  "drug_description": "Olux-E (clobetasol propionate) is a topical steroid formulated in VersaFoam emulsion foam drug delivery vehicle indicated for the treatment of psoriasis and eczema in patients 12 years of age or older.",
  "previous application": "Olux-E Stiefel Laboratories, Inc. - Treatment for Psoriasis and Eczema Olux-E (clobetasol propionate) FDA Approval History"
},{
  "title": "Lialda (mesalamine)   Delayed Release Tablets ",
  "date_of_approval": "January 16, 2007",
  "company": " Shire plc",
  "treatment": " Ulcerative Colitis",
  "drug_description": "Lialda (mesalamine) is a locally acting 5-aminosalicylic acid (5-ASA) indicated for the induction of remission in adults with active, mild to moderate ulcerative \r colitis and for the maintenance of remission of ulcerative colitis.",
  "previous application": "Lialda Shire plc - Treatment for Ulcerative Colitis Lialda (mesalamine) FDA Approval History"
},{
  "title": "Lialda (mesalamine)   Delayed Release Tablets ",
  "date_of_approval": "January 16, 2007",
  "company": " Shire plc",
  "treatment": " Ulcerative Colitis",
  "drug_description": "Lialda (mesalamine) is a locally acting 5-aminosalicylic acid (5-ASA) indicated for the induction of remission in adults with active, mild to moderate ulcerative \r colitis and for the maintenance of remission of ulcerative colitis.",
  "previous application": "FDA Approves Lialda (mesalamine), the First Oral Once-Daily Mesalamine for Patients With Active, Mild to Moderate Ulcerative Colitis Lialda (mesalamine) FDA Approval History"
},{
  "title": "Flector (diclofenac epolamine)  Topical Patch ",
  "date_of_approval": "January 31, 2007",
  "company": " Institut Biochimique SA",
  "treatment": " Pain",
  "drug_description": "Flector is a transdermal patch formulation of the nonsteroidal anti-inflammatory drug diclofenac, indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions.",
  "previous application": "Flector Approved - Institut Biochimique SA - Treatment for acute pain due to minor strains, sprains, and contusions. Flector (diclofenac epolamine) FDA Approval History"
},{
  "title": "Amrix (cyclobenzaprine)  Extended-Release Capsules ",
  "date_of_approval": "February 1, 2007",
  "company": " ECR Pharmaceuticals",
  "treatment": " Muscle Spasm",
  "drug_description": "Amrix is an extended-release formulation of the skeletal muscle relaxant cyclobenzaprine, indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions.",
  "previous application": "Amrix Approved - ECR Pharmaceuticals - relief of muscle spasm associated with acute, painful musculoskeletal conditions Amrix (cyclobenzaprine) FDA Approval History"
},{
  "title": "Alli (orlistat)  60 mg Capsules ",
  "date_of_approval": "February 7, 2007",
  "company": " GlaxoSmithKline Consumer Healthcare",
  "treatment": " Weight Loss",
  "drug_description": "Alli is an over-the-counter weight-loss product containing orlistat, the same ingredient in prescription strength Xenical. Alli is indicated for weight loss in overweight adults 18 years and older when used along with a reduced-calorie, low-fat diet.",
  "previous application": "FDA Approves alli (orlistat 60 mg capsules) Over-The-Counter Alli (orlistat) FDA Approval History"
},{
  "title": "Vyvanse (lisdexamfetamine dimesylate)  Capsules ",
  "date_of_approval": "February 23, 2007",
  "company": " Shire plc",
  "treatment": " Attention Deficit Disorder",
  "drug_description": "Vyvanse (lisdexamfetamine dimesylate) is an amphetamine derivative prodrug administered once-daily for the treatment of attention deficit hyperactivity disorder (ADHD) and binge-eating disorder.",
  "previous application": "Shire Receives FDA Approval of Vyvanse for ADHD Vyvanse (lisdexamfetamine dimesylate) FDA Approval History"
},{
  "title": "Tekturna (aliskiren)  Tablets and Oral Pellets  - formerly Rasilez",
  "date_of_approval": "March 5, 2007",
  "company": " Novartis",
  "treatment": " Hypertension",
  "drug_description": "Tekturna (aliskiren) is a direct renin inhibitor indicated as a once-daily oral therapy for the treatment of high blood pressure.",
  "previous application": "Tekturna - The First New Type of High Blood Pressure Medicine In\r More Than a Decade - Receives Its First Approval in the US Tekturna (aliskiren) FDA Approval History"
},{
  "title": "Tykerb (lapatinib ditosylate)  Tablets ",
  "date_of_approval": "March 13, 2007",
  "company": " GlaxoSmithKline",
  "treatment": " Breast Cancer",
  "drug_description": "Tykerb (lapatinib) is a kinase inhibitor indicated for the combination treatment of patients with advanced or metastatic breast cancer.",
  "previous application": "FDA Approves Tykerb (lapatinib) in Combination With Xeloda(capecitabine) for the Treatment of Advanced or Metastatic BreastCancer in Women Who Have Progressed on Prior Therapy Tykerb (lapatinib ditosylate) FDA Approval History"
},{
  "title": "Soliris (eculizumab)  Injection ",
  "date_of_approval": "March 16, 2007",
  "company": " Alexion Pharmaceuticals, Inc.",
  "treatment": " Paroxysmal Nocturnal Hemoglobinuria, Hemolytic Uremic Syndrome, Myasthenia Gravis",
  "drug_description": "Soliris is a complement inhibitor indicated for:",
  "previous application": "FDA Approves Soliris (eculizumab) for Paroxysmal Nocturnal Hemoglobinuria Soliris (eculizumab) FDA Approval History"
},{
  "title": "Ceprotin (protein C)  Injection ",
  "date_of_approval": "March 30, 2007",
  "company": " Baxter Healthcare Corporation",
  "treatment": " Protein C Deficiency",
  "drug_description": "Ceprotin is a plasma-derived Protein C concentrate for use as replacement therapy in patients with life-threatening blood-clotting complications related to severe congenital Protein C deficiency.",
  "previous application": "Baxter Announces FDA Approval Of Ceprotin For Severe Congential\r Protein C Deficiency Ceprotin (protein C) FDA Approval History"
},{
  "title": "Janumet (metformin and sitagliptin)  Tablets ",
  "date_of_approval": "March 30, 2007",
  "company": " Merck &amp; Co., Inc.",
  "treatment": " Diabetes Type 2",
  "drug_description": "Janumet is a combination of the oral antihyperglycemic drugs sitagliptin and metformin indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus.",
  "previous application": "FDA Approves Janumet for Type 2 Diabetes, Offering Powerful GlucoseControl of a DPP-4 Inhibitor and Metformin in a Single Tablet Janumet (metformin and sitagliptin) FDA Approval History"
},{
  "title": "Altabax (retapamulin)  Ointment ",
  "date_of_approval": "April 12, 2007",
  "company": " GlaxoSmithKline",
  "treatment": " Impetigo",
  "drug_description": "Altabax (retapamulin) is a topical antibiotic indicated for the treatment of impetigo in adults and children aged 9 months and older.",
  "previous application": "GSK Announces FDA Approval of Altabax (Retapamulin Ointment), 1% Altabax (retapamulin) FDA Approval History"
},{
  "title": "Reclast (zoledronic acid)  Injection  - formerly Aclasta",
  "date_of_approval": "April 16, 2007",
  "company": " Novartis",
  "treatment": " Paget's Disease, Prevention of Osteoporosis, Prevention of Fractures",
  "drug_description": "Reclast (zoledronic acid) is a bisphosphonate indicated for the treatment for Paget's disease, postmenopausal osteoporosis and prevention of fractures.",
  "previous application": "Reclast Receives US Approval as a Highly Effective Treatment for\r Patients with Paget's Disease of the Bone Reclast (zoledronic acid) FDA Approval History"
},{
  "title": "Influenza Virus Vaccine, H5N1 ()  Injection ",
  "date_of_approval": "April 17, 2007",
  "company": "NONE",
  "treatment": " Prevention of H5N1 Influenza (Avian Influenza)\r ",
  "drug_description": "Influenza Virus Vaccine, H5N1 is a vaccine indicated for the prevention of H5N1 influenza virus, commonly referred to as avian influenza or \"bird flu.\"",
  "previous application": "FDA Approves First U.S. Vaccine for Humans Against the Avian\r Influenza Virus H5N1 Influenza Virus Vaccine, H5N1 FDA Approval History"
},{
  "title": "Veramyst (fluticasone furoate)  Nasal Spray ",
  "date_of_approval": "April 27, 2007",
  "company": " GlaxoSmithKline",
  "treatment": " Allergic Rhinitis",
  "drug_description": "Marketing Status: Discontinued",
  "previous application": "FDA Approves Once-Daily Veramyst (fluticasone furoate) Nasal Sprayfor Treatment of Seasonal and Year-Round Allergy Symptoms in Adultsand Children as Young as Two Years Veramyst (fluticasone furoate) FDA Approval History"
},{
  "title": "AzaSite (azithromycin)  Ophthalmic Solution ",
  "date_of_approval": "April 27, 2007",
  "company": " InSite Vision Incorporated",
  "treatment": " Bacterial Conjunctivitis",
  "drug_description": "AzaSite is an ophthalmic formulation of the well-known, broad-spectrum antibiotic azithromycin indicated for the treatment of bacterial conjunctivitis.",
  "previous application": "Inspire Announces FDA Approval Of AzaSite AzaSite (azithromycin) FDA Approval History"
},{
  "title": "Perlane (dermal filler) ",
  "date_of_approval": "May 2, 2007",
  "company": " Medicis",
  "treatment": " Facial Wrinkles",
  "drug_description": "Perlane is a dermal filler for\r the correction of moderate to severe facial folds and wrinkles, such as nasolabial folds.",
  "previous application": "Medicis Announces FDA Approval of Perlane Perlane (dermal filler) FDA Approval History"
},{
  "title": "Supprelin-LA (histrelin acetate)  Subcutaneous Implant ",
  "date_of_approval": "May 3, 2007",
  "company": " Indevus Pharmaceuticals, Inc.",
  "treatment": " Precocious Puberty",
  "drug_description": "Supprelin-LA is a once-yearly implant of the gonadotropin releasing hormone (GnRH) analog histrelin, indicated for the treatment of central precocious puberty (CPP), the premature onset of puberty in children.",
  "previous application": "Indevus Announces FDA Approval of Supprelin-LA Supprelin-LA (histrelin acetate) FDA Approval History"
},{
  "title": "Neupro (rotigotine)  Transdermal System ",
  "date_of_approval": "May 9, 2007",
  "company": " Schwarz Pharma",
  "treatment": " Parkinson's Disease, Restless Legs Syndrome",
  "drug_description": "Neupro (rotigotine) is a dopamine agonist transdermal system indicated for the treatment of Parkinson\u2019s disease and Restless Legs Syndrome.",
  "previous application": "FDA Approves Schwarz Pharma's Neupro (Rotigotine TransdermalSystem) for the Treatment of Early-Stage Parkinson's Disease in USA Neupro (rotigotine) FDA Approval History"
},{
  "title": "Perforomist (formoterol fumarate)  Inhalation Solution ",
  "date_of_approval": "May 11, 2007",
  "company": " Dey, L.P.",
  "treatment": " Chronic Obstructive Pulmonary Disease",
  "drug_description": "Perforomist is an inhalation solution formulation of the long-acting beta(2)-adrenergic agonist formoterol fumarate, indicated for the long-term, twice-daily maintenance treatment of bronchoconstriction for emphysema and chronic bronchitis, also known as Chronic Obstructive Pulmonary Disease (COPD).",
  "previous application": "FDA Approves Dey, L.P.'s Perforomist (Formoterol Fumarate)\r Inhalation Solution for Maintenance Treatment of COPD Perforomist (formoterol fumarate) FDA Approval History"
},{
  "title": "Seroquel XR (quetiapine)  Tablets ",
  "date_of_approval": "May 17, 2007",
  "company": " AstraZeneca",
  "treatment": " Schizophrenia, Bipolar Disorder, Depression",
  "drug_description": "Seroquel XR (quetiapine) is an atypical antipsychotic agent indicated for the acute and maintenance treatment of schizophrenia, bipolar disorder and as an adjunctive\r treatment to antidepressants in adults with Major Depressive Disorder.",
  "previous application": "FDA Approves Astrazeneca's Once-Daily Seroquel XR Extended-ReleaseTablets for the Treatment of Schizophrenia Seroquel XR (quetiapine) FDA Approval History"
},{
  "title": "Lybrel (levonorgestrel and ethinyl estradiol)  Tablets ",
  "date_of_approval": "May 22, 2007",
  "company": " Wyeth Pharmaceuticals Inc.",
  "treatment": " Contraception",
  "drug_description": "",
  "previous application": "FDA Approves Lybrel, First Low Dose Combination Oral ContraceptiveOffering Women the Opportunity to Be Period-Free Over Time Lybrel (levonorgestrel and ethinyl estradiol) FDA Approval History"
},{
  "title": "Xyzal (levocetirizine dihydrochloride) ",
  "date_of_approval": "May 25, 2007",
  "company": " UCB, Inc. and sanofi-aventis",
  "treatment": " Allergic Rhinitis, Allergic Urticaria",
  "drug_description": "Xyzal (levocetirizine) is an antihistamine for the relief of symptoms associated with allergic rhinitis and urticaria.",
  "previous application": "FDA Approves Xyzal (Levocetirizine Dihydrochloride) Tablets for theRelief of Seasonal and Year Round Allergies, and Chronic Hives Xyzal (levocetirizine dihydrochloride) FDA Approval History"
},{
  "title": "Torisel (temsirolimus)  Injection ",
  "date_of_approval": "May 30, 2007",
  "company": " Wyeth Pharmaceuticals, Inc.",
  "treatment": " Renal Cell Carcinoma",
  "drug_description": "Torisel (temsirolimus), an inhibitor of mTOR kinase, is an antineoplastic agent indicated for the treatment of patients with advanced renal cell carcinoma.",
  "previous application": "FDA Approves Torisel, a Targeted First-in-Class mTOR Inhibitor forthe Treatment of Advanced Kidney Cancer Torisel (temsirolimus) FDA Approval History"
},{
  "title": "Divigel (estradiol)  Gel ",
  "date_of_approval": "June 4, 2007",
  "company": "NONE",
  "treatment": " Postmenopausal Symptoms",
  "drug_description": "Divigel (estradiol) is a low dose topical estrogen gel, which is applied to the skin of the thigh once daily for the treatment of moderate to severe hot flashes associated with menopause.",
  "previous application": "FDA Approves Divigel (estradiol gel) 0.1 Percent for Treatment ofModerate to Severe Hot Flashes Associated with Menopause Divigel (estradiol) FDA Approval History"
},{
  "title": "Extina (ketoconazole)  Foam ",
  "date_of_approval": "June 12, 2007",
  "company": " Stiefel Laboratories, Inc.",
  "treatment": " Seborrheic Dermatitis",
  "drug_description": "Extina Foam is a topical formulation of the antifungal ketoconazole in VersaFoam for the treatment of seborrheic dermatitis.",
  "previous application": "FDA Approves Extina for the Treatment of Seborrheic Dermatitis Extina (ketoconazole) FDA Approval History"
},{
  "title": "Letairis (ambrisentan)  Tablets ",
  "date_of_approval": "June 15, 2007",
  "company": " Gilead Sciences, Inc.",
  "treatment": " Pulmonary Hypertension",
  "drug_description": "Letairis (ambrisentan) is an endothelin receptor antagonist (ERA) indicated for the once-daily oral treatment of pulmonary arterial hypertension.",
  "previous application": "U.S. Food and Drug Administration Approves Gilead's Letairis\r (ambrisentan) 5 mg and 10 mg Tablets for the Once-Daily Treatment\r of Pulmonary Arterial Hypertension (WHO Group 1) in Patients with\r WHO Functional Class II or III Symptoms Letairis (ambrisentan) FDA Approval History"
},{
  "title": "Nuvigil (armodafinil)  Tablets ",
  "date_of_approval": "June 15, 2007",
  "company": " Cephalon, Inc.",
  "treatment": " Narcolepsy",
  "drug_description": "Nuvigil (armodafinil) is a non-amphetamine wake-promoting agent for the treatment of excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSAHS), narcolepsy, and shift work sleep disorder (SWSD).",
  "previous application": "Cephalon Receives FDA Approval of Nuvigil for the Treatment ofExcessive Sleepiness Associated with Three Disorders Nuvigil (armodafinil) FDA Approval History"
},{
  "title": "Exforge (amlodipine and valsartan)  Tablets ",
  "date_of_approval": "June 20, 2007",
  "company": " Novartis",
  "treatment": " Hypertension",
  "drug_description": "Exforge is a single-tablet combination of an angiotensin receptor blocker (valsartan) and a calcium channel blocker (amlodipine) taken once-daily for the treatment of hypertension.",
  "previous application": "Exforge Receives Final US Approval as New and Powerful TreatmentOption for Patients With High Blood Pressure Exforge (amlodipine and valsartan) FDA Approval History"
},{
  "title": "Endometrin (progesterone)  Vaginal Insert ",
  "date_of_approval": "June 21, 2007",
  "company": " Ferring Pharmaceuticals, Inc.",
  "treatment": " Female Infertility",
  "drug_description": "Endometrin is a progesterone vaginal insert indicated to support embryo implantation and early pregnancy as part of an Assisted\r Reproductive Technology (ART) treatment for infertile women.",
  "previous application": "FDA Approves Ferring Pharmaceuticals' Endometrin for Luteal Phase\r Support in Assisted Reproductive Technology Treatment Endometrin (progesterone) FDA Approval History"
},{
  "title": "Atralin (tretinoin)  Gel ",
  "date_of_approval": "July 26, 2007",
  "company": " Coria Laboratories, Ltd.",
  "treatment": " Acne",
  "drug_description": "Atralin (tretinoin) gel is a retinoid indicated for topical treatment of acne vulgaris.",
  "previous application": "FDA Approves Atralin Gel for Topical Treatment of Acne Vulgaris Atralin (tretinoin) FDA Approval History"
},{
  "title": "Privigen (immune globulin intravenous (human))  Liquid ",
  "date_of_approval": "July 26, 2007",
  "company": " CSL Behring",
  "treatment": " Primary Immunodeficiency Syndrome, Idiopathic (Immune) Thrombocytopenic Purpura, Chronic Inflammatory Demyelinating Polyradiculoneuropathy",
  "drug_description": "Privigen is an immune globulin intravenous (human), 10% liquid indicated for the treatment of primary humoral immunodeficiency (PI), chronic immune thrombocytopenic purpura (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP).",
  "previous application": "CSL Behring Announces FDA Approval of Privigen-- First\r Proline-Stabilized 10 Percent Liquid IVIg Privigen (immune globulin intravenous (human)) FDA Approval History"
},{
  "title": "CaloMist (cyanocobalamin)  Nasal Spray ",
  "date_of_approval": "July 27, 2007",
  "company": " Fleming &amp; Company, Pharmaceuticals",
  "treatment": " Vitamin B12 Deficiency",
  "drug_description": "",
  "previous application": "FDA Approves CaloMist Nasal Spray for Vitamin B12 Deficiency CaloMist (cyanocobalamin) FDA Approval History"
},{
  "title": "EvaMist (estradiol)  Transdermal Spray ",
  "date_of_approval": "July 27, 2007",
  "company": " VIVUS, Inc.",
  "treatment": " Postmenopausal Symptoms",
  "drug_description": "EvaMist is an estradiol transdermal spray administered once daily for the treatment of vasomotor symptoms (hot flashes) associated with menopause.",
  "previous application": "KV Pharmaceutical Announces U.S. Food and Drug Administration\r Approval of EvaMist EvaMist (estradiol) FDA Approval History"
},{
  "title": "Selzentry (maraviroc)  Tablets ",
  "date_of_approval": "August 6, 2007",
  "company": " ViiV Healthcare",
  "treatment": " HIV Infection",
  "drug_description": "Selzentry (maraviroc) is a CCR5 co-receptor antagonist indicated in combination with other antiretroviral agents for the treatment of only CCR5-tropic HIV-1 infection in patients 2 years of age and older.",
  "previous application": "Pfizer's Selzentry (Maraviroc) Tablets, Novel Treatment for HIV,\r Approved by FDA Selzentry (maraviroc) FDA Approval History"
},{
  "title": "Zingo (lidocaine hydrochloride monohydrate)  Dermal PowderJect ",
  "date_of_approval": "August 16, 2007",
  "company": " Anesiva, Inc.",
  "treatment": " Local Anesthesia",
  "drug_description": "Zingo (lidocaine hydrochloride monohydrate) is a needle-free, local anesthetic intradermal injection system, which provides rapid, topical, local analgesia to reduce the pain associated with venous access procedures, such as IV insertions or blood draws.",
  "previous application": "Anesiva Receives FDA Approval for Zingo, a New, Innovative Productto Reduce Pain Associated with Needle Insertion Procedures inChildren Zingo (lidocaine hydrochloride monohydrate) FDA Approval History"
},{
  "title": "Evithrom (human thrombin) ",
  "date_of_approval": "August 27, 2007",
  "company": " Omrix Biopharmaceuticals, Ltd,",
  "treatment": " Bleeding",
  "drug_description": "Evithrom is a highly purified human thrombin used as an aid to hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques is ineffective or impractical.",
  "previous application": "FDA Approves Evithrom (human thrombin) for Topical Use in Surgery Evithrom (human thrombin) FDA Approval History"
},{
  "title": "Somatuline Depot (lanreotide acetate)  Injection ",
  "date_of_approval": "August 30, 2007",
  "company": " Ipsen Biopharmaceuticals, Inc.",
  "treatment": " Acromegaly; Gastroenteropancreatic Neuroendocrine Tumors; Carcinoid Syndrome",
  "drug_description": "Somatuline Depot (lanreotide) is a long acting somatostatin analogue indicated for the treatment of acromegaly, gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome.",
  "previous application": "Ipsen: Somatuline Depot Receives Marketing Approval in the United\r States for the Treatment of Acromegaly Somatuline Depot (lanreotide acetate) FDA Approval History"
},{
  "title": "ACAM2000 (Smallpox (Vaccinia) Vaccine, Live) ",
  "date_of_approval": "August 31, 2007",
  "company": " Acambis Inc.",
  "treatment": " Smallpox Prophylaxis",
  "drug_description": "ACAM2000 is live vaccinia virus smallpox vaccine intended for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection. ACAM2000 is the first biodefense vaccine to be approved as part of the US response to the 2001 bioterrorism attacks.",
  "previous application": "FDA Approves ACAM2000 Vaccine for Protection Against Smallpox ACAM2000 (Smallpox (Vaccinia) Vaccine, Live) FDA Approval History"
},{
  "title": "Totect (dexrazoxane) ",
  "date_of_approval": "September 6, 2007",
  "company": " TopoTarget A/S",
  "treatment": " Anthracycline Extravasation",
  "drug_description": "Totect (dexrazoxane) is a topoisomerase inhibitor used as a detoxifying agent for the treatment of extravasation resulting from intravenous anthracycline chemotherapy.",
  "previous application": "Totect Approved in the United States Totect (dexrazoxane) FDA Approval History"
},{
  "title": "Azor (amlodipine and olmesartan)  Tablets  - formerly amlodipine and olmesartan",
  "date_of_approval": "September 26, 2007",
  "company": " Daiichi Sankyo, Inc.",
  "treatment": " Hypertension",
  "drug_description": "Azor is a fixed-dose combination of two antihypertensives, the calcium channel blocker amlodipine besylate and the angiotensin receptor blocker olmesartan medoxomil. Azor is indicated for the treatment of hypertension.",
  "previous application": "Azor Receives FDA Approval for Treatment of High Blood Pressure Azor (amlodipine and olmesartan) FDA Approval History"
},{
  "title": "Afluria (influenza virus vaccine, inactivated)  Injection ",
  "date_of_approval": "September 28, 2007",
  "company": " Seqirus",
  "treatment": " Influenza Prophylaxis",
  "drug_description": "Afluria is an inactivated influenza virus vaccine indicated for active immunization against influenza disease in persons 6 months of age and older.",
  "previous application": "CSL Biotherapies Announces FDA Marketing Approval of Afluria Afluria (influenza virus vaccine, inactivated) FDA Approval History"
},{
  "title": "Isentress (raltegravir)  Tablets ",
  "date_of_approval": "October 12, 2007",
  "company": " Merck &amp; Co., Inc.",
  "treatment": " HIV Infection",
  "drug_description": "Isentress (raltegravir) is a human immunodeficiency virus integrase strand transfer inhibitor (HIV-1 INSTI) indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.",
  "previous application": "FDA Approves of Isentress (raltegravir) Isentress (raltegravir) FDA Approval History"
},{
  "title": "Doribax (doripenem)  Injection ",
  "date_of_approval": "October 12, 2007",
  "company": " Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",
  "treatment": " Intraabdominal Infection, Urinary Tract Infection",
  "drug_description": "",
  "previous application": "FDA Approves Doribax for the Treatment of ComplicatedIntra-Abdominal and Complicated Urinary Tract Infections Doribax (doripenem) FDA Approval History"
},{
  "title": "Ixempra (ixabepilone)  Injection ",
  "date_of_approval": "October 16, 2007",
  "company": " R-Pharm US",
  "treatment": " Breast Cancer",
  "drug_description": "Ixempra (ixabepilone) is a semisynthetic analog of epothilone B indicated for the treatment of patients with\r metastatic or locally advanced breast cancer.",
  "previous application": "FDA Approves Ixempra (ixabepilone), a Semi-Synthetic Analog of\r Epothilone B, for the Treatment of Advanced Breast Cancer Ixempra (ixabepilone) FDA Approval History"
},{
  "title": "Voltaren Gel (diclofenac sodium)  Topical Gel ",
  "date_of_approval": "October 17, 2007",
  "company": " GlaxoSmithKline Consumer Healthcare",
  "treatment": " Osteoarthritis",
  "drug_description": "Voltaren Gel (diclofenac sodium) is a topical non-steroidal anti-inflammatory (NSAID) medication indicated for the temporary relief of joint pain due to osteoarthritis.",
  "previous application": "Voltaren Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis Voltaren Gel (diclofenac sodium) FDA Approval History"
},{
  "title": "Renvela (sevelamer carbonate)  Tablets ",
  "date_of_approval": "October 19, 2007",
  "company": " Genzyme Corporation",
  "treatment": " Hyperphosphatemia of Renal Failure",
  "drug_description": "Renvela (sevelamer carbonate) is a calcium-free, metal-free, non-absorbed phosphate binder indicated for the control of serum phosphorus in patients with chronic kidney disease on dialysis.",
  "previous application": "FDA Approves Genzyme's Renvela for Dialysis Patients Renvela (sevelamer carbonate) FDA Approval History"
},{
  "title": "Tasigna (nilotinib)  Capsules ",
  "date_of_approval": "October 29, 2007",
  "company": " Novartis",
  "treatment": " Chronic Myelogenous Leukemia",
  "drug_description": "Tasigna (nilotinib) is a kinase inhibitor indicated for the treatment of chronic\r phase and accelerated phase Philadelphia chromosome positive chronic\r myelogenous leukemia (CML).",
  "previous application": "Tasigna Receives US Approval Providing New Hope to Chronic Myeloid\r Leukemia Patients with Resistance or Intolerance to Existing\r Therapies Tasigna (nilotinib) FDA Approval History"
},{
  "title": "Combigan (brimonidine tartrate and timolol maleate)  Ophthalmic Solution ",
  "date_of_approval": "October 30, 2007",
  "company": " Allergan Inc.",
  "treatment": " Intraocular Hypertension, Glaucoma",
  "drug_description": "Combigan (brimonidine tartrate and timolol maleate) is an alpha\r adrenergic receptor agonist and beta adrenergic receptor inhibitor combination ophthalmic solution for the reduction of elevated intraocular pressure (IOP)\r in patients with glaucoma or ocular hypertension who require\r adjunctive or replacement therapy due to inadequately controlled\r IOP.",
  "previous application": "Allergan, Inc. Receives FDA Approval for Combigan (brimonidine\r tartrate/timolol maleate ophthalmic solution) 0.2%/0.5% Combigan (brimonidine tartrate and timolol maleate) FDA Approval History"
},{
  "title": "Mircera (epoetin beta-methoxy polyethylene glycol)  Injection ",
  "date_of_approval": "November 14, 2007",
  "company": " Roche",
  "treatment": " Anemia Associated with Chronic Renal Failure",
  "drug_description": "Mircera (epoetin beta-methoxy polyethylene glycol) is an erythropoiesis-stimulating agent indicated for the treatment of anemia associated with chronic renal failure.",
  "previous application": "FDA Approves Mircera: First Renal Anemia Treatment in the US withMonthly Maintenance Dosing Mircera (epoetin beta-methoxy polyethylene glycol) FDA Approval History"
},{
  "title": "Triesence (triamcinolone acetonide)  Injectable Suspension ",
  "date_of_approval": "November 29, 2007",
  "company": " Alcon, Inc.",
  "treatment": " Temporal Arteritis, Uveitis",
  "drug_description": "Triesence (triamcinolone acetonide) is a synthetic corticosteroid indicated for visualization during vitrectomy and treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.",
  "previous application": "Alcon Receives FDA Approval of Triesence Injectable Triamcinolone\r Suspension for Use in Eye Surgery Triesence (triamcinolone acetonide) FDA Approval History"
},{
  "title": "Kuvan (sapropterin dihydrochloride)  Tablets ",
  "date_of_approval": "December 13, 2007",
  "company": " BioMarin Pharmaceutical Inc.",
  "treatment": " Phenylketonuria",
  "drug_description": "Kuvan (sapropterin dihydrochloride) is the synthetic form of 6R-BH4 (tetrahydrobiopterin), a naturally occurring enzyme cofactor that works in conjunction with phenylalanine hydroxylase to metabolize phenylalanine (Phe). Kuvan is indicated for the treatment of phenylketonuria, an inherited metabolic disease caused by a deficiency of the enzyme phenylalanine hydroxylase.",
  "previous application": "BioMarin Announces FDA Approval for Kuvan Kuvan (sapropterin dihydrochloride) FDA Approval History"
},{
  "title": "Bystolic (nebivolol) ",
  "date_of_approval": "December 17, 2007",
  "company": " Allergan, Inc.",
  "treatment": " Hypertension",
  "drug_description": "Bystolic (nebivolol) is a once daily beta blocker approved for the treatment of hypertension.",
  "previous application": "Bystolic, a Novel Beta Blocker, is Now Approved by the FDA for the\r Treatment of Hypertension Bystolic (nebivolol) FDA Approval History"
},{
  "title": "Alvesco (ciclesonide)  Inhalation Aerosol ",
  "date_of_approval": "January 10, 2008",
  "company": " Nycomed",
  "treatment": " Asthma",
  "drug_description": "Alvesco (ciclesonide) is an inhaled corticosteroid indicated for the maintenance treatment of asthma and as prophylactic therapy in adult and adolescent patients aged 12 years and older.",
  "previous application": "Alvesco Gains FDA Approval for the U.S. Market Alvesco (ciclesonide) FDA Approval History"
},{
  "title": "Flo-Pred (prednisolone acetate)  Oral Suspension ",
  "date_of_approval": "January 17, 2008",
  "company": " Taro Pharmaceutical Industries Ltd.",
  "treatment": " Asthma, Anti-inflammatory",
  "drug_description": "",
  "previous application": "Taro Receives FDA Approval of New Drug Application for Flo-Pred\r (Prednisolone Acetate Oral Suspension) Flo-Pred (prednisolone acetate) FDA Approval History"
},{
  "title": "Recothrom (Thrombin, topical (Recombinant))  - formerly rhThrombin",
  "date_of_approval": "January 17, 2008",
  "company": " ZymoGenetics, Inc.",
  "treatment": " Hemostasis During Surgery",
  "drug_description": "Recothrom is a recombinant form of human thrombin indicated as an aid to hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques is ineffective or impractical. Recothrom may be used in conjunction with an absorbable gelatin sponge, USP.",
  "previous application": "FDA Approves ZymoGenetics' Recothrom Thrombin, topical(Recombinant) Recothrom (Thrombin, topical (Recombinant)) FDA Approval History"
},{
  "title": "Intelence (etravirine)  Tablets  - formerly TMC125",
  "date_of_approval": "January 18, 2008",
  "company": " Tibotec Pharmaceuticals Ltd.",
  "treatment": " HIV Infection",
  "drug_description": "Intelence (etravirine) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of human immunodeficiency virus type 1\r (HIV-1) infection.",
  "previous application": "FDA Approves Intelence (etravirine) for HIV Combination Therapy Intelence (etravirine) FDA Approval History"
},{
  "title": "Tekturna HCT (aliskiren and hydrochlorothiazide)  Tablets ",
  "date_of_approval": "January 18, 2008",
  "company": " Novartis Pharmaceuticals Corporation",
  "treatment": " Hypertension",
  "drug_description": "Tekturna HCT (aliskiren and hydrochlorothiazide) is a single-tablet combination therapy for the treatment of high blood pressure.",
  "previous application": "Tekturna HCT, a Single-Tablet Combination of Tekturna and a\r Diuretic, Receives US Approval for Treatment of High Blood Pressure Tekturna HCT (aliskiren and hydrochlorothiazide) FDA Approval History"
},{
  "title": "Moxatag (amoxicillin)  Extended Release Tablets ",
  "date_of_approval": "January 23, 2008",
  "company": " Pragma",
  "treatment": " Tonsillitis/Pharyngitis",
  "drug_description": "",
  "previous application": "FDA Approves MiddleBrook's Moxatag - Amoxicillin PULSYS - for\r Pharyngitis/Tonsillitis in Adolescents and Adults Moxatag (amoxicillin) FDA Approval History"
},{
  "title": "Accretropin (somatropin (rDNA origin))  Subcutaneous Injection ",
  "date_of_approval": "January 23, 2008",
  "company": " Emergent",
  "treatment": " Pediatric Growth Hormone Deficiency, Turner Syndrome",
  "drug_description": "",
  "previous application": "Cangene's Recombinant Human Growth Hormone Accretropin Approved by the U.S.\r Food and Drug Administration Accretropin (somatropin (rDNA origin)) FDA Approval History"
},{
  "title": "Simcor (niacin ER and simvastatin)  Tablets ",
  "date_of_approval": "February 15, 2008",
  "company": " Abbott",
  "treatment": " Hyperlipidemia",
  "drug_description": "",
  "previous application": "Abbott Receives FDA Approval for Simcor (Niaspan / simvastatin), a\r Novel Combination Medicine for Comprehensive Cholesterol Management Simcor (niacin ER and simvastatin) FDA Approval History"
},{
  "title": "Xyntha (antihemophilic factor (recombinant), plasma/albumin free ) ",
  "date_of_approval": "February 21, 2008",
  "company": " Wyeth Pharmaceuticals Inc.",
  "treatment": " Hemophilia A",
  "drug_description": "Xyntha (Antihemophilic Factor (Recombinant) Plasma/Albumin Free) is a genetically engineered version of factor VIII, a protein essential for the clotting of\r blood. Xyntha is indicated for the control and prevention of bleeding episodes and for surgical prophylaxis in patients with hemophilia A.",
  "previous application": "FDA Licenses Xyntha, a New Hemophilia Treatment Xyntha (antihemophilic factor (recombinant), plasma/albumin free ) FDA Approval History"
},{
  "title": "Arcalyst (rilonacept)  Injection  - formerly Interleukin-1 Trap",
  "date_of_approval": "February 27, 2008",
  "company": " Regeneron Pharmaceuticals, Inc.",
  "treatment": " Cryopyrin-Associated Periodic Syndromes",
  "drug_description": "Arcalyst (rilonacept) is an interleukin-1 inhibitor for the long-term treatment of Cryopyrin-Associated Periodic Syndromes (CAPS).",
  "previous application": "FDA Approves Arcalyst - New Orphan Drug for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) Arcalyst (rilonacept) FDA Approval History"
},{
  "title": "Pristiq (desvenlafaxine)  Extended-Release Tablets ",
  "date_of_approval": "February 29, 2008",
  "company": " Wyeth Pharmaceuticals",
  "treatment": " Depression",
  "drug_description": "Pristiq (desvenlafaxine) is a serotonin-norepinephrine reuptake inhibitor (SNRI) approved for the treatment for adult patients with major depressive disorder. Pristiq is also currently under review as a treatment for moderate-to-severe vasomotor symptoms associated with menopause.",
  "previous application": "FDA Approves Pristiq for the Treatment of Adult Patients with MajorDepressive Disorder Pristiq (desvenlafaxine) FDA Approval History"
},{
  "title": "Fusilev (levoleucovorin)  for Injection ",
  "date_of_approval": "March 7, 2008",
  "company": " Spectrum Pharmaceuticals, Inc.",
  "treatment": " Methotrexate Rescue, Folic Acid Antagonist Overdose, Colorectal Cancer",
  "drug_description": "Fusilev (levoleucovorin calcium) is a folate analog indicated for rescue after high-dose methotrexate therapy in osteosarcoma, diminishing the toxicity and counteracting the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists, and for use in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer.",
  "previous application": "FDA Approves New Drug Application for Levoleucovorin, Spectrum's\r First Proprietary Oncology Drug Fusilev (levoleucovorin) FDA Approval History"
},{
  "title": "Artiss (fibrin sealant (human))  Topical Solution ",
  "date_of_approval": "March 19, 2008",
  "company": " Baxter Healthcare Corporation",
  "treatment": " Burns - External",
  "drug_description": "Artiss (fibrin sealant (human)) is a slow-setting fibrin sealant indicated for use in\r adhering skin grafts in adult and pediatric burn patients and for\r tissue adherence in facial rhytidectomy (face-lift) surgery.",
  "previous application": "FDA Approves Artiss Medical Adhesive to Treat Burn Patients Artiss (fibrin sealant (human)) FDA Approval History"
},{
  "title": "Treanda (bendamustine hydrochloride)  Injection ",
  "date_of_approval": "March 20, 2008",
  "company": " Cephalon, Inc.",
  "treatment": " Chronic Lymphocytic Leukemia, non-Hodgkin's Lymphoma",
  "drug_description": "Treanda (bendamustine) is a purine alkylator\r hybrid chemotherapy agent indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) and relapsed indolent non-Hodgkin's lymphoma.",
  "previous application": "Cephalon Receives FDA Approval for Treanda, a Novel Chemotherapyfor Chronic Lymphocytic Leukemia Treanda (bendamustine hydrochloride) FDA Approval History"
},{
  "title": "Rotarix (rotavirus vaccine, live attenuated)  Oral Suspension ",
  "date_of_approval": "April 3, 2008",
  "company": " GlaxoSmithKline",
  "treatment": " Prevention of Rotavirus Gastroenteritis",
  "drug_description": "Rotarix (rotavirus vaccine live) is an oral, two-dose, live attenuated vaccine for the prevention of rotavirus gastroenteritis in children.",
  "previous application": "FDA Approves Rotarix Vaccine to Prevent Gastroenteritis Caused by\r Rotavirus Rotarix (rotavirus vaccine, live attenuated) FDA Approval History"
},{
  "title": "Lexiscan (regadenoson)  Injection ",
  "date_of_approval": "April 10, 2008",
  "company": " CV Therapeutics, Inc.",
  "treatment": " Diagnostic",
  "drug_description": "Lexiscan (regadenoson) is an A2A\r adenosine receptor agonist indicated for use as a pharmacologic stress agent\r in radionuclide myocardial perfusion imaging (MPI), a test that\r detects and characterizes coronary artery disease, in patients\r unable to undergo adequate exercise stress.",
  "previous application": "CV Therapeutics and Astellas Announce FDA Approval for Lexiscan(regadenoson) Injection Lexiscan (regadenoson) FDA Approval History"
},{
  "title": "Treximet (sumatriptan succinate and naproxen sodium)  Tablets  - formerly Trexima",
  "date_of_approval": "April 15, 2008",
  "company": " Pernix Therapeutics Holdings, Inc.",
  "treatment": " Migraine",
  "drug_description": "Treximet is a combination of sumatriptan (a migraine-specific triptan) and naproxen (an anti-inflammatory pain reliever) in a single tablet for the acute treatment of migraine.",
  "previous application": "Treximet (sumatriptan and naproxen sodium) Tablets Approved by FDAfor Acute Treatment of Migraine Treximet (sumatriptan succinate and naproxen sodium) FDA Approval History"
},{
  "title": "Patanase (olopatadine hydrochloride)  Nasal Spray ",
  "date_of_approval": "April 15, 2008",
  "company": " Alcon, Inc.",
  "treatment": " Allergic Rhinitis",
  "drug_description": "Patanase (olopatadine) is an antihistamine nasal spray for the treatment of symptoms of\r seasonal allergic rhinitis in adults and adolescents twelve years of age and older.",
  "previous application": "Alcon's Patanase Nasal Spray Approved by FDA for Treatment of Nasal\r Allergy Symptoms Patanase (olopatadine hydrochloride) FDA Approval History"
},{
  "title": "Cimzia (certolizumab pegol)  Injection ",
  "date_of_approval": "April 22, 2008",
  "company": " UCB, Inc.",
  "treatment": " Crohn's Disease -- Acute, Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, Ankylosing Spondylitis",
  "drug_description": "Cimzia (certolizumab) is a PEGylated anti-TNF (tumor necrosis factor) biologic therapy for the treatment of Crohn\u2019s disease, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, and non-radiographic axial spondyloarthritis.",
  "previous application": "Cimzia Approved in the US for the Treatment of Moderate to Severe\r Crohn's Disease Cimzia (certolizumab pegol) FDA Approval History"
},{
  "title": "Aplenzin (bupropion hydrobromide)  Extended-Release Tablets  - formerly BVF-033",
  "date_of_approval": "April 23, 2008",
  "company": " Biovail Corporation",
  "treatment": " Depression",
  "drug_description": "Aplenzin is a once-daily formulation of bupropion hydrobromide indicated for the treatment of depression in adults.",
  "previous application": "Biovail Receives FDA Approval for Aplenzin (BVF-033) Aplenzin (bupropion hydrobromide) FDA Approval History"
},{
  "title": "Relistor (methylnaltrexone bromide)  Tablets and Subcutaneous Injection ",
  "date_of_approval": "April 25, 2008",
  "company": " Salix Pharmaceuticals, Inc.",
  "treatment": " Constipation",
  "drug_description": "Relistor (methylnaltrexone) is a peripherally acting mu-opioid receptor antagonist indicated to treat opioid-induced constipation.",
  "previous application": "Progenics and Wyeth Announce FDA Has Approved Relistor Relistor (methylnaltrexone bromide) FDA Approval History"
},{
  "title": "OraVerse (phentolamine mesylate)  Injection ",
  "date_of_approval": "May 9, 2008",
  "company": " Novalar Pharmaceuticals, Inc.",
  "treatment": " Reversal of Anesthesia",
  "drug_description": "OraVerse is a dental anesthetic reversal agent that accelerates the return to normal sensation and function following dental procedures.",
  "previous application": "Novalar Pharmaceuticals, Inc. Receives FDA Approval for OraVerse OraVerse (phentolamine mesylate) FDA Approval History"
},{
  "title": "Entereg (alvimopan)  Capsules ",
  "date_of_approval": "May 20, 2008",
  "company": " Adolor Corporation",
  "treatment": " Postoperative Ileus",
  "drug_description": "Entereg (alvimopan) is a peripherally-acting mu opioid receptor antagonist used to help patients regain gastrointestinal (GI) function earlier following bowel resection\r surgery.",
  "previous application": "Adolor and GlaxoSmithKline Announce FDA Approval of Entereg\r (alvimopan) for the Management of Postoperative Ileus (POI) Entereg (alvimopan) FDA Approval History"
},{
  "title": "Trivaris (triamcinolone acetonide)  Intravitreal Injection ",
  "date_of_approval": "June 16, 2008",
  "company": " Allergan, Inc.",
  "treatment": " Ocular Inflammatory Conditions",
  "drug_description": "",
  "previous application": "Allergan Receives U.S. Food and Drug Administration Approval for\r Trivaris (triamcinolone acetonide injectable suspension) 80 mg/mL Trivaris (triamcinolone acetonide) FDA Approval History"
},{
  "title": "Pentacel (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine) ",
  "date_of_approval": "June 20, 2008",
  "company": " Sanofi pasteur",
  "treatment": " Diphtheria Prophylaxis, Tetanus Prophylaxis, Pertussis Prophylaxis, Poliomyelitis Prophylaxis, Haemophilus influenzae Prophylaxis",
  "drug_description": "Pentacel is a combination vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b in children 6 weeks through 4 years of age.",
  "previous application": "U.S. FDA Licenses Sanofi Pasteur's New Pediatric CombinationVaccine, Pentacel Pentacel (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine) FDA Approval History"
},{
  "title": "PrandiMet (repaglinide and metformin)  Tablets ",
  "date_of_approval": "June 23, 2008",
  "company": " Sciele Pharma, Inc. and Novo Nordisk Inc.",
  "treatment": " Diabetes Type 2",
  "drug_description": "",
  "previous application": "FDA Approves PrandiMet, a Replaglinide and Metformin Fixed-Dose\r Combination Tablet for Treatment of Type 2 Diabetes PrandiMet (repaglinide and metformin) FDA Approval History"
},{
  "title": "Durezol (difluprednate)  Ophthalmic Emulsion ",
  "date_of_approval": "June 23, 2008",
  "company": " Sirion Therapeutics, Inc.",
  "treatment": " Postoperative Ocular Inflammation",
  "drug_description": "Durezol (difluprednate ophthalmic emulsion) is a topical steroid for the treatment of postoperative ocular inflammation and pain.",
  "previous application": "Sirion Therapeutics Announces FDA Approval of Durezol for Treatmentof Postoperative Ocular Inflammation and Pain Durezol (difluprednate) FDA Approval History"
},{
  "title": "Kinrix (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine) ",
  "date_of_approval": "June 24, 2008",
  "company": " GlaxoSmithKline",
  "treatment": " Diphtheria Prophylaxis, Tetanus Prophylaxis, Poliomyelitis Prophylaxis, Pertussis Prophylaxis",
  "drug_description": "Kinrix [Diphtheria and\r Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated\r Poliovirus Vaccine] is a combination vaccine\r for protection against diphtheria, tetanus, pertussis and polio diseases in children.",
  "previous application": "FDA Approves Kinrix - New Combination Vaccine for Children Kinrix (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine) FDA Approval History"
},{
  "title": "Evolence (dermal filler) ",
  "date_of_approval": "June 27, 2008",
  "company": " OrthoNeutrogena",
  "treatment": " Facial Wrinkles",
  "drug_description": "Evolence is a collagen-based structural dermal filler for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds.",
  "previous application": "FDA Approves Evolence, a New Generation Collagen-Based Facial\r Filler Evolence (dermal filler) FDA Approval History"
},{
  "title": "Eovist (gadoxetate disodium) ",
  "date_of_approval": "July 3, 2008",
  "company": " Bayer HealthCare Pharmaceuticals Inc.",
  "treatment": " Diagnostic",
  "drug_description": "Eovist (gadoxetate disodium) is a gadolinium-based contrast agent for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize\r lesions in adults with known or suspected focal liver disease.",
  "previous application": "FDA Approves Eovist to Detect and Characterize Focal Liver Lesions Eovist (gadoxetate disodium) FDA Approval History"
},{
  "title": "Navstel (balanced salt ophthalmic solution with hypromellose, dextrose and glutathione)  Intraocular Irrigating Solution ",
  "date_of_approval": "July 24, 2008",
  "company": " Alcon Laboratories, Inc.",
  "treatment": " Intraocular Irrigation",
  "drug_description": "",
  "previous application": "FDA Approves Navstel Intraocular Irrigating Solution Navstel (balanced salt ophthalmic solution with hypromellose, dextrose and glutathione) FDA Approval History"
},{
  "title": "Stavzor (valproic acid)  Capsules ",
  "date_of_approval": "July 29, 2008",
  "company": " Noven Pharmaceuticals, Inc.",
  "treatment": " Bipolar Disorder, Seizures, Epilepsy, Migraine Prophylaxis",
  "drug_description": "",
  "previous application": "Noven Announces Final FDA Approval of Stavzor for the Treatment of Bipolar Disorder, Seizures and Migraine Headaches Stavzor (valproic acid) FDA Approval History"
},{
  "title": "Cleviprex  (clevidipine butyrate)  Injectable Emulsion ",
  "date_of_approval": "August 1, 2008",
  "company": " The Medicines Company",
  "treatment": " Hypertension",
  "drug_description": "Cleviprex (clevidipine) is an intravenous, ultrashort-acting calcium channel blocker under development for the treatment of severely elevated blood pressure in the hospital setting when oral therapy is not feasible or desirable.",
  "previous application": "The Medicines Company\u2019s Cleviprex Receives FDA Approval Cleviprex  (clevidipine butyrate) FDA Approval History"
},{
  "title": "Xenazine (tetrabenazine) ",
  "date_of_approval": "August 15, 2008",
  "company": " Prestwick Pharmaceuticals, Inc.",
  "treatment": " Huntington\u2019s Chorea",
  "drug_description": "Xenazine (tetrabenazine) is a selective and reversible centrally-acting dopamine depleting drug indicated for the treatment of chorea associated with Huntington's disease.",
  "previous application": "Xenazine (Tetrabenazine) Approved by FDA for Patients with Chorea Associated with Huntington's Disease Xenazine (tetrabenazine) FDA Approval History"
},{
  "title": "Nplate (romiplostim) ",
  "date_of_approval": "August 22, 2008",
  "company": " Amgen Inc.",
  "treatment": " Idiopathic (Immune) Thrombocytopenic Purpura",
  "drug_description": "Nplate (romiplostim) is a thrombopoietin mimetic peptibody for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP).",
  "previous application": "FDA Approves Nplate for Long-Term Treatment of Adult Chronic ITP Nplate (romiplostim) FDA Approval History"
},{
  "title": "Sancuso (granisetron)  Transdermal Patch ",
  "date_of_approval": "September 12, 2008",
  "company": " ProStrakan Group plc",
  "treatment": " Nausea/Vomiting -- Chemotherapy Induced",
  "drug_description": "Sancuso (granisetron transdermal system) is an anti-emetic transdermal delivery system indicated for the control of nausea and vomiting in patients receiving moderately and/or highly nausea-inducing chemotherapy.",
  "previous application": "FDA Approves Sancuso, the First and Only Patch for Preventing Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy Sancuso (granisetron) FDA Approval History"
},{
  "title": "AdreView (iobenguane I 123)  Injection ",
  "date_of_approval": "September 19, 2008",
  "company": " GE Healthcare",
  "treatment": " Diagnostic",
  "drug_description": "AdreView is a diagnostic radiopharmaceutical agent indicated for use in the detection of rare neuroendocrine tumors in children and adults.",
  "previous application": "FDA Approves GE Healthcare's AdreView (Iobenguane I 123 Injection) Diagnostic Agent for Detecting Neuroendocrine Tumors in Children, Adults AdreView (iobenguane I 123) FDA Approval History"
},{
  "title": "Akten (lidocaine hydrochloride)  Ophthalmic Gel ",
  "date_of_approval": "October 7, 2008",
  "company": " Akorn, Inc.",
  "treatment": " Ocular Anesthesia",
  "drug_description": "Akten (lidocaine hydrochloride) Ophthalmic Gel is a topical, ocular anesthetic formulation for use in ocular procedures that require a topical anesthetic agent.",
  "previous application": "Akorn, Inc. Announces the FDA Approval of Akten Ophthalmic Gel 3.5% Akten (lidocaine hydrochloride) FDA Approval History"
},{
  "title": "Rapaflo (silodosin)  Capsules ",
  "date_of_approval": "October 8, 2008",
  "company": " Allergan, Inc.",
  "treatment": " Benign Prostatic Hyperplasia",
  "drug_description": "Rapaflo (silodosin) is an alpha(1)- adrenoreceptor antagonist for\r the treatment of the signs and symptoms associated with benign prostatic hyperplasia (BPH), or enlarged prostate.",
  "previous application": "Watson Receives US FDA Approval for Rapaflo (silodosin) for the Treatment of Benign Prostatic Hyperplasia (BPH) Rapaflo (silodosin) FDA Approval History"
},{
  "title": "Cinryze (C1 esterase inhibitor (human))  Injection ",
  "date_of_approval": "October 10, 2008",
  "company": " Shire plc",
  "treatment": " Hereditary Angioedema",
  "drug_description": "Cinryze is a C1-esterase inhibitor indicated for routine prophylaxis against angioedema attacks in patients with hereditary angioedema (HAE).",
  "previous application": "Cinryze Receives FDA Approval for Prophylaxis Against Hereditary Angioedema Attacks Cinryze (C1 esterase inhibitor (human)) FDA Approval History"
},{
  "title": "Astepro (azelastine)  Nasal Spray ",
  "date_of_approval": "October 15, 2008",
  "company": " Meda AB",
  "treatment": " Allergic Rhinitis",
  "drug_description": "Astepro (azelastine) is a nasal antihistamine for the treatment of seasonal allergic rhinitis.",
  "previous application": "FDA Approves Astepro Astepro (azelastine) FDA Approval History"
},{
  "title": "Acanya (benzoyl peroxide and clindamycin phosphate)  Topical Gel ",
  "date_of_approval": "October 21, 2008",
  "company": " Dow Pharmaceutical Sciences, Inc.",
  "treatment": " Acne",
  "drug_description": "Acanya (benzoyl peroxide and clindamycin phosphate) is a topical antibacterial and antibiotic combination for the treatment of acne.",
  "previous application": "FDA Approves Acanya Acanya (benzoyl peroxide and clindamycin phosphate) FDA Approval History"
},{
  "title": "LoSeasonique (ethinyl estradiol and levonorgestrel)  Extended-Cycle Oral Contraceptive Tablets ",
  "date_of_approval": "October 24, 2008",
  "company": " Duramed Pharmaceuticals, Inc.",
  "treatment": " Contraception",
  "drug_description": "LoSeasonique is a lower-dose, extended-cycle oral contraceptive indicated for the prevention of pregnancy.",
  "previous application": "FDA Approves Duramed's LoSeasonique Oral Contraceptive LoSeasonique (ethinyl estradiol and levonorgestrel) FDA Approval History"
},{
  "title": "Vimpat (lacosamide)  Tablets, Injection, Oral Solution ",
  "date_of_approval": "October 28, 2008",
  "company": " UCB",
  "treatment": " Seizures",
  "drug_description": "Vimpat (lacosamide) is an anti-convulsant indicated for the treatment of partial-onset seizures, and as an adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older.",
  "previous application": "UCB's Vimpat Approved By U.S. FDA As Adjunctive Therapy for Partial Onset Seizures in Adults Vimpat (lacosamide) FDA Approval History"
},{
  "title": "Toviaz (fesoterodine fumarate)  Extended Release Tablets  ",
  "date_of_approval": "October 31, 2008",
  "company": " Pfizer Inc.",
  "treatment": " Urinary Frequency",
  "drug_description": "Toviaz (fesoterodine fumarate) is a competitive muscarinic receptor antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary\r incontinence, urgency, and frequency.",
  "previous application": "Pfizer's Toviaz (fesoterodine fumarate) Receives FDA Approval for the Treatment of Overactive Bladder Toviaz (fesoterodine fumarate) FDA Approval History"
},{
  "title": "Apriso (mesalamine)  Extended-Release Capsules  ",
  "date_of_approval": "October 31, 2008",
  "company": " Salix Pharmaceuticals, Ltd.",
  "treatment": " Ulcerative Colitis",
  "drug_description": "Apriso (mesalamine) is a once-daily, locally-acting aminosalicylate indicated for the maintenance of remission of ulcerative colitis (UC) in adults.",
  "previous application": "Apriso Granted FDA Marketing Approval for Maintenance of Remission of Ulcerative Colitis Apriso (mesalamine) FDA Approval History"
},{
  "title": "Banzel (rufinamide) ",
  "date_of_approval": "November 14, 2008",
  "company": " Eisai Medical Research Inc.",
  "treatment": " Lennox-Gastaut Syndrome",
  "drug_description": "Banzel (rufinamide) is a triazole derivative antiepileptic drug for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome.",
  "previous application": "FDA Approves Banzel (rufinamide) as Adjunctive Treatment for Severe Epilepsy Disorder Banzel (rufinamide) FDA Approval History"
},{
  "title": "Promacta (eltrombopag)  Tablets ",
  "date_of_approval": "November 20, 2008",
  "company": " Novartis Pharmaceuticals Corporation",
  "treatment": " Idiopathic (Immune) Thrombocytopenic Purpura, Thrombocytopenia, Aplastic Anemia",
  "drug_description": "Promacta (eltrombopag) is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura, thrombocytopenia in patients with chronic hepatitis C, and patients with severe aplastic anemia.",
  "previous application": "FDA Approves Promacta (eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder Promacta (eltrombopag) FDA Approval History"
},{
  "title": "Nucynta (tapentadol)  Tablets ",
  "date_of_approval": "November 20, 2008",
  "company": " Ortho-McNeil-Janssen Pharmaceuticals, Inc.",
  "treatment": " Pain",
  "drug_description": "Nucynta (tapentadol) is a centrally acting oral analgesic indicated for the relief of moderate to severe acute pain.",
  "previous application": "FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain Nucynta (tapentadol) FDA Approval History"
},{
  "title": "SCE-A (Synthetic Conjugated Estrogens-A)  Vaginal Cream ",
  "date_of_approval": "November 28, 2008",
  "company": " Duramed Pharmaceuticals, Inc.",
  "treatment": " Postmenopausal Symptoms",
  "drug_description": "",
  "previous application": "FDA Approves Duramed's Synthetic Conjugated Estrogens-A Vaginal Cream SCE-A (Synthetic Conjugated Estrogens-A) FDA Approval History"
},{
  "title": "Lusedra (fospropofol disodium)  Injection ",
  "date_of_approval": "December 12, 2008",
  "company": " Eisai Corporation of North America",
  "treatment": " Sedation",
  "drug_description": "",
  "previous application": "FDA Approves Lusedra (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation Lusedra (fospropofol disodium) FDA Approval History"
},{
  "title": "Trilipix (fenofibric acid)  Delayed-Release Capsules  ",
  "date_of_approval": "December 15, 2008",
  "company": " Abbott",
  "treatment": " Hypertriglyceridemia, Hyperlipidemia",
  "drug_description": "Trilipix (fenofibric acid) is a peroxisome proliferator receptor alpha (PPAR\u03b1) activator\r indicated for use along with diet to help lower triglycerides and LDL cholesterol, and to raise HDL cholesterol in patients with lipid problems. Trilipix is the first and only fibrate to be approved for use in combination with a statin.",
  "previous application": "Abbott Receives FDA Approval for Trilipix (fenofibric acid), First and Only Fibrate Indicated for Use in Combination With a Statin for Cholesterol Management Trilipix (fenofibric acid) FDA Approval History"
},{
  "title": "Mozobil (plerixafor) ",
  "date_of_approval": "December 15, 2008",
  "company": " Genzyme Corporation",
  "treatment": " Bone Marrow Transplantation",
  "drug_description": "Mozobil (plerixafor) is a small molecule CXCR4 chemokine receptor antagonist used in combination with granulocyte-colony stimulating factor to mobilize hematopoietic stem cells to the bloodstream for collection and subsequent autologous transplantation in patients with non-Hodgkin\u2019s lymphoma and multiple myeloma.",
  "previous application": "FDA Approves Genzyme's Mozobil Mozobil (plerixafor) FDA Approval History"
},{
  "title": "Oforta (fludarabine phosphate)  Tablets ",
  "date_of_approval": "December 18, 2008",
  "company": " sanofi-aventis U.S.",
  "treatment": " Chronic Lymphocytic Leukemia",
  "drug_description": "",
  "previous application": "Antisoma Receives FDA Approval for Oral Fludarabine, Plans Commercialization Deal to Bring Drug to US Patients Oforta (fludarabine phosphate) FDA Approval History"
},{
  "title": "Zolpimist (zolpidem tartrate)  Oral Spray ",
  "date_of_approval": "December 19, 2008",
  "company": " NovaDel Pharma, Inc.",
  "treatment": " Insomnia",
  "drug_description": "Zolpimist is an oral spray formulation of zolpidem, the drug contained in Ambien. Zolpimist is indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation.",
  "previous application": "NovaDel Pharma Receives FDA Approval of Zolpimist Zolpimist (zolpidem tartrate) FDA Approval History"
},{
  "title": "Ablavar (gadofosveset trisodium)  - formerly Vasovist",
  "date_of_approval": "December 22, 2008",
  "company": " EPIX Pharmaceuticals, Inc.",
  "treatment": " Diagnostic",
  "drug_description": "",
  "previous application": "EPIX Pharmaceuticals Announces FDA Approval of Vasovist (gadofosveset trisodium) Ablavar (gadofosveset trisodium) FDA Approval History"
},{
  "title": "Firmagon (degarelix)  for Injection ",
  "date_of_approval": "December 24, 2008",
  "company": " Ferring Pharmaceuticals, USA",
  "treatment": " Prostate Cancer",
  "drug_description": "Firmagon (degarelix) is an injectable gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for patients with advanced prostate cancer.",
  "previous application": "FDA Approves Ferring Pharmaceuticals' Degarelix for Treatment of Advanced Prostate Cancer Firmagon (degarelix) FDA Approval History"
},{
  "title": "Latisse (bimatoprost)  Ophthalmic Solution ",
  "date_of_approval": "December 24, 2008",
  "company": " Allergan, Inc.",
  "treatment": " Hypotrichosis of Eyelashes",
  "drug_description": "Latisse (bimatoprost ophthalmic) is a prostamide indicated for the treatment of hypotrichosis (or reduced amount of hair) of the eyelashes. Growth of the eyelashes is a well documented side effect of bimatoprost which is currently approved as Lumigan for the treatment of glaucoma.",
  "previous application": "Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes Latisse (bimatoprost) FDA Approval History"
},{
  "title": "Ryzolt (tramadol)  Extended Release Tablets ",
  "date_of_approval": "December 30, 2008",
  "company": " Labopharm Inc.",
  "treatment": " Pain",
  "drug_description": "",
  "previous application": "Labopharm Announces FDA Approval of Once-Daily Ryzolt for\u00a0Moderate to Moderately Severe Chronic Pain Ryzolt (tramadol) FDA Approval History"
},{
  "title": "Nexterone (amiodarone HCl)  Injection ",
  "date_of_approval": "December 24, 2008",
  "company": " Prism Pharmaceuticals",
  "treatment": " Ventricular Fibrillation, Ventricular Tachycardia",
  "drug_description": "Nexterone (amiodarone HCl) Injection is a cosolvent free formulation of the antiarrhythmic agent Amiodarone IV, originally marketed in the US by Wyeth as Cordarone Intravenous. Nexterone is indicated for the treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy.",
  "previous application": "Prism Pharmaceuticals Receives FDA Approval of Nexterone for Life-Threatening Ventricular Fibrillation and Ventricular Tachycardia Nexterone (amiodarone HCl) FDA Approval History"
},{
  "title": "Epiduo (adapalene and benzoyl peroxide)  Gel ",
  "date_of_approval": "December 8, 2008",
  "company": " Galderma Laboratories, L.P.",
  "treatment": " Acne",
  "drug_description": "Epiduo (adapalene and benzoyl peroxide) Gel is a once-daily, topical retinoid and antimicrobial combination for the treatment of acne.",
  "previous application": "Galderma Announces Availability Of Epiduo Gel, The First And Only Combination Treatment With A Retinoid And Benzoyl Peroxide To Treat Acne Epiduo (adapalene and benzoyl peroxide) FDA Approval History"
},{
  "title": "AllerNaze (triamcinolone acetonide)  Nasal Spray  - formerly AllerNase",
  "date_of_approval": "January 7, 2009",
  "company": " Collegium Pharmaceutical, Inc.",
  "treatment": " Allergic Rhinitis",
  "drug_description": "",
  "previous application": "Collegium Pharmaceutical Announces FDA Approval of AllerNaze, a Nasal Inhaled Steroid for the Treatment of Allergic Rhinitis AllerNaze (triamcinolone acetonide) FDA Approval History"
},{
  "title": "Savella (milnacipran) ",
  "date_of_approval": "January 14, 2009",
  "company": " Allergan, Inc.",
  "treatment": " Fibromyalgia",
  "drug_description": "Savella (milnacipran) is a selective serotonin and norepinephrine reuptake inhibitor indicated for the management of fibromyalgia.",
  "previous application": "Forest and Cypress Announce FDA Approval of Savella for the Management of Fibromyalgia Savella (milnacipran) FDA Approval History"
},{
  "title": "RiaSTAP (Fibrinogen Concentrate (Human)) ",
  "date_of_approval": "January 16, 2009",
  "company": " CSL Behring",
  "treatment": " Congenital Fibrinogen Deficiency",
  "drug_description": "RiaSTAP (Fibrinogen Concentrate (Human)) is lyophilized fibrinogen for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.",
  "previous application": "CSL Behring Receives FDA Approval of RiaSTAP, First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency RiaSTAP (Fibrinogen Concentrate (Human)) FDA Approval History"
},{
  "title": "Gelnique (oxybutynin hydrochloride)  Topical Gel  - formerly OTG",
  "date_of_approval": "January 27, 2009",
  "company": " Watson Pharmaceuticals, Inc.",
  "treatment": " Overactive Bladder",
  "drug_description": "Gelnique (oxybutynin chloride) Gel is a transdermal antispasmodic which is applied to the skin once daily for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency.",
  "previous application": "Watson's Gelnique (oxybutynin chloride) Gel 10% Approved by FDA for the Treatment of Overactive Bladder Gelnique (oxybutynin hydrochloride) FDA Approval History"
},{
  "title": "Dexilant (dexlansoprazole)  Delayed Release Capsules  - formerly Kapidex",
  "date_of_approval": "January 30, 2009",
  "company": " Takeda Pharmaceutical Company Limited",
  "treatment": " Erosive Esophagitis, Gastroesophageal Reflux Disease",
  "drug_description": "Dexilant (dexlansoprazole) is a proton\r pump inhibitor with a novel delivery system  approved for the treatment of erosive esophagitis and heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD).",
  "previous application": "FDA Approves Kapidex (dexlansoprazole) for the Treatment of GERD Dexilant (dexlansoprazole) FDA Approval History"
},{
  "title": "Vectical (calcitriol)  Ointment ",
  "date_of_approval": "January 23, 2009",
  "company": " Galderma Laboratories, L.P.",
  "treatment": " Psoriasis",
  "drug_description": "Vectical Ointment is a Vitamin D analog indicated for the topical treatment of mild to moderate plaque psoriasis in adults 18 years and older.",
  "previous application": "Galderma Wins FDA Approval for Vectical Ointment, a Novel Topical Therapy for Mild-to-Moderate Plaque Psoriasis Vectical (calcitriol) FDA Approval History"
},{
  "title": "ATryn (Antithrombin (Recombinant)) ",
  "date_of_approval": "February 6, 2009",
  "company": " GTC Biotherapeutics, Inc.",
  "treatment": " Antithrombin III Deficiency",
  "drug_description": "ATryn (Antithrombin (Recombinant)) is a recombinant form of human antithrombin for the prevention of peri-operative and peri-partum thromboembolic events in hereditary antithrombin deficient patients.",
  "previous application": "ATryn (Antithrombin [Recombinant]) Approved by the FDA ATryn (Antithrombin (Recombinant)) FDA Approval History"
},{
  "title": "Uloric (febuxostat)  Tablets ",
  "date_of_approval": "February 13, 2009",
  "company": " Takeda Pharmaceutical Company Limited",
  "treatment": " Gout",
  "drug_description": "Uloric (febuxostat) is a xanthine oxidase inhibitor indicated for the chronic management of hyperuricemia in patients with gout.",
  "previous application": "FDA Approves Uloric (febuxostat) for the Chronic Management of Hyperuricemia in Patients with Gout Uloric (febuxostat) FDA Approval History"
},{
  "title": "Edluar (zolpidem)  Sublingual Tablets  - formerly Sublinox",
  "date_of_approval": "March 13, 2009",
  "company": " Orexo and Meda AB",
  "treatment": " Insomnia",
  "drug_description": "Edluar (formerly Sublinox) is a fast-acting sublingual tablet formulation of the widely used drug zolpidem. Edluar is approved for the short-term treatment of insomnia characterized by difficulties with sleep initiation.",
  "previous application": "Orexo's Edluar (formerly Sublinox) receives FDA approval for the treatment of insomnia Edluar (zolpidem) FDA Approval History"
},{
  "title": "Afinitor (everolimus)  Tablets ",
  "date_of_approval": "March 30, 2009",
  "company": " Novartis AG",
  "treatment": " Renal Cell Carcinoma, Breast Cancer, Neuroendocrine Carcinoma",
  "drug_description": "Afinitor (everolimus) is an oral once-daily inhibitor of mTOR indicated for the treatment of patients with advanced HR+, HER2- breast cancer; progressive neuroendocrine \r tumors of pancreatic origin (PNET); progressive neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin; advanced renal cell carcinoma; and subependymal giant cell astrocytoma (SEGA) and renal angiomyolipomas associated with tuberous sclerosis.",
  "previous application": "Afinitor approved in US as first treatment for patients with advanced kidney cancer after failure of either sunitinib or sorafenib Afinitor (everolimus) FDA Approval History"
},{
  "title": "Ixiaro (Japanese Encephalitis Virus Vaccine, Inactivated, Adsorbed) ",
  "date_of_approval": "March 30, 2009",
  "company": " Intercell AG",
  "treatment": " Japanese Encephalitis Virus Prophylaxis",
  "drug_description": "Ixiaro (Japanese Encephalitis Virus Vaccine, Inactivated, Adsorbed) is a purified, inactivated product for active immunization against viral infections of Japanese Encephalitis.",
  "previous application": "Intercell Announces FDA Approval of Ixiaro, a Novel Vaccine to Prevent Japanese Encephalitis Ixiaro (Japanese Encephalitis Virus Vaccine, Inactivated, Adsorbed) FDA Approval History"
},{
  "title": "Coartem (artemether and lumefantrine)  Tablets ",
  "date_of_approval": "April 7, 2009",
  "company": " Novartis",
  "treatment": " Malaria",
  "drug_description": "Coartem (artemether and lumefantrine) is an artemisinin-based combination treatment for the treatment of malaria.",
  "previous application": "Coartem receives FDA approval becoming first artemisinin-based combination treatment (ACT) for malaria in the US Coartem (artemether and lumefantrine) FDA Approval History"
},{
  "title": "Ulesfia (benzyl alcohol)  Lotion 5%  - formerly Summers\u2019 Lice Asphyxiator",
  "date_of_approval": "April 9, 2009",
  "company": " Sciele Pharma, Inc.",
  "treatment": " Lice",
  "drug_description": "Ulesfia (benzyl alcohol) Lotion is a non-toxic, insecticide-free head lice treatment which prevents lice from closing their spiracles (sophisticated breathing apparatus) thereby killing the lice by asphyxiation.",
  "previous application": "Sciele Pharma Announces FDA Approval of Benzyl Alcohol Lotion 5%, First Prescription Non-Neurotoxic Head Lice Treatment Ulesfia (benzyl alcohol) FDA Approval History"
},{
  "title": "Simponi (golimumab)  Injection ",
  "date_of_approval": "April 24, 2009",
  "company": " Centocor, Inc.",
  "treatment": " Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Ulcerative Colitis",
  "drug_description": "Simponi (golimumab)  is a tumor necrosis factor (TNF) blocker indicated for the treatment of adult patients with:",
  "previous application": "Simponi (golimumab) Receives FDA Approval as First Once-Monthly Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Simponi (golimumab) FDA Approval History"
},{
  "title": "Dysport (abobotulinumtoxinA)  Injection ",
  "date_of_approval": "April 29, 2009",
  "company": " Medicis and Ipsen",
  "treatment": " Cervical Dystonia, Glabellar Lines, Upper Limb Spasticity, Lower Limb Spasticity",
  "drug_description": "Dysport (abobotulinumtoxinA) is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for:",
  "previous application": "FDA Approves Dysport (abobotulinumtoxinA) for Cervical Dystonia and Glabellar Lines Dysport (abobotulinumtoxinA) FDA Approval History"
},{
  "title": "Exforge HCT (amlodipine, valsartan and hydrochlorothiazide)  Tablets ",
  "date_of_approval": "April 30, 2009",
  "company": " Novartis AG",
  "treatment": " Hypertension",
  "drug_description": "Exforge HCT is a combination of the calcium channel blocker amlodipine, the angiotensin receptor blocker valsartan, and the diuretic hydrochlorothiazide indicated for the once-daily combination treatment of hypertension.",
  "previous application": "FDA approves Exforge HCT - the only high blood pressure treatment to combine three medications in a single pill Exforge HCT (amlodipine, valsartan and hydrochlorothiazide) FDA Approval History"
},{
  "title": "Creon (pancrelipase)  Delayed-Release Capsules ",
  "date_of_approval": "April 30, 2009",
  "company": " Solvay Pharmaceuticals, Inc.",
  "treatment": " Pancreatic Exocrine Dysfunction",
  "drug_description": "Creon (pancrelipase) is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions.",
  "previous application": "Creon (pancrelipase) Delayed-Release Capsules First and Only Pancreatic Enzyme Product to Receive FDA Approval Under New Guidelines Creon (pancrelipase) FDA Approval History"
},{
  "title": "Cetraxal (ciprofloxacin otic)  Solution ",
  "date_of_approval": "May 1, 2009",
  "company": " Salvat",
  "treatment": " Otitis Externa",
  "drug_description": "Cetraxal (ciprofloxacin otic) is an antibiotic ear solution for the treatment of acute otitis externa.",
  "previous application": "FDA Approves Cetraxal Otic Solution Cetraxal (ciprofloxacin otic) FDA Approval History"
},{
  "title": "Cycloset (bromocriptine mesylate)  Tablets ",
  "date_of_approval": "May 5, 2009",
  "company": " VeroScience and S2 Therapeutics, Inc. ",
  "treatment": " Diabetes Type 2",
  "drug_description": "Cycloset (bromocriptine) is a first-in-class, central acting agent for the treatment of Type 2 Diabetes.",
  "previous application": "VeroScience Announces FDA Approval of Cycloset for Treatment of Type 2 Diabetes Cycloset (bromocriptine mesylate) FDA Approval History"
},{
  "title": "Fanapt (iloperidone)  Tablets ",
  "date_of_approval": "May 6, 2009",
  "company": " Vanda Pharmaceuticals Inc.",
  "treatment": " Schizophrenia",
  "drug_description": "Fanapt (iloperidone) is a 5HT2/D2 antagonist (atypical) antipsychotic for the treatment of schizophrenia.",
  "previous application": "FDA Approves Fanapt to Treat Schizophrenia Fanapt (iloperidone) FDA Approval History"
},{
  "title": "Samsca (tolvaptan)  Tablets ",
  "date_of_approval": "May 19, 2009",
  "company": " Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",
  "treatment": " Hyponatremia",
  "drug_description": "Samsca (tolvaptan) is an oral selective vasopressin antagonist for the treatment of patients with clinically significant hypervolemic and euvolemic hyponatremia.",
  "previous application": "FDA Approves Samsca (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia Samsca (tolvaptan) FDA Approval History"
},{
  "title": "Adcirca (tadalafil)  Tablets ",
  "date_of_approval": "May 22, 2009",
  "company": " United Therapeutics Corporation",
  "treatment": " Pulmonary Hypertension",
  "drug_description": "Adcirca (tadalafil) is a once-daily phosphodiesterase type 5 (PDE5) inhibitor for the treatment of pulmonary arterial hypertension (PAH).",
  "previous application": "FDA Approves Adcirca (tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension Adcirca (tadalafil) FDA Approval History"
},{
  "title": "Besivance (besifloxacin)  Ophthalmic Suspension ",
  "date_of_approval": "May 28, 2009",
  "company": " Bausch &amp; Lomb",
  "treatment": " Bacterial Conjunctivitis",
  "drug_description": "Besivance (besifloxacin ophthalmic suspension) is a topical quinolone antimicrobial for the treatment of bacterial conjunctivitis, commonly referred to as \"pink eye.\"",
  "previous application": "Bausch & Lomb Receives FDA Approval of Besivance, New Topical Ophthalmic Antibacterial for the Treatment of Bacterial Conjunctivitis ('Pink Eye') Besivance (besifloxacin) FDA Approval History"
},{
  "title": "Caldolor (ibuprofen)  Intravenous Injection ",
  "date_of_approval": "June 11, 2009",
  "company": " Cumberland Pharmaceuticals",
  "treatment": " Pain, Fever",
  "drug_description": "Caldolor is an intravenous formulation of ibuprofen indicated for the management of mild to moderate pain and management of moderate to severe pain as an adjunct to opioid analgesics, as well as the reduction of fever in adults.",
  "previous application": "Cumberland Pharmaceuticals Announces FDA Approval of Caldolor Caldolor (ibuprofen) FDA Approval History"
},{
  "title": "Zipsor (diclofenac potassium)  Capsules ",
  "date_of_approval": "June 16, 2009",
  "company": " Xanodyne Pharmaceuticals, Inc.",
  "treatment": " Pain",
  "drug_description": "Zipsor is a rapid release diclofenac potassium formulation for the treatment of patients with mild to moderate acute pain.",
  "previous application": "Xanodyne Receives Approval From the U.S. Food and Drug Administration for Zipsor (diclofenac potassium) Liquid Filled Capsules Zipsor (diclofenac potassium) FDA Approval History"
},{
  "title": "Ilaris (canakinumab)  Injection ",
  "date_of_approval": "June 17, 2009",
  "company": " Novartis Pharmaceuticals Corporation",
  "treatment": " Cryopyrin-Associated Periodic Syndrome, Juvenile Idiopathic Arthritis, Familial Cold Autoinflammatory Syndrome, Muckle Wells Snydrome, Familial Mediterranean Fever, Still's Disease, Tumor Necrosis Factor Receptor Associated Periodic Fever Syndrome, Hyperimmunoglobulin D Periodic Fever Syndrome",
  "drug_description": "Ilaris (canakinumab) is a human anti-interleukin-1\u03b2 monoclonal antibody for the treatment of Periodic Fever Syndromes (Cryopyrin-Associated Periodic Syndromes, Tumor Necrosis Factor Receptor Associated Periodic Syndrome, Hyperimmunoglobulin D Syndrome/Mevalonate Kinase Deficiency, Familial Mediterranean Fever), and active Still\u2019s disease, including Adult-Onset Still\u2019s Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA).",
  "previous application": "New Biological Therapy Ilaris Approved In US To Treat Children And Adults With CAPS, A Serious Life-Long Auto-Inflammatory Disease Ilaris (canakinumab) FDA Approval History"
},{
  "title": "Ozurdex (dexamethasone)  Intravitreal Implant ",
  "date_of_approval": "June 17, 2009",
  "company": " Allergan, Inc.",
  "treatment": " Macular Edema, Uveitis",
  "drug_description": "Ozurdex (dexamethasone intravitreal implant) is a sustained-release, corticosteroid implant for the treatment of macular edema, non-infectious uveitis, and diabetic macular edema.",
  "previous application": "Allergan Receives FDA Approval for Ozurdex Biodegradable, Injectable Steroid Implant with Extended Drug Release for Retinal Disease Ozurdex (dexamethasone) FDA Approval History"
},{
  "title": "Cambia (diclofenac potassium)  for Oral Solution  - formerly PRO-513",
  "date_of_approval": "June 17, 2009",
  "company": " Kowa Pharmaceuticals America, Inc.",
  "treatment": " Migraine",
  "drug_description": "Cambia (diclofenac potassium) is a non-steroidal anti-inflammatory drug combined with potassium bicarbonate for the treatment of acute migraine with or without aura in adults.",
  "previous application": "FDA Approves Cambia for Migraine Cambia (diclofenac potassium) FDA Approval History"
},{
  "title": "Feraheme (ferumoxytol)  Intravenous Injection ",
  "date_of_approval": "June 30, 2009",
  "company": " AMAG Pharmaceuticals, Inc.",
  "treatment": " Anemia Associated with Chronic Renal Failure, Iron Deficiency Anemia",
  "drug_description": "Feraheme (ferumoxytol) is an iron replacement therapy for the treatment of iron deficiency anemia in adult patients.",
  "previous application": "FDA Approves Feraheme to Treat Iron Deficiency Anemia in Adult Chronic Kidney Disease Patients Feraheme (ferumoxytol) FDA Approval History"
},{
  "title": "Multaq (dronedarone)  Tablets ",
  "date_of_approval": "July 1, 2009",
  "company": " Sanofi-aventis",
  "treatment": " Atrial Fibrillation, Atrial Flutter",
  "drug_description": "Multaq (dronedarone) is antiarrhythmic drug indicated to reduce the risk of cardiovascular hospitalization in patients with atrial fibrillation or atrial flutter.",
  "previous application": "FDA Approves Multaq for Patients with Atrial Fibrillation or Atrial Flutter Multaq (dronedarone) FDA Approval History"
},{
  "title": "Effient (prasugrel)  Tablets ",
  "date_of_approval": "July 10, 2009",
  "company": " Daiichi Sankyo Company, Limited and Eli Lilly and Company",
  "treatment": " Acute Coronary Syndrome",
  "drug_description": "Effient (prasugrel) is an oral antiplatelet agent for the treatment of patients with acute coronary syndrome (ACS) who are managed with percutaneous coronary intervention including coronary stenting.",
  "previous application": "Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient Effient (prasugrel) FDA Approval History"
},{
  "title": "Plan B One-Step (levonorgestrel)  Tablet ",
  "date_of_approval": "July 10, 2009",
  "company": " Teva Pharmaceuticals, Inc.",
  "treatment": " Emergency Contraception",
  "drug_description": "Plan B One-Step (levonorgestrel) is a single dose emergency contraceptive pill to help prevent an unintended pregnancy after unprotected sex or contraceptive failure.",
  "previous application": "FDA Approves Plan B One-Step, a New One-Pill Emergency Contraceptive Plan B One-Step (levonorgestrel) FDA Approval History"
},{
  "title": "Sumavel DosePro (sumatriptan)  Injection ",
  "date_of_approval": "July 15, 2009",
  "company": " Zogenix, Inc.",
  "treatment": " Migraine, Cluster Headache",
  "drug_description": "",
  "previous application": "Sumavel DosePro (sumatriptan injection) Approved by FDA for Acute Migraine and Cluster Headache: First Product Featuring Novel DosePro Needle-Free Delivery System Sumavel DosePro (sumatriptan) FDA Approval History"
},{
  "title": "Onsolis (fentanyl)  Buccal Soluble Film ",
  "date_of_approval": "July 16, 2009",
  "company": " BioDelivery Sciences International, Inc.",
  "treatment": " Pain",
  "drug_description": "",
  "previous application": "BioDelivery Sciences and Meda Announce FDA Approval of Onsolis Onsolis (fentanyl) FDA Approval History"
},{
  "title": "Acuvail (ketorolac tromethamine)  Ophthalmic Solution ",
  "date_of_approval": "July 22, 2009",
  "company": " Allergan, Inc.",
  "treatment": " Postoperative Ocular Inflammation",
  "drug_description": "Acuvail (ketorolac tromethamine) is a preservative-free formulation of ketorolac, a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of pain and inflammation following cataract surgery.",
  "previous application": "Allergan Receives FDA Approval for Acuvail Ophthalmic Solution for the Treatment of Pain and Inflammation Following Cataract Surgery Acuvail (ketorolac tromethamine) FDA Approval History"
},{
  "title": "Tyvaso (treprostinil)  Inhalation Solution ",
  "date_of_approval": "July 30, 2009",
  "company": " United Therapeutics Corporation",
  "treatment": " Pulmonary Hypertension",
  "drug_description": "Tyvaso (treprostinil) is an inhaled prostanoid analogue indicated for the treatment of pulmonary arterial hypertension.",
  "previous application": "FDA Approves Tyvaso (treprostinil) Inhalation Solution for the Treatment of Pulmonary Arterial Hypertension Tyvaso (treprostinil) FDA Approval History"
},{
  "title": "Colcrys (colchicine)  Tablets ",
  "date_of_approval": "July 29, 2009",
  "company": " Mutual Pharmaceutical Company, Inc.",
  "treatment": " Gout, Familial Mediterranean Fever, Gout -- Prophylaxis, Acute Gout",
  "drug_description": "Colcrys (colchicine) is compound derived from the dried seeds of the autumn crocus or meadow saffron (Colchicum\r autumnale). Colcrys is approved for the prophylaxis and treatment of acute gout flares, and for the treatment of patients with familial Mediterranean fever.",
  "previous application": "FDA Approves Colcrys (colchicine) for Acute Gout, Mediterranean Fever Colcrys (colchicine) FDA Approval History"
},{
  "title": "Onglyza (saxagliptin)  Tablets ",
  "date_of_approval": "July 31, 2009",
  "company": " AstraZeneca",
  "treatment": " Diabetes Type 2",
  "drug_description": "Onglyza (saxagliptin) is a dipeptidyl peptidase-4 (DPP4) inhibitor indicated for the treatment of type 2 diabetes mellitus in adults.",
  "previous application": "FDA Approves Onglyza (saxagliptin) for Type 2 Diabetes Onglyza (saxagliptin) FDA Approval History"
},{
  "title": "Invega Sustenna (paliperidone palmitate)  Extended-Release Injectable Suspension ",
  "date_of_approval": "July 31, 2009",
  "company": " Janssen Pharmaceuticals,  Inc.",
  "treatment": " Schizophrenia, Schizoaffective Disorder",
  "drug_description": "Invega Sustenna (1-month paliperidone palmitate) is a  long-acting injectable atypical antipsychotic indicated \r for the treatment of schizophrenia and schizoaffective disorder.",
  "previous application": "FDA Approves Invega Sustenna for the Acute and Maintenance Treatment of Schizophrenia Invega Sustenna (paliperidone palmitate) FDA Approval History"
},{
  "title": "Xerese (acyclovir and hydrocortisone)  Topical Cream  - formerly Lipsovir",
  "date_of_approval": "July 31, 2009",
  "company": " Meda Pharmaceuticals Inc.",
  "treatment": " Herpes Simplex Labialis",
  "drug_description": "Xerese (acyclovir and hydrocortisone) is a topical antiviral and anti-inflammatory combination for the prevention and treatment of cold sores.",
  "previous application": "The US FDA approves Lipsovir for marketing and sales in US Xerese (acyclovir and hydrocortisone) FDA Approval History"
},{
  "title": "Livalo (pitavastatin)  Tablets ",
  "date_of_approval": "August 3, 2009",
  "company": " Kowa Company, Ltd.",
  "treatment": " High Cholesterol",
  "drug_description": "Livalo (pitavastatin) is an HMG CoA reductase inhibitor indicated for the primary treatment of hypercholesterolemia and combined dyslipidemia.",
  "previous application": "FDA Approves Livalo for Primary Hypercholesterolemia and Combined Dyslipidemia Livalo (pitavastatin) FDA Approval History"
},{
  "title": "Embeda (morphine sulfate and naltrexone hydrochloride)  Extended Release Capsules ",
  "date_of_approval": "August 13, 2009",
  "company": " King Pharmaceuticals , Inc.",
  "treatment": " Pain",
  "drug_description": "Embeda is an abuse-deterrent, extended-release morphine preparation for the treatment of chronic pain.",
  "previous application": "FDA Approves Embeda For Management of Moderate to Severe Chronic Pain Embeda (morphine sulfate and naltrexone hydrochloride) FDA Approval History"
},{
  "title": "Saphris (asenapine)  Sublingual Tablets ",
  "date_of_approval": "August 13, 2009",
  "company": " Allergan, Inc.",
  "treatment": " Schizophrenia, Bipolar Disorder",
  "drug_description": "Saphris (asenapine) is an atypical antipsychotic for the treatment of schizophrenia and acute mania or mixed episodes associated with bipolar I disorder.",
  "previous application": "Schering-Plough Announces FDA Approval of Saphris (asenapine) Saphris (asenapine) FDA Approval History"
},{
  "title": "Extavia (interferon beta-1b) ",
  "date_of_approval": "August 14, 2009",
  "company": "NONE",
  "treatment": " Multiple Sclerosis",
  "drug_description": "Extavia is a branded version of interferon beta-1b, a first-line disease-modifying therapy that has been a standard-of-care for multiple sclerosis for many years. Extavia is indicated for the treatment of MS patients with relapsing forms of the disease and for newly diagnosed patients.",
  "previous application": "US FDA Approves Extavia - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with This Devastating Disease Extavia (interferon beta-1b) FDA Approval History"
},{
  "title": "Hiberix (Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate))  Solution for Intramuscular Injection ",
  "date_of_approval": "August 19, 2009",
  "company": " GlaxoSmithKline",
  "treatment": " Haemophilus influenzae Prophylaxis",
  "drug_description": "Hiberix is a vaccine indicated for active immunization as a booster dose for the prevention of invasive disease caused by Haemophilus influenzae type b. Hiberix is approved for use in children aged six weeks through four years of age (prior to fifth birthday).",
  "previous application": "FDA Approves GSK's Hib Vaccine, Hiberix Hiberix (Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate)) FDA Approval History"
},{
  "title": "Sabril (vigabatrin)  Tablets and Oral Solution ",
  "date_of_approval": "August 21, 2009",
  "company": " Lundbeck Inc.",
  "treatment": " Epilepsy, Seizures",
  "drug_description": "Sabril (vigabatrin) is an oral irreversible GABA-transaminase inhibitor for the treatment of Infantile Spasms and refractory complex partial seizures.",
  "previous application": "Lundbeck Inc. Announces FDA Marketing Approval for Sabril for the Treatment of Two Difficult-to-Treat Epilepsies Sabril (vigabatrin) FDA Approval History"
},{
  "title": "Zenpep (pancrelipase)  Capsules  - formerly Zentase",
  "date_of_approval": "August 27, 2009",
  "company": " Allergan, Inc.",
  "treatment": " Pancreatic Exocrine Dysfunction",
  "drug_description": "Zenpep (pancrelipase) is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, or other conditions.",
  "previous application": "Eurand Granted FDA Approval for Zenpep Zenpep (pancrelipase) FDA Approval History"
},{
  "title": "Intuniv (guanfacine)  Extended Release Tablets  - formerly Connexyn",
  "date_of_approval": "September 2, 2009",
  "company": " Shire plc",
  "treatment": " Attention-Deficit Hyperactivity Disorder",
  "drug_description": "Intuniv (guanfacine) is a nonstimulant selective alpha-2A-receptor agonist for the treatment of children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD).",
  "previous application": "Shire Announces FDA Approval of Once-Daily Intuniv (guanfacine) Extended Release Tablets for the Treatment of ADHD in Children and Adolescents Aged 6 to 17 Intuniv (guanfacine) FDA Approval History"
},{
  "title": "Metozolv ODT (metoclopramide)  Orally Disintegrating Tablets ",
  "date_of_approval": "September 4, 2009",
  "company": " Salix Pharmaceuticals, Ltd.",
  "treatment": " Gastroesophageal Reflux Disease, Gastroparesis",
  "drug_description": "",
  "previous application": "Salix Receives FDA Marketing Approval for Metozolv ODT (Orally Disintegrating Tablets) for Relief of Diabetic Gastroparesis and Symptomatic Documented GERD Metozolv ODT (metoclopramide) FDA Approval History"
},{
  "title": "Bepreve (bepotastine)  Ophthalmic Solution ",
  "date_of_approval": "September 8, 2009",
  "company": " ISTA Pharmaceuticals, Inc.",
  "treatment": " Allergic Conjunctivitis",
  "drug_description": "Bepreve (bepotastine ophthalmic solution) is an antihistamine and mast cell stabilizer for treatment of the symptoms of allergic conjunctivitis.",
  "previous application": "Ista Pharmaceuticals' Bepreve Receives FDA Approval for the Treatment of Ocular Itching Due to Allergies Bepreve (bepotastine) FDA Approval History"
},{
  "title": "Vibativ  (telavancin)  Injection ",
  "date_of_approval": "September 11, 2009",
  "company": " Theravance Inc.",
  "treatment": " Skin and Structure Infection, Pneumonia",
  "drug_description": "Vibativ (telavancin) is a bactericidal, once-daily injectable antibiotic for the treatment of complicated skin and skin structure infections (cSSSI), and hospital-acquired and ventilator-associated bacterial pneumonia.",
  "previous application": "Theravance and Astellas Announce FDA Approval of Vibativ (telavancin) for the Treatment of Complicated Skin and Skin Structure Infections Vibativ  (telavancin) FDA Approval History"
},{
  "title": "Zirgan (ganciclovir)  Ophthalmic Gel ",
  "date_of_approval": "September 15, 2009",
  "company": " Sirion Therapeutics, Inc.",
  "treatment": " Herpetic Keratitis",
  "drug_description": "Zirgan (ganciclovir ophthalmic gel) is a topical ophthalmic antiviral preparation for the treatment of acute herpetic keratitis (dendritic ulcers).",
  "previous application": "Sirion Therapeutics Announces FDA Approval of Zirgan (ganciclovir ophthalmic gel) 0.15% for Herpetic Keratitis Zirgan (ganciclovir) FDA Approval History"
},{
  "title": "Influenza A (H1N1) 2009 Monovalent Vaccine (H1N1 influenza virus vaccine) ",
  "date_of_approval": "September 15, 2009",
  "company": " CSL Limited; Novartis Vaccines and Diagnostics Limited; Sanofi Pasteur, Inc.; MedImmune LLC",
  "treatment": " Prevention of H1N1 Influenza",
  "drug_description": "Influenza A (H1N1) 2009 Monovalent Vaccine is an inactivated influenza virus vaccine indicated for active immunization of persons 6 months of age and older against influenza disease caused by pandemic (H1N1) 2009 virus.",
  "previous application": "FDA Approves Vaccines for 2009 H1N1 Influenza Virus Influenza A (H1N1) 2009 Monovalent Vaccine (H1N1 influenza virus vaccine) FDA Approval History"
},{
  "title": "Valturna (aliskiren and valsartan)  Tablets ",
  "date_of_approval": "September 16, 2009",
  "company": " Novartis",
  "treatment": " Hypertension",
  "drug_description": "",
  "previous application": "Novartis receives FDA approval for Valturna, a single-pill combination of valsartan and aliskiren, to treat high blood pressure Valturna (aliskiren and valsartan) FDA Approval History"
},{
  "title": "Folotyn (pralatrexate)  Injection ",
  "date_of_approval": "September 24, 2009",
  "company": " Allos Therapeutics, Inc.",
  "treatment": " Peripheral T-cell Lymphoma",
  "drug_description": "Folotyn (pralatrexate) is a folate analogue metabolic inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).",
  "previous application": "FDA Approves Folotyn (pralatrexate) for Treatment of Peripheral T-cell Lymphoma Folotyn (pralatrexate) FDA Approval History"
},{
  "title": "Stelara (ustekinumab)  Injection ",
  "date_of_approval": "September 25, 2009",
  "company": " Janssen Biotech, Inc.",
  "treatment": " Psoriasis, Psoriatic Arthritis, Crohn's Disease -- Maintenance, Ulcerative Colitis",
  "drug_description": "Stelara (ustekinumab) is a human interleukin-12 and -23 antagonist indicated for the treatment of moderate to severe plaque psoriasis (Ps), active psoriatic arthritis (PsA), moderately to severely active Crohn\u2019s disease (CD), and moderately to severely active ulcerative colitis.",
  "previous application": "FDA Approves Stelara (ustekinumab) to Treat Psoriasis Stelara (ustekinumab) FDA Approval History"
},{
  "title": "Berinert (C1 esterase inhibitor (human))  Injection ",
  "date_of_approval": "October 9, 2009",
  "company": " CSL Behring",
  "treatment": " Angioedema",
  "drug_description": "Berinert (C1-esterase inhibitor (human)) is a plasma derived C1 esterase inhibitor indicated for the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) in adult and adolescent patients.",
  "previous application": "CSL Behring Announces FDA Approval of Berinert, First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Hereditary Angioedema in U.S. Berinert (C1 esterase inhibitor (human)) FDA Approval History"
},{
  "title": "Cervarix (human papillomavirus bivalent (types 16 and 18) vaccine, recombinant)  Injection ",
  "date_of_approval": "October 16, 2009",
  "company": " GlaxoSmithKline",
  "treatment": " Human Papillomavirus Prophylaxis",
  "drug_description": "",
  "previous application": "FDA approves Cervarix, GlaxoSmithKline's cervical cancer vaccine Cervarix (human papillomavirus bivalent (types 16 and 18) vaccine, recombinant) FDA Approval History"
},{
  "title": "Twynsta (telmisartan and amlodipine)  Tablets ",
  "date_of_approval": "October 16, 2009",
  "company": " Boehringer Ingelheim Pharmaceuticals Inc.",
  "treatment": " Hypertension",
  "drug_description": "Twynsta (telmisartan/amlodipine) is an angiotensin II receptor blocker (ARB) and a dihydropyridine calcium channel blocker (DHP-CCB) combination product indicated for the treatment of hypertension alone or with other antihypertensive agents.",
  "previous application": "FDA Approves Twynsta (telmisartan/amlodipine) for Hypertension Twynsta (telmisartan and amlodipine) FDA Approval History"
},{
  "title": "Votrient (pazopanib)  Tablets ",
  "date_of_approval": "October 19, 2009",
  "company": " GlaxoSmithKline ",
  "treatment": " Renal Cell Carcinoma, Soft Tissue Sarcoma",
  "drug_description": "Votrient (pazopanib) is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma and advanced soft tissue sarcoma.",
  "previous application": "FDA Approves GlaxoSmithKline\u2019s Votrient for Advanced Renal Cell Cancer Votrient (pazopanib) FDA Approval History"
},{
  "title": "Arzerra (ofatumumab)  Injection ",
  "date_of_approval": "October 26, 2009",
  "company": " GlaxoSmithKline",
  "treatment": " Chronic Lymphocytic Leukemia",
  "drug_description": "Arzerra (ofatumumab) is a CD20-directed cytolytic monoclonal antibody indicated for the treatment of patients with chronic lymphocytic leukemia.",
  "previous application": "FDA Approves Arzerra (ofatumumab) for Chronic Lymphocytic Leukemia Arzerra (ofatumumab) FDA Approval History"
},{
  "title": "Pennsaid (diclofenac sodium)  Topical Solution ",
  "date_of_approval": "November 4, 2009",
  "company": " Nuvo Research Inc.",
  "treatment": " Osteoarthritis",
  "drug_description": "Pennsaid is a topical non-steroidal anti-inflammatory drug (NSAID) used for the treatment of signs and symptoms of osteoarthritis of the knee.",
  "previous application": "FDA Approves Pennsaid Topical Solution Pennsaid (diclofenac sodium) FDA Approval History"
},{
  "title": "Istodax (romidepsin)  for Injection ",
  "date_of_approval": "November 5, 2009",
  "company": " Gloucester Pharmaceuticals",
  "treatment": " Cutaneous T-cell Lymphoma",
  "drug_description": "Istodax (romidepsin) a histone deacetylase (HDAC) inhibitor indicated the treatment of cutaneous T-cell lymphoma and peripheral T-cell lymphoma.",
  "previous application": "FDA Approves Gloucester Pharmaceuticals' Istodax for Patients with Cutaneous T-cell Lymphoma Istodax (romidepsin) FDA Approval History"
},{
  "title": "Lysteda  (tranexamic acid)  Tablets  - formerly XP12B",
  "date_of_approval": "November 13, 2009",
  "company": " Xanodyne Pharmaceuticals, Inc.",
  "treatment": " Menorrhagia",
  "drug_description": "Lysteda (tranexamic acid) is an antifibrinolytic agent for the treatment of women with menorrhagia, heavy menstrual bleeding (HMB), and its accompanying symptoms.",
  "previous application": "Xanodyne Announces FDA Approval of Lysteda (Tranexamic Acid) for Treatment of Women with Heavy Menstrual Bleeding Lysteda  (tranexamic acid) FDA Approval History"
},{
  "title": "Qutenza (capsaicin)  Transdermal Patch ",
  "date_of_approval": "November 16, 2009",
  "company": " Averitas Pharma, Inc.",
  "treatment": " Neuropathic Pain, Postherpetic Neuralgia, Diabetic Neuropathy",
  "drug_description": "Qutenza (capsaicin) is a TRPV1 channel agonist indicated for the treatment of\r neuropathic pain associated with postherpetic neuralgia (PHN) and neuropathic\r pain associated with diabetic peripheral neuropathy (DPN) of the feet.",
  "previous application": "NeurogesX Receives FDA Approval of Qutenza (capsaicin) 8% Patch for Treatment of Postherpetic Neuralgia (PHN) Qutenza (capsaicin) FDA Approval History"
},{
  "title": "Agriflu (influenza virus vaccine, inactivated)  Injection ",
  "date_of_approval": "November 27, 2009",
  "company": " Novartis Vaccines and Diagnostics, Inc.",
  "treatment": " Influenza Prophylaxis",
  "drug_description": "Agriflu (influenza virus vaccine, inactivated) is a vaccine indicated for the active immunization of adults 18 years of age and older against influenza disease caused by influenza virus subtypes A and type B present in the vaccine.",
  "previous application": "FDA Approves Agriflu Seasonal Influenza Vaccine Agriflu (influenza virus vaccine, inactivated) FDA Approval History"
},{
  "title": "Zegerid OTC (omeprazole and sodium bicarbonate)  Capsules ",
  "date_of_approval": "December 1, 2009",
  "company": " Merck &amp; Co. and Santarus Inc.",
  "treatment": " Heartburn",
  "drug_description": "Zegerid OTC (omeprazole and sodium bicarbonate) is an over-the-counter version of the prescription heartburn\r drug Zegerid.",
  "previous application": "FDA Approves OTC Version Of Heartburn Drug Zegerid Zegerid OTC (omeprazole and sodium bicarbonate) FDA Approval History"
},{
  "title": "Kalbitor (ecallantide)  Injection  - formerly DX-88",
  "date_of_approval": "December 1, 2009",
  "company": " Dyax Corp.",
  "treatment": " Angioedema",
  "drug_description": "Kalbitor (ecallantide) is plasma kallikrein inhibitor indicated for treatment of\r acute attacks of hereditary angioedema in patients 16 years of age and older.",
  "previous application": "Dyax Announces FDA Approval of Kalbitor (ecallantide) for the Treatment of Acute Attacks of Hereditary Angioedema in Patients 16 Years of Age and Older Kalbitor (ecallantide) FDA Approval History"
},{
  "title": "Wilate (von Willebrand Factor/Coagulation Factor VIII Complex (Human))  Injection ",
  "date_of_approval": "December 4, 2009",
  "company": " Octapharma USA",
  "treatment": " von Willebrand's Disease",
  "drug_description": "Wilate is a von Willebrand Factor/Coagulation Factor VIII Complex (Human) indicated for the treatment of spontaneous and trauma-induced bleeding episodes in patients with severe von Willebrand disease (VWD).",
  "previous application": "Octapharma USA Announces FDA Approval of Wilate - the First Replacement Therapy Developed Specifically for von Willebrand Disease Wilate (von Willebrand Factor/Coagulation Factor VIII Complex (Human)) FDA Approval History"
},{
  "title": "Zyprexa Relprevv (olanzapine)  for Extended Release Injectable Suspension ",
  "date_of_approval": "December 11, 2009",
  "company": " Lilly",
  "treatment": " Schizophrenia",
  "drug_description": "Zyprexa Relprevv (olanzapine) is a long-acting atypical antipsychotic for intramuscular injection indicated for the treatment of schizophrenia.",
  "previous application": "FDA Approves Lilly's Zyprexa Relprevv for Treatment of Schizophrenia in Adults Zyprexa Relprevv (olanzapine) FDA Approval History"
},{
  "title": "Actemra (tocilizumab)  Injection ",
  "date_of_approval": "January 8, 2010",
  "company": " Genentech USA, Inc.",
  "treatment": " Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Giant Cell Arteritis",
  "drug_description": "Actemra (tocilizumab) is a humanized interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody for the treatment rheumatoid arthritis; systemic juvenile idiopathic arthritis (SJIA); polyarticular juvenile idiopathic arthritis (PJIA); giant cell arteritis; and CAR T cell-induced severe or life-threatening cytokine release syndrome.",
  "previous application": "FDA Approves Actemra for the Treatment of Moderately to Severely Active Rheumatoid Arthritis Actemra (tocilizumab) FDA Approval History"
},{
  "title": "Ampyra (dalfampridine)  Extended Release Tablets  - formerly Fampridine-SR",
  "date_of_approval": "January 22, 2010",
  "company": " Acorda Therapeutics, Inc.",
  "treatment": " Multiple Sclerosis",
  "drug_description": "Ampyra (dalfampridine) is an oral potassium channel blocker indicated to improve walking ability in people with multiple sclerosis.",
  "previous application": "FDA Approves Ampyra to Improve Walking in Adults with Multiple Sclerosis Ampyra (dalfampridine) FDA Approval History"
},{
  "title": "Victoza (liraglutide)  Injection ",
  "date_of_approval": "January 25, 2010",
  "company": " Novo Nordisk A/S",
  "treatment": " Diabetes Type 2",
  "drug_description": "Victoza (liraglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated to improve glycemic control in patients 10 years and older with type 2 diabetes mellitus, and to reduce the risk of heart attack, stroke and cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.",
  "previous application": "FDA Approves Novo-Nordisk's Diabetes Drug Victoza Victoza (liraglutide) FDA Approval History"
},{
  "title": "Oleptro (trazodone)  Extended Release Tablets ",
  "date_of_approval": "February 2, 2010",
  "company": " Labopharm Inc.",
  "treatment": " Depression",
  "drug_description": "",
  "previous application": "Labopharm Receives FDA Approval for Oleptro Oleptro (trazodone) FDA Approval History"
},{
  "title": "Xiaflex (collagenase clostridium histolyticum) ",
  "date_of_approval": "February 3, 2010",
  "company": " BioSpecifics Technologies Corp.",
  "treatment": " Dupuytren's Contracture",
  "drug_description": "Xiaflex (collagenase clostridium histolyticum) is a collagenase product for the treatment of Dupuytren's contracture, a condition that affects the connective tissue that lies beneath the skin in the palm.",
  "previous application": "Auxilium Announces U.S. Food and Drug Administration Approval for Xiaflex for the Treatment of Dupuytren's Contracture Xiaflex (collagenase clostridium histolyticum) FDA Approval History"
},{
  "title": "Menveo (meningococcal conjugate vaccine) ",
  "date_of_approval": "February 19, 2010",
  "company": " Novartis Vaccines and Diagnostics",
  "treatment": " Meningococcal Meningitis Prophylaxis",
  "drug_description": "Menveo (Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine) is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135.",
  "previous application": "Novartis Gets US Approval for Menveo Meningitis Vaccine Menveo (meningococcal conjugate vaccine) FDA Approval History"
},{
  "title": "Cayston (aztreonam lysine)  Inhalation Solution ",
  "date_of_approval": "February 22, 2010",
  "company": " Gilead Sciences, Inc.",
  "treatment": " Pneumonia with Cystic Fibrosis",
  "drug_description": "Cayston (aztreonam lysine for inhalation) is an inhaled anti-pseudomonal therapy for people with cystic fibrosis (CF) who have pulmonary Pseudomonas\r aeruginosa infection.",
  "previous application": "U.S. Food and Drug Administration Approves Cayston (Aztreonam for Inhalation Solution) for the Improvement of Respiratory Symptoms in Cystic Fibrosis Patients with Pseudomonas Aeruginosa Cayston (aztreonam lysine) FDA Approval History"
},{
  "title": "Prevnar 13 (pneumococcal 13-valent conjugate vaccine) ",
  "date_of_approval": "February 24, 2010",
  "company": " Pfizer Inc.",
  "treatment": " Pneumococcal Disease Prophylaxis",
  "drug_description": "Prevnar 13 (pneumococcal 13-valent conjugate vaccine) is a vaccine indicated for active immunization against invasive pneumococcal disease.",
  "previous application": "FDA Approves Prevnar 13 Pneumococcal Disease Vaccine Prevnar 13 (pneumococcal 13-valent conjugate vaccine) FDA Approval History"
},{
  "title": "VPRIV (velaglucerase alfa)  for Injection ",
  "date_of_approval": "February 26, 2010",
  "company": " Shire plc",
  "treatment": " Gaucher Disease",
  "drug_description": "VPRIV (velaglucerase alfa) is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy for pediatric and adult patients with Type 1 Gaucher disease.",
  "previous application": "FDA Approves VPRIV to Treat Gaucher Disease VPRIV (velaglucerase alfa) FDA Approval History"
},{
  "title": "Exalgo (hydromorphone)  Extended Release Tablets ",
  "date_of_approval": "March 1, 2010",
  "company": " Covidien",
  "treatment": " Pain in Opioid Tolerant Patients",
  "drug_description": "",
  "previous application": "FDA Approves Exaglo (hydromorphone HCl) Extended-Release Tablets Exalgo (hydromorphone) FDA Approval History"
},{
  "title": "Hizentra (immune globulin subcutaneous (human))  Liquid ",
  "date_of_approval": "March 4, 2010",
  "company": " CSL Behring",
  "treatment": " Primary Immunodeficiency Syndrome, Chronic Inflammatory Demyelinating Polyradiculoneuropathy",
  "drug_description": "Hizentra (immune globulin subcutaneous (human)) is an immune globulin indicated for the treatment of primary immunodeficiency, and for the maintenance treatment of chronic inflammatory demyelinating\r polyneuropathy.",
  "previous application": "CSL Behring Receives FDA Approval of Hizentra, First 20 Percent Subcutaneous Immunoglobulin Therapy Hizentra (immune globulin subcutaneous (human)) FDA Approval History"
},{
  "title": "Silenor (doxepin)  Tablets ",
  "date_of_approval": "March 17, 2010",
  "company": " Somaxon Pharmaceuticals, Inc.",
  "treatment": " Insomnia",
  "drug_description": "Silenor (doxepin) is a low-dose oral tablet\r formulation of the H1 receptor antagonist doxepin indicated for the treatment of insomnia characterized by difficulties with sleep maintenance.",
  "previous application": "Somaxon Announces FDA Approval of\r Silenor (doxepin) for the Treatment of Insomnia Silenor (doxepin) FDA Approval History"
},{
  "title": "Carbaglu (carglumic acid)  Tablets ",
  "date_of_approval": "March 18, 2010",
  "company": " Orphan Europe",
  "treatment": " NAGS Deficiency Hyperammonemia",
  "drug_description": "Carbaglu (carglumic acid) is a carbamoyl phosphate synthetase 1 (CPS 1) activator indicated for the treatment of hyperammonemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS).",
  "previous application": "FDA Approves Carbaglu to Treat Condition That Causes Elevated Ammonia Levels Carbaglu (carglumic acid) FDA Approval History"
},{
  "title": "Zyclara (imiquimod)  Cream ",
  "date_of_approval": "March 25, 2010",
  "company": " Graceway Pharmaceuticals, LLC",
  "treatment": " Keratosis, Condylomata Acuminata",
  "drug_description": "Zyclara (imiquimod) is an immune response modifier indicated for the topical treatment of actinic keratoses and external genital warts.",
  "previous application": "FDA Approves Zyclara (imiquimod) Cream, 3.75% for the Treatment of Actinic Keratoses Zyclara (imiquimod) FDA Approval History"
},{
  "title": "Asclera (polidocanol)  Injection ",
  "date_of_approval": "March 30, 2010",
  "company": " Chemische Fabrik Kreussler &amp; Co.",
  "treatment": " Varicose Vein",
  "drug_description": "Asclera (polidocanol) is a sclerosing agent used for the treatment of varicose veins.",
  "previous application": "FDA Approves Asclera to Treat Small Varicose Veins Asclera (polidocanol) FDA Approval History"
},{
  "title": "Pancreaze (pancrelipase)  Delayed-Release Capsules ",
  "date_of_approval": "April 12, 2010",
  "company": " Ortho-McNeil-Janssen Pharmaceuticals, Inc.",
  "treatment": " Pancreatic Exocrine Dysfunction",
  "drug_description": "Pancreaze (pancrelipase) is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions.",
  "previous application": "FDA Approves Pancreatic Enzyme Product, Pancreaze Pancreaze (pancrelipase) FDA Approval History"
},{
  "title": "Oravig (miconazole)  Buccal Tablets  - formerly Loramyc",
  "date_of_approval": "April 16, 2010",
  "company": " BioAlliance Pharma SA",
  "treatment": " Oral Thrush",
  "drug_description": "Oravig (miconazole) is a mucoadhesive buccal   azole antifungal therapy indicated for the local treatment of oropharyngeal candidiasis in adults.",
  "previous application": "FDA Approves Oravig (miconazole) Buccal Tablets for Treatment of Oropharyngeal Candidiasis Oravig (miconazole) FDA Approval History"
},{
  "title": "Zortress (everolimus)  Tablets  - formerly Certican",
  "date_of_approval": "April 22, 2010",
  "company": " Novartis Pharma AG",
  "treatment": " Organ Transplant -- Rejection Prophylaxis",
  "drug_description": "Zortress (everolimus) is an oral inhibitor of the mTOR pathway indicated for the prevention of rejection of kidney transplants in adult patients at low-to-moderate immunologic risk.",
  "previous application": "Novartis Receives US FDA Approval for Zortress (everolimus) to Prevent Organ Rejection in Adult Kidney Transplant Recipients Zortress (everolimus) FDA Approval History"
},{
  "title": "Provenge (sipuleucel-T)  Suspension for Intravenous Infusion  - formerly APC8015",
  "date_of_approval": "April 29, 2010",
  "company": " Dendreon Corporation",
  "treatment": " Prostate Cancer",
  "drug_description": "Provenge (sipuleucel-T) is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.",
  "previous application": "FDA Approves Provenge - a Cellular Immunotherapy for Men With Advanced Prostate Cancer Provenge (sipuleucel-T) FDA Approval History"
},{
  "title": "Vimovo (naproxen and esomeprazole magnesium)  - formerly PN 400",
  "date_of_approval": "April 30, 2010",
  "company": " Pozen Inc. and AstraZeneca",
  "treatment": " Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis, NSAID-Induced Ulcer Prophylaxis",
  "drug_description": "Vimovo is a combination of the pain reliever naproxen (NSAID) and esomeprazole magnesium (proton pump inhibitor) indicated for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, and\r ankylosing spondylitis, and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers.",
  "previous application": "FDA Approved Vimovo for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers Vimovo (naproxen and esomeprazole magnesium) FDA Approval History"
},{
  "title": "Natazia (dienogest and estradiol valerate)  - formerly Qlaira",
  "date_of_approval": "May 6, 2010",
  "company": " Bayer HealthCare Pharmaceuticals Inc.",
  "treatment": " Contraception, Heavy Menstrual Bleeding",
  "drug_description": "Natazia (dienogest and estradiol valerate) is a combination oral contraceptive indicated for use by women to prevent pregnancy and to treat heavy menstrual bleeding.",
  "previous application": "FDA Approves Natazia - New Combination Product Oral Contraceptive Natazia (dienogest and estradiol valerate) FDA Approval History"
},{
  "title": "Sprix (ketorolac tromethamine)  Nasal Spray  - formerly ROX-888",
  "date_of_approval": "May 14, 2010",
  "company": " Egalet Corporation",
  "treatment": " Pain",
  "drug_description": "Sprix (ketorolac tromethamine) is an  intranasal analgesic for the management of acute moderate to severe pain.",
  "previous application": "Roxro Announces FDA Approval of Sprix Sprix (ketorolac tromethamine) FDA Approval History"
},{
  "title": "Zymaxid (gatifloxacin)  Ophthalmic Solution ",
  "date_of_approval": "May 18, 2010",
  "company": " Allergan, Inc.",
  "treatment": " Bacterial Conjunctivitis",
  "drug_description": "Zymaxid (gatifloxacin ophthalmic) is a fluoroquinolone anti-infective\r indicated for the treatment of bacterial conjunctivitis.",
  "previous application": "Allergan Receives FDA Approval for Zymaxid Ophthalmic Solution Zymaxid (gatifloxacin) FDA Approval History"
},{
  "title": "Lumizyme (alglucosidase alfa) ",
  "date_of_approval": "May 24, 2010",
  "company": " Genzyme Corporation",
  "treatment": " Pompe disease",
  "drug_description": "Lumizyme (alglucosidase alfa) is a lysosomal glycogen-specific enzyme indicated for patients with Pompe disease.",
  "previous application": "FDA Approves Lumizyme for Late-Onset Pompe Disease Lumizyme (alglucosidase alfa) FDA Approval History"
},{
  "title": "Cysview (hexaminolevulinate)  for Intravesical Solution  - formerly Hexvix",
  "date_of_approval": "May 28, 2010",
  "company": " Photocure ASA",
  "treatment": " Diagnostic",
  "drug_description": "Cysview (hexaminolevulinate HCl) is an optical imaging agent indicated for use in the cystoscopic detection of non-muscle invasive papillary cancer of the bladder.",
  "previous application": "Cysview (Hexaminolevulinate HCl) Approved by the FDA for Cystoscopic Detection of Papillary Bladder Cancer Cysview (hexaminolevulinate) FDA Approval History"
},{
  "title": "Prolia (denosumab)  Injection ",
  "date_of_approval": "June 1, 2010",
  "company": " Amgen Inc.",
  "treatment": " Osteoporosis",
  "drug_description": "Prolia is a RANK ligand (RANKL) inhibitor indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, for the treatment of bone loss in patients with prostate or breast cancer undergoing hormone ablation therapy, as a treatment to increase bone mass in men with osteoporosis at high risk for fracture, and for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture.",
  "previous application": "FDA Approves Amgen's Prolia (Denosumab) for Treatment of Postmenopausal Women With Osteoporosis at High Risk for Fracture Prolia (denosumab) FDA Approval History"
},{
  "title": "Jalyn (dutasteride and tamsulosin)  Capsules ",
  "date_of_approval": "June 14, 2010",
  "company": " GlaxoSmithKline",
  "treatment": " Benign Prostatic Hyperplasia",
  "drug_description": "Jalyn is a combination of dutasteride (5\u03b1-reductase inhibitor) and tamsulosin (alpha-adrenergic antagonist) indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate.",
  "previous application": "FDA approves Jalyn, a fixed-dose combination of dutasteride and tamsulosin, for symptomatic BPH in men with an enlarged prostate Jalyn (dutasteride and tamsulosin) FDA Approval History"
},{
  "title": "Jevtana (cabazitaxel)  Injection ",
  "date_of_approval": "June 17, 2010",
  "company": " Sanofi-aventis",
  "treatment": " Prostate Cancer",
  "drug_description": "Jevtana (cabazitaxel) is a microtubule inhibitor indicated in combination with prednisone for treatment of patients with hormone-refractory metastatic prostate cancer.",
  "previous application": "Jevtana (cabazitaxel) Injection Approved by U.S. FDA After Priority Review Jevtana (cabazitaxel) FDA Approval History"
},{
  "title": "Staxyn (vardenafil)  Orally Disintegrating Tablets ",
  "date_of_approval": "June 17, 2010",
  "company": " GlaxoSmithKline and Merck &amp; Co., Inc.",
  "treatment": " Erectile Dysfunction",
  "drug_description": "Staxyn (vardenafil) is a phosphodiesterase type 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction.",
  "previous application": "FDA approves Staxyn (vardenafil HCl) orally disintegrating tablets for erectile dysfunction (ED) Staxyn (vardenafil) FDA Approval History"
},{
  "title": "Dulera (mometasone furoate and formoterol fumarate)  Inhaler ",
  "date_of_approval": "June 22, 2010",
  "company": " Merck &amp; Co., Inc.",
  "treatment": " Asthma",
  "drug_description": "Dulera (mometasone furoate and formoterol fumarate) is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist indicated for the treatment of asthma in patients 5 years of age and older.",
  "previous application": "FDA Approves Merck's Dulera (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol for the Treatment of Asthma in Patients 12 Years of Age and Older Dulera (mometasone furoate and formoterol fumarate) FDA Approval History"
},{
  "title": "Butrans (buprenorphine)  Transdermal System ",
  "date_of_approval": "June 30, 2010",
  "company": " Purdue Pharma L.P.",
  "treatment": " Pain",
  "drug_description": "Butrans (buprenorphine) is a transdermal opioid analgesic for the management of moderate to severe chronic pain in patients\r requiring continuous treatment for an extended period of time.",
  "previous application": "Purdue Pharma L.P. Receives FDA Approval for Butrans (buprenorphine) Transdermal System CIII Butrans (buprenorphine) FDA Approval History"
},{
  "title": "Alsuma (sumatriptan)  Injection ",
  "date_of_approval": "June 29, 2010",
  "company": " King Pharmaceuticals, Inc.",
  "treatment": " Migraine, Cluster Headache",
  "drug_description": "",
  "previous application": "FDA Approves Alsuma Auto-Injector Alsuma (sumatriptan) FDA Approval History"
},{
  "title": "Zuplenz (ondansetron)  Oral Soluble Film ",
  "date_of_approval": "July 2, 2010",
  "company": " Strativa Pharmaceuticals",
  "treatment": " Prevention of Chemotherapy-Induced, Radiotherapy-Induced, and Postoperative Nausea and Vomiting",
  "drug_description": "Zuplenz is an oral\r soluble film formulation of ondansetron for the prevention of postoperative, highly and\r moderately emetogenic cancer chemotherapy-induced, and\r radiotherapy-induced nausea and vomiting.",
  "previous application": "FDA Approves Strativa Pharmaceuticals' Zuplenz (ondansetron) Oral Soluble Film Zuplenz (ondansetron) FDA Approval History"
},{
  "title": "Glassia (alpha1-proteinase inhibitor (human))  Injection  - formerly AAT-IV",
  "date_of_approval": "July 1, 2010",
  "company": " Kamada Ltd.",
  "treatment": " Alpha-1 Proteinase Inhibitor Deficiency",
  "drug_description": "Glassia is an alpha1-proteinase inhibitor that is indicated for chronic augmentation and maintenance therapy in adults with emphysema due to congenital deficiency of alpha1-proteinase inhibitor (Alpha1-PI), also known as alpha1antitrypsin deficiency.",
  "previous application": "Kamada Wins FDA Approval for Glassia - a New Liquid, Ready-to-Use Treatment for Alpha-1 Antitrypsin Deficiency Glassia (alpha1-proteinase inhibitor (human)) FDA Approval History"
},{
  "title": "Veltin (clindamycin and tretinoin)  Gel  - formerly Velac",
  "date_of_approval": "July 16, 2010",
  "company": " Stiefel  Laboratories, Inc.",
  "treatment": " Acne",
  "drug_description": "Veltin Gel (clindamycin phosphate and tretinoin) is a combination of an antibiotic and a retinoid indicated for the topical treatment of acne vulgaris.",
  "previous application": "Stiefel, a GSK company, Receives FDA Approval of Veltin (clindamycin phosphate and tretinoin) Gel 1.2%/0.025% Veltin (clindamycin and tretinoin) FDA Approval History"
},{
  "title": "Tribenzor (amlodipine, hydrochlorothiazide and olmesartan)  Tablets ",
  "date_of_approval": "July 23, 2010",
  "company": " Daiichi Sankyo, Inc.",
  "treatment": " Hypertension",
  "drug_description": "Tribenzor (amlodipine, hydrochlorothiazide and olmesartan) is a three-in-one combination product taken once-daily for the treatment of hypertension.",
  "previous application": "FDA Approves Tribenzor, A New Three-In-One Combination Product for the Treatment of High Blood Pressure Tribenzor (amlodipine, hydrochlorothiazide and olmesartan) FDA Approval History"
},{
  "title": "Lastacaft (alcaftadine)  Ophthalmic Solution ",
  "date_of_approval": "July 28, 2010",
  "company": " Allergan, Inc.",
  "treatment": " Allergic Conjunctivitis",
  "drug_description": "Lastacaft (alcaftadine ophthalmic solution) is a topical H1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis.",
  "previous application": "FDA Approves Lastacaft (alcaftadine ophthalmic solution) for Prevention of Itching Associated with Allergic Conjunctivitis  Lastacaft (alcaftadine) FDA Approval History"
},{
  "title": "Cuvposa (glycopyrrolate)  Oral Solution ",
  "date_of_approval": "July 28, 2010",
  "company": " Shionogi Pharma Inc.",
  "treatment": " Chronic Drooling in Children",
  "drug_description": "Cuvposa (glycopyrrolate) oral solution is an anticholinergic for the treatment of chronic severe drooling caused by neurologic\r disorders in children.",
  "previous application": "FDA Approves Cuvposa for Chronic Drooling in Children Cuvposa (glycopyrrolate) FDA Approval History"
},{
  "title": "Xeomin (incobotulinumtoxinA)  Injection ",
  "date_of_approval": "July 30, 2010",
  "company": " Merz Pharmaceuticals, LLC",
  "treatment": " Cervical Dystonia, Blepharospasm, Glabellar Lines, Upper Limb Spasticity, Excessive Salivation",
  "drug_description": "Xeomin (incobotulinumtoxinA) is a botulinum toxin type A for the treatment of cervical dystonia, blepharospasm, glabellar lines, upper limb spasticity, and excessive drooling.",
  "previous application": "FDA Approves Merz Pharmaceuticals' Xeomin (incobotulinumtoxinA) for the Treatment of Cervical Dystonia and Blepharospasm Xeomin (incobotulinumtoxinA) FDA Approval History"
},{
  "title": "Suprep (sodium sulfate, potassium sulfate, magnesium sulfate)  Oral Solution ",
  "date_of_approval": "August 5, 2010",
  "company": " Braintree Laboratories, Inc.",
  "treatment": " Bowel Preparation",
  "drug_description": "Suprep (sodium sulfate, potassium sulfate, magnesium sulfate) is an osmotic laxative indicated for cleansing of the colon in preparation for colonoscopy in adults.",
  "previous application": "FDA Approves Suprep Bowel Prep Kit Suprep (sodium sulfate, potassium sulfate, magnesium sulfate) FDA Approval History"
},{
  "title": "ella (ulipristal acetate) ",
  "date_of_approval": "August 13, 2010",
  "company": " HRA Pharma",
  "treatment": " Postcoital Contraception",
  "drug_description": "ella is a progesterone agonist/antagonist emergency contraceptive indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure.",
  "previous application": "FDA Approves ella Tablets for Prescription Emergency Contraception ella (ulipristal acetate) FDA Approval History"
},{
  "title": "Tekamlo (aliskiren and amlodipine)  Tablets ",
  "date_of_approval": "August 26, 2010",
  "company": " Novartis Pharmaceuticals Corporation",
  "treatment": " Hypertension",
  "drug_description": "",
  "previous application": "Novartis receives FDA approval of Tekamlo, a single-pill combination of aliskiren and amlodipine to treat high blood pressure Tekamlo (aliskiren and amlodipine) FDA Approval History"
},{
  "title": "Krystexxa (pegloticase)  Injection ",
  "date_of_approval": "September 14, 2010",
  "company": " Savient Pharmaceuticals, Inc.",
  "treatment": " Gout",
  "drug_description": "Krystexxa (pegloticase) is a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy.",
  "previous application": "FDA Approves Krystexxa (pegloticase) for Gout Krystexxa (pegloticase) FDA Approval History"
},{
  "title": "Gilenya (fingolimod)  Capsules  - formerly FTY720",
  "date_of_approval": "September 21, 2010",
  "company": " Novartis",
  "treatment": " Multiple Sclerosis",
  "drug_description": "Gilenya (fingolimod) is a sphingosine 1-phosphate receptor modulator indicated for the treatment of patients with relapsing forms of multiple sclerosis.",
  "previous application": "Novartis Gains FDA Approval For Gilenya, A Novel First-Line Multiple Sclerosis Treatment Shown To Significantly Reduce Relapses And Delay Disability Progression Gilenya (fingolimod) FDA Approval History"
},{
  "title": "Beyaz (drospirenone, ethinyl estradiol and levomefolate calcium)  Tablets ",
  "date_of_approval": "September 24, 2010",
  "company": " Bayer HealthCare Pharmaceuticals Inc.",
  "treatment": " Contraception, Premenstrual Dysphoric Disorder, Acne",
  "drug_description": "Beyaz (drospirenone, ethinyl estradiol and levomefolate calcium) is an estrogen/progestin combined oral contraceptive containing a folate, indicated for use by women to prevent pregnancy, treat symptoms of premenstrual dysphoric disorder, treat moderate acne and to raise folate levels in women who choose to use an oral contraceptive for contraception.",
  "previous application": "FDA Approves Beyaz - Combination Contraceptive Containing a Folate Beyaz (drospirenone, ethinyl estradiol and levomefolate calcium) FDA Approval History"
},{
  "title": "Kapvay (clonidine hydrochloride)  Extended-Release Tablets ",
  "date_of_approval": "September 28, 2010",
  "company": " Shionogi Inc.",
  "treatment": " Attention Deficit Hyperactivity Disorder (ADHD) ",
  "drug_description": "Kapvay (clonidine hydrochloride) is a centrally acting alpha2-adrenergic agonist indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy or as adjunctive therapy to stimulant medications.",
  "previous application": "Shionogi Announces FDA Approval of Kapvay - The First and Only Therapy Approved for Use with Stimulant Medication for the Treatment of ADHD Kapvay (clonidine hydrochloride) FDA Approval History"
},{
  "title": "Aridol (mannitol)  Inhalation Powder ",
  "date_of_approval": "October 5, 2010",
  "company": " Pharmaxis Ltd.",
  "treatment": " Bronchial Challenge Test",
  "drug_description": "Aridol (mannitol inhalation powder) is a bronchial challenge test designed to help in the correct diagnosis and assessment of asthma.",
  "previous application": "United States Food and Drug Administration Approves Aridol Aridol (mannitol) FDA Approval History"
},{
  "title": "Atelvia (risedronate sodium)  Delayed-Release Tablets ",
  "date_of_approval": "October 8, 2010",
  "company": " Warner Chilcott plc",
  "treatment": " Osteoporosis",
  "drug_description": "Atelvia (risedronate sodium) is a bisphosphonate in a delayed-release formulation\r for treatment of postmenopausal osteoporosis.",
  "previous application": "Warner Chilcott Announces FDA Approval of Atelvia - Next Generation Actonel Atelvia (risedronate sodium) FDA Approval History"
},{
  "title": "Sorilux (calcipotriene)  Foam ",
  "date_of_approval": "October 7, 2010",
  "company": " Mayne Pharma",
  "treatment": " Psoriasis",
  "drug_description": "Sorilux (calcipotriene) is a vitamin D analog indicated for the topical treatment of plaque psoriasis in patients 12 years and older.",
  "previous application": "Stiefel, a GSK company, Receives FDA Approval of Sorilux (calcipotriene) Foam, 0.005% Sorilux (calcipotriene) FDA Approval History"
},{
  "title": "Gamunex-C (immune globulin intravenous and subcutaneous)  Injection ",
  "date_of_approval": "October 13, 2010",
  "company": " Talecris Biotherapeutics, Inc.",
  "treatment": " Primary Immunodeficiency Syndrome",
  "drug_description": "Gamunex-C (immune globulin intravenous and subcutaneous) is indicated for the treatment of primary immunodeficiency (PI).",
  "previous application": "Talecris Biotherapeutics Receives FDA Approval for Gamunex-C Gamunex-C (immune globulin intravenous and subcutaneous) FDA Approval History"
},{
  "title": "Pradaxa (dabigatran etexilate)  Capsules ",
  "date_of_approval": "October 19, 2010",
  "company": " Boehringer Ingelheim Pharmaceuticals, Inc.",
  "treatment": " Prevention of Thromboembolism in Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism",
  "drug_description": "Pradaxa (dabigatran etexilate) is a direct thrombin inhibitor indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation; and for the treatment and reduction of risk of deep vein thrombosis and pulmonary embolism.",
  "previous application": "FDA Approves Pradaxa to Prevent Stroke in People With Atrial Fibrillation Pradaxa (dabigatran etexilate) FDA Approval History"
},{
  "title": "Bromday (bromfenac)  Ophthalmic Solution  - formerly XiDay",
  "date_of_approval": "October 16, 2010",
  "company": " ISTA Pharmaceuticals, Inc.",
  "treatment": " Postoperative Ocular Inflammation",
  "drug_description": "",
  "previous application": "ISTA Pharmaceuticals Receives FDA Approval for Bromday Bromday (bromfenac) FDA Approval History"
},{
  "title": "Lo Loestrin Fe (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate)  Tablets ",
  "date_of_approval": "October 21, 2010",
  "company": " Warner Chilcott plc",
  "treatment": " Contraception",
  "drug_description": "Lo Loestrin Fe (norethindrone acetate and\r ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate) is an estrogen/progestin COC indicated for use by women to prevent pregnancy.",
  "previous application": "Warner Chilcott Announces FDA Approval of New Oral Contraceptive Lo Loestrin Fe Lo Loestrin Fe (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate) FDA Approval History"
},{
  "title": "Latuda (lurasidone)  Tablets ",
  "date_of_approval": "October 28, 2010",
  "company": " Dainippon Sumitomo Pharma America, Inc.",
  "treatment": " Schizophrenia, Bipolar Disorder",
  "drug_description": "Latuda (lurasidone) is an atypical antipsychotic agent for the treatment of\r schizophrenia and bipolar depression.",
  "previous application": "FDA approves Latuda to treat schizophrenia in adults Latuda (lurasidone) FDA Approval History"
},{
  "title": "Nuedexta (dextromethorphan and quinidine)  - formerly Zenvia",
  "date_of_approval": "October 29, 2010",
  "company": " Avanir Pharmaceuticals",
  "treatment": " Pseudobulbar Affect",
  "drug_description": "Nuedexta (dextromethorphan and quinidine) is a first-in-class dual action glutamate inhibitor indicated for the treatment of pseudobulbar affect.",
  "previous application": "Avanir Pharmaceuticals Announces FDA Approval of Nuedexta Nuedexta (dextromethorphan and quinidine) FDA Approval History"
},{
  "title": "Teflaro (ceftaroline fosamil)  Injection ",
  "date_of_approval": "October 29, 2010",
  "company": " Allergan, Inc.",
  "treatment": " Pneumonia, Skin and Structure Infection",
  "drug_description": "Teflaro (ceftaroline fosamil) is a cephalosporin antibacterial indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).",
  "previous application": "FDA Approves Teflaro for Bacterial Infections Teflaro (ceftaroline fosamil) FDA Approval History"
},{
  "title": "Ofirmev (acetaminophen)  Intravenous Injection  - formerly Acetavance",
  "date_of_approval": "November 2, 2010",
  "company": " Cadence Pharmaceuticals, Inc.",
  "treatment": " Pain, Fever",
  "drug_description": "Ofirmev (acetaminophen) is an intravenous analgesic product for the treatment of acute pain and fever in adults and children.",
  "previous application": "Cadence Pharmaceuticals Announces FDA Approval of Ofirmev (acetaminophen) injection for the Management of Pain and Fever Ofirmev (acetaminophen) FDA Approval History"
},{
  "title": "Kombiglyze XR (saxagliptin and metformin)  Extended-Release Tablets ",
  "date_of_approval": "November 5, 2010",
  "company": " AstraZeneca",
  "treatment": " Diabetes Type 2",
  "drug_description": "Kombiglyze XR (saxagliptin and metformin) is a once-daily fixed dose combination of the dipeptidyl peptidase-4 (DPP-4) inhibitor Onglyza (saxagliptin) and extended release metformin for the treatment of type 2 diabetes.",
  "previous application": "Kombiglyze XR (Saxagliptin and Metformin HCl Extended-Release) Tablets Approved in the U.S. for the Treatment of Type 2 Diabetes Mellitus in Adults Kombiglyze XR (saxagliptin and metformin) FDA Approval History"
},{
  "title": "Egrifta (tesamorelin)  Injection ",
  "date_of_approval": "November 10, 2010",
  "company": " Theratechnologies",
  "treatment": " Reduction of Excess Abdominal Fat in HIV-Infected Patients with Lipodystrophy",
  "drug_description": "Egrifta (tesamorelin) is a synthetic analogue of growth hormone releasing factor (GRF) for the treatment of excess abdominal fat in HIV patients with lipodystrophy.",
  "previous application": "FDA Approves Egrifta (tesamorelin for injection): First and Only Treatment for the Reduction of Excess Abdominal Fat in HIV-infected Patients with Lipodystrophy Egrifta (tesamorelin) FDA Approval History"
},{
  "title": "Halaven (eribulin mesylate)  Injection ",
  "date_of_approval": "November 15, 2010",
  "company": " Eisai Co., Ltd.",
  "treatment": "NONE",
  "drug_description": "Halaven (eribulin mesylate) is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer, and liposarcoma.",
  "previous application": "FDA Approves Halaven for Late-Stage Breast Cancer Halaven (eribulin mesylate) FDA Approval History"
},{
  "title": "Xgeva (denosumab)  Injection ",
  "date_of_approval": "November 18, 2010",
  "company": " Amgen Inc.",
  "treatment": " Osteolytic Bone Metastases of Solid Tumors, Osteolytic Bone Lesions of Multiple Myeloma, Giant Cell Tumor of Bone, Hypercalcemia of Malignancy",
  "drug_description": "Xgeva (denosumab) is a RANK ligand (RANKL) inhibitor indicated for the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. Xgeva is also indicated for treatment giant cell tumor of bone and for the treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy.",
  "previous application": "FDA Approves Amgen's Xgeva (denosumab) for the Prevention of Skeletal-Related Events in Patients with Bone Metastases from Solid Tumors Xgeva (denosumab) FDA Approval History"
},{
  "title": "Moxeza (moxifloxacin)  Ophthalmic Solution ",
  "date_of_approval": "November 19, 2010",
  "company": " Alcon, Inc.",
  "treatment": " Bacterial Conjunctivitis",
  "drug_description": "Moxeza (moxifloxacin hydrochloride ophthalmic solution) is a topical fluoroquinolone \r anti-infective indicated for the treatment of bacterial conjunctivitis.",
  "previous application": "FDA Approves Moxeza for Bacterial Conjunctivitis Moxeza (moxifloxacin) FDA Approval History"
},{
  "title": "Gablofen (baclofen)  Injection ",
  "date_of_approval": "November 19, 2010",
  "company": " CNS Therapeutics",
  "treatment": " Cerebral Spasticity, Chronic Spasticity",
  "drug_description": "Gablofen (baclofen) is a gamma-aminobutyric acid (GABA) ergic agonist indicated for use in the management of severe spasticity.",
  "previous application": "FDA Approves Movement Disorder Drug from CNS Therapeutics: Gablofen (Baclofen Injection) for the Treatment of Severe Spasticity Gablofen (baclofen) FDA Approval History"
},{
  "title": "Axiron (testosterone)  Topical Solution ",
  "date_of_approval": "November 23, 2010",
  "company": " Eli Lilly and Company",
  "treatment": " Hypogonadism -- Male",
  "drug_description": "",
  "previous application": "Lilly and Acrux Receive FDA Approval for Axiron (Testosterone) Topical Solution CIII Axiron (testosterone) FDA Approval History"
},{
  "title": "Safyral (drospirenone, ethinyl estradiol and levomefolate calcium)  Tablets ",
  "date_of_approval": "December 16, 2010",
  "company": " Bayer HealthCare Pharmaceuticals, Inc.",
  "treatment": " Contraception",
  "drug_description": "Safyral (drospirenone, ethinyl estradiol and levomefolate calcium) is an estrogen/progestin combined oral contraceptive containing a folate, indicated for use by women to prevent pregnancy, and to raise folate levels in women who choose to use an oral contraceptive for contraception.",
  "previous application": "FDA Approves Safyral - Oral Contraceptive That Also Raises Folate Levels Safyral (drospirenone, ethinyl estradiol and levomefolate calcium) FDA Approval History"
},{
  "title": "Amturnide (aliskiren, amlodipine and hydrochlorothiazide)  Tablets ",
  "date_of_approval": "December 21, 2010",
  "company": " Novartis Pharmaceuticals Corporation",
  "treatment": " Hypertension",
  "drug_description": "",
  "previous application": "Novartis Gains FDA Approval for Amturnide, a Triple-Combination Pill to Treat High Blood Pressure in Patients Uncontrolled on Two Medications Amturnide (aliskiren, amlodipine and hydrochlorothiazide) FDA Approval History"
},{
  "title": "Fortesta (testosterone)  Gel ",
  "date_of_approval": "December 29, 2010",
  "company": " Endo Pharmaceuticals",
  "treatment": " Hypogonadism -- Male",
  "drug_description": "Fortesta (testosterone) Gel is a topical androgen indicated for replacement therapy in male hypogonadism.",
  "previous application": "Endo Pharmaceuticals Receives FDA Approval for Fortesta (Testosterone) Gel as a Class III Product for Topical Use for Men With Low Testosterone Fortesta (testosterone) FDA Approval History"
},{
  "title": "Abstral (fentanyl)  Sublingual Tablets ",
  "date_of_approval": "January 7, 2011",
  "company": " Orexo AB",
  "treatment": " Pain",
  "drug_description": "",
  "previous application": "FDA Approval for Abstral (Fentanyl) Sublingual Tablets Abstral (fentanyl) FDA Approval History"
},{
  "title": "DaTscan (ioflupane I 123)  Injection ",
  "date_of_approval": "January 14, 2011",
  "company": " GE Healthcare",
  "treatment": " Diagnostic",
  "drug_description": "DaTscan (ioflupane I 123 injection) is a radiopharmaceutical indicated for \r striatal dopamine transporter visualization using single photon emission \r computed tomography (SPECT) brain imaging to assist in the evaluation of \r adult patients with suspected Parkinsonian syndromes (PS).",
  "previous application": "FDA Approves DaTscan (Ioflupane I 123 Injection) for Visualization of Dopamine Transporters in Patients with Suspected Parkinsonian Syndromes DaTscan (ioflupane I 123) FDA Approval History"
},{
  "title": "Natroba (spinosad)  Topical Suspension ",
  "date_of_approval": "January 18, 2011",
  "company": " ParaPRO LLC",
  "treatment": " Lice",
  "drug_description": "Natroba (spinosad) is a pediculicide indicated for the topical treatment of head lice infestations.",
  "previous application": "FDA Approves Natroba Head Lice Treatment for Children and Adults Natroba (spinosad) FDA Approval History"
},{
  "title": "Viibryd (vilazodone)  Tablets ",
  "date_of_approval": "January 21, 2011",
  "company": " Allergan, Inc.",
  "treatment": " Depression",
  "drug_description": "Viibryd (vilazodone) is a dual-acting potent and selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist indicated for the treatment of major depressive disorder (MDD).",
  "previous application": "FDA Approves Viibryd to Treat Major Depressive Disorder Viibryd (vilazodone) FDA Approval History"
},{
  "title": "Gralise (gabapentin)  Extended Release Tablets  - formerly DM-1796",
  "date_of_approval": "January 28, 2011",
  "company": " Depomed, Inc.",
  "treatment": " Postherpetic Neuralgia",
  "drug_description": "Gralise (gabapentin) is an extended release, tablet formulation of the approved antiepileptic agent gabapentin, indicated for the once-daily treatment of post-herpetic neuralgia (PHN).",
  "previous application": "Depomed Announces US Food and Drug Administration Approval of Gralise (gabapentin) Once-Daily Tablets for Treatment of Post-Herpetic Neuralgia Gralise (gabapentin) FDA Approval History"
},{
  "title": "Makena (hydroxyprogesterone caproate)  Injection  - formerly Gestiva",
  "date_of_approval": "February 3, 2011",
  "company": " Hologic, Inc.",
  "treatment": " Premature Labor",
  "drug_description": "Makena (hydroxyprogesterone caproate) is a long acting form of natural progesterone for the prevention of preterm birth in pregnant women.",
  "previous application": "FDA Approves Makena to Reduce Risk of Preterm Birth in At-Risk Pregnant Women Makena (hydroxyprogesterone caproate) FDA Approval History"
},{
  "title": "Corifact (factor XIII concentrate (human)) ",
  "date_of_approval": "February 17, 2011",
  "company": " CSL Behring LLC ",
  "treatment": " Factor XIII Deficiency",
  "drug_description": "Corifact (factor XIII concentrate (human)) is a is a fibrin-stabilizing factor concentrate indicated to prevent bleeding in people with congenital Factor XIII deficiency.",
  "previous application": "FDA Approves Corifact to Prevent Bleeding in People With Rare Genetic Defect Corifact (factor XIII concentrate (human)) FDA Approval History"
},{
  "title": "Edarbi (azilsartan medoxomil)  Tablets ",
  "date_of_approval": "February 25, 2011",
  "company": " Takeda Pharmaceutical Company Limited",
  "treatment": " Hypertension",
  "drug_description": "Edarbi (azilsartan medoxomil) is an angiotensin II receptor blocker (ARB) for the treatment of hypertension.",
  "previous application": "FDA Approves Edarbi to Treat High Blood Pressure Edarbi (azilsartan medoxomil) FDA Approval History"
},{
  "title": "Daliresp (roflumilast)  Tablets  - formerly Daxas",
  "date_of_approval": "February 28, 2011",
  "company": " Allergan, Inc.",
  "treatment": " Chronic Obstructive Pulmonary Disease",
  "drug_description": "Daliresp (roflumilast) is an orally administered phosphodiesterase 4 (PDE4) enzyme inhibitor indicated as a treatment to reduce the risk of COPD  exacerbations in patients with severe COPD associated with \r chronic bronchitis and a history of exacerbations.",
  "previous application": "FDA Approves Daliresp to Treat Chronic Obstructive Pulmonary Disease Daliresp (roflumilast) FDA Approval History"
},{
  "title": "Benlysta (belimumab)  Injection ",
  "date_of_approval": "March 10, 2011",
  "company": " Human Genome Sciences, Inc. and GlaxoSmithKline",
  "treatment": " Systemic Lupus Erythematosus",
  "drug_description": "Benlysta (belimumab) is B-lymphocyte stimulator (BLyS)-specific inhibitor indicated for the treatment of patients with systemic lupus erythematosus.",
  "previous application": "FDA Approves Benlysta to Treat Lupus Benlysta (belimumab) FDA Approval History"
},{
  "title": "Gadavist (gadobutrol)  Injection ",
  "date_of_approval": "March 14, 2011",
  "company": " Bayer HealthCare Pharmaceuticals Inc.",
  "treatment": " Diagnostic",
  "drug_description": "Gadavist (gadobutrol) is a gadolinium-based contrast agent indicated for use in diagnostic magnetic resonance imaging (MRI).",
  "previous application": "U.S. FDA Approves Bayer's Gadavist (gadobutrol) Injection for MRI of the Central Nervous System Gadavist (gadobutrol) FDA Approval History"
},{
  "title": " (adenovirus type 4 and type 7 vaccine) ",
  "date_of_approval": "March 16, 2011",
  "company": " Barr Laboratories, Inc.",
  "treatment": " Infection Prophylaxis",
  "drug_description": "Adenovirus type 4 and type 7 vaccine is an oral vaccine indicated for the prevention of febrile acute respiratory disease caused by adenovirus type 4 and type 7 in military populations.",
  "previous application": "FDA Approves the New Adenovirus Vaccine adenovirus type 4 and type 7 vaccine FDA Approval History"
},{
  "title": "Yervoy (ipilimumab)  Injection ",
  "date_of_approval": "March 25, 2011",
  "company": " Bristol-Myers Squibb",
  "treatment": " Melanoma -- Metastatic, Renal Cell Carcinoma, Colorectal Cancer, Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Malignant Pleural Mesothelioma",
  "drug_description": "Yervoy (ipilimumab) is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for the treatment of melanoma. Yervoy is also used in combination with Opdivo (nivolumab) for the treatment of advanced renal cell carcinoma, microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, and malignant pleural mesothelioma.",
  "previous application": "FDA Approves Yervoy for Late-Stage Melanoma Yervoy (ipilimumab) FDA Approval History"
},{
  "title": "Sylatron (peginterferon alfa-2b) ",
  "date_of_approval": "March 29, 2011",
  "company": " Merck",
  "treatment": " Malignant Melanoma",
  "drug_description": "Sylatron (peginterferon alfa-2b) is an alpha interferon indicated for the adjuvant treatment of melanoma.",
  "previous application": "FDA Approves Merck's Sylatron (peginterferon alfa-2b) for Injection, a New Adjuvant Treatment for Melanoma with Microscopic or Gross Nodal Involvement Sylatron (peginterferon alfa-2b) FDA Approval History"
},{
  "title": "Caprelsa (vandetanib)  Tablets ",
  "date_of_approval": "April 6, 2011",
  "company": " AstraZeneca",
  "treatment": " Thyroid Cancer",
  "drug_description": "Caprelsa (vandetanib) is a kinase inhibitor indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable (non-operable) locally advanced or metastatic disease.",
  "previous application": "FDA Approves Orphan Drug Vandetanib for Advanced Medullary Thyroid Cancer Caprelsa (vandetanib) FDA Approval History"
},{
  "title": "Horizant (gabapentin enacarbil)  Extended Release Tablets  - formerly Solzira",
  "date_of_approval": "April 6, 2011",
  "company": " GlaxoSmithKline and XenoPort, Inc.",
  "treatment": " Restless Legs Syndrome, Postherpetic Neuralgia",
  "drug_description": "Horizant (gabapentin enacarbil) is a  gabapentin prodrug indicated for the once-daily treatment of restless legs syndrome and postherpetic neuralgia.",
  "previous application": "GlaxoSmithKline and XenoPort Receive FDA Approval for Horizant Horizant (gabapentin enacarbil) FDA Approval History"
},{
  "title": "Duexis (famotidine and ibuprofen)  Tablets ",
  "date_of_approval": "April 23, 2011",
  "company": " Horizon Pharma, Inc.",
  "treatment": " Osteoarthritis, Rheumatoid Arthritis, NSAID-Induced Ulcer Prophylaxis",
  "drug_description": "Duexis (ibuprofen and famotidine) is an NSAID and histamine H2-receptor antagonist combination indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper GI ulcers.",
  "previous application": "Horizon Pharma Announces FDA Approval of Duexis (Ibuprofen/Famotidine) Duexis (famotidine and ibuprofen) FDA Approval History"
},{
  "title": "Zytiga (abiraterone)  Tablets ",
  "date_of_approval": "April 28, 2011",
  "company": " Centocor Ortho Biotech Inc.",
  "treatment": " Prostate Cancer",
  "drug_description": "Zytiga (abiraterone acetate) is a CYP17 inhibitor indicated for the treatment of patients with metastatic castration-resistant prostate cancer and metastatic high-risk castration-sensitive prostate cancer.",
  "previous application": "FDA Approves Zytiga for Late-Stage Prostate Cancer Zytiga (abiraterone) FDA Approval History"
},{
  "title": "Tradjenta (linagliptin)  Tablets ",
  "date_of_approval": "May 2, 2011",
  "company": " Boehringer Ingelheim Pharmaceuticals Inc.",
  "treatment": " Diabetes Type 2",
  "drug_description": "Tradjenta (linagliptin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.",
  "previous application": "FDA Approves Tradjenta for Type 2 Diabetes Tradjenta (linagliptin) FDA Approval History"
},{
  "title": "Docefrez (docetaxel)  for Injection ",
  "date_of_approval": "May 3, 2011",
  "company": " Sun Pharmaceutical Industries Ltd.",
  "treatment": " Breast Cancer, Non-Small Cell Lung Cancer, Prostate Cancer",
  "drug_description": "",
  "previous application": "Sun Pharma Announces US FDA Approval for Docefrez (docetaxel) for Injection Docefrez (docetaxel) FDA Approval History"
},{
  "title": "Victrelis (boceprevir) ",
  "date_of_approval": "May 13, 2011",
  "company": " Merck",
  "treatment": " Chronic Hepatitis C",
  "drug_description": "",
  "previous application": "FDA Approves Merck's Victrelis (boceprevir), First-in-Class Oral Hepatitis C Virus (HCV) Protease Inhibitor Victrelis (boceprevir) FDA Approval History"
},{
  "title": "Edurant (rilpivirine)  Tablets ",
  "date_of_approval": "May 20, 2011",
  "company": " Tibotec Pharmaceuticals",
  "treatment": " HIV Infection",
  "drug_description": "Edurant (rilpivirine) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) indicated in combination with other antiretroviral drugs for the treatment of HIV-1 infection in adults who have never taken HIV therapy (treatment-na\u00efve).",
  "previous application": "FDA Approves New HIV Treatment Edurant (rilpivirine) Edurant (rilpivirine) FDA Approval History"
},{
  "title": "Incivek (telaprevir)  Tablets ",
  "date_of_approval": "May 23, 2011",
  "company": " Vertex Pharmaceuticals Incorporated",
  "treatment": " Chronic Hepatitis C",
  "drug_description": "",
  "previous application": "FDA Approves Incivek (telaprevir) for People with Hepatitis C Incivek (telaprevir) FDA Approval History"
},{
  "title": "Dificid (fidaxomicin) ",
  "date_of_approval": "May 27, 2011",
  "company": " Merck",
  "treatment": " Clostridial Infection",
  "drug_description": "Dificid (fidaxomicin) is a macrolide antibacterial drug indicated for the treatment of  Clostridioides difficile -associated diarrhea.",
  "previous application": "FDA Approves Dificid for Clostridium difficile Infection Dificid (fidaxomicin) FDA Approval History"
},{
  "title": "Potiga (ezogabine)  Tablets ",
  "date_of_approval": "June 10, 2011",
  "company": " GlaxoSmithKline and Valeant Pharmaceuticals International",
  "treatment": " Seizures",
  "drug_description": "",
  "previous application": "Valeant and GlaxoSmithKline Announce U.S. FDA Approval of Potiga (ezogabine) Potiga (ezogabine) FDA Approval History"
},{
  "title": "Nulojix (belatacept)  Injection ",
  "date_of_approval": "June 15, 2011",
  "company": " Bristol-Myers Squibb Company",
  "treatment": " Organ Transplant -- Rejection Prophylaxis",
  "drug_description": "Nulojix (belatacept) is a selective T-cell costimulation blocker indicated for prophylaxis of organ rejection in adult patients receiving a kidney transplant.",
  "previous application": "FDA Approves Nulojix for Kidney Transplant Patients Nulojix (belatacept) FDA Approval History"
},{
  "title": "Oxecta (oxycodone)  Tablets  - formerly Acurox",
  "date_of_approval": "June 17, 2011",
  "company": " Pfizer Inc. and Acura Pharmaceuticals Inc.",
  "treatment": " Pain",
  "drug_description": "",
  "previous application": "Pfizer and Acura Announce FDA Approval of Oxecta (Oxycodone HCl, USP) CII Oxecta (oxycodone) FDA Approval History"
},{
  "title": "Rectiv (nitroglycerin)  Ointment ",
  "date_of_approval": "June 21, 2011",
  "company": " Allergan, Inc.",
  "treatment": " Anal Fissure and Fistula",
  "drug_description": "Rectiv (nitroglycerin) is a topical ointment for the treatment of moderate to severe pain associated with chronic anal fissures.",
  "previous application": "ProStrakan Receives FDA Approval for Rectiv for the Treatment of Moderate to Severe Pain Associated With Chronic Anal Fissures Rectiv (nitroglycerin) FDA Approval History"
},{
  "title": "LaViv (azficel-T) ",
  "date_of_approval": "June 21, 2011",
  "company": " Fibrocell Science, Inc.",
  "treatment": " Wrinkles",
  "drug_description": "Azficel-T is an autologous cellular product indicated for improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults.",
  "previous application": "Fibrocell Science, Inc. Announces FDA Approval for laViv (azficel-T) LaViv (azficel-T) FDA Approval History"
},{
  "title": "Zutripro (chlorpheniramine, hydrocodone and pseudoephedrine)  Oral Solution ",
  "date_of_approval": "June 8, 2011",
  "company": " Cypress Pharmaceutical, Inc.",
  "treatment": " Cough and Nasal Congestion",
  "drug_description": "Zutripro (chlorpheniramine, hydrocodone and pseudoephedrine) Oral Solution is a combination product containing an antitussive, an antihistamine, and a nasal decongestant indicated for the relief of cough and nasal congestion associated with the common cold and upper respiratory allergies.",
  "previous application": "FDA Approves Zutripro (hydrocodone bitartrate, chlorpheniramine maleate and pseudoephedrine HCl) Oral Solution Zutripro (chlorpheniramine, hydrocodone and pseudoephedrine) FDA Approval History"
},{
  "title": "Rezira (hydrocodone and pseudoephedrine)  Oral Solution ",
  "date_of_approval": "June 8, 2011",
  "company": " Cypress Pharmaceutical, Inc.",
  "treatment": " Cough and Nasal Congestion",
  "drug_description": "Rezira (hydrocodone and pseudoephedrine) Oral Solution is a combination product containing an antitussive and \r nasal decongestant indicated for the relief of cough and nasal congestion associated with the common cold.",
  "previous application": "FDA Approves Rezira (hydrocodone bitartrate and pseudoephedrine HCl) Oral Solution  Rezira (hydrocodone and pseudoephedrine) FDA Approval History"
},{
  "title": "Lazanda (fentanyl)  Nasal Spray  - formerly NasalFent",
  "date_of_approval": "June 30, 2011",
  "company": " Archimedes Pharma",
  "treatment": " Pain",
  "drug_description": "Lazanda (fentanyl) is an opioid analgesic nasal spray for the management of breakthrough pain in cancer patients.",
  "previous application": "FDA Approves Lazanda - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients Lazanda (fentanyl) FDA Approval History"
},{
  "title": "Xarelto (rivaroxaban)  Tablets ",
  "date_of_approval": "July 1, 2011",
  "company": " Janssen Pharmaceuticals, Inc.",
  "treatment": " Deep Vein Thrombosis Prophylaxis after Knee Replacement Surgery, Deep Vein Thrombosis Prophylaxis after Hip Replacement Surgery, Prevention of Thromboembolism in Atrial Fibrillation, Coronary Artery Disease, Peripheral Arterial Disease, Deep Vein Thrombosis, Pulmonary Embolism",
  "drug_description": "Xarelto (rivaroxaban) is a factor Xa inhibitor indicated:",
  "previous application": "FDA Approves Xarelto (rivaroxaban) to Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement Surgery Xarelto (rivaroxaban) FDA Approval History"
},{
  "title": "Arcapta (indacaterol)  Neohaler  - formerly QAB149",
  "date_of_approval": "July 1, 2011",
  "company": " Novartis Pharmaceuticals Corp.",
  "treatment": " Chronic Obstructive Pulmonary Disease",
  "drug_description": "Arcapta (indacaterol inhalation powder) is a long-acting beta2-agonist (LABA) for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).",
  "previous application": "FDA Approves Arcapta Neohaler to treat Chronic Obstructive Pulmonary Disease Arcapta (indacaterol) FDA Approval History"
},{
  "title": "Brilinta (ticagrelor)  Tablets ",
  "date_of_approval": "July 20, 2011",
  "company": " AstraZeneca",
  "treatment": " Acute Coronary Syndrome, Coronary Artery Disease, Cardiovascular Risk Reduction, Ischemic Stroke -- Prophylaxis",
  "drug_description": "",
  "previous application": "FDA approves blood-thinning drug Brilinta to treat acute coronary syndromes Brilinta (ticagrelor) FDA Approval History"
},{
  "title": "Anascorp (antivenom (centruroides scorpion))  Injection ",
  "date_of_approval": "August 3, 2011",
  "company": "NONE",
  "treatment": " Scorpion Stings",
  "drug_description": "Anascorp (Centruroides (Scorpion) Immune F(ab\u2019)2 (Equine)) is an antivenom indicated for treatment of clinical signs of scorpion \r envenomation.",
  "previous application": "FDA Approves Anascorp - First Specific Treatment for Scorpion Stings Anascorp (antivenom (centruroides scorpion)) FDA Approval History"
},{
  "title": "Complera (emtricitabine, rilpivirine and tenofovir disoproxil fumarate)  Tablets ",
  "date_of_approval": "August 10, 2011",
  "company": " Gilead Sciences, Inc.",
  "treatment": " HIV Infection",
  "drug_description": "Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) is a combination of three\r antiretroviral medications indicated for the once daily treatment of HIV-1 infection\r in treatment-na\u00efve adults.",
  "previous application": "U.S. Food and Drug Administration Approves Gilead Sciences' Complera, a New Complete Once-Daily, Single-Tablet Regimen for HIV-1 Infection in Treatment-Na\u00efve Adults Complera (emtricitabine, rilpivirine and tenofovir disoproxil fumarate) FDA Approval History"
},{
  "title": "Propel (mometasone furoate)  Implant ",
  "date_of_approval": "August 15, 2011",
  "company": " Intersect ENT, Inc.",
  "treatment": " Sinusitis",
  "drug_description": "Propel (mometasone furoate) is a corticosteroid\r implant offering localized, controlled drug delivery for chronic sinusitis patients.",
  "previous application": "Intersect ENT Announces U.S. Food and Drug Administration Approval for Propel - First Drug Releasing Implant for Chronic Sinusitis Patients Propel (mometasone furoate) FDA Approval History"
},{
  "title": "Zelboraf (vemurafenib)  Tablets ",
  "date_of_approval": "August 17, 2011",
  "company": " Genentech, Inc.",
  "treatment": " Melanoma -- Metastatic",
  "drug_description": "Zelboraf (vemurafenib) is a kinase inhibitor indicated for the treatment of patients \r with metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test, and for the treatment of patients with Erdheim-Chester Disease with BRAF V600 mutation.",
  "previous application": "FDA Approves Zelboraf and Companion Diagnostic Test for Late-Stage Skin Cancer Zelboraf (vemurafenib) FDA Approval History"
},{
  "title": "Adcetris (brentuximab vedotin)  Injection ",
  "date_of_approval": "August 19, 2011",
  "company": " Seattle Genetics, Inc.",
  "treatment": " Lymphoma, Hodgkin's Disease, Mycosis Fungoides",
  "drug_description": "Adcetris (brentuximab vedotin) is a CD30-directed antibody-drug conjugate (ADC) indicated for the treatment of adult patients with:",
  "previous application": "FDA Approves Adcetris to Treat Two Types of Lymphoma Adcetris (brentuximab vedotin) FDA Approval History"
},{
  "title": "Firazyr (icatibant)  Injection ",
  "date_of_approval": "August 25, 2011",
  "company": " Shire plc",
  "treatment": " Angioedema",
  "drug_description": "Firazyr (icatibant) is a selective B2 bradykinin receptor antagonist indicated for the treatment of acute attacks of hereditary angioedema.",
  "previous application": "FDA Approves Shire's Firazyr (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE) Firazyr (icatibant) FDA Approval History"
},{
  "title": "Xalkori (crizotinib)  Capsules ",
  "date_of_approval": "August 26, 2011",
  "company": " Pfizer Inc.",
  "treatment": " Non-Small Cell Lung Cancer",
  "drug_description": "Xalkori (crizotinib) is an oral anaplastic lymphoma kinase (ALK) inhibitor for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors are ALK-positive or ROS1-positive.",
  "previous application": "FDA Approves Xalkori with Companion Diagnostic for a Type of Late-Stage Lung Cancer  Xalkori (crizotinib) FDA Approval History"
},{
  "title": "Juvisync (simvastatin and sitagliptin)  Tablets ",
  "date_of_approval": "October 7, 2011",
  "company": " Merck &amp; Co., Inc.",
  "treatment": " Diabetes Type 2, Homozygous Familial Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia, Hypertriglyceridemia",
  "drug_description": "",
  "previous application": "FDA Approves Combination Therapy Juvisync Juvisync (simvastatin and sitagliptin) FDA Approval History"
},{
  "title": "Ferriprox (deferiprone)  Tablets and Oral Solution ",
  "date_of_approval": "October 14, 2011",
  "company": " ApoPharma Inc.",
  "treatment": " Thalassemia, Iron Overload",
  "drug_description": "Ferriprox (deferiprone) is an iron chelator indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate.",
  "previous application": "FDA Approves Ferriprox to Treat Patients with Excess Iron in the Body Ferriprox (deferiprone) FDA Approval History"
},{
  "title": "Onfi (clobazam)  Tablets ",
  "date_of_approval": "October 21, 2011",
  "company": " Lundbeck Inc.",
  "treatment": " Lennox-Gastaut Syndrome",
  "drug_description": "Onfi (clobazam) is a benzodiazepine antiepileptic drug for the treatment of patients with Lennox-Gastaut syndrome (LGS).",
  "previous application": "FDA Approves Onfi for Seizures Associated with Lennox-Gastaut Syndrome\r  Onfi (clobazam) FDA Approval History"
},{
  "title": "Exparel (bupivacaine liposome)  Injectable Suspension ",
  "date_of_approval": "October 28, 2011",
  "company": " Pacira Pharmaceuticals, Inc.",
  "treatment": " Pain",
  "drug_description": "Exparel (bupivacaine liposome injectable suspension) is a long-acting non-opioid local analgesic for postsurgical local analgesia, and for use as a nerve block (interscalene brachial plexus block) to provide pain relief following shoulder surgeries.",
  "previous application": "Pacira Pharmaceuticals, Inc. Announces U.S. FDA Approval of Exparel For Postsurgical Pain Management Exparel (bupivacaine liposome) FDA Approval History"
},{
  "title": "Forfivo XL (bupropion hydrochloride)  Extended Release Tablets ",
  "date_of_approval": "November 10, 2011",
  "company": " IntelGenx Corp.",
  "treatment": " Depression",
  "drug_description": "Forfivo XL (bupropion) is a high-strength formulation of the aminoketone antidepressant bupropion (contained in Wellbutrin) indicated for the treatment of major depressive disorder.",
  "previous application": "IntelGenx Announces FDA Approval of its High Dose Anti-Depressant Forfivo XL Forfivo XL (bupropion hydrochloride) FDA Approval History"
},{
  "title": "Belotero Balance (dermal filler) ",
  "date_of_approval": "November 16, 2011",
  "company": " Merz Pharmaceuticals, LLC",
  "treatment": " Glabellar Lines",
  "drug_description": "Belotero Balance (dermal filler) is a hyaluronic acid-based cohesive gel dermal filler for the correction of moderate to severe facial wrinkles and folds.",
  "previous application": "Merz Aesthetics Announces FDA Approval of Belotero Balance Dermal Filler for the Correction of Moderate-to-Severe Facial Wrinkles and Folds Belotero Balance (dermal filler) FDA Approval History"
},{
  "title": "Jakafi (ruxolitinib)  Tablets ",
  "date_of_approval": "November 16, 2011",
  "company": " Incyte Corporation",
  "treatment": " Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease",
  "drug_description": "Jakafi (ruxolitinib) is a Janus kinase (JAK) inhibitor indicated for the treatment of:",
  "previous application": "FDA Approves Jakafi to Treat Myelofibrosis Jakafi (ruxolitinib) FDA Approval History"
},{
  "title": "Erwinaze (asparaginase Erwinia chrysanthemi)  Injection ",
  "date_of_approval": "November 18, 2011",
  "company": " Jazz Pharmaceuticals",
  "treatment": " Acute Lymphoblastic Leukemia",
  "drug_description": "Erwinaze (asparaginase Erwinia chrysanthemi) is an antineoplastic agent used to treat patients with acute lymphoblastic leukemia (ALL) who have developed an allergy (hypersensitivity) to E. coli derived asparaginase and pegapargase chemotherapy drugs.",
  "previous application": "FDA Approves Erwinaze to Treat Acute Lymphoblastic Leukemia Erwinaze (asparaginase Erwinia chrysanthemi) FDA Approval History"
},{
  "title": "Eylea (aflibercept)  Injection ",
  "date_of_approval": "November 18, 2011",
  "company": " Regeneron Pharmaceuticals, Inc.",
  "treatment": " Macular Degeneration; Macular Edema; Diabetic Retinopathy; Diabetic Macular Edema",
  "drug_description": "Eylea (aflibercept) is a VEGF inhibitor indicated for the treatment of patients with neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.",
  "previous application": "FDA Approves Eylea for Wet Age-Related Macular Degeneration Eylea (aflibercept) FDA Approval History"
},{
  "title": "Intermezzo (zolpidem tartrate)  Sublingual Tablets ",
  "date_of_approval": "November 23, 2011",
  "company": " Transcept Pharmaceuticals, Inc.",
  "treatment": " Insomnia",
  "drug_description": "",
  "previous application": "FDA Approves Intermezzo for Middle-of-the-Night Waking Followed by Difficulty Returning to Sleep Intermezzo (zolpidem tartrate) FDA Approval History"
},{
  "title": "Anturol (oxybutynin)  Gel ",
  "date_of_approval": "December 7, 2011",
  "company": " Antares Pharma, Inc.",
  "treatment": " Overactive Bladder",
  "drug_description": "",
  "previous application": "Anturol Approved by FDA for the Treatment of Overactive Bladder Anturol (oxybutynin) FDA Approval History"
},{
  "title": "Edarbyclor (azilsartan medoxomil and chlorthalidone)  Tablets ",
  "date_of_approval": "December 20, 2011",
  "company": " Takeda Pharmaceutical Company Limited",
  "treatment": " Hypertension",
  "drug_description": "Edarbyclor (azilsartan medoxomil and chlorthalidone) is a fixed-dose combination of an angiotensin II receptor blocker (ARB) and a diuretic, indicated for the\r treatment of hypertension.",
  "previous application": "FDA Approves Edarbyclor (azilsartan medoxomil and chlorthalidone) for the Treatment of Hypertension Edarbyclor (azilsartan medoxomil and chlorthalidone) FDA Approval History"
},{
  "title": "Subsys (fentanyl)  Sublingual Spray ",
  "date_of_approval": "January 4, 2012",
  "company": " INSYS Therapeutics, Inc.",
  "treatment": " Pain",
  "drug_description": "Subsys (fentanyl) is an opioid analgesic sublingual spray formulation indicated for the treatment of breakthrough cancer pain.",
  "previous application": "Insys Therapeutics Announces FDA Approval of Subsys Fentanyl Sublingual Spray Subsys (fentanyl) FDA Approval History"
},{
  "title": "Voraxaze (glucarpidase)  Injection ",
  "date_of_approval": "January 17, 2012",
  "company": " BTG International Inc.",
  "treatment": " Toxic Methotrexate Levels",
  "drug_description": "Voraxaze (glucarpidase) is a carboxypeptidase enzyme indicated for the treatment of toxic plasma methotrexate levels in patients with delayed methotrexate clearance due to impaired renal function.",
  "previous application": "FDA Approves Voraxaze to Treat Patients with Toxic Methotrexate Levels   Voraxaze (glucarpidase) FDA Approval History"
},{
  "title": "Zetonna (ciclesonide)  Nasal Aerosol ",
  "date_of_approval": "January 20, 2012",
  "company": " Sunovion Pharmaceuticals Inc.",
  "treatment": " Allergic Rhinitis",
  "drug_description": "Zetonna (ciclesonide) is corticosteroid nasal spray indicated for the treatment of symptoms associated with seasonal and perennial allergic rhinitis.",
  "previous application": "FDA Approves Zetonna (ciclesonide) Nasal Aerosol for Allergic Rhinitis Zetonna (ciclesonide) FDA Approval History"
},{
  "title": "Picato (ingenol mebutate)  Topical Gel ",
  "date_of_approval": "January 23, 2012",
  "company": " Leo Pharma",
  "treatment": " Actinic Keratosis",
  "drug_description": "Picato (ingenol mebutate) is an inducer of cell death indicated for the topical treatment of actinic keratosis.",
  "previous application": "FDA Approves Picato (ingenol mebutate) Gel, the First and Only Topical Actinic Keratosis (AK) Therapy With 2 or 3 Consecutive Days of Once-Daily Dosing Picato (ingenol mebutate) FDA Approval History"
},{
  "title": "Inlyta (axitinib)  Tablets ",
  "date_of_approval": "January 27, 2012",
  "company": " Pfizer Inc.",
  "treatment": " Renal Cell Carcinoma",
  "drug_description": "Inlyta (axitinib) is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma.",
  "previous application": "FDA Approves Inlyta for Advanced Renal Cell Carcinoma Inlyta (axitinib) FDA Approval History"
},{
  "title": "Bydureon (exenatide)  Extended-Release Injectable Suspension ",
  "date_of_approval": "January 27, 2012",
  "company": " AstraZeneca",
  "treatment": " Diabetes Type 2",
  "drug_description": "Bydureon (exenatide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated to improve glycemic control in patients with type 2 diabetes.",
  "previous application": "FDA Approves Bydureon - The First and Only Once-Weekly Treatment for Type 2 Diabetes Bydureon (exenatide) FDA Approval History"
},{
  "title": "Erivedge (vismodegib)  Capsules ",
  "date_of_approval": "January 30, 2012",
  "company": " Genentech",
  "treatment": " Basal Cell Carcinoma",
  "drug_description": "Erivedge (vismodegib) is a hedgehog pathway inhibitor for the treatment of patients with advanced basal cell carcinoma (BCC).",
  "previous application": "FDA Approves Erivedge for Basal Cell Carcinoma Erivedge (vismodegib) FDA Approval History"
},{
  "title": "Kalydeco (ivacaftor)  Tablets and Oral Granules ",
  "date_of_approval": "January 31, 2012",
  "company": " Vertex Pharmaceuticals Incorporated",
  "treatment": " Cystic Fibrosis",
  "drug_description": "Kalydeco (ivacaftor) is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator indicated for the treatment of cystic fibrosis (CF) in patients ages 4 months and older who have one mutation in the CFTR gene that is responsive to ivacaftor.",
  "previous application": "FDA Approves Kalydeco to Treat Rare Form of Cystic Fibrosis Kalydeco (ivacaftor) FDA Approval History"
},{
  "title": "Jentadueto (linagliptin and metformin hydrochloride)  Tablets ",
  "date_of_approval": "January 30, 2012",
  "company": " Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly",
  "treatment": " Diabetes Type 2",
  "drug_description": "Jentadueto (linagliptin and metformin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor and biguanide combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.",
  "previous application": "FDA Approves Jentadueto (linagliptin/metformin hydrochloride) for the Treatment of Adult Patients with Type 2 Diabetes Jentadueto (linagliptin and metformin hydrochloride) FDA Approval History"
},{
  "title": "Sklice (ivermectin)  Lotion ",
  "date_of_approval": "February 7, 2012",
  "company": " Arbor Pharmaceuticals, LLC",
  "treatment": " Lice",
  "drug_description": "Sklice (ivermectin) Lotion is a pediculicide indicated for the topical treatment of head lice infestations in patients 6 months of age and older.",
  "previous application": "Sanofi Announces FDA Approval of Sklice Lotion for the Treatment of Head Lice Sklice (ivermectin) FDA Approval History"
},{
  "title": "Mitosol (mitomycin)  Ophthalmic Solution ",
  "date_of_approval": "February 7, 2012",
  "company": " Mobius Therapeutics, LLC",
  "treatment": " Glaucoma Surgery",
  "drug_description": "Mitosol (mitomycin) is an antimetabolite indicated as an adjunct to ab externo glaucoma surgery.",
  "previous application": "Mobius Therapeutics Receives Final FDA Approval for New Glaucoma Drug Mitosol Mitosol (mitomycin) FDA Approval History"
},{
  "title": "Zioptan (tafluprost)  Ophthalmic Solution ",
  "date_of_approval": "February 10, 2012",
  "company": " Merck &amp; Co., Inc.",
  "treatment": " Glaucoma (Open Angle), Intraocular Hypertension",
  "drug_description": "Zioptan (tafluprost ophthalmic solution) is a prostaglandin analog indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.",
  "previous application": "FDA Approves Zioptan (tafluprost ophthalmic solution), Merck's Once-Daily, Preservative-Free Ophthalmic Medication Zioptan (tafluprost) FDA Approval History"
},{
  "title": "Testosterone Gel (testosterone)  Topical Gel  - formerly Bio-T-Gel",
  "date_of_approval": "February 14, 2012",
  "company": " ANI Pharmaceuticals, Inc.",
  "treatment": " Hypogonadism -- Male",
  "drug_description": "Testosterone gel is a once-daily transdermal testosterone gel for the treatment of male hypogonadism or low\r testosterone levels.",
  "previous application": "BioSante Pharmaceuticals Announces FDA Approval for Male Testosterone Gel Testosterone Gel (testosterone) FDA Approval History"
},{
  "title": "Korlym (mifepristone)  Tablets ",
  "date_of_approval": "February 17, 2012",
  "company": " Corcept Therapeutics",
  "treatment": " Cushing's Syndrome",
  "drug_description": "Korlym (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance.",
  "previous application": "FDA Approves Korlym for Patients with Endogenous Cushing's Syndrome Korlym (mifepristone) FDA Approval History"
},{
  "title": "Ultresa (pancrelipase)  Delayed Release Capsules ",
  "date_of_approval": "March 1, 2012",
  "company": " Allergan, Inc.",
  "treatment": " Pancreatic Exocrine Dysfunction",
  "drug_description": "",
  "previous application": "Aptalis Pharma Announces FDA Approval of Ultresa (Pancrelipase) Delayed Release Capsules Ultresa (pancrelipase) FDA Approval History"
},{
  "title": "Viokace (pancrelipase)  Tablets ",
  "date_of_approval": "March 1, 2012",
  "company": " Allergan, Inc.",
  "treatment": " Pancreatic Exocrine Dysfunction",
  "drug_description": "Viokace (pancrelipase) is a combination of porcine-derived lipases, proteases, and amylases. Viokace, in combination with a proton pump inhibitor, is indicated in adults for the treatment of exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatectomy.",
  "previous application": "Aptalis Pharma Announces FDA Approval of Viokace (Pancrelipase) Tablets Viokace (pancrelipase) FDA Approval History"
},{
  "title": "Surfaxin (lucinactant)  Intratracheal Suspension ",
  "date_of_approval": "March 6, 2012",
  "company": " Discovery Laboratories, Inc.",
  "treatment": " Respiratory Distress Syndrome",
  "drug_description": "",
  "previous application": "Discovery Labs Announces FDA Approval of Surfaxin (lucinactant) for Prevention of Respiratory Distress Syndrome Surfaxin (lucinactant) FDA Approval History"
},{
  "title": "Binosto (alendronate)  Effervescent Tablets ",
  "date_of_approval": "March 12, 2012",
  "company": " EffRx Pharmaceuticals SA",
  "treatment": " Osteoporosis",
  "drug_description": "Binosto (alendronate) is a buffered effervescent dosage form of the bisphosphonate drug alendronate sodium administered once weekly for the treatment of osteoporosis.",
  "previous application": "FDA Approves Binosto, First and Only Effervescent Osteoporosis Treatment in a Buffered Solution Binosto (alendronate) FDA Approval History"
},{
  "title": "QNASL (beclomethasone dipropionate)  Nasal Aerosol ",
  "date_of_approval": "March 23, 2012",
  "company": " Teva Pharmaceutical Industries Ltd.",
  "treatment": " Allergic Rhinitis",
  "drug_description": "QNASL (beclomethasone dipropionate) is an intranasal corticosteroid non-aqueous \"dry\" spray formulation for the treatment of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR).",
  "previous application": "Teva Announces FDA Approval of QNASL (beclomethasone dipropionate), a New Nonaqueous Nasal Aerosol, for the Treatment of Allergic Rhinitis QNASL (beclomethasone dipropionate) FDA Approval History"
},{
  "title": "Omontys (peginesatide)  Injection ",
  "date_of_approval": "March 27, 2012",
  "company": " Affymax, Inc. and Takeda Pharmaceutical Company Limited",
  "treatment": " Anemia Associated with Chronic Renal Failure",
  "drug_description": "",
  "previous application": "Affymax and Takeda Announce FDA Approval of Omontys (peginesatide) Injection for the Treatment of Anemia Due to Chronic Kidney Disease (CKD) in Adult Patients on Dialysis Omontys (peginesatide) FDA Approval History"
},{
  "title": "Amyvid (florbetapir F 18)  Injection ",
  "date_of_approval": "April 6, 2012",
  "company": " Eli Lilly and Company and Avid Radiopharmaceuticals, Inc.",
  "treatment": " Diagnostic",
  "drug_description": "Amyvid (florbetapir F 18) is a radioactive diagnostic agent used for brain imaging of beta-amyloid plaques in patients who are being evaluated for Alzheimer's Disease and other causes of cognitive decline.",
  "previous application": "FDA Approves Amyvid (Florbetapir F 18 Injection) for Use in Patients Being Evaluated for Alzheimer's Disease and Other Causes of Cognitive Decline Amyvid (florbetapir F 18) FDA Approval History"
},{
  "title": "Stendra (avanafil)  Tablets ",
  "date_of_approval": "April 27, 2012",
  "company": " Vivus, Inc.",
  "treatment": " Erectile Dysfunction",
  "drug_description": "Stendra (avanafil) is a phosphodiesterase type 5 (PDE5) inhibitor for the treatment of erectile dysfunction (ED).",
  "previous application": "FDA Approves Stendra for Erectile Dysfunction Stendra (avanafil) FDA Approval History"
},{
  "title": "Elelyso (taliglucerase alfa)  - formerly Uplyso",
  "date_of_approval": "May 1, 2012",
  "company": " Protalix BioTherapeutics, Inc.",
  "treatment": " Gaucher Disease",
  "drug_description": "Elelyso (taliglucerase alfa) is a plant-cell expressed recombinant form of glucocerebrosidase for the treatment of Gaucher disease.",
  "previous application": "FDA Approves New Orphan Drug Elelyso to Treat a Form of Gaucher Disease Elelyso (taliglucerase alfa) FDA Approval History"
},{
  "title": "Dymista (azelastine and fluticasone)  Nasal Spray ",
  "date_of_approval": "May 1, 2012",
  "company": " Meda Pharmaceuticals, Inc.",
  "treatment": " Allergic Rhinitis",
  "drug_description": "Dymista (azelastine and fluticasone) nasal spray is an H1-receptor antagonist and corticosteroid combination indicated for the relief of symptoms of seasonal allergic rhinitis.",
  "previous application": "MEDA Announces Dymista Approved by the FDA Dymista (azelastine and fluticasone) FDA Approval History"
},{
  "title": "Fabior (tazarotene)  Foam ",
  "date_of_approval": "May 11, 2012",
  "company": " Stiefel Laboratories, Inc.",
  "treatment": " Acne",
  "drug_description": "Fabior (tazarotene) Foam is a retinoid indicated for the topical treatment of acne vulgaris.",
  "previous application": "Stiefel Receives US FDA Approval of Fabior Foam, 0.1% Fabior (tazarotene) FDA Approval History"
},{
  "title": "Pertzye (pancrelipase)  Delayed Release Capsules ",
  "date_of_approval": "May 17, 2012",
  "company": " Digestive Care, Inc.",
  "treatment": " Pancreatic Exocrine Dysfunction",
  "drug_description": "Pertzye (pancrelipase) is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions.",
  "previous application": "Digestive Care, Inc. Announces FDA Approval of Pertzye (pancrelipase) Delayed-Release Capsules Pertzye (pancrelipase) FDA Approval History"
},{
  "title": "Perjeta (pertuzumab)  Injection ",
  "date_of_approval": "June 8, 2012",
  "company": " Genentech",
  "treatment": " Breast cancer",
  "drug_description": "Perjeta (pertuzumab) is a humanized monoclonal antibody indicated for the treatment of HER2-positive breast cancer.",
  "previous application": "FDA Approves Perjeta (pertuzumab) for People With HER2-Positive Metastatic Breast Cancer Perjeta (pertuzumab) FDA Approval History"
},{
  "title": "MenHibrix (Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine) ",
  "date_of_approval": "June 14, 2012",
  "company": " GlaxoSmithKline",
  "treatment": " Haemophilus influenzae Prophylaxis, Meningococcal Meningitis Prophylaxis",
  "drug_description": "MenHibrix (Hib-MenCY-TT) is a combination vaccine for the active immunization of infants and young children 6 weeks through 18 months of age for the prevention of invasive diseases caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b (Hib).",
  "previous application": "GSK Receives FDA Approval for MenHibrix MenHibrix (Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine) FDA Approval History"
},{
  "title": "Belviq (lorcaserin)  Tablets ",
  "date_of_approval": "June 27, 2012",
  "company": " Arena Pharmaceuticals, Inc.",
  "treatment": " Obesity",
  "drug_description": "Belviq (lorcaserin) is a serotonin 2C receptor agonist indicated for chronic weight management in adults who are obese, or overweight and who have at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol.",
  "previous application": "FDA Approves Belviq to Treat Some Overweight or Obese Adults Belviq (lorcaserin) FDA Approval History"
},{
  "title": "Myrbetriq (mirabegron)  Extended Release Tablets ",
  "date_of_approval": "June 28, 2012",
  "company": " Astellas Pharma Inc.",
  "treatment": " Overactive Bladder",
  "drug_description": "Myrbetriq (mirabegron) is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.",
  "previous application": "FDA Approves Myrbetriq for Overactive Bladder Myrbetriq (mirabegron) FDA Approval History"
},{
  "title": "Prepopik (sodium picosulfate, magnesium oxide and citric acid)  for Oral Solution ",
  "date_of_approval": "July 16, 2012",
  "company": " Ferring Pharmaceuticals",
  "treatment": " Bowel Preparation",
  "drug_description": "",
  "previous application": "FDA Approves Prepopik for Colonoscopy Prep Prepopik (sodium picosulfate, magnesium oxide and citric acid) FDA Approval History"
},{
  "title": "Qsymia (phentermine and topiramate)  Extended-Release Capsules  - formerly Qnexa",
  "date_of_approval": "July 17, 2012",
  "company": " Vivus, Inc.",
  "treatment": " Obesity",
  "drug_description": "Qsymia (phentermine and topiramate) is a combination of phentermine, a sympathomimetic amine anorectic, and topiramate extended-release, an antiepileptic drug, indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults.",
  "previous application": "FDA Approves Weight-Management Drug Qsymia Qsymia (phentermine and topiramate) FDA Approval History"
},{
  "title": "Kyprolis (carfilzomib)  Injection ",
  "date_of_approval": "July 20, 2012",
  "company": " Amgen Inc.",
  "treatment": " Multiple Myeloma",
  "drug_description": "Kyprolis (carfilzomib) is a proteasome inhibitor indicated for the treatment of patients with multiple myeloma.",
  "previous application": "FDA Approves Kyprolis (carfilzomib) for Patients with Advanced Multiple Myeloma Kyprolis (carfilzomib) FDA Approval History"
},{
  "title": "Tudorza (aclidinium bromide)  Pressair ",
  "date_of_approval": "July 23, 2012",
  "company": " Allergan, Inc.",
  "treatment": " Chronic Obstructive Pulmonary Disease",
  "drug_description": "Tudorza Pressair (aclidinium bromide inhalation powder) is an anticholinergic indicated for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.",
  "previous application": "FDA Approves Tudorza Pressair to Treat Chronic Obstructive Pulmonary Disease Tudorza (aclidinium bromide) FDA Approval History"
},{
  "title": "Vascepa (icosapent ethyl)  Capsules ",
  "date_of_approval": "July 26, 2012",
  "company": " Amarin Corporation plc",
  "treatment": " Hypertriglyceridemia, Cardiovascular Risk Reduction",
  "drug_description": "Vascepa (icosapent ethyl) is an ethyl ester of eicosapentaenoic acid (EPA) indicated as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia, and as an adjunct to statin therapy to reduce the risk of of cardiovascular events.",
  "previous application": "Amarin Announces FDA Approval of Vascepa (icosapent ethyl) Capsules for the Reduction of Triglyceride Levels in Adult Patients With Severe Hypertriglyceridemia Vascepa (icosapent ethyl) FDA Approval History"
},{
  "title": "Rayos (prednisone)  Delayed-Release Tablets  - formerly Lodotra",
  "date_of_approval": "July 26, 2012",
  "company": " Horizon Pharma, Inc.",
  "treatment": " Rheumatoid Arthritis, Polymyalgia Rheumatica, Psoriatic Arthritis, Ankylosing Spondylitis, Asthma, Chronic Obstructive Pulmonary Disease",
  "drug_description": "Rayos (prednisone) is a delayed release corticosteroid indicated as an anti-inflammatory or immunosuppressive agent to treat a broad\r range of diseases including rheumatoid arthritis, polymyalgia\r rheumatica, psoriatic arthritis, ankylosing spondylitis, asthma and chronic obstructive pulmonary disease (COPD).",
  "previous application": "Horizon Pharma Announces FDA Approval of Rayos (prednisone) Delayed-Release Tablets for Rheumatoid Arthritis and Multiple Additional Indications Rayos (prednisone) FDA Approval History"
},{
  "title": "Zaltrap (ziv-aflibercept)  Injection ",
  "date_of_approval": "August 3, 2012",
  "company": " Sanofi and Regeneron Pharmaceuticals, Inc.",
  "treatment": " Colorectal Cancer",
  "drug_description": "Zaltrap (ziv-aflibercept) is an angiogenesis inhibitor for the combination treatment of patients with metastatic colorectal cancer.",
  "previous application": "FDA Approves Zaltrap for Metastatic Colorectal Cancer Zaltrap (ziv-aflibercept) FDA Approval History"
},{
  "title": "Marqibo (vincristine sulfate liposomes)  Injection  - formerly Onco TCS",
  "date_of_approval": "August 9, 2012",
  "company": " Talon Therapeutics Inc.",
  "treatment": " Acute Lymphoblastic Leukemia",
  "drug_description": "Marqibo (vincristine sulfate liposome injection) is a vinca alkaloid indicated for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).",
  "previous application": "FDA Approves Marqibo for Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Marqibo (vincristine sulfate liposomes) FDA Approval History"
},{
  "title": "Auvi-Q (epinephrine)  Injection ",
  "date_of_approval": "August 10, 2012",
  "company": " Sanofi",
  "treatment": " Anaphylaxis, Allergic Reaction",
  "drug_description": "Auvi-Q (epinephrine injection) is a voice-guided epinephrine auto-injector for the emergency treatment of life-threatening allergic reactions in people who are at risk for or have a history of anaphylaxis.",
  "previous application": "Sanofi Announces FDA Approval for Auvi-Q, First Voice-guided Epinephrine Auto-injector for Patients with Life-threatening Allergies Auvi-Q (epinephrine) FDA Approval History"
},{
  "title": "Stribild (cobicistat, elvitegravir, emtricitabine and tenofovir)  Tablets ",
  "date_of_approval": "August 27, 2012",
  "company": " Gilead Sciences, Inc.",
  "treatment": " HIV Infection",
  "drug_description": "Stribild (cobicistat, elvitegravir, emtricitabine and tenofovir) is a complete once-daily single tablet regimen for HIV-1 infection for treatment-na\u00efve adults.",
  "previous application": "FDA Approves New Combination Pill Stribild for HIV Treatment Stribild (cobicistat, elvitegravir, emtricitabine and tenofovir) FDA Approval History"
},{
  "title": "Granix (tbo-filgrastim)  Injection ",
  "date_of_approval": "August 29, 2012",
  "company": " Teva Pharmaceutical Industries Ltd.",
  "treatment": " Neutropenia Associated with Chemotherapy",
  "drug_description": "Granix (tbo-filgrastim) is a leukocyte growth factor indicated for the reduction in the duration of severe neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs.",
  "previous application": "FDA Approves Tbo-filgrastim for Severe Neutropenia in Certain Cancer Patients Granix (tbo-filgrastim) FDA Approval History"
},{
  "title": "Linzess (linaclotide)  Capsules ",
  "date_of_approval": "August 30, 2012",
  "company": " Allergan, Inc.",
  "treatment": " Irritable Bowel Syndrome, Constipation -- Chronic",
  "drug_description": "Linzess (linaclotide) is a guanylate cyclase-C agonist indicated in adults for treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).",
  "previous application": "FDA Approves Linzess to Treat Certain Cases of Irritable Bowel Syndrome and Constipation Linzess (linaclotide) FDA Approval History"
},{
  "title": "Xtandi (enzalutamide)  Capsules ",
  "date_of_approval": "August 31, 2012",
  "company": " Astellas Pharma Inc.",
  "treatment": " Prostate Cancer",
  "drug_description": "Xtandi (enzalutamide) is an androgen receptor inhibitor indicated for the treatment of patients with castration-resistant prostate cancer, and metastatic castration-sensitive prostate cancer.",
  "previous application": "FDA Approves Xtandi for Late-Stage Castration-Resistant Prostate Cancer  Xtandi (enzalutamide) FDA Approval History"
},{
  "title": "Bosulif (bosutinib)  Tablets ",
  "date_of_approval": "September 4, 2012",
  "company": " Pfizer Inc.",
  "treatment": " Chronic Myelogenous Leukemia",
  "drug_description": "Bosulif (bosutinib) is a kinase inhibitor indicated for the treatment of adult patients with chronic, accelerated, or blast phase Ph+ chronic myelogenous leukemia (CML).",
  "previous application": "FDA Approves Bosulif for Chronic Myelogenous Leukemia Bosulif (bosutinib) FDA Approval History"
},{
  "title": "Aubagio (teriflunomide)  Tablets ",
  "date_of_approval": "September 12, 2012",
  "company": " Sanofi",
  "treatment": " Multiple Sclerosis",
  "drug_description": "Aubagio (teriflunomide) is an oral pyrimidine synthesis inhibitor indicated for the treatment of patients with relapsing forms of multiple sclerosis.",
  "previous application": "FDA Approves New Multiple Sclerosis Treatment Aubagio\r  Aubagio (teriflunomide) FDA Approval History"
},{
  "title": "Stivarga (regorafenib)  Tablets ",
  "date_of_approval": "September 27, 2012",
  "company": " Bayer HealthCare Pharmaceuticals Inc.",
  "treatment": " Colorectal Cancer, Gastrointestinal Stromal Tumor, Hepatocellular Carcinoma",
  "drug_description": "Stivarga (regorafenib) is an oral multi-kinase inhibitor for the treatment of\r patients with metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma.",
  "previous application": "FDA Approves Stivarga for Advanced Colorectal Cancer Stivarga (regorafenib) FDA Approval History"
},{
  "title": "Quillivant XR (methylphenidate)  for Extended-Release Oral Suspension ",
  "date_of_approval": "September 27, 2012",
  "company": " NextWave Pharmaceuticals, Inc.",
  "treatment": " Attention Deficit Disorder",
  "drug_description": "Quillivant XR (methylphenidate) is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).",
  "previous application": "NextWave Pharmaceuticals Receives FDA Approval of Quillivant XR for Once-Daily Treatment of ADHD Quillivant XR (methylphenidate) FDA Approval History"
},{
  "title": "Cystaran (cysteamine hydrochloride)  Ophthalmic Solution ",
  "date_of_approval": "October 2, 2012",
  "company": " Sigma-Tau Pharmaceuticals, Inc. ",
  "treatment": " Cystinosis",
  "drug_description": "Cystaran (cysteamine cysteamine ophthalmic solution) is a  cystine-depleting agent indicated for the treatment of corneal cystine crystal accumulation in patients with cystinosis.",
  "previous application": "Sigma-Tau Pharmaceuticals, Inc. Receives FDA Approval of Cystaran (cysteamine ophthalmic solution) 0.44% Cystaran (cysteamine hydrochloride) FDA Approval History"
},{
  "title": "Jetrea (ocriplasmin)  Intravitreal Injection ",
  "date_of_approval": "October 17, 2012",
  "company": " ThromboGenics NV",
  "treatment": " Vitreomacular Adhesion",
  "drug_description": "Jetrea (ocriplasmin) is a proteolytic enzyme indicated for the treatment of symptomatic vitreomacular adhesion.",
  "previous application": "FDA Approves Jetrea for Symptomatic Vitreomacular Adhesion in the Eyes Jetrea (ocriplasmin) FDA Approval History"
},{
  "title": "Fycompa (perampanel)  Tablets and Oral Suspension ",
  "date_of_approval": "October 22, 2012",
  "company": " Eisai Inc.",
  "treatment": " Epilepsy, Seizures",
  "drug_description": "Fycompa (perampanel) is a non-competitive AMPA glutamate receptor antagonist indicated for the treatment of partial-onset seizures, and as adjunctive therapy in the treatment of primary generalized tonic-clonic (PGTC) seizures in patients with epilepsy.",
  "previous application": "FDA Approves Fycompa (perampanel) to Treat Partial Onset Seizures Fycompa (perampanel) FDA Approval History"
},{
  "title": "Synribo (omacetaxine mepesuccinate) ",
  "date_of_approval": "October 26, 2012",
  "company": " Teva Pharmaceuticals",
  "treatment": " Chronic Myelogenous Leukemia",
  "drug_description": "Synribo (omacetaxine mepesuccinate) is a first-in-class small molecule drug for the treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia.",
  "previous application": "FDA Approves Synribo for Chronic Myelogenous Leukemia Synribo (omacetaxine mepesuccinate) FDA Approval History"
},{
  "title": "Xeljanz (tofacitinib)  Tablets and Oral Solution ",
  "date_of_approval": "November 6, 2012",
  "company": " Pfizer Inc.",
  "treatment": " Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis, Juvenile Idiopathic Arthritis",
  "drug_description": "Xeljanz (tofacitinib) is an oral Janus kinase (JAK) inhibitor used for the treatment of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and polyarticular course juvenile idiopathic arthritis.",
  "previous application": "FDA Approves Xeljanz for Rheumatoid Arthritis Xeljanz (tofacitinib) FDA Approval History"
},{
  "title": "Cometriq (cabozantinib)  Capsules ",
  "date_of_approval": "November 29, 2012",
  "company": " Exelixis, Inc.",
  "treatment": " Thyroid Cancer",
  "drug_description": "Cometriq (cabozantinib) is a kinase inhibitor indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer.",
  "previous application": "FDA Approves Cometriq (cabozantinib) to Treat Rare Type of Thyroid Cancer Cometriq (cabozantinib) FDA Approval History"
},{
  "title": "Fluarix Quadrivalent (influenza virus vaccine, inactivated)  Injection ",
  "date_of_approval": "December 14, 2012",
  "company": " GlaxoSmithKline",
  "treatment": " Influenza Prophylaxis",
  "drug_description": "Fluarix Quadrivalent is an inactivated influenza virus vaccine indicated for the prevention of influenza disease in people aged 6 months and older.",
  "previous application": "Fluarix GlaxoSmithKline - Treatment for Influenza Vaccination Fluarix Quadrivalent (influenza virus vaccine, inactivated) FDA Approval History"
},{
  "title": "Evarrest (fibrin sealant)  Patch ",
  "date_of_approval": "December 5, 2012",
  "company": " Ethicon, Inc.",
  "treatment": " Bleeding",
  "drug_description": "Evarrest (fibrin sealant patch) is indicated for use with manual compression as an adjunct to hemostasis for problematic soft tissue bleeding during surgery.",
  "previous application": "FDA Approves Evarrest Fibrin Sealant Patch Evarrest (fibrin sealant) FDA Approval History"
},{
  "title": "Iclusig (ponatinib)  Tablets ",
  "date_of_approval": "December 14, 2012",
  "company": " Ariad Pharmaceuticals, Inc.",
  "treatment": " Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia",
  "drug_description": "Iclusig (ponatinib) is a kinase inhibitor  for the treatment of chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL).",
  "previous application": "FDA Approves Iclusig to Treat Two Rare Types of Leukemia Iclusig (ponatinib) FDA Approval History"
},{
  "title": " (raxibacumab) ",
  "date_of_approval": "December 14, 2012",
  "company": " GlaxoSmithKline",
  "treatment": " Inhalation Bacillus anthracis",
  "drug_description": "Raxibacumab is a human monoclonal antibody drug for the treatment of inhalational anthrax.",
  "previous application": "FDA Approves Raxibacumab to Treat Inhalational Anthrax raxibacumab FDA Approval History"
},{
  "title": "Signifor (pasireotide)  Injection ",
  "date_of_approval": "December 14, 2012",
  "company": " Novartis Pharmaceuticals Corporation",
  "treatment": " Cushing's Syndrome",
  "drug_description": "Signifor (pasireotide) is a multireceptor targeting somatostatin analog for the treatment of patients with Cushing's disease.",
  "previous application": "FDA Approves Signifor, a New Orphan Drug for Cushing\u2019s Disease Signifor (pasireotide) FDA Approval History"
},{
  "title": "Adasuve (loxapine)  Inhalation Powder  - formerly AZ-004",
  "date_of_approval": "December 21, 2012",
  "company": " Alexza Pharmaceuticals, Inc.",
  "treatment": " Agitation, Schizophrenia, Bipolar Disorder",
  "drug_description": "Adasuve (loxapine) is a typical antipsychotic indicated for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults.",
  "previous application": "FDA Approves Adasuve (loxapine) Inhalation Powder for the Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I Disorder in Adults Adasuve (loxapine) FDA Approval History"
},{
  "title": "Bivigam (immune globulin intravenous)  Infusion ",
  "date_of_approval": "December 21, 2012",
  "company": " Biotest Pharmaceuticals Corporation",
  "treatment": " Primary Immunodeficiency Syndrome",
  "drug_description": "Bivigam is an immune globulin intravenous (human) indicated for the treatment of primary humoral immunodeficiency.",
  "previous application": "FDA Approves Biotest's Bivigam, an Intravenous Immune Globulin (Human), 10% Liquid Bivigam (immune globulin intravenous) FDA Approval History"
},{
  "title": "Gattex (teduglutide)  for Injection ",
  "date_of_approval": "December 21, 2012",
  "company": " NPS Pharmaceuticals, Inc.",
  "treatment": " Short Bowel Syndrome",
  "drug_description": "Gattex (teduglutide) is a recombinant analog of human glucagon-like peptide 2 for the treatment of short bowel syndrome in adults and pediatric patients one year of age and older.",
  "previous application": "FDA Approves Gattex to Treat Short Bowel Syndrome Gattex (teduglutide) FDA Approval History"
},{
  "title": "VariZIG (varicella zoster immune globulin)  for Injection ",
  "date_of_approval": "December 20, 2012",
  "company": " Cangene Corporation",
  "treatment": " Varicella-Zoster",
  "drug_description": "VariZIG is a varicella zoster immune globulin (human) intended to reduce the severity of chickenpox (varicella) infections in high risk individuals.",
  "previous application": "FDA Approves Varizig for Reducing Chickenpox Symptoms VariZIG (varicella zoster immune globulin) FDA Approval History"
},{
  "title": "Juxtapid (lomitapide)  Capsules ",
  "date_of_approval": "December 21, 2012",
  "company": " Aegerion Pharmaceuticals Inc.",
  "treatment": " Homozygous Familial Hypercholesterolemia",
  "drug_description": "Juxtapid (lomitapide) is a microsomal triglyceride transfer protein inhibitor indicated for the treatment of patients with homozygous familial hypercholesterolemia.",
  "previous application": "FDA Approves Juxtapid - New Orphan Drug for Rare Cholesterol Disorder Juxtapid (lomitapide) FDA Approval History"
},{
  "title": "Eliquis (apixaban)  Tablets ",
  "date_of_approval": "December 28, 2012",
  "company": " Bristol-Myers Squibb Company and Pfizer Inc.",
  "treatment": " Prevention of Thromboembolism in Atrial Fibrillation, Deep Vein Thrombosis Prophylaxis after Knee Replacement Surgery, Deep Vein Thrombosis Prophylaxis after Hip Replacement Surgery",
  "drug_description": "Eliquis (apixaban) is a factor Xa inhibitor anticoagulant indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, and for the prophylaxis of deep vein thrombosis (DVT) in patients who have undergone hip or knee replacement surgery.",
  "previous application": "FDA Approves Eliquis to Reduce the Risk of Stroke, Blood Clots in Patients with Non-Valvular Atrial Fibrillation Eliquis (apixaban) FDA Approval History"
},{
  "title": "Sirturo (bedaquiline)  Tablets ",
  "date_of_approval": "December 28, 2012",
  "company": " Janssen Research &amp; Development, LLC",
  "treatment": " Tuberculosis -- Resistant",
  "drug_description": "Sirturo (bedaquiline) is an oral diarylquinoline antimycobacterial drug indicated for the treatment of pulmonary multi-drug resistant tuberculosis.",
  "previous application": "FDA Approves Sirturo to Treat Multi-Drug Resistant Tuberculosis Sirturo (bedaquiline) FDA Approval History"
},{
  "title": "Mytesi (crofelemer)  Delayed-Release Tablets  - formerly Fulyzaq",
  "date_of_approval": "December 31, 2012",
  "company": " Napo Pharmaceuticals, Inc.",
  "treatment": " Diarrhea",
  "drug_description": "Mytesi (crofelemer) is a proanthocyanidin oligomer indicated to relieve symptoms of diarrhea in HIV/AIDS patients taking antiretroviral therapy.",
  "previous application": "FDA Approves Fulyzaq - First Anti-Diarrheal Drug for HIV/AIDS Patients Mytesi (crofelemer) FDA Approval History"
},{
  "title": "Skyla (levonorgestrel)  Intrauterine System ",
  "date_of_approval": "January 9, 2013",
  "company": " Bayer HealthCare Pharmaceuticals Inc.",
  "treatment": " Contraception",
  "drug_description": "Skyla (levonorgestrel) is a progestin-containing intrauterine system (IUS) indicated for prevention of pregnancy for up to three years.",
  "previous application": "U.S. FDA Approves Bayer's Skyla (Levonorgestrel-Releasing Intrauterine System) 13.5 mg For Prevention Of Pregnancy For Up To Three Years Skyla (levonorgestrel) FDA Approval History"
},{
  "title": "Uceris (budesonide) ",
  "date_of_approval": "January 14, 2013",
  "company": " Santarus, Inc.",
  "treatment": " Ulcerative Colitis",
  "drug_description": "Uceris (budesonide) is a glucocorticosteroid indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis.",
  "previous application": "Santarus Receives FDA Approval of Uceris (budesonide) for the Induction of Remission in Patients with Active, Mild to Moderate Ulcerative Colitis Uceris (budesonide) FDA Approval History"
},{
  "title": "Octaplas (pooled plasma (human))  Solution for Intravenous Infusion ",
  "date_of_approval": "January 17, 2013",
  "company": " Octapharma",
  "treatment": " Bleeding",
  "drug_description": "Octaplas is a solvent/detergent (S/D) treated, pooled human plasma indicated for the replacement of multiple coagulation factors in patients with acquired deficiencies and plasma exchange in patients with thrombotic thrombocytopenic purpura.",
  "previous application": "FDA Approves Octaplas to Treat Patients with Blood Clotting Disorders Octaplas (pooled plasma (human)) FDA Approval History"
},{
  "title": "Zecuity (sumatriptan)  Transdermal Patch ",
  "date_of_approval": "January 17, 2013",
  "company": " NuPathe Inc.",
  "treatment": " Migraine",
  "drug_description": "",
  "previous application": "NuPathe's Zecuity Approved by the FDA for the Acute Treatment of Migraine Zecuity (sumatriptan) FDA Approval History"
},{
  "title": "Oxytrol for Women (oxybutynin)  Transdermal System ",
  "date_of_approval": "January 25, 2013",
  "company": " Merck",
  "treatment": " Overactive Bladder",
  "drug_description": "Oxytrol for Women (oxybutynin) is a muscarinic receptor antagonist transdermal patch available over-the-counter for the treatment of overactive bladder in women.",
  "previous application": "FDA Approves Over-the-Counter Oxytrol for Women to treat Overactive Bladder Oxytrol for Women (oxybutynin) FDA Approval History"
},{
  "title": "Nesina (alogliptin)  Tablets  - formerly SYR-322",
  "date_of_approval": "January 25, 2013",
  "company": " Takeda Pharmaceutical Company Limited ",
  "treatment": " Diabetes Type 2",
  "drug_description": "Nesina (alogliptin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of type 2 diabetes.",
  "previous application": "Takeda Receives FDA Approval for Nesina (alogliptin) for Type 2 Diabetes Nesina (alogliptin) FDA Approval History"
},{
  "title": "Oseni (alogliptin and pioglitazone)  Tablets  - formerly SYR-322/Actos",
  "date_of_approval": "January 25, 2013",
  "company": " Takeda Pharmaceutical Company Limited",
  "treatment": " Diabetes Type 2",
  "drug_description": "Oseni (alogliptin and pioglitazone) is a dipeptidyl peptidase-4 (DPP-4) inhibitor and thiazolidinedione fixed-dose combination for the treatment of type 2 diabetes.",
  "previous application": "Takeda Receives FDA Approval for Oseni (alogliptin and pioglitazone) for Type 2 Diabetes Oseni (alogliptin and pioglitazone) FDA Approval History"
},{
  "title": "Kazano (alogliptin and metformin)  Tablets ",
  "date_of_approval": "January 25, 2013",
  "company": " Takeda Pharmaceutical Company Limited",
  "treatment": " Diabetes Type 2",
  "drug_description": "Kazano (alogliptin and metformin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor and biguanide antihyperglycemic fixed-dose combination for the treatment of type 2 diabetes.",
  "previous application": "Takeda Receives FDA Approval for Kazano (alogliptin and metformin) for Type 2 Diabetes Kazano (alogliptin and metformin) FDA Approval History"
},{
  "title": "Kynamro (mipomersen)  Injection ",
  "date_of_approval": "January 29, 2013",
  "company": " Kastle Therapeutics",
  "treatment": " Homozygous Familial Hypercholesterolemia",
  "drug_description": "",
  "previous application": "FDA Approves New Orphan Drug Kynamro to Treat Inherited Cholesterol Disorder Kynamro (mipomersen) FDA Approval History"
},{
  "title": "Ravicti (glycerol phenylbutyrate)  Oral Liquid ",
  "date_of_approval": "February 1, 2013",
  "company": " Hyperion Therapeutics",
  "treatment": " Urea Cycle Disorders",
  "drug_description": "Ravicti (glycerol phenylbutyrate) is a nitrogen-binding agent for the chronic management of patients with urea cycle disorders.",
  "previous application": "FDA Approves Ravicti for the Chronic Management of Some Urea Cycle Disorders Ravicti (glycerol phenylbutyrate) FDA Approval History"
},{
  "title": "Delzicol (mesalamine)  Delayed-Release Capsules ",
  "date_of_approval": "February 1, 2013",
  "company": " Allergan, Inc.",
  "treatment": " Ulcerative Colitis",
  "drug_description": "Delzicol (mesalamine) is an aminosalicylate indicated for the treatment of mildly to moderately active ulcerative colitis and for the maintenance of remission of ulcerative colitis.",
  "previous application": "Warner Chilcott Announces FDA Approval of New Ulcerative Colitis Product Delzicol Delzicol (mesalamine) FDA Approval History"
},{
  "title": "Pomalyst (pomalidomide)  Capsules ",
  "date_of_approval": "February 8, 2013",
  "company": " Bristol Myers Squibb",
  "treatment": " Multiple Myeloma, Kaposi's Sarcoma",
  "drug_description": "Pomalyst (pomalidomide) is a thalidomide analogue indicated for the treatment of patients with multiple myeloma and AIDS-related and HIV-negative Kaposi sarcoma.",
  "previous application": "FDA Approves Pomalyst for Advanced Multiple Myeloma Pomalyst (pomalidomide) FDA Approval History"
},{
  "title": "Kadcyla (ado-trastuzumab emtansine)  Injection ",
  "date_of_approval": "February 22, 2013",
  "company": " Genentech, Inc.",
  "treatment": " Breast Cancer",
  "drug_description": "Kadcyla (ado-trastuzumab emtansine) is a HER2-targeted antibody and microtubule inhibitor conjugate indicated for the treatment of patients with HER2-positive, metastatic breast cancer.",
  "previous application": "FDA Approves Kadcyla for Late-Stage Breast Cancer Kadcyla (ado-trastuzumab emtansine) FDA Approval History"
},{
  "title": "Osphena (ospemifene)  Tablets ",
  "date_of_approval": "February 26, 2013",
  "company": " Duchesnay Inc.",
  "treatment": " Dyspareunia, Atrophic Vaginitis",
  "drug_description": "Osphena (ospemifene) is an estrogen agonist/antagonist indicated for the treatment of symptoms of vulvar and vaginal atrophy due to menopause, including severe dyspareunia and moderate to severe vaginal dryness.",
  "previous application": "FDA Approves Osphena for Postmenopausal Women Experiencing Dyspareunia Osphena (ospemifene) FDA Approval History"
},{
  "title": "Vituz (chlorpheniramine and hydrocodone)  Oral Solution ",
  "date_of_approval": "February 20, 2013",
  "company": " Hawthorn Pharmaceuticals, Inc.",
  "treatment": " Cough, Cold Symptoms",
  "drug_description": "Vituz (chlorpheniramine and hydrocodone) Oral Solution is an antihistamine/antitussive combination indicated for the relief of cough and symptoms associated with upper respiratory allergies or a common cold.",
  "previous application": "Pernix Therapeutics Receives FDA Approval for Vituz Vituz (chlorpheniramine and hydrocodone) FDA Approval History"
},{
  "title": "Abilify Maintena (aripiprazole)  for Extended-Release Injectable Suspension ",
  "date_of_approval": "February 28, 2013",
  "company": " Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S",
  "treatment": " Schizophrenia, Bipolar Disorder",
  "drug_description": "Abilify Maintena (aripiprazole) is an atypical antipsychotic indicated for the treatment of schizophrenia, and maintenance monotherapy treatment of bipolar I disorder.",
  "previous application": "FDA Approves Once-Monthly Abilify Maintena (aripiprazole) for Extended-Release Injectable Suspension for the Treatment of Schizophrenia Abilify Maintena (aripiprazole) FDA Approval History"
},{
  "title": "Lymphoseek (technetium Tc 99m tilmanocept)  Injection ",
  "date_of_approval": "March 13, 2013",
  "company": " Navidea Biopharmaceuticals",
  "treatment": " Diagnostic",
  "drug_description": "Lymphoseek (technetium Tc 99m tilmanocept) Injection is a radioactive\r diagnostic agent indicated for lymphatic mapping in patients with breast cancer or melanoma, and for guiding sentinel lymph node\r biopsy in patients with squamous cell\r carcinoma of the oral cavity.",
  "previous application": "FDA Approves Lymphoseek to Help Locate Lymph Nodes in Patients with Certain Cancers Lymphoseek (technetium Tc 99m tilmanocept) FDA Approval History"
},{
  "title": "Dotarem (gadoterate meglumine)  Injection ",
  "date_of_approval": "March 20, 2013",
  "company": " Guerbet",
  "treatment": " Diagnostic",
  "drug_description": "Dotarem (gadoterate meglumine) is a gadolinium-based contrast agent indicated for use in magnetic resonance imaging (MRI).",
  "previous application": "FDA Approves Dotarem, a New Magnetic Resonance Imaging Agent\r  Dotarem (gadoterate meglumine) FDA Approval History"
},{
  "title": "TOBI Podhaler (tobramycin)  Inhalation Powder ",
  "date_of_approval": "March 22, 2013",
  "company": " Novartis Pharmaceuticals Corporation",
  "treatment": " Cystic Fibrosis",
  "drug_description": "TOBI Podhaler (tobramycin  inhalation powder) is an antibacterial aminoglycoside indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa.",
  "previous application": "FDA Approves TOBI Podhaler to Treat a Type of Bacterial Lung Infection in Cystic Fibrosis Patients TOBI Podhaler (tobramycin) FDA Approval History"
},{
  "title": "Tecfidera (dimethyl fumarate)  Delayed-Release Capsules  - formerly BG-12",
  "date_of_approval": "March 27, 2013",
  "company": " Biogen Idec",
  "treatment": " Multiple Sclerosis",
  "drug_description": "Tecfidera (dimethyl fumarate) is an oral Nrf2 pathway activator for the treatment of relapsing forms of multiple sclerosis.",
  "previous application": "FDA Approves Tecfidera - a New Treatment for Multiple Sclerosis Tecfidera (dimethyl fumarate) FDA Approval History"
},{
  "title": "Invokana (canagliflozin)  Tablets ",
  "date_of_approval": "March 29, 2013",
  "company": " Janssen Research &amp; Development, LLC",
  "treatment": " Diabetes Type 2, Cardiovascular Risk Reduction, Diabetic Nephropathy",
  "drug_description": "Invokana (canagliflozin) is a selective sodium glucose co-transporter 2 (SGLT2) inhibitor indicated:",
  "previous application": "FDA Approves Invokana to Treat Type 2 Diabetes Invokana (canagliflozin) FDA Approval History"
},{
  "title": "Quartette (levonorgestrel/ethinyl estradiol and ethinyl estradiol)  Tablets ",
  "date_of_approval": "March 28, 2013",
  "company": " Teva Branded Pharmaceutical Products R&amp;D, Inc.",
  "treatment": " Contraception",
  "drug_description": "Quartette (levonorgestrel/ethinyl estradiol and ethinyl estradiol) is a 91-day extended regimen oral contraceptive indicated for the prevention of pregnancy.",
  "previous application": "FDA Approves Quartette (levonorgestrel/ethinyl estradiol and ethinyl estradiol) Tablets for the Prevention of Pregnancy Quartette (levonorgestrel/ethinyl estradiol and ethinyl estradiol) FDA Approval History"
},{
  "title": "Karbinal ER (carbinoxamine)  Extended-Release Oral Suspension ",
  "date_of_approval": "March 28, 2013",
  "company": " Tris Pharma, Inc.",
  "treatment": " Allergic Conjunctivitis, Allergic Reaction, Allergic Rhinitis, Allergic Urticaria",
  "drug_description": "Karbinal ER (carbinoxamine maleate) extended-release oral suspension is an H1 receptor antagonist indicated for the symptomatic treatment of seasonal and perennial allergic rhinitis.",
  "previous application": "FDA Approves Tris Pharma's New Drug Application for Karbinal ER  Karbinal ER (carbinoxamine) FDA Approval History"
},{
  "title": "Prolensa (bromfenac)  Ophthalmic Solution ",
  "date_of_approval": "April 5, 2013",
  "company": " Bausch + Lomb",
  "treatment": " Postoperative Ocular Inflammation",
  "drug_description": "Prolensa (bromfenac ophthalmic solution) is\r a topical nonsteroidal anti-inflammatory indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.",
  "previous application": "Bausch + Lomb Receives FDA Approval for Prolensa Prolensa (bromfenac) FDA Approval History"
},{
  "title": "Diclegis (doxylamine and pyridoxine)  Delayed-Release Tablets ",
  "date_of_approval": "April 8, 2013",
  "company": " Duchesnay Inc.",
  "treatment": " Nausea and Vomiting of Pregnancy",
  "drug_description": "Diclegis (doxylamine and pyridoxine) is an antihistamine and vitamin B6 analog combination indicated for the treatment of nausea and vomiting of pregnancy in women\r who do not respond to conservative management.",
  "previous application": "FDA Approves Diclegis for Pregnant Women Experiencing Nausea and Vomiting Diclegis (doxylamine and pyridoxine) FDA Approval History"
},{
  "title": "Sitavig (acyclovir)  Buccal Tablets ",
  "date_of_approval": "April 12, 2013",
  "company": " BioAlliance Pharma SA",
  "treatment": " Herpes Simplex Labialis",
  "drug_description": "Sitavig (acyclovir) is a mucoadhesive buccal tablet formulation of the antiviral drug acyclovir indicated for the treatment of recurrent orofacial herpes (cold sores).",
  "previous application": "BioAlliance Pharma's Sitavig Receives FDA Approval for the Treatment of Herpes Labialis Sitavig (acyclovir) FDA Approval History"
},{
  "title": "Simbrinza (brimonidine and brinzolamide)  Ophthalmic Suspension ",
  "date_of_approval": "April 19, 2013",
  "company": " Alcon",
  "treatment": " Glaucoma",
  "drug_description": "Simbrinza (brimonidine and brinzolamide) is a fixed combination of an alpha 2 adrenergic receptor agonist and a carbonic anhydrase inhibitor indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.",
  "previous application": "Alcon Announces FDA Approval of Simbrinza Suspension, a New Beta Blocker-Free, Fixed-Combination Therapy for Glaucoma Patients Simbrinza (brimonidine and brinzolamide) FDA Approval History"
},{
  "title": "Kcentra (prothrombin complex concentrate, human) ",
  "date_of_approval": "April 29, 2013",
  "company": " CSL Behring",
  "treatment": " Reversal of Vitamin K Antagonist (VKA) Anticoagulation",
  "drug_description": "",
  "previous application": "FDA Approves Kcentra for the Urgent Reversal of Anticoagulation in Adults with Major Bleeding Kcentra (prothrombin complex concentrate, human) FDA Approval History"
},{
  "title": "Procysbi (cysteamine bitartrate)  Delayed-Release Capsules ",
  "date_of_approval": "April 30, 2013",
  "company": " Raptor Pharmaceutical Corp.",
  "treatment": " Nephropathic Cystinosis",
  "drug_description": "Procysbi (cysteamine bitartrate) is a cystine depleting agent indicated for the treatment of nephropathic cystinosis in adults and pediatric patients 1 year of age and older.",
  "previous application": "FDA Approves Procysbi for Nephropathic Cystinosis Procysbi (cysteamine bitartrate) FDA Approval History"
},{
  "title": "Liptruzet (atorvastatin and ezetimibe)  Tablets ",
  "date_of_approval": "May 3, 2013",
  "company": " Merck",
  "treatment": " Heterozygous Familial Hypercholesterolemia",
  "drug_description": "",
  "previous application": "FDA Approves Merck\u2019s Liptruzet (ezetimibe and atorvastatin), a New Product That Can Help Lower LDL Cholesterol Liptruzet (atorvastatin and ezetimibe) FDA Approval History"
},{
  "title": "Breo Ellipta (fluticasone and vilanterol)  Inhalation Powder ",
  "date_of_approval": "May 10, 2013",
  "company": " GlaxoSmithKline plc (GSK) and Theravance, Inc.",
  "treatment": " Chronic Obstructive Pulmonary Disease, Asthma",
  "drug_description": "Breo Ellipta (fluticasone and vilanterol) is a once-a-day inhaled corticosteroid/long-acting beta2 agonist (LABA) combination indicated for the treatment of patients with chronic obstructive pulmonary disease (COPD) and asthma.",
  "previous application": "FDA Approves Breo Ellipta to Treat Chronic Obstructive Pulmonary Disease (COPD) Breo Ellipta (fluticasone and vilanterol) FDA Approval History"
},{
  "title": "Nymalize (nimodipine)  Oral Solution ",
  "date_of_approval": "May 10, 2013",
  "company": " Arbor Pharmaceuticals",
  "treatment": " Subarachnoid Hemorrhage",
  "drug_description": "Nymalize (nimodipine) is a calcium channel blocker indicated to improve neurological outcome following subarachnoid hemorrhage.",
  "previous application": "Arbor Pharmaceuticals Announces FDA Approval of Nymalize Nymalize (nimodipine) FDA Approval History"
},{
  "title": "Xofigo (radium Ra 223 dichloride)  Injection ",
  "date_of_approval": "May 15, 2013",
  "company": " Bayer HealthCare Pharmaceuticals Inc.",
  "treatment": " Prostate Cancer",
  "drug_description": "Xofigo (radium 223 dichloride) is an alpha\r particle-emitting radioactive therapeutic\r agent indicated for the treatment of\r patients with castration-resistant prostate cancer.",
  "previous application": "FDA Approves Xofigo for Advanced Prostate Cancer Xofigo (radium Ra 223 dichloride) FDA Approval History"
},{
  "title": "Tafinlar (dabrafenib)  Capsules ",
  "date_of_approval": "May 29, 2013",
  "company": " GlaxoSmithKline",
  "treatment": " Melanoma -- Metastatic, Non-Small Cell Lung Cancer, Thyroid Cancer",
  "drug_description": "Tafinlar is also indicated, in combination with trametinib (Mekinist), for:",
  "previous application": "FDA Approves Tafinlar (dabrafenib) for Advanced Melanoma Tafinlar (dabrafenib) FDA Approval History"
},{
  "title": "Mekinist (trametinib)  Tablets ",
  "date_of_approval": "May 29, 2013",
  "company": " GlaxoSmithKline",
  "treatment": " Melanoma -- Metastatic, Non-Small Cell Lung Cancer, Thyroid Cancer",
  "drug_description": "",
  "previous application": "FDA Approves Mekinist (trametinib) for Advanced Melanoma Mekinist (trametinib) FDA Approval History"
},{
  "title": "Bloxiverz (neostigmine methylsulfate)  Injection ",
  "date_of_approval": "May 31, 2013",
  "company": " Flamel Technologies",
  "treatment": " Reversal of Nondepolarizing Muscle Relaxants",
  "drug_description": "Bloxiverz (neostigmine methylsulfate) is a cholinesterase inhibitor used for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery.",
  "previous application": "Flamel Technologies Announces FDA Approval of Bloxiverz Bloxiverz (neostigmine methylsulfate) FDA Approval History"
},{
  "title": "Rixubis (coagulation factor IX (recombinant))  Injection ",
  "date_of_approval": "June 26, 2013",
  "company": " Baxter International Inc.",
  "treatment": " Hemophilia B",
  "drug_description": "Rixubis (coagulation factor IX, recombinant) is an antihemophilic factor indicated for the\r control and prevention of bleeding episodes in adults with hemophilia B.",
  "previous application": "FDA Approves Rixubis - First Recombinant Coagulation Factor IX For Use in Preventing Bleeding Episodes Rixubis (coagulation factor IX (recombinant)) FDA Approval History"
},{
  "title": "Brisdelle (paroxetine mesylate)  Capsules ",
  "date_of_approval": "June 28, 2013",
  "company": " Noven Pharmaceuticals, Inc.",
  "treatment": " Hot Flashes Associated with Menopause",
  "drug_description": "Brisdelle (paroxetine mesylate) is a low-dose\r selective serotonin reuptake inhibitor\r (SSRI) indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause.",
  "previous application": "FDA Approves Brisdelle - First Non-Hormonal Treatment for Hot Flashes Associated with Menopause Brisdelle (paroxetine mesylate) FDA Approval History"
},{
  "title": "Zubsolv (buprenorphine and naloxone)  Sublingual Tablets ",
  "date_of_approval": "July 3, 2013",
  "company": " Orexo AB",
  "treatment": " Opiate Dependence",
  "drug_description": "Zubsolv (buprenorphine and naloxone) is a sublingual partial opioid agonist indicated for the maintenance treatment of opioid dependence.",
  "previous application": "FDA Approves Zubsolv for the Maintenance Treatment of Opioid Dependence Zubsolv (buprenorphine and naloxone) FDA Approval History"
},{
  "title": "Khedezla (desvenlafaxine)  Extended-Release Tablets ",
  "date_of_approval": "July 10, 2013",
  "company": " Osmotica Pharmaceutical Corp.",
  "treatment": " Depression",
  "drug_description": "Khedezla (desvenlafaxine) is a serotonin and norepinephrine reuptake inhibitor (SNRI)\r indicated for the treatment of major depressive disorder.",
  "previous application": "FDA Approves Khedezla for Major Depressive Disorder  Khedezla (desvenlafaxine) FDA Approval History"
},{
  "title": "Gilotrif (afatinib)  Tablets ",
  "date_of_approval": "July 12, 2013",
  "company": " Boehringer Ingelheim Pharmaceuticals Inc.",
  "treatment": " Non-Small Cell Lung Cancer",
  "drug_description": "Gilotrif (afatinib) is a kinase inhibitor indicated for the treatment of\r patients with metastatic non-small cell lung cancer (NSCLC).",
  "previous application": "FDA Approves Gilotrif for Late Stage Non-Small Cell Lung Cancer  Gilotrif (afatinib) FDA Approval History"
},{
  "title": "Simponi Aria (golimumab)  Injection ",
  "date_of_approval": "July 18, 2013",
  "company": " Janssen Biotech, Inc.",
  "treatment": "NONE",
  "drug_description": "Simponi Aria (golimumab) is a tumor necrosis factor (TNF) blocker indicated for the treatment of:",
  "previous application": "Simponi Aria (golimumab) for Infusion Receives FDA Approval for Treatment of Moderately to Severely Active Rheumatoid Arthritis Simponi Aria (golimumab) FDA Approval History"
},{
  "title": "Astagraf XL (tacrolimus)  Extended-Release Capsules ",
  "date_of_approval": "July 19, 2013",
  "company": " Astellas Pharma US, Inc.",
  "treatment": " Organ Transplant -- Rejection Prophylaxis",
  "drug_description": "Astagraf XL (tacrolimus) is a calcineurin-inhibitor immunosuppressant for the prophylaxis of organ rejection in patients receiving a kidney transplant.",
  "previous application": "Astellas Announces FDA Approval of Astagraf XL (tacrolimus extended-release capsules) for the Prophylaxis of Organ Rejection Astagraf XL (tacrolimus) FDA Approval History"
},{
  "title": "Lo Minastrin Fe (ethinyl estradiol and norethindrone, ethinyl estradiol, and ferrous fumarate)  Tablets ",
  "date_of_approval": "July 24, 2013",
  "company": " Warner Chilcott plc",
  "treatment": " Contraception",
  "drug_description": "",
  "previous application": "Warner Chilcott Announces FDA Approval of Lo Minastrin Fe Lo Minastrin Fe (ethinyl estradiol and norethindrone, ethinyl estradiol, and ferrous fumarate) FDA Approval History"
},{
  "title": "Injectafer (ferric carboxymaltose)  Injection ",
  "date_of_approval": "July 25, 2013",
  "company": " Luitpold Pharmaceuticals, Inc.",
  "treatment": " Iron Deficiency Anemia",
  "drug_description": "Injectafer (ferric carboxymaltose) is an iron replacement product indicated for the treatment of iron deficiency anemia.",
  "previous application": "FDA Approves Injectafer for Iron Deficiency Anemia Injectafer (ferric carboxymaltose) FDA Approval History"
},{
  "title": "Fetzima (levomilnacipran)  Extended-Release Capsules ",
  "date_of_approval": "July 25, 2013",
  "company": " Allergan, Inc.",
  "treatment": " Depression",
  "drug_description": "Fetzima (levomilnacipran) is a serotonin and norepinephrine reuptake inhibitor (SNRI)\r indicated for the treatment of major depressive disorder.",
  "previous application": "Forest Laboratories and Pierre Fabre Laboratories Announce FDA Approval of Fetzima for the Treatment of Major Depressive Disorder in Adults Fetzima (levomilnacipran) FDA Approval History"
},{
  "title": "Zubsolv (buprenorphine and naloxone)  Sublingual Tablets ",
  "date_of_approval": "July 3, 2013",
  "company": " Orexo AB",
  "treatment": " Opiate Dependence",
  "drug_description": "Zubsolv (buprenorphine and naloxone) is a sublingual partial opioid agonist indicated for the maintenance treatment of opioid dependence.",
  "previous application": "FDA Approves Unique Low Dosage of Zubsolv Zubsolv (buprenorphine and naloxone) FDA Approval History"
},{
  "title": "FluLaval Quadrivalent (influenza virus vaccine, inactivated) ",
  "date_of_approval": "August 16, 2013",
  "company": " GlaxoSmithKline",
  "treatment": " Influenza Prophylaxis",
  "drug_description": "FluLaval Quadrivalent is an inactivated influenza virus vaccine indicated for active immunization against influenza disease in people aged 6 months and older.",
  "previous application": "FDA Approves FluLaval for Upcoming Influenza Season FluLaval Quadrivalent (influenza virus vaccine, inactivated) FDA Approval History"
},{
  "title": "Tivicay (dolutegravir)  Tablets ",
  "date_of_approval": "August 12, 2013",
  "company": " ViiV Healthcare",
  "treatment": " HIV Infection",
  "drug_description": "Tivicay (dolutegravir) is a human immunodeficiency virus type 1\r (HIV-1) integrase strand transfer inhibitor (INSTI) indicated for use in combination with other antiretroviral (ARV) agents for the treatment of HIV-1.",
  "previous application": "FDA Approves Tivicay (dolutegravir) to Treat HIV Infection Tivicay (dolutegravir) FDA Approval History"
},{
  "title": "Epaned (enalapril maleate)  Oral Solution ",
  "date_of_approval": "August 13, 2013",
  "company": " Silvergate Pharmaceuticals Inc.",
  "treatment": " Hypertension, Congestive Heart Failure, Left Ventricular Dysfunction",
  "drug_description": "Epaned (enalapril maleate) is an angiotensin-converting enzyme inhibitor indicated for the treatment of hypertension in adults and children older than one month, symptomatic heart failure, and asymptomatic left ventricular dysfunction.",
  "previous application": "FDA Approves Epaned, a Liquid Form of Enalapril for Children and Adults Epaned (enalapril maleate) FDA Approval History"
},{
  "title": "FluLaval Quadrivalent (influenza virus vaccine, inactivated) ",
  "date_of_approval": "August 16, 2013",
  "company": " GlaxoSmithKline",
  "treatment": " Influenza Prophylaxis",
  "drug_description": "FluLaval Quadrivalent is an inactivated influenza virus vaccine indicated for active immunization against influenza disease in people aged 6 months and older.",
  "previous application": "FDA Approves FluLaval Quadrivalent FluLaval Quadrivalent (influenza virus vaccine, inactivated) FDA Approval History"
},{
  "title": "Trokendi XR (topiramate) ",
  "date_of_approval": "August 16, 2013",
  "company": " Supernus Pharmaceuticals, Inc.",
  "treatment": " Epilepsy",
  "drug_description": "Trokendi XR (topiramate) is an antiepileptic drug indicated for the treatment of epilepsy.",
  "previous application": "Supernus Announces Final FDA Approval and Upcoming Launch of Trokendi XR Trokendi XR (topiramate) FDA Approval History"
},{
  "title": "Valchlor (mechlorethamine)  Topical Gel ",
  "date_of_approval": "August 23, 2013",
  "company": " Ceptaris Therapeutics, Inc.",
  "treatment": " Mycosis Fungoides",
  "drug_description": "Valchlor (mechlorethamine) gel an alkylating\r agent indicated for the topical treatment of\r Stage IA and IB mycosis fungoides\u2010type cutaneous T\u2010cell lymphoma.",
  "previous application": "Ceptaris Receives FDA Approval for Valchlor (mechlorethamine) Gel for the Treatment of Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma Valchlor (mechlorethamine) FDA Approval History"
},{
  "title": "Mirvaso (brimonidine)  Topical Gel ",
  "date_of_approval": "August 23, 2013",
  "company": " Galderma Laboratories, L.P.",
  "treatment": " Acne Rosacea",
  "drug_description": "Mirvaso (brimonidine) topical gel is an alpha adrenergic agonist indicated for the topical treatment of facial erythema\r of rosacea.",
  "previous application": "Galderma Receives FDA Approval of Mirvaso for the Topical Treatment of Facial Erythema of Rosacea Mirvaso (brimonidine) FDA Approval History"
},{
  "title": "Epaned (enalapril maleate)  Oral Solution ",
  "date_of_approval": "August 13, 2013",
  "company": " Silvergate Pharmaceuticals Inc.",
  "treatment": " Hypertension, Congestive Heart Failure, Left Ventricular Dysfunction",
  "drug_description": "Epaned (enalapril maleate) is an angiotensin-converting enzyme inhibitor indicated for the treatment of hypertension in adults and children older than one month, symptomatic heart failure, and asymptomatic left ventricular dysfunction.",
  "previous application": "FDA Approves Two New Indications for Epaned, the First and Only Enalapril Powder for Oral Solution Epaned (enalapril maleate) FDA Approval History"
},{
  "title": "Epaned (enalapril maleate)  Oral Solution ",
  "date_of_approval": "August 13, 2013",
  "company": " Silvergate Pharmaceuticals Inc.",
  "treatment": " Hypertension, Congestive Heart Failure, Left Ventricular Dysfunction",
  "drug_description": "Epaned (enalapril maleate) is an angiotensin-converting enzyme inhibitor indicated for the treatment of hypertension in adults and children older than one month, symptomatic heart failure, and asymptomatic left ventricular dysfunction.",
  "previous application": "Epaned (enalapril maleate) Oral Solution is Now Available Epaned (enalapril maleate) FDA Approval History"
},{
  "title": "Trintellix (vortioxetine)  Tablets  - formerly Brintellix",
  "date_of_approval": "September 30, 2013",
  "company": " Takeda Pharmaceutical Company Limited and H. Lundbeck A/S",
  "treatment": " Depression",
  "drug_description": "Trintellix (vortioxetine) is a multimodal antidepressant for the treatment of major depressive disorder (MDD).",
  "previous application": "FDA Approves Brintellix to Treat Major Depressive Disorder Trintellix (vortioxetine) FDA Approval History"
},{
  "title": "Duavee (bazedoxifene and conjugated estrogens)  Tablets ",
  "date_of_approval": "October 3, 2013",
  "company": " Pfizer Inc.",
  "treatment": " Postmenopausal Symptoms, Prevention of Osteoporosis",
  "drug_description": "Duavee (bazedoxifene and conjugated estrogens) is an estrogen\r agonist/antagonist and conjugated estrogens combination indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause, and prevention of postmenopausal osteoporosis in women with an intact uterus.",
  "previous application": "FDA Approves Duavee to Treat Hot Flashes and Prevent Osteoporosis Duavee (bazedoxifene and conjugated estrogens) FDA Approval History"
},{
  "title": "Clinolipid (lipid injectable emulsion) ",
  "date_of_approval": "October 3, 2013",
  "company": " Baxter Healthcare Corporation",
  "treatment": " Parenteral Nutrition",
  "drug_description": "",
  "previous application": "FDA Approves Clinolipid for Intravenous Nutrition Clinolipid (lipid injectable emulsion) FDA Approval History"
},{
  "title": "Adempas (riociguat)  Tablets ",
  "date_of_approval": "October 8, 2013",
  "company": " Bayer HealthCare Pharmaceuticals Inc.",
  "treatment": " Pulmonary Hypertension",
  "drug_description": "Adempas (riociguat) is an oral soluble guanylate cyclase (sGC) stimulator for the treatment of pulmonary hypertension.",
  "previous application": "FDA Approves Adempas to Treat Pulmonary Hypertension Adempas (riociguat) FDA Approval History"
},{
  "title": "Otrexup (methotrexate)  Subcutaneous Injection ",
  "date_of_approval": "October 11, 2013",
  "company": " Antares Pharma, Inc.",
  "treatment": " Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriasis",
  "drug_description": "Otrexup (methotrexate) is a folate analog metabolic inhibitor self-administered once weekly for use in the treatment of rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and psoriasis.",
  "previous application": "Otrexup (Methotrexate) Injection Approved By FDA Otrexup (methotrexate) FDA Approval History"
},{
  "title": "Novoeight (turoctocog alfa)  for Intravenous Injection ",
  "date_of_approval": "October 15, 2013",
  "company": " Novo Nordisk",
  "treatment": " Hemophilia A",
  "drug_description": "Novoeight (turoctocog alfa) is an antihemophilic factor (recombinant) indicated\r for use in adults and children with hemophilia A.",
  "previous application": "NovoEight (turoctocog alfa) Receives Approval from the FDA Novoeight (turoctocog alfa) FDA Approval History"
},{
  "title": "Zorvolex (diclofenac)  Capsules ",
  "date_of_approval": "October 18, 2013",
  "company": " Iroko Pharmaceuticals, LLC",
  "treatment": " Pain, Osteoarthritis",
  "drug_description": "Zorvolex (diclofenac) is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of mild to moderate acute pain, and for the management of osteoarthritis pain.",
  "previous application": "Iroko Pharmaceuticals Receives FDA Approval for Zorvolex Zorvolex (diclofenac) FDA Approval History"
},{
  "title": "Opsumit (macitentan)  Tablets ",
  "date_of_approval": "October 18, 2013",
  "company": " Actelion Pharmaceuticals Ltd.",
  "treatment": " Pulmonary Hypertension",
  "drug_description": "Opsumit (macitentan) is a dual endothelin receptor antagonist for the treatment of patients with pulmonary arterial hypertension.",
  "previous application": "FDA Approves Opsumit to Treat Pulmonary Arterial Hypertension Opsumit (macitentan) FDA Approval History"
},{
  "title": "Zohydro ER (hydrocodone)  Extended-Release Capsules ",
  "date_of_approval": "October 25, 2013",
  "company": " Zogenix, Inc.",
  "treatment": " Pain",
  "drug_description": "Zohydro ER (hydrocodone) is a single-entity (without acetaminophen) extended-release opioid analgesic for around-the-clock management of moderate to severe chronic pain.",
  "previous application": "FDA Approves Zohydro ER, an Extended-Release, Single-Entity Hydrocodone Product Zohydro ER (hydrocodone) FDA Approval History"
},{
  "title": "Vizamyl (flutemetamol F 18)  Injection ",
  "date_of_approval": "October 25, 2013",
  "company": " GE Healthcare",
  "treatment": " Diagnostic",
  "drug_description": "Vizamyl (flutemetamol F 18) is a PET amyloid imaging agent for the evaluation of Alzheimer's disease or other cognitive disorders.",
  "previous application": "FDA Approves Vizamyl Brain Imaging Drug to Help Evaluate Patients for Alzheimer\u2019s Disease, Dementia Vizamyl (flutemetamol F 18) FDA Approval History"
},{
  "title": "Gazyva (obinutuzumab)  Injection ",
  "date_of_approval": "November 1, 2013",
  "company": " Genentech",
  "treatment": " Chronic Lymphocytic Leukemia, Follicular Lymphoma",
  "drug_description": "Gazyva (obinutuzumab) is a CD20-directed\r cytolytic antibody indicated for the combination treatment of patients with chronic lymphocytic leukemia and follicular lymphoma.",
  "previous application": "FDA Approves Gazyva for Chronic Lymphocytic Leukemia Gazyva (obinutuzumab) FDA Approval History"
},{
  "title": "Aptiom (eslicarbazepine acetate)  Tablets  - formerly Stedesa",
  "date_of_approval": "November 8, 2013",
  "company": " Sunovion Pharmaceuticals Inc.",
  "treatment": " Epilepsy, Seizures",
  "drug_description": "Aptiom (eslicarbazepine acetate) is a voltage-gated sodium channel blocker for the treatment of partial-onset seizures in patients with epilepsy.",
  "previous application": "FDA Approves Aptiom to Treat Seizures in Adults Aptiom (eslicarbazepine acetate) FDA Approval History"
},{
  "title": "Imbruvica (ibrutinib)  Capsules and Tablets ",
  "date_of_approval": "November 13, 2013",
  "company": " AbbVie Inc.",
  "treatment": " Mantle Cell Lymphoma; Chronic Lymphocytic Leukemia; Waldenstr\u00f6m\u2019s Macroglobulinemia; Small Lymphocytic Lymphoma; Marginal Zone Lymphoma; Chronic Graft Versus Host Disease",
  "drug_description": "Imbruvica (ibrutinib) is an oral Bruton's tyrosine kinase (BTK) inhibitor  indicated for the treatment of adult patients with:",
  "previous application": "FDA Approves Imbruvica (ibrutinib) for Mantle Cell Lymphoma Imbruvica (ibrutinib) FDA Approval History"
},{
  "title": "Luzu (luliconazole)  Topical Cream ",
  "date_of_approval": "November 14, 2013",
  "company": " Valeant Pharmaceuticals International, Inc.",
  "treatment": " Tinea Corporis, Tinea Pedis, Tinea Cruris",
  "drug_description": "Luzu (luliconazole) Cream  is an azole antifungal indicated for the\r topical treatment of interdigital tinea\r pedis, tinea cruris, and tinea corporis.",
  "previous application": "Valeant Pharmaceuticals Announces U.S. Approval Of Luzu Cream, 1% Luzu (luliconazole) FDA Approval History"
},{
  "title": "Olysio (simeprevir)  Capsules ",
  "date_of_approval": "November 22, 2013",
  "company": " Janssen Research &amp; Development, LLC",
  "treatment": " Chronic Hepatitis C",
  "drug_description": "Olysio (simeprevir) is a protease inhibitor for the treatment of chronic hepatitis C virus infection.",
  "previous application": "FDA Approves Olysio (simeprevir) for Hepatitis C Virus\r  Olysio (simeprevir) FDA Approval History"
},{
  "title": "Varithena (polidocanol)  Injectable Foam ",
  "date_of_approval": "November 25, 2013",
  "company": " BTG plc",
  "treatment": " Varicose Vein",
  "drug_description": "Varithena (polidocanol) injectable foam is a sclerosing agent indicated for\r the treatment of varicose veins.",
  "previous application": "FDA Approves Varithena (Polidocanol Injectable Foam) for the Treatment of Patients with Varicose Veins  Varithena (polidocanol) FDA Approval History"
},{
  "title": "Velphoro (sucroferric oxyhydroxide)  Chewable Tablets ",
  "date_of_approval": "November 27, 2013",
  "company": " Vifor Fresenius Medical Care Renal Pharma",
  "treatment": " Hyperphosphatemia of Renal Failure",
  "drug_description": "Velphoro (sucroferric oxyhydroxide) is a chewable, iron-based phosphate binder for the control of serum phosphorus levels in patients with Chronic Kidney Disease (CKD) on dialysis.",
  "previous application": "Velphoro Receives US FDA Approval for the Treatment of Hyperphosphatemia in Chronic Kidney Disease Patients on Dialysis Velphoro (sucroferric oxyhydroxide) FDA Approval History"
},{
  "title": "Sovaldi (sofosbuvir)  Tablets and Oral Pellets ",
  "date_of_approval": "December 6, 2013",
  "company": " Gilead Sciences",
  "treatment": " Chronic Hepatitis C",
  "drug_description": "Sovaldi (sofosbuvir) is a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor indicated for the treatment of:",
  "previous application": "FDA Approves Sovaldi for Chronic Hepatitis C Sovaldi (sofosbuvir) FDA Approval History"
},{
  "title": "Anoro Ellipta (umeclidinium bromide and vilanterol) ",
  "date_of_approval": "December 18, 2013",
  "company": " GlaxoSmithKline plc (GSK) and Theravance, Inc.",
  "treatment": " Chronic Obstructive Pulmonary Disease",
  "drug_description": "Anoro Ellipta (umeclidinium bromide and vilanterol) is a long-acting muscarinic antagonist (LAMA) and long-acting beta2 agonist (LABA) combination for the treatment of COPD.",
  "previous application": "FDA Approves Anoro Ellipta to Treat Chronic Obstructive Pulmonary Disease Anoro Ellipta (umeclidinium bromide and vilanterol) FDA Approval History"
},{
  "title": "Tretten (coagulation factor XIII A-subunit (recombinant)) ",
  "date_of_approval": "December 23, 2013",
  "company": " Novo Nordisk A/S",
  "treatment": " Factor XIII A-Subunit Deficiency",
  "drug_description": "Tretten (coagulation factor XIII A-subunit (recombinant)) is a recombinant analogue of the human Factor XIII A-subunit for the prevention of bleeding in patients who have  the rare clotting disorder congenital Factor XIII A-subunit deficiency.",
  "previous application": "FDA Approves Tretten to Treat Rare Genetic Clotting Disorder Tretten (coagulation factor XIII A-subunit (recombinant)) FDA Approval History"
},{
  "title": "Orenitram (treprostinil)  Extended-Release Tablets ",
  "date_of_approval": "December 20, 2013",
  "company": " United Therapeutics Corporation",
  "treatment": " Pulmonary Hypertension",
  "drug_description": "Orenitram (treprostinil extended-release) is an oral prostacyclin for the treatment of pulmonary arterial hypertension.",
  "previous application": "FDA Approves Orenitram (treprostinil) Extended-Release Tablets for the Treatment of Pulmonary Arterial Hypertension Orenitram (treprostinil) FDA Approval History"
},{
  "title": "Farxiga (dapagliflozin)  Tablets ",
  "date_of_approval": "January 8, 2014",
  "company": " AstraZeneca",
  "treatment": " Diabetes Type 2",
  "drug_description": "Farxiga (dapagliflozin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated for the treatment of type 2 diabetes mellitus and heart failure.",
  "previous application": "FDA Approves Farxiga to Treat Type 2 Diabetes Farxiga (dapagliflozin) FDA Approval History"
},{
  "title": "Aleve PM (diphenhydramine hydrochloride and naproxen sodium)  Caplets ",
  "date_of_approval": "January 16, 2014",
  "company": " Bayer HealthCare LLC, Consumer Care",
  "treatment": " Pain, Insomnia",
  "drug_description": "Aleve PM (diphenhydramine hydrochloride and naproxen sodium) is an over-the-counter antihistamine and nonsteroidal anti-inflammatory drug (NSAID) combination for the relief of occasional sleeplessness associated with minor aches and pains.",
  "previous application": "FDA Approves Aleve PM (diphenhydramine hydrochloride and naproxen sodium) Aleve PM (diphenhydramine hydrochloride and naproxen sodium) FDA Approval History"
},{
  "title": "Hetlioz (tasimelteon)  Capsules ",
  "date_of_approval": "January 31, 2014",
  "company": " Vanda Pharmaceuticals Inc.",
  "treatment": " Non-24-Hour Disorder; Smith-Magenis Syndrome Sleep Disturbance",
  "drug_description": "Hetlioz (tasimelteon) is a melatonin receptor agonist for the treatment of Non-24-Hour Disorder in adults, and nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) in patients 16 years of age and older.",
  "previous application": "FDA Approves Hetlioz: First Treatment for Non-24 Hour Sleep-Wake Disorder in Blind Individuals  Hetlioz (tasimelteon) FDA Approval History"
},{
  "title": "Vimizim (elosufase alfa)  Injection ",
  "date_of_approval": "February 14, 2014",
  "company": " BioMarin Pharmaceutical Inc.",
  "treatment": " Mucopolysaccharidosis Type IVA",
  "drug_description": "Vimizim (elosufase alfa) is an enzyme replacement therapy for patients with Mucopolysaccharidosis Type IVA (Morquio A syndrome).",
  "previous application": "FDA Approves Vimizim to Treat Mucopolysaccharidosis Type IVA Vimizim (elosufase alfa) FDA Approval History"
},{
  "title": "Northera (droxidopa)  Capsules ",
  "date_of_approval": "February 18, 2014",
  "company": " Chelsea Therapeutics International, Ltd.",
  "treatment": " Neurogenic Orthostatic Hypotension",
  "drug_description": "Northera (droxidopa) is an orally active synthetic precursor of norepinephrine indicated for the treatment of neurogenic orthostatic hypotension.",
  "previous application": "FDA Approves Northera to treat Neurogenic Orthostatic Hypotension Northera (droxidopa) FDA Approval History"
},{
  "title": "Myalept (metreleptin)  Injection ",
  "date_of_approval": "February 24, 2014",
  "company": " Amylin Pharmaceuticals, Inc.",
  "treatment": " Lipodystrophy",
  "drug_description": "Myalept (metreleptin) is a leptin analog\r indicated to treat the complications of leptin deficiency in patients with\r congenital or acquired generalized lipodystrophy.",
  "previous application": "FDA Approves Myalept to Treat Generalized Lipodystrophy Myalept (metreleptin) FDA Approval History"
},{
  "title": "Tivorbex (indomethacin)  Capsules ",
  "date_of_approval": "February 24, 2014",
  "company": " Iroko Pharmaceuticals, LLC",
  "treatment": " Pain",
  "drug_description": "Tivorbex (indomethacin) is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of mild to moderate acute pain.",
  "previous application": "Iroko Pharmaceuticals Receives FDA Approval for Tivorbex Tivorbex (indomethacin) FDA Approval History"
},{
  "title": "Monovisc (sodium hyaluronate)  Injection ",
  "date_of_approval": "February 24, 2014",
  "company": " Anika Therapeutics, Inc.",
  "treatment": " Osteoarthritis",
  "drug_description": "Monovisc (sodium hyaluronate) is a viscoelastic supplement indicated for the treatment of pain associated with osteoarthritis of the knee.",
  "previous application": "FDA Approves Monovisc, a New Single Injection Treatment for Pain Due to Osteoarthritis of the Knee Monovisc (sodium hyaluronate) FDA Approval History"
},{
  "title": "Aveed (testosterone undecanoate)  Intramuscular Injection  - formerly Nebido",
  "date_of_approval": "March 5, 2014",
  "company": " Endo Pharmaceuticals",
  "treatment": " Hypogonadism -- Male",
  "drug_description": "Aveed (testosterone undecanoate) is a long-acting androgen depot injection for the treatment of male hypogonadism.",
  "previous application": "FDA Approves Aveed (testosterone undecanoate) Injectable Testosterone Replacement Therapy Aveed (testosterone undecanoate) FDA Approval History"
},{
  "title": "Xartemis XR (acetaminophen and oxycodone hydrochloride)  Extended-Release Tablets ",
  "date_of_approval": "March 11, 2014",
  "company": " Mallinckrodt",
  "treatment": " Pain",
  "drug_description": "",
  "previous application": "FDA Approves Xartemis XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII) Xartemis XR (acetaminophen and oxycodone hydrochloride) FDA Approval History"
},{
  "title": "Qudexy XR (topiramate)  Extended-Release Capsules ",
  "date_of_approval": "March 11, 2014",
  "company": " Upsher-Smith Laboratories, Inc.",
  "treatment": " Seizures, Lennox-Gastaut Syndrome, Migraine Prophylaxis",
  "drug_description": "Qudexy XR (topiramate) is an antiepileptic drug indicated for the treatment of partial onset seizures, primary generalized tonic-clonic seizures, and seizures associated with Lennox-Gastaut Syndrome in adults and children; and for the prophylaxis of migraine headache in adults and adolescents.",
  "previous application": "Upsher-Smith Receives FDA Approval for Qudexy XR (topiramate) Extended-Release Capsules Qudexy XR (topiramate) FDA Approval History"
},{
  "title": "Hemangeol (propranolol hydrochloride)  Oral Solution ",
  "date_of_approval": "March 14, 2014",
  "company": " Pierre Fabre Dermatologie",
  "treatment": " Infantile Hemangioma",
  "drug_description": "Hemangeol (propranolol hydrochloride) is a pediatric beta-blocker formulation indicated for the treatment of proliferating infantile hemangioma.",
  "previous application": "Pierre Fabre Obtains FDA Approval to Market Hemangeol for the Treatment of Infantile Hemangioma Hemangeol (propranolol hydrochloride) FDA Approval History"
},{
  "title": "Impavido (miltefosine)  Capsules ",
  "date_of_approval": "March 19, 2014",
  "company": " Paladin Labs Inc. ",
  "treatment": " Leishmaniasis",
  "drug_description": "Impavido (miltefosine) is an oral alkylphosphocholine antiparasitic for the treatment of leishmaniasis.",
  "previous application": "FDA Approves Impavido to Treat Tropical Disease Leishmaniasis Impavido (miltefosine) FDA Approval History"
},{
  "title": "Neuraceq (florbetaben F18)  Injection ",
  "date_of_approval": "March 19, 2014",
  "company": " Piramal Imaging",
  "treatment": " Positron Emission Tomography Imaging",
  "drug_description": "Neuraceq (florbetaben F18) is a radioactive diagnostic agent indicated for PET imaging of the brain to estimate \u03b2-amyloid neuritic plaquedensity in adult patients with cognitive impairment who are being evaluated\r for Alzheimer\u2019s Disease (AD) and other causes of cognitive decline.",
  "previous application": "FDA Approves Neuraceq (florbetaben F18 injection) for PET Imaging of Beta-Amyloid Plaques Neuraceq (florbetaben F18) FDA Approval History"
},{
  "title": "Otezla (apremilast)  Tablets ",
  "date_of_approval": "March 21, 2014",
  "company": " Celgene Corporation",
  "treatment": " Psoriatic Arthritis, Plaque Psoriasis, Behcet's Disease",
  "drug_description": "Otezla (apremilast) is a phosphodiesterase 4 (PDE4) inhibitor indicated for the treatment of psoriatic arthritis, plaque psoriasis, and oral ulcers associated with Beh\u00e7et\u2019s Disease.",
  "previous application": "FDA Approves Otezla (apremilast) to Treat Psoriatic Arthritis Otezla (apremilast) FDA Approval History"
},{
  "title": "Alprolix (coagulation factor IX (recombinant)) ",
  "date_of_approval": "March 28, 2014",
  "company": " Biogen Idec, Inc.",
  "treatment": " Hemophilia B",
  "drug_description": "Alprolix (coagulation factor IX (recombinant)) is a clotting factor IX therapy indicated to prevent bleeding in patients with hemophilia B.",
  "previous application": "FDA Approves Alprolix (recombinant coagulation factor IX) for patients with Hemophilia B Alprolix (coagulation factor IX (recombinant)) FDA Approval History"
},{
  "title": "Evzio (naloxone hydrochloride) ",
  "date_of_approval": "April 3, 2014",
  "company": " Kaleo Inc.",
  "treatment": " Opioid Overdose",
  "drug_description": "Evzio (naloxone hydrochloride) is an opioid antagonist hand-held auto-injector indicated for the emergency treatment of known or suspected opioid overdose.",
  "previous application": "FDA Approves Evzio (naloxone) Hand-Held Auto-Injector to Reverse Opioid Overdose Evzio (naloxone hydrochloride) FDA Approval History"
},{
  "title": "Tanzeum (albiglutide)  Injection ",
  "date_of_approval": "April 15, 2014",
  "company": " GlaxoSmithKline (GSK) plc",
  "treatment": " Diabetes Type 2",
  "drug_description": "Tanzeum (albiglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of type 2 diabetes.",
  "previous application": "FDA Approves Tanzeum (albiglutide) to Treat Type 2 Diabetes Tanzeum (albiglutide) FDA Approval History"
},{
  "title": "Ragwitek (ragweed pollen allergen extract) ",
  "date_of_approval": "April 17, 2014",
  "company": " Merck &amp; Co., Inc.",
  "treatment": " Ragweed Allergies",
  "drug_description": "Ragwitek (short ragweed pollen allergen extract) is a sublingual immunotherapy for the treatment of ragweed allergies.",
  "previous application": "FDA Approves Ragwitek for Short Ragweed Pollen Allergies  Ragwitek (ragweed pollen allergen extract) FDA Approval History"
},{
  "title": "Xulane (ethinyl estradiol and norelgestromin)  Transdermal System ",
  "date_of_approval": "April 16, 2014",
  "company": " Mylan Inc.",
  "treatment": " Contraception",
  "drug_description": "Xulane (ethinyl estradiol and norelgestromin transermal system) is a generic version of Ortho Evra, a birth control patch used to prevent pregnancy.",
  "previous application": "Mylan Launches Xulane - First Generic Ortho Evra Patch Xulane (ethinyl estradiol and norelgestromin) FDA Approval History"
},{
  "title": "Cyramza (ramucirumab)  Injection ",
  "date_of_approval": "April 21, 2014",
  "company": " Eli Lilly and Company",
  "treatment": " Gastric Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer, Hepatocellular Carcinoma",
  "drug_description": "Cyramza (ramucirumab) is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated:",
  "previous application": "FDA Approves Cyramza for Stomach Cancer Cyramza (ramucirumab) FDA Approval History"
},{
  "title": "Sylvant (siltuximab)  for Injection ",
  "date_of_approval": "April 22, 2014",
  "company": " Janssen Research &amp; Development, LLC",
  "treatment": " Multicentric Castleman's Disease",
  "drug_description": "Sylvant (siltuximab) is an interleukin-6 (IL-6) antagonist indicated for the treatment of patients with multicentric Castleman\u2019s disease.",
  "previous application": "FDA Approves Sylvant for Multicentric Castleman\u2019s Disease Sylvant (siltuximab) FDA Approval History"
},{
  "title": "Zykadia (ceritinib)  Capsules ",
  "date_of_approval": "April 29, 2014",
  "company": " Novartis Pharmaceuticals Corporation",
  "treatment": " Non-Small Cell Lung Cancer",
  "drug_description": "Zykadia (ceritinib) is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer.",
  "previous application": "FDA Approves Zykadia (ceritinib) for Metastatic Non-Small Cell Lung Cancer Zykadia (ceritinib) FDA Approval History"
},{
  "title": "Purixan (mercaptopurine)  Oral Suspension ",
  "date_of_approval": "April 28, 2014",
  "company": " Nova Laboratories, Ltd.",
  "treatment": " Acute Lymphoblastic Leukemia",
  "drug_description": "Purixan (mercaptopurine) is a nucleoside metabolic inhibitor indicated\r for the treatment of\r patients with acute lymphoblastic leukemia.",
  "previous application": "FDA Approves Purixan (mercaptopurine) Oral Suspension Purixan (mercaptopurine) FDA Approval History"
},{
  "title": "Incruse Ellipta (umeclidinium)  Inhalation Powder ",
  "date_of_approval": "April 30, 2014",
  "company": " GlaxoSmithKline",
  "treatment": " Chronic Obstructive Pulmonary Disease -- Maintenance",
  "drug_description": "Incruse Ellipta (umeclidinium) is an anticholinergic bronchodilator indicated for the maintenance treatment of chronic\r obstructive pulmonary disease (COPD).",
  "previous application": "FDA Approves Incruse Ellipta (umeclidinium) for the Treatment of COPD Incruse Ellipta (umeclidinium) FDA Approval History"
},{
  "title": "Epanova (omega-3-carboxylic acids)  Capsules ",
  "date_of_approval": "May 5, 2014",
  "company": " AstraZeneca",
  "treatment": " Hypertriglyceridemia",
  "drug_description": "",
  "previous application": "FDA Approves Epanova for Severe Hypertriglyceridemia Epanova (omega-3-carboxylic acids) FDA Approval History"
},{
  "title": "Zontivity (vorapaxar)  Tablets ",
  "date_of_approval": "May 8, 2014",
  "company": " Merck",
  "treatment": " Cardiovascular Risk Reduction",
  "drug_description": "Zontivity (vorapaxar) is a protease-activated receptor-1 (PAR-1) antagonist for the prevention of cardiovascular events in high risk patients.",
  "previous application": "FDA Approves Zontivity to Reduce the Risk of Heart Attacks and Stroke Zontivity (vorapaxar) FDA Approval History"
},{
  "title": "Entyvio (vedolizumab)  Injection ",
  "date_of_approval": "May 20, 2014",
  "company": " Takeda Pharmaceutical Company Limited",
  "treatment": " Crohn's Disease -- Acute, Ulcerative Colitis",
  "drug_description": "Entyvio (vedolizumab) is an integrin receptor antagonist for the treatment of Crohn's disease and ulcerative colitis.",
  "previous application": "FDA Approves Entyvio (vedolizumab) to treat Ulcerative Colitis and Crohn's Disease Entyvio (vedolizumab) FDA Approval History"
},{
  "title": "Dalvance (dalbavancin)  Injection ",
  "date_of_approval": "May 23, 2014",
  "company": " Allergan, Inc.",
  "treatment": " Skin and Structure Infection",
  "drug_description": "Dalvance (dalbavancin) is a second generation lipoglycopeptide antibiotic for the treatment of adult patients with complicated skin and skin structure infections, including those caused by\r methicillin-resistant Staphylococcus aureus (MRSA).",
  "previous application": "FDA Approves Dalvance (dalbavancin) to Treat Skin Infections Dalvance (dalbavancin) FDA Approval History"
},{
  "title": "Natesto (testosterone)  Intranasal Gel  - formerly CompleoTRT",
  "date_of_approval": "May 28, 2014",
  "company": " Trimel Pharmaceuticals Corporation",
  "treatment": " Hypogonadism -- Male",
  "drug_description": "Natesto (testosterone) is a bioadhesive intranasal gel testosterone product for the treatment of male hypogonadism.",
  "previous application": "FDA Approves Natesto (testosterone) Nasal Gel to Treat Men with Low Testosterone Natesto (testosterone) FDA Approval History"
},{
  "title": "Omidria (ketorolac and phenylephrine)  Injection ",
  "date_of_approval": "May 30, 2014",
  "company": " Omeros Corporation",
  "treatment": " Intraocular Lens Replacement Procedures",
  "drug_description": "Omidria (ketorolac and phenylephrine) is an anti-inflammatory and mydriatic combination added to irrigation solution during cataract surgery and intraocular lens replacement procedures.",
  "previous application": "FDA Approves Omidria for Use in Cataract and Other Intraocular Lens Replacement Procedures Omidria (ketorolac and phenylephrine) FDA Approval History"
},{
  "title": "Vogelxo (testosterone)  Transdermal Gel ",
  "date_of_approval": "June 4, 2014",
  "company": " Upsher-Smith Laboratories, Inc.",
  "treatment": " Hypogonadism -- Male",
  "drug_description": "Vogelxo (testosterone) transdermal gel is an androgen indicated for testosterone\r replacement therapy in males with hypogonadism.",
  "previous application": "Upsher-Smith Receives Final NDA Approval For Vogelxo (testosterone) Gel Vogelxo (testosterone) FDA Approval History"
},{
  "title": "Eloctate (antihemophilic factor (recombinant))  for Injection ",
  "date_of_approval": "June 6, 2014",
  "company": " Biogen Idec, Inc.",
  "treatment": " Hemophilia A",
  "drug_description": "Eloctate (antihemophilic factor (recombinant) Fc Fusion Protein is a recombinant DNA derived, antihemophilic factor indicated for the treatment of patients with Hemophilia A.",
  "previous application": "FDA Approves Eloctate - first Antihemophilic Factor, Fc Fusion Protein for Patients with Hemophilia A Eloctate (antihemophilic factor (recombinant)) FDA Approval History"
},{
  "title": "Jublia (efinaconazole)  Topical Solution ",
  "date_of_approval": "June 6, 2014",
  "company": " Valeant Pharmaceuticals International, Inc.",
  "treatment": " Onychomycosis -- Toenail",
  "drug_description": "Jublia (efinaconazole) is a topical triazole antifungal for the treatment of onychomycosis of the toenails.",
  "previous application": "Valeant Pharmaceuticals Announces FDA Approval Of Jublia for the Treatment of Onychomycosis Jublia (efinaconazole) FDA Approval History"
},{
  "title": "Bunavail (buprenorphine and naloxone)  Buccal Film ",
  "date_of_approval": "June 6, 2014",
  "company": " BioDelivery Sciences International, Inc.",
  "treatment": " Opiate Dependence",
  "drug_description": "Bunavail (buprenorphine and naloxone) buccal film is an opioid analgesic/opioid antagonist formulation for the maintenance treatment of opioid dependence.",
  "previous application": "FDA Approves Bunavail Buccal Film for the Maintenance Treatment of Opioid Dependence Bunavail (buprenorphine and naloxone) FDA Approval History"
},{
  "title": "Sivextro (tedizolid phosphate)  Tablets and Injection ",
  "date_of_approval": "June 20, 2014",
  "company": " Cubist Pharmaceuticals, Inc.",
  "treatment": " Skin and Structure Infection",
  "drug_description": "Sivextro (tedizolid phosphate) is an oxazolidinone antibiotic drug indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI).",
  "previous application": "FDA Approves Sivextro (tedizolid phosphate) to Treat Skin Infections Sivextro (tedizolid phosphate) FDA Approval History"
},{
  "title": "Afrezza (insulin human [rDNA origin])  Inhalation Powder  - formerly Afresa",
  "date_of_approval": "June 27, 2014",
  "company": " MannKind Corporation",
  "treatment": " Diabetes Type 1, Diabetes Type 2",
  "drug_description": "Afrezza (insulin human [rDNA origin]) is a rapid acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus.",
  "previous application": "FDA Approves Afrezza to Treat Diabetes Afrezza (insulin human [rDNA origin]) FDA Approval History"
},{
  "title": "Vazculep (phenylephrine hydrochloride)  Injection ",
  "date_of_approval": "June 27, 2014",
  "company": " Flamel Technologies",
  "treatment": " Hypotension",
  "drug_description": "Vazculep (phenylephrine hydrochloride) injection is an alpha-1 adrenergic\r receptor agonist indicated for the treatment of hypotension resulting primarily from vasodilation in the setting of anesthesia.",
  "previous application": "Flamel Technologies Announces FDA Approval of Vazculep Vazculep (phenylephrine hydrochloride) FDA Approval History"
},{
  "title": "Beleodaq (belinostat)  Injection ",
  "date_of_approval": "July 3, 2014",
  "company": " Spectrum Pharmaceuticals, Inc.",
  "treatment": " Peripheral T-cell Lymphoma",
  "drug_description": "Beleodaq (belinostat) is a histone deacetylase (HDAC) inhibitor for the treatment of peripheral T-cell lymphoma (PTCL).",
  "previous application": "FDA Approves Beleodaq (belinostat) for Peripheral T-Cell Lymphoma Beleodaq (belinostat) FDA Approval History"
},{
  "title": "Kerydin (tavaborole)  Topical Solution ",
  "date_of_approval": "July 7, 2014",
  "company": " Anacor Pharmaceuticals",
  "treatment": " Onychomycosis -- Toenail",
  "drug_description": "Kerydin (tavaborole) is an oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails.",
  "previous application": "FDA Approves Kerydin (tavaborole) Topical Solution for Onychomycosis of the Toenails Kerydin (tavaborole) FDA Approval History"
},{
  "title": "Rasuvo (methotrexate)  Injection  - formerly MPI-2505",
  "date_of_approval": "July 11, 2014",
  "company": " Medac Pharma, Inc.",
  "treatment": " Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis, Psoriasis",
  "drug_description": "Rasuvo (methotrexate) is a subcutaneous, ready-to-use autopen formulation of methotrexate for the treatment of  rheumatoid arthritis (RA), poly-articular-course juvenile RA and psoriasis.",
  "previous application": "FDA Approves Rasuvo (methotrexate) Injection Rasuvo (methotrexate) FDA Approval History"
},{
  "title": "Ruconest (C1 esterase inhibitor (recombinant))  - formerly Rhucin",
  "date_of_approval": "July 16, 2014",
  "company": " Pharming Group NV",
  "treatment": " Hereditary Angioedema",
  "drug_description": "Ruconest is a C1 esterase inhibitor [recombinant] indicated for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE).",
  "previous application": "FDA Approves Ruconest for Hereditary Angioedema Ruconest (C1 esterase inhibitor (recombinant)) FDA Approval History"
},{
  "title": "Zydelig (idelalisib)  Tablets ",
  "date_of_approval": "July 23, 2014",
  "company": " Gilead Sciences, Inc.",
  "treatment": " non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Follicular Lymphoma",
  "drug_description": "Zydelig (idelalisib) is a phosphoinositide 3-kinase (PI3K) delta inhibitor for the treatment of chronic lymphocytic leukemia, relapsed follicular B-cell non-Hodgkin lymphoma, and relapsed small lymphocytic lymphoma.",
  "previous application": "FDA Approves Zydelig (idelalisib) for CLL and Lymphoma Zydelig (idelalisib) FDA Approval History"
},{
  "title": "Targiniq ER (naloxone and oxycodone)  Extended-Release Tablets ",
  "date_of_approval": "July 23, 2014",
  "company": " Purdue Pharma L.P.",
  "treatment": " Pain",
  "drug_description": "",
  "previous application": "FDA Approves Targiniq ER Extended-Release Oxycodone with Abuse-Deterrent Properties Targiniq ER (naloxone and oxycodone) FDA Approval History"
},{
  "title": "Ryanodex (dantrolene)  Injectable Suspension ",
  "date_of_approval": "July 22, 2014",
  "company": " Eagle Pharmaceuticals, Inc.",
  "treatment": " Malignant Hyperthermia",
  "drug_description": "Ryanodex (dantrolene) is a skeletal muscle relaxant in a concentrated formulation for the treatment of malignant hyperthermia.",
  "previous application": "FDA Approves Ryanodex for the Treatment of Malignant Hyperthermia  Ryanodex (dantrolene) FDA Approval History"
},{
  "title": "Flonase Allergy Relief (fluticasone propionate)  Nasal Spray ",
  "date_of_approval": "July 23, 2014",
  "company": " GlaxoSmithKline plc",
  "treatment": " Allergic Rhinitis",
  "drug_description": "Flonase Allergy Relief (fluticasone propionate) is a once-a-day, over-the-counter corticosteroid nasal spray indicated for the relief hay fever symptoms.",
  "previous application": "FDA Approves Flonase Allergy Relief for Sale Over-the-Counter in the United States Flonase Allergy Relief (fluticasone propionate) FDA Approval History"
},{
  "title": "Acticlate (doxycycline hyclate)  Tablets ",
  "date_of_approval": "July 25, 2014",
  "company": " Aqua Pharmaceuticals, LLC",
  "treatment": " Bacterial Infection, Acne",
  "drug_description": "Acticlate (doxycycline hyclate) is a tetracycline-class antibacterial indicated for the treatment of a number of infections,\r including adjunctive therapy in severe acne.",
  "previous application": "Aqua Pharmaceuticals Announces FDA Approval of Acticlate (doxycycline hyclate USP) Tablets Acticlate (doxycycline hyclate) FDA Approval History"
},{
  "title": "Striverdi Respimat (olodaterol)  Inhalation Spray ",
  "date_of_approval": "July 31, 2014",
  "company": " Boehringer Ingelheim Pharmaceuticals Inc.",
  "treatment": " Chronic Obstructive Pulmonary Disease",
  "drug_description": "Striverdi Respimat (olodaterol) is a once-daily, long-acting beta-agonist (LABA) for the maintenance treatment of chronic obstructive pulmonary disease (COPD).",
  "previous application": "FDA Approves Striverdi Respimat to Treat Chronic Obstructive Pulmonary Disease Striverdi Respimat (olodaterol) FDA Approval History"
},{
  "title": "Jardiance (empagliflozin)  Tablets ",
  "date_of_approval": "August 1, 2014",
  "company": " Boehringer Ingelheim Pharmaceuticals, Inc.",
  "treatment": " Diabetes Type 2",
  "drug_description": "Jardiance (empagliflozin) is a sodium glucose co-transporter-2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults\r with type 2 diabetes, and to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease.",
  "previous application": "FDA Approves Jardiance (empagliflozin) to Treat Type 2 Diabetes Jardiance (empagliflozin) FDA Approval History"
},{
  "title": "Orbactiv (oritavancin)  Injection ",
  "date_of_approval": "August 6, 2014",
  "company": " The Medicines Company",
  "treatment": " Skin and Structure Infection",
  "drug_description": "Orbactiv (oritavancin) is a semi-synthetic lipoglycopeptide antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI).",
  "previous application": "FDA Approves Orbactiv (oritavancin) to Treat Skin and Skin Structure Infections Orbactiv (oritavancin) FDA Approval History"
},{
  "title": "Invokamet (canagliflozin and metformin)  Tablets ",
  "date_of_approval": "August 8, 2014",
  "company": " Janssen Research &amp; Development, LLC",
  "treatment": " Diabetes Type 2, Cardiovascular Risk Reduction",
  "drug_description": "Invokamet (canagliflozin/metformin) is a selective sodium glucose co-transporter 2 (SGLT2) inhibitor and biguanide combination indicated for the treatment of type 2 diabetes, and to reduce the risk of cardiovascular events (including heart attack, stroke or death) in adults with type 2 diabetes and established cardiovascular disease.",
  "previous application": "FDA Approves Invokamet (canagliflozin/metformin) for Type 2 Diabetes Invokamet (canagliflozin and metformin) FDA Approval History"
},{
  "title": "Belsomra (suvorexant)  Tablets ",
  "date_of_approval": "August 13, 2014",
  "company": " Merck, Sharpe &amp; Dohme Corp.",
  "treatment": " Insomnia",
  "drug_description": "Belsomra (suvorexant) is an orexin receptor antagonist for use in patients with difficulty falling or staying asleep (insomnia).",
  "previous application": "FDA Approves Belsomra (suvorexant) for Insomnia Belsomra (suvorexant) FDA Approval History"
},{
  "title": "Plegridy (peginterferon beta-1a)  Injection ",
  "date_of_approval": "August 15, 2014",
  "company": " Biogen Idec",
  "treatment": " Multiple Sclerosis",
  "drug_description": "Plegridy (peginterferon beta-1a) is a pegylated interferon beta indicated for the treatment of patients with relapsing forms of multiple sclerosis.",
  "previous application": "FDA Approves Plegridy (peginterferon beta-1a) for the Treatment of Multiple Sclerosis Plegridy (peginterferon beta-1a) FDA Approval History"
},{
  "title": "Cerdelga (eliglustat)  Capsules ",
  "date_of_approval": "August 19, 2014",
  "company": " Genzyme Corporation",
  "treatment": " Gaucher Disease",
  "drug_description": "Cerdelga (eliglustat) is a glucosylceramide synthase inhibitor indicated for the long-\r term treatment of adult patients with\r Gaucher disease type 1.",
  "previous application": "FDA Approves Cerdelga (eliglustat) for Type 1 Gaucher Disease Cerdelga (eliglustat) FDA Approval History"
},{
  "title": "Arnuity Ellipta (fluticasone furoate)  Inhalation Powder ",
  "date_of_approval": "August 20, 2014",
  "company": " GlaxoSmithKline plc",
  "treatment": " Asthma, Asthma -- Maintenance",
  "drug_description": "Arnuity Ellipta (fluticasone furoate inhalation powder) is a once-daily inhaled corticosteroid for the maintenance treatment of asthma.",
  "previous application": "FDA Approves Arnuity Ellipta (fluticasone furoate) for the Treatment of Asthma  Arnuity Ellipta (fluticasone furoate) FDA Approval History"
},{
  "title": "Triumeq (abacavir, dolutegravir and lamivudine)  Tablets ",
  "date_of_approval": "August 22, 2014",
  "company": " ViiV Healthcare",
  "treatment": " HIV Infection",
  "drug_description": "Triumeq (abacavir, dolutegravir and lamivudine) is a fixed-dose combination containing the INSTI dolutegravir and the NRTIs abacavir and lamivudine for the treatment of HIV-1 infection.",
  "previous application": "FDA Approves Triumeq for the Treatment of HIV-1 Infection  Triumeq (abacavir, dolutegravir and lamivudine) FDA Approval History"
},{
  "title": "Kabiven (amino acids, electrolytes, dextrose and lipid)  Injectable Emulsion ",
  "date_of_approval": "August 25, 2014",
  "company": " Fresenius Kabi USA",
  "treatment": " Parenteral Nutrition",
  "drug_description": "Kabiven (amino acids, electrolytes, dextrose\r and lipid injectable emulsion) is indicated as a source of calories, protein, electrolytes and essential fatty acids for adult patients requiring parenteral nutrition.",
  "previous application": "Fresenius Kabi Receives FDA Approval for Kabiven and Perikabiven Kabiven (amino acids, electrolytes, dextrose and lipid) FDA Approval History"
},{
  "title": "Keytruda (pembrolizumab)  for Injection ",
  "date_of_approval": "September 4, 2014",
  "company": " Merck &amp; Co., Inc.",
  "treatment": " Melanoma -- Metastatic, Non-Small Cell Lung Cancer, Head and Neck Cancer, Hodgkin's Disease, Urothelial Carcinoma, Gastric Cancer, Cervical Cancer, Hepatocellular Carcinoma, Merkel Cell Carcinoma, Renal Cell Carcinoma, Small Cell Lung Cancer, Esophageal Carcinoma, Endometrial Carcinoma, Squamous Cell Carcinoma",
  "drug_description": "Keytruda (pembrolizumab) is a human PD-1 (programmed death receptor-1)-blocking antibody indicated for the treatment of melanoma, non-small cell lung cancer, small cell lung cancer, head and neck squamous cell carcinoma, classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, urothelial carcinoma, microsatellite instability-high cancer, gastric cancer, esophageal cancer, cervical cancer, hepatocellular carcinoma, Merkel cell carcinoma, renal cell carcinoma, endometrial carcinoma, tumor mutational burden-high (TMB-H) cancer, cutaneous squamous cell carcinoma, and triple-negative breast cancer.",
  "previous application": "FDA Approves Keytruda (pembrolizumab) for Advanced Melanoma Keytruda (pembrolizumab) FDA Approval History"
},{
  "title": "Auryxia (ferric citrate)  Tablets ",
  "date_of_approval": "September 5, 2014",
  "company": " Keryx Biopharmaceuticals, Inc.",
  "treatment": " Hyperphosphatemia of Renal Failure, Anemia Associated with Chronic Renal Failure",
  "drug_description": "Auryxia (ferric citrate) is a phosphate binder indicated for the control of serum phosphorus levels in dialysis patients; and an iron replacement product for the treatment of iron deficiency anemia in adult patients with chronic kidney disease who are not on dialysis.",
  "previous application": "Keryx Biopharmaceuticals Receives FDA Approval of Ferric Citrate for Dialysis Patients With Hyperphosphatemia Auryxia (ferric citrate) FDA Approval History"
},{
  "title": "Contrave (bupropion and naltrexone)  Tablets ",
  "date_of_approval": "September 10, 2014",
  "company": " Orexigen Therapeutics, Inc.",
  "treatment": " Obesity",
  "drug_description": "Contrave (bupropion/naltrexone) is an aminoketone antidepressant and opioid antagonist combination indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic\r weight management.",
  "previous application": "FDA Approves Contrave (bupropion/naltrexone) for Weight Management Contrave (bupropion and naltrexone) FDA Approval History"
},{
  "title": "Movantik (naloxegol)  Tablets ",
  "date_of_approval": "September 16, 2014",
  "company": " AstraZeneca Pharmaceuticals LP",
  "treatment": " Opioid-Induced Constipation",
  "drug_description": "Movantik (naloxegol) is a peripherally-acting mu-opioid receptor antagonist indicated for the treatment of opioid-induced constipation.",
  "previous application": "FDA Approves Movantik (naloxegol) for Opioid-Induced Constipation Movantik (naloxegol) FDA Approval History"
},{
  "title": "Trulicity (dulaglutide)  Injection ",
  "date_of_approval": "September 18, 2014",
  "company": " Eli Lilly and Company",
  "treatment": " Diabetes Type 2, Cardiovascular Risk Reduction",
  "drug_description": "Trulicity (dulaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist  indicated for use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.",
  "previous application": "FDA Approves Trulicity (dulaglutide) for Type 2 Diabetes Trulicity (dulaglutide) FDA Approval History"
},{
  "title": "Vitekta (elvitegravir)  Tablets ",
  "date_of_approval": "September 24, 2014",
  "company": " Gilead Sciences, Inc.",
  "treatment": " HIV Infection",
  "drug_description": "",
  "previous application": "FDA Approves Vitekta (elvitegravir) for HIV-1 Infection Vitekta (elvitegravir) FDA Approval History"
},{
  "title": "Tybost (cobicistat)  Tablets ",
  "date_of_approval": "September 24, 2014",
  "company": " Gilead Sciences, Inc.",
  "treatment": " HIV Infection",
  "drug_description": "Tybost (cobicistat) is a potent inhibitor of cytochrome P450 3A (CYP3A) which acts as a pharmacoenhancing or \"boosting\" agent for antiviral drugs used in the treatment of HIV infection.",
  "previous application": "FDA Approves Tybost (cobicistat) for use in the treatment of HIV-1 Infection Tybost (cobicistat) FDA Approval History"
},{
  "title": "Iluvien (fluocinolone acetonide)  Intravitreal Implant ",
  "date_of_approval": "September 26, 2014",
  "company": " pSivida Corp.",
  "treatment": " Diabetic Macular Edema",
  "drug_description": "Iluvien (fluocinolone acetonide) is an intravitreal implant for the treatment of diabetic macular edema.",
  "previous application": "FDA Approves Iluvien for Diabetic Macular Edema Iluvien (fluocinolone acetonide) FDA Approval History"
},{
  "title": "Akynzeo (netupitant and palonosetron)  Capsules ",
  "date_of_approval": "October 10, 2014",
  "company": " Helsinn Group",
  "treatment": " Nausea/Vomiting -- Chemotherapy Induced",
  "drug_description": "Akynzeo (netupitant and palonosetron) is a substance P/neurokinin 1 (NK1) receptor antagonist and serotonin-3 (5-HT3) receptor antagonist fixed-dose combination indicated for the prevention of chemotherapy-induced nausea and vomiting (CINV).",
  "previous application": "FDA Approves Akynzeo (netupitant and palonosetron) for Chemotherapy-Induced Nausea and Vomiting Akynzeo (netupitant and palonosetron) FDA Approval History"
},{
  "title": "Harvoni (ledipasvir and sofosbuvir)  Tablets and Oral Pellets ",
  "date_of_approval": "October 10, 2014",
  "company": " Gilead Sciences, Inc.",
  "treatment": " Chronic Hepatitis C",
  "drug_description": "Harvoni (ledipasvir and sofosbuvir) is a fixed-dose combination of ledipasvir, a hepatitis C virus\r (HCV) NS5A inhibitor, and sofosbuvir, an HCV nucleotide analog NS5B polymerase inhibitor, indicated for the treatment of chronic hepatitis C virus (HCV) in adults and pediatric patients 3 years of age and older:",
  "previous application": "FDA Approves Harvoni (ledipasvir and sofosbuvir) for Hepatitis C Harvoni (ledipasvir and sofosbuvir) FDA Approval History"
},{
  "title": "Lumason (sulfur hexafluoride lipid microsphere)  Injectable Suspension ",
  "date_of_approval": "October 10, 2014",
  "company": " Bracco Diagnostics Inc.",
  "treatment": " Diagnostic",
  "drug_description": "Lumason (sulfur hexafluoride lipid microsphere) is a contrast agent used for ultrasound imaging.",
  "previous application": "FDA Approves Lumason Ultrasound Imaging Agent Lumason (sulfur hexafluoride lipid microsphere) FDA Approval History"
},{
  "title": "Esbriet (pirfenidone)  Capsules ",
  "date_of_approval": "October 15, 2014",
  "company": " InterMune, Inc.",
  "treatment": " Idiopathic Pulmonary Fibrosis",
  "drug_description": "Esbriet (pirfenidone) is a TGF-beta synthesis inhibitor for the treatment of patients with idiopathic pulmonary fibrosis (IPF).",
  "previous application": "FDA Approves Esbriet (pirfenidone)  for Idiopathic Pulmonary Fibrosis Esbriet (pirfenidone) FDA Approval History"
},{
  "title": "Ofev (nintedanib)  Capsules ",
  "date_of_approval": "October 15, 2014",
  "company": " Boehringer Ingelheim Pharmaceuticals, Inc.",
  "treatment": " Idiopathic Pulmonary Fibrosis; Interstitial Lung Disease",
  "drug_description": "Ofev (nintedanib) is a small molecule tyrosine kinase inhibitor (TKI) indicated for:",
  "previous application": "FDA Approves Ofev (nintedanib) for Idiopathic Pulmonary Fibrosis Ofev (nintedanib) FDA Approval History"
},{
  "title": "Sotylize (sotalol hydrochloride)  Oral Solution ",
  "date_of_approval": "October 22, 2014",
  "company": " Arbor Pharmaceuticals",
  "treatment": " Ventricular Arrhythmia, Atrial Fibrillation, Atrial Flutter",
  "drug_description": "Sotylize (sotalol hydrochloride) is an antiarrhythmic indicated for the treatment of ventricular arrhythmias and the maintenance of normal sinus rhythm in patients with history of highly symptomatic atrial fibrillation/flutter.",
  "previous application": "Arbor Pharmaceuticals Announces FDA Approval of Sotylize Sotylize (sotalol hydrochloride) FDA Approval History"
},{
  "title": "Obizur (antihemophilic factor (recombinant)) ",
  "date_of_approval": "October 23, 2014",
  "company": " Baxter International Inc.",
  "treatment": " Hemophilia A",
  "drug_description": "Obizur (antihemophilic factor [recombinant]) is an\r antihemophilic factor indicated for the treatment of bleeding episodes in  adults with acquired hemophilia A.",
  "previous application": "FDA Approves Obizur [Antihemophilic Factor (Recombinant)] for Acquired Hemophilia A Obizur (antihemophilic factor (recombinant)) FDA Approval History"
},{
  "title": "Trumenba (meningococcal group B vaccine) ",
  "date_of_approval": "October 29, 2014",
  "company": " Pfizer Inc.",
  "treatment": " Meningococcal Meningitis Prophylaxis",
  "drug_description": "Trumenba (meningococcal group B vaccine) is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B\r in adolescents and young adults.",
  "previous application": "FDA Approves Trumenba - First Vaccine to Prevent Serogroup B Meningococcal Disease Trumenba (meningococcal group B vaccine) FDA Approval History"
},{
  "title": "Xigduo XR (dapagliflozin and metformin hydrochloride)  Extended-Release Tablets ",
  "date_of_approval": "October 30, 2014",
  "company": " AstraZeneca",
  "treatment": " Diabetes Type 2",
  "drug_description": "Xigduo XR (dapagliflozin and metformin hydrochloride) is a once-daily sodium-glucose cotransporter 2 (SGLT2) inhibitor and biguanide combination for the treatment of type 2 diabetes.",
  "previous application": "FDA Approves Xigduo XR (dapagliflozin and metformin hydrochloride) for Type 2 Diabetes Xigduo XR (dapagliflozin and metformin hydrochloride) FDA Approval History"
},{
  "title": "Lemtrada (alemtuzumab)  Injection ",
  "date_of_approval": "November 14, 2014",
  "company": " Genzyme",
  "treatment": " Multiple Sclerosis",
  "drug_description": "Lemtrada (alemtuzumab) is a CD52-directed cytolytic monoclonal antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS).",
  "previous application": "FDA Approves Lemtrada (alemtuzumab) for Relapsing Forms of Multiple Sclerosis Lemtrada (alemtuzumab) FDA Approval History"
},{
  "title": "Hysingla ER (hydrocodone bitartrate)  Extended-Release Tablets ",
  "date_of_approval": "November 20, 2014",
  "company": " Purdue Pharma L.P.",
  "treatment": " Chronic Pain",
  "drug_description": "Hysingla ER (hydrocodone) is a single-entity (without acetaminophen) extended-release opioid analgesic for around-the-clock management of moderate to severe chronic pain.",
  "previous application": "FDA Approves Hysingla ER - Extended-Release Hydrocodone with Abuse-Deterrent Properties Hysingla ER (hydrocodone bitartrate) FDA Approval History"
},{
  "title": "Onexton (benzoyl peroxide and clindamycin phosphate)  Gel ",
  "date_of_approval": "November 25, 2014",
  "company": " Valeant Pharmaceuticals International, Inc.",
  "treatment": " Acne",
  "drug_description": "Onexton (benzoyl peroxide and clindamycin phosphate) is an antimicrobial and lincosamide antibacterial combination for the once-daily topical treatment of acne vulgaris.",
  "previous application": "Valeant Pharmaceuticals Announces FDA Approval of Onexton Gel for Acne Vulgaris Onexton (benzoyl peroxide and clindamycin phosphate) FDA Approval History"
},{
  "title": "Kitabis Pak (tobramycin)  Inhalation Solution ",
  "date_of_approval": "December 2, 2014",
  "company": " PulmoFlow, Inc.",
  "treatment": " Cystic Fibrosis",
  "drug_description": "Kitabis Pak (tobramycin) is an aminoglycoside inhalation\tsolution co-packaged with a PARI LC PLUS\u00ae Reusable\tNebulizer\tfor the management of cystic fibrosis.",
  "previous application": "FDA Approves PulmoFlow's Kitabis Pak Tobramycin & Nebulizer Combination for Cystic Fibrosis Kitabis Pak (tobramycin) FDA Approval History"
},{
  "title": "Blincyto (blinatumomab)  Injection ",
  "date_of_approval": "December 3, 2014",
  "company": " Amgen Inc.",
  "treatment": " Acute Lymphoblastic Leukemia",
  "drug_description": "Blincyto (blinatumomab) is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), and minimal residual disease (MRD)-positive B-cell precursor ALL.",
  "previous application": "FDA Approves Blincyto (blinatumomab) for Precursor B-Cell Acute Lymphoblastic Leukemia Blincyto (blinatumomab) FDA Approval History"
},{
  "title": "Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant)  Injection ",
  "date_of_approval": "December 10, 2014",
  "company": " Merck &amp; Co., Inc.",
  "treatment": " Human Papillomavirus Prophylaxis",
  "drug_description": "Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant) is a 9-valent HPV vaccine indicated for use in:",
  "previous application": "FDA Approves Gardasil 9 for Prevention of Certain Cancers Caused by Five Additional Types of HPV Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant) FDA Approval History"
},{
  "title": "Signifor LAR (pasireotide)  for Injectable Suspension ",
  "date_of_approval": "December 15, 2014",
  "company": " Novartis",
  "treatment": " Acromegaly",
  "drug_description": "Signifor LAR (pasireotide) is a long acting a somatostatin analog formulation for the treatment of patients with acromegaly.",
  "previous application": "Novartis Gains FDA Approval for Signifor LAR to Treat Patients with Acromegaly Signifor LAR (pasireotide) FDA Approval History"
},{
  "title": "Xtoro (finafloxacin)  Otic Suspension ",
  "date_of_approval": "December 17, 2014",
  "company": " Alcon Laboratories, Inc.",
  "treatment": " Otitis Externa",
  "drug_description": "",
  "previous application": "FDA Approves Xtoro (finafloxacin) Otic Suspension to Treat Swimmer\u2019s Ear Xtoro (finafloxacin) FDA Approval History"
},{
  "title": "Lynparza (olaparib)  Tablets ",
  "date_of_approval": "December 19, 2014",
  "company": " AstraZeneca",
  "treatment": " Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer",
  "drug_description": "Lynparza (olaparib) is a first-in-class oral poly ADP ribose polymerase (PARP) inhibitor indicated for the treatment of ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer.",
  "previous application": "FDA Approves Lynparza (olaparib) to Treat Advanced Ovarian Cancer Lynparza (olaparib) FDA Approval History"
},{
  "title": "Viekira Pak (ombitasvir/paritaprevir/ritonavir with dasabuvir)  Tablets ",
  "date_of_approval": "December 19, 2014",
  "company": " AbbVie Inc.",
  "treatment": " Chronic Hepatitis C",
  "drug_description": "Viekira Pak (ombitasvir/paritaprevir/ritonavir with dasabuvir) is an NS5A inhibitor, NS3/4A\r protease inhibitor and CYP3A inhibitor combination co-packaged with a non-nucleoside NS5B palm polymerase inhibitor for the treatment of patients with genotype 1 chronic hepatitis C virus (HCV) infection.",
  "previous application": "FDA Approves Viekira Pak (ombitasvir/paritaprevir/ritonavir with dasabuvir) to Treat Hepatitis C Viekira Pak (ombitasvir/paritaprevir/ritonavir with dasabuvir) FDA Approval History"
},{
  "title": "Zerbaxa (ceftolozane and tazobactam)  Injection ",
  "date_of_approval": "December 19, 2014",
  "company": " Cubist Pharmaceuticals, Inc.",
  "treatment": " Intraabdominal Infection, Urinary Tract Infection, Pneumonia",
  "drug_description": "Zerbaxa (ceftolozane and tazobactam) is a cephalosporin and beta-lactamase inhibitor combination for the treatment of:",
  "previous application": "FDA Approves Zerbaxa (ceftolozane/tazobactam) for Complicated Intra-Abdominal/Urinary Tract Infections Zerbaxa (ceftolozane and tazobactam) FDA Approval History"
},{
  "title": "Opdivo (nivolumab)  Injection ",
  "date_of_approval": "December 22, 2014",
  "company": " Bristol-Myers Squibb Company",
  "treatment": " Melanoma -- Metastatic, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Hodgkin's Disease, Head and Neck Cancer, Urothelial Carcinoma, Colorectal Cancer, Hepatocellular Carcinoma, Small Cell Lung Cancer, Esophageal Carcinoma, Malignant Pleural Mesothelioma",
  "drug_description": "Opdivo (nivolumab) is a programmed death receptor-1 (PD-1) blocking antibody for the treatment of melanoma, non-small cell lung cancer, small cell lung cancer, malignant pleural mesothelioma, renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of the head and neck, urothelial carcinoma, MSI-H or dMMR metastatic colorectal cancer, hepatocellular carcinoma, and esophageal squamous cell carcinoma.",
  "previous application": "FDA Approves Opdivo (nivolumab) for Advanced Melanoma Opdivo (nivolumab) FDA Approval History"
},{
  "title": "Rapivab (peramivir)  Injection ",
  "date_of_approval": "December 19, 2014",
  "company": " BioCryst Pharmaceuticals, Inc.",
  "treatment": " Influenza",
  "drug_description": "Rapivab (peramivir) is an influenza virus neuraminidase inhibitor indicated for the treatment of acute uncomplicated influenza.",
  "previous application": "FDA Approves Rapivab (peramivir) to Treat Influenza Infection Rapivab (peramivir) FDA Approval History"
},{
  "title": "Soolantra (ivermectin)  Cream ",
  "date_of_approval": "December 19, 2014",
  "company": " Galderma Laboratories, L.P.",
  "treatment": " Acne Rosacea",
  "drug_description": "Soolantra (ivermectin) is a topical antiparasitic with anti-inflammatory properties for the treatment of rosacea potentially caused by the microscopic skin mite Demodex folliculorum.",
  "previous application": "Galderma Receives FDA Approval of Soolantra (ivermectin) Cream for Rosacea Soolantra (ivermectin) FDA Approval History"
},{
  "title": "Saxenda (liraglutide)  Injection ",
  "date_of_approval": "December 23, 2014",
  "company": " Novo Nordisk Inc.",
  "treatment": " Obesity",
  "drug_description": "Saxenda (liraglutide) is a once-daily glucagon-like peptide-1 (GLP-1) analogue for the treatment of obesity.",
  "previous application": "FDA Approves Saxenda (liraglutide [rDNA origin] injection) for Obesity Saxenda (liraglutide) FDA Approval History"
},{
  "title": "Namzaric (donepezil and memantine) ",
  "date_of_approval": "December 23, 2014",
  "company": " Allergan, Inc.",
  "treatment": " Alzheimer's Disease",
  "drug_description": "Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) is an NMDA receptor antagonist and acetylcholinesterase inhibitor fixed-dose combination for the treatment of moderate to severe Alzheimer\u2019s disease.",
  "previous application": "Actavis and Adamas Announce FDA Approval of Namzaric (memantine/donepezil) for Alzheimer's Disease Namzaric (donepezil and memantine) FDA Approval History"
},{
  "title": "Dyloject (diclofenac sodium)  Injection ",
  "date_of_approval": "December 23, 2014",
  "company": " Pfizer Inc.",
  "treatment": " Pain",
  "drug_description": "",
  "previous application": "Hospira Receives U.S. FDA Approval of Proprietary Analgesic Dyloject (diclofenac sodium) Injection Dyloject (diclofenac sodium) FDA Approval History"
},{
  "title": "Opdivo (nivolumab)  Injection ",
  "date_of_approval": "December 22, 2014",
  "company": " Bristol-Myers Squibb Company",
  "treatment": " Melanoma -- Metastatic, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Hodgkin's Disease, Head and Neck Cancer, Urothelial Carcinoma, Colorectal Cancer, Hepatocellular Carcinoma, Small Cell Lung Cancer, Esophageal Carcinoma, Malignant Pleural Mesothelioma",
  "drug_description": "Opdivo (nivolumab) is a programmed death receptor-1 (PD-1) blocking antibody for the treatment of melanoma, non-small cell lung cancer, small cell lung cancer, malignant pleural mesothelioma, renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of the head and neck, urothelial carcinoma, MSI-H or dMMR metastatic colorectal cancer, hepatocellular carcinoma, and esophageal squamous cell carcinoma.",
  "previous application": "FDA Approves Opdivo (nivolumab) + Yervoy (ipilimumab) for Patients with Hepatocellular Carcinoma (HCC) Previously Treated with Sorafenib Opdivo (nivolumab) FDA Approval History"
},{
  "title": "Rytary (carbidopa and levodopa)  Extended Release Capsules ",
  "date_of_approval": "January 7, 2015",
  "company": " Impax Laboratories, Inc.",
  "treatment": " Parkinson's Disease",
  "drug_description": "Rytary (carbidopa and levodopa) is an extended release aromatic amino acid decarboxylation inhibitor and aromatic amino acid combination indicated for the treatment of Parkinson\u2019s disease.",
  "previous application": "Impax Pharmaceuticals Announce FDA Approval of Rytary (carbidopa and levodopa) for Parkinson's Disease Rytary (carbidopa and levodopa) FDA Approval History"
},{
  "title": "Savaysa (edoxaban)  Tablets ",
  "date_of_approval": "January 8, 2015",
  "company": " Daiichi Sankyo Company",
  "treatment": " Prevention of Thromboembolism in Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism",
  "drug_description": "Savaysa (edoxaban) is an oral, once-daily factor Xa inhibitor anticoagulant indicated for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, and for the treatment of deep vein thrombosis, and pulmonary embolism.",
  "previous application": "FDA Approves Savaysa (edoxaban) to Prevent Embolic Events in Non-Valvular Atrial Fibrillation Savaysa (edoxaban) FDA Approval History"
},{
  "title": "Duopa (carbidopa and levodopa)  Enteral Suspension ",
  "date_of_approval": "January 12, 2015",
  "company": " AbbVie Inc.",
  "treatment": " Parkinson's Disease",
  "drug_description": "Duopa (carbidopa and levodopa) is an aromatic amino acid decarboxylation inhibitor and aromatic amino acid combination formulated as an enteral suspension for the treatment of motor fluctuations in patients with advanced Parkinson\u2019s disease.",
  "previous application": "FDA Approves Duopa (carbidopa and levodopa) Enteral Suspension for Parkinson's Disease Duopa (carbidopa and levodopa) FDA Approval History"
},{
  "title": "Phoxillum (renal replacement solution) ",
  "date_of_approval": "January 13, 2015",
  "company": " Baxter International Inc.",
  "treatment": " Continuous Renal Replacement Therapy",
  "drug_description": "Phoxillum (renal replacement solution) is a replacement solution used for electrolyte management in Continuous Renal Replacement Therapy (CRRT).",
  "previous application": "Baxter Receives FDA Approval for Phoxillum Solution for Electrolyte Management During Continuous Renal Replacement Therapy Phoxillum (renal replacement solution) FDA Approval History"
},{
  "title": "Cosentyx (secukinumab)  Injection ",
  "date_of_approval": "January 21, 2015",
  "company": " Novartis Pharmaceuticals Corporation",
  "treatment": " Plaque Psoriasis, Ankylosing Spondylitis, Psoriatic Arthritis",
  "drug_description": "Cosentyx (secukinumab) is a selective interleukin-17A (IL-17A) inhibitor for the treatment of plaque psoriasis, ankylosing spondylitis, psoriatic arthritis, and non-radiographic axial spondyloarthritis.",
  "previous application": "FDA Approves Cosentyx (secukinumab) for Plaque Psoriasis Cosentyx (secukinumab) FDA Approval History"
},{
  "title": "Prestalia (amlodipine besylate and perindopril arginine)  Tablets ",
  "date_of_approval": "January 21, 2015",
  "company": " Symplmed",
  "treatment": " Hypertension",
  "drug_description": "Prestalia (amlodipine besylate and perindopril arginine) is a calcium channel blocker and long-acting angiotensin-converting enzyme (ACE) inhibitor combination for the treatment of hypertension.",
  "previous application": "FDA Approves Prestalia (amlodipine and perindopril) for Hypertension Prestalia (amlodipine besylate and perindopril arginine) FDA Approval History"
},{
  "title": "Natpara (parathyroid hormone)  Injection ",
  "date_of_approval": "January 23, 2015",
  "company": " NPS Pharmaceuticals, Inc. ",
  "treatment": " Hypoparathyroidism",
  "drug_description": "Natpara (parathyroid hormone) is recombinant human parathyroid hormone 1-84 indicated to control hypocalcemia in patients with hypoparathyroidism.",
  "previous application": "FDA Approves Natpara (parathyroid hormone) for Hypocalcemia in Patients with Hypoparathyroidism Natpara (parathyroid hormone) FDA Approval History"
},{
  "title": "Bexsero (meningococcal group B vaccine)  Injection ",
  "date_of_approval": "January 23, 2015",
  "company": " Novartis Vaccines and Diagnostics Inc.",
  "treatment": " Meningitis -- Meningococcal",
  "drug_description": "Bexsero (meningococcal group B vaccine) is a vaccine to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B.",
  "previous application": "FDA Approves Bexsero Vaccine to Prevent Serogroup B Meningococcal Disease Bexsero (meningococcal group B vaccine) FDA Approval History"
},{
  "title": "Triferic (ferric pyrophosphate citrate) ",
  "date_of_approval": "January 23, 2015",
  "company": " Rockwell Medical, Inc.",
  "treatment": " Anemia Associated with Chronic Renal Failure",
  "drug_description": "Triferic (ferric pyrophosphate citrate) is an iron-replacement drug for treating iron deficiency in chronic kidney disease patients receiving hemodialysis.",
  "previous application": "FDA Approves Triferic for Iron Replacement and Maintenance of Hemoglobin in Hemodialysis Patients Triferic (ferric pyrophosphate citrate) FDA Approval History"
},{
  "title": "Evotaz (atazanavir and cobicistat)  Tablets ",
  "date_of_approval": "January 29, 2015",
  "company": " Bristol-Myers Squibb Company",
  "treatment": " HIV Infection",
  "drug_description": "Evotaz (atazanavir and cobicistat) is a two-drug combination of atazanavir, a human immunodeficiency virus (HIV-1) protease inhibitor, and cobicistat, a CYP3A inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV\u20111infection in adults and pediatric patients weighing at least 35 kg.",
  "previous application": "FDA Approves Evotaz (atazanavir and cobicistat) for HIV-1 Infection in Adults Evotaz (atazanavir and cobicistat) FDA Approval History"
},{
  "title": "Prezcobix (cobicistat and darunavir)  Tablets ",
  "date_of_approval": "January 29, 2015",
  "company": " Janssen Research &amp; Development, LLC",
  "treatment": " HIV Infection",
  "drug_description": "Prezcobix (darunavir and cobicistat) is a once-daily fixed-dose combination containing a protease inhibitor and a pharmacokinetic enhancer for the treatment of HIV-1 infection.",
  "previous application": "FDA Approves Prezcobix (darunavir and cobicistat) for HIV-1 Infection in Adults Prezcobix (cobicistat and darunavir) FDA Approval History"
},{
  "title": "Pazeo (olopatadine hydrochloride)  Ophthalmic Solution ",
  "date_of_approval": "January 30, 2015",
  "company": " Alcon Laboratories, Inc.",
  "treatment": " Allergic Conjunctivitis",
  "drug_description": "Pazeo (olopatadine hydrochloride) is a mast cell stabilizer for the treatment of ocular itching associated with allergic conjunctivitis.",
  "previous application": "Alcon Receives FDA Approval of Pazeo (olopatadine HCl) Ophthalmic Solution for Allergic Conjunctivitis Pazeo (olopatadine hydrochloride) FDA Approval History"
},{
  "title": "Glyxambi (empagliflozin and linagliptin)  Tablets ",
  "date_of_approval": "January 30, 2015",
  "company": " Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company",
  "treatment": " Diabetes Type 2",
  "drug_description": "Glyxambi (empagliflozin and linagliptin) is a sodium glucose co-transporter-2 (SGLT2) inhibitor and dipeptidyl peptidase-4 (DPP-4) inhibitor combination for the treatment of adults with type 2 diabetes.",
  "previous application": "FDA Approves Glyxambi (empagliflozin and linagliptin) for Type 2 Diabetes Glyxambi (empagliflozin and linagliptin) FDA Approval History"
},{
  "title": "Ibrance (palbociclib)  Capsules and Tablets ",
  "date_of_approval": "February 3, 2015",
  "company": " Pfizer Inc.",
  "treatment": " Breast Cancer",
  "drug_description": "Ibrance (palbociclib) is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor\r receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with:",
  "previous application": "FDA Approves Ibrance (palbociclib) for Postmenopausal Women with Advanced Breast Cancer Ibrance (palbociclib) FDA Approval History"
},{
  "title": "Dutrebis (lamivudine and raltegravir)  Tablets ",
  "date_of_approval": "February 6, 2015",
  "company": " Merck",
  "treatment": " HIV Infection",
  "drug_description": "",
  "previous application": "FDA Approves Dutrebis (lamivudine and raltegravir) for HIV-1 Infection Dutrebis (lamivudine and raltegravir) FDA Approval History"
},{
  "title": "Lenvima (lenvatinib)  Capsules ",
  "date_of_approval": "February 13, 2015",
  "company": " Eisai Inc.",
  "treatment": " Thyroid Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma, Endometrial Carcinoma",
  "drug_description": "Lenvima (lenvatinib) is a multiple receptor tyrosine kinase (RTK) inhibitor for the treatment of  thyroid cancer, renal cell carcinoma, hepatocellular carcinoma, and endometrial carcinoma.",
  "previous application": "FDA Approves Lenvima (lenvatinib) for Differentiated Thyroid Cancer Lenvima (lenvatinib) FDA Approval History"
},{
  "title": "Farydak (panobinostat)  Capsules ",
  "date_of_approval": "February 23, 2015",
  "company": " Novartis Pharmaceuticals Corporation",
  "treatment": " Multiple Myeloma",
  "drug_description": "Farydak (panobinostat) is a histone deacetylase inhibitor for the combination treatment of multiple myeloma.",
  "previous application": "FDA Approves Farydak (panobinostat) for Multiple Myeloma Farydak (panobinostat) FDA Approval History"
},{
  "title": "Avycaz (avibactam and ceftazidime)  Injection ",
  "date_of_approval": "February 25, 2015",
  "company": " Actavis plc",
  "treatment": " Intraabdominal Infection, Urinary Tract Infection, Pneumonia",
  "drug_description": "Avycaz (avibactam and ceftazidime) is a next generation, non-\u03b2 lactam \u03b2-lactamase inhibitor and third-generation, antipseudomonal cephalosporin antibiotic combination for the treatment of complicated intra-abdominal infections, complicated urinary tract infections, hospital-acquired bacterial pneumonia, and ventilator-associated bacterial pneumonia.",
  "previous application": "FDA Approves Avycaz (ceftazidime and avibactam) for Complicated Abdominal and Urinary Tract Infections Avycaz (avibactam and ceftazidime) FDA Approval History"
},{
  "title": "Toujeo SoloStar (insulin glargine [rDNA origin])  Injection  - formerly Toujeo",
  "date_of_approval": "February 25, 2015",
  "company": " Sanofi",
  "treatment": " Diabetes Type 1, Diabetes Type 2",
  "drug_description": "Toujeo SoloStar (insulin glargine [rDNA origin] is a once-daily long-acting basal insulin used to improve glycemic control in adults with type 1 and type 2 diabetes.",
  "previous application": "Sanofi Receives FDA Approval of Once-Daily Basal Insulin Toujeo Toujeo SoloStar (insulin glargine [rDNA origin]) FDA Approval History"
},{
  "title": "Liletta (levonorgestrel)  Intrauterine Device ",
  "date_of_approval": "February 26, 2015",
  "company": " Medicines360 and Allergan plc",
  "treatment": " Contraception",
  "drug_description": "Liletta (levonorgestrel) is a hormonal intrauterine device (IUD) for use by women to prevent pregnancy for up to six years.",
  "previous application": "FDA Approves Liletta (levonorgestrel-releasing intrauterine system) to Prevent Pregnancy for up to Three Years Liletta (levonorgestrel) FDA Approval History"
},{
  "title": "Zarxio (filgrastim-sndz)  Injection ",
  "date_of_approval": "March 6, 2015",
  "company": " Sandoz",
  "treatment": " Neutropenia Associated with Chemotherapy",
  "drug_description": "Zarxio (filgrastim-sndz) is a leukocyte growth factor biosimilar to the reference product Neupogen, indicated for the treatment of neutropenia associated with chemotherapy.",
  "previous application": "FDA Approves First Biosimilar Product Zarxio (filgrastim-sndz) Zarxio (filgrastim-sndz) FDA Approval History"
},{
  "title": "Cresemba (isavuconazonium)  Capsules and Injection ",
  "date_of_approval": "March 6, 2015",
  "company": " Astellas Pharma US, Inc.",
  "treatment": " Invasive Aspergillosis; Invasive Mucormycosis",
  "drug_description": "Cresemba (isavuconazonium) is an azole antifungal indicated for the treatment of invasive aspergillosis and invasive mucormycosis.",
  "previous application": "FDA Approves Cresemba (isavuconazonium sulfate) For Fungal Infections Cresemba (isavuconazonium) FDA Approval History"
},{
  "title": "Unituxin (dinutuximab)  Injection ",
  "date_of_approval": "March 10, 2015",
  "company": " United Therapeutics Corporation",
  "treatment": " Neuroblastoma",
  "drug_description": "Unituxin (dinutuximab) is a chimeric monoclonal antibody used for the treatment of pediatric neuroblastoma.",
  "previous application": "FDA Approves Unituxin (dinutuximab) for Pediatric High-Risk Neuroblastoma Unituxin (dinutuximab) FDA Approval History"
},{
  "title": "Cholbam (cholic acid)  Capsules ",
  "date_of_approval": "March 17, 2015",
  "company": " Asklepion Pharmaceuticals LLC",
  "treatment": " Bile Acid Synthesis Disorders",
  "drug_description": "Cholbam (cholic acid) is a bile acid preparation for the treatment of patients with bile acid synthesis disorders due to single enzyme defects, and for patients with peroxisomal disorders (including Zellweger spectrum disorders).",
  "previous application": "FDA Approves Cholbam (cholic acid) for Rare Bile Acid Synthesis Disorders Cholbam (cholic acid) FDA Approval History"
},{
  "title": "Anthrasil (Anthrax Immune Globulin Intravenous (Human))  Injection ",
  "date_of_approval": "March 24, 2015",
  "company": " Cangene Corporation",
  "treatment": " Inhalation Anthrax",
  "drug_description": "Anthrasil [Anthrax Immune Globulin Intravenous (Human)] is an immune globulin used to treat patients with inhalational anthrax in combination with appropriate antibacterial drugs.",
  "previous application": "FDA Approves Anthrasil, [Anthrax Immune Globulin Intravenous (Human)], for Inhalation Anthrax Anthrasil (Anthrax Immune Globulin Intravenous (Human)) FDA Approval History"
},{
  "title": "Quadracel (Diphtheria and Tetanus Toxoids and Acellular Pertussis Absorbed and Inactivated Poliovirus; DTaP-IPV Vaccine)  Injection ",
  "date_of_approval": "March 24, 2015",
  "company": " Sanofi Pasteur",
  "treatment": " Diphtheria Prophylaxis, Tetanus Prophylaxis, Poliomyelitis Prophylaxis, Pertussis Prophylaxis",
  "drug_description": "Quadracel (Diphtheria and Tetanus Toxoids and Acellular Pertussis Absorbed and Inactivated Poliovirus; DTaP-IPV) is a vaccine for active immunization against diphtheria, tetanus, pertussis and poliomyelitis in children 4 through 6 years of age.",
  "previous application": "Sanofi Pasteur Announces FDA Approval of Quadracel DTaP-IPV Vaccine for Children 4 through 6 Years of Age Quadracel (Diphtheria and Tetanus Toxoids and Acellular Pertussis Absorbed and Inactivated Poliovirus; DTaP-IPV Vaccine) FDA Approval History"
},{
  "title": "Jadenu (deferasirox)  Tablets ",
  "date_of_approval": "March 30, 2015",
  "company": " Novartis Pharmaceuticals Corporation",
  "treatment": " Iron Overload",
  "drug_description": "Jadenu (deferasirox) is a tablet formulation of Exjade, an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older.",
  "previous application": "FDA Approves Jadenu (deferasirox) Tablets for Chronic Iron Overload Jadenu (deferasirox) FDA Approval History"
},{
  "title": "ProAir RespiClick (albuterol sulfate)  Inhalation Powder ",
  "date_of_approval": "March 31, 2015",
  "company": " Teva Pharmaceutical Industries Ltd.",
  "treatment": " Asthma",
  "drug_description": "ProAir RespiClick (albuterol sulfate) is a breath-actuated, dry-powder, short-acting beta-agonist (SABA) inhaler for the relief of acute asthma symptoms.",
  "previous application": "Teva Announces FDA Approval of ProAir RespiClick ProAir RespiClick (albuterol sulfate) FDA Approval History"
},{
  "title": "Corlanor (ivabradine)  Tablets and Oral Solution ",
  "date_of_approval": "April 15, 2015",
  "company": " Amgen Inc.",
  "treatment": " Chronic Heart Failure",
  "drug_description": "Corlanor (ivabradine) is a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated for the treatment of chronic heart failure.",
  "previous application": "FDA Approves Corlanor (ivabradine) to Treat Heart Failure Corlanor (ivabradine) FDA Approval History"
},{
  "title": "Glatopa (glatiramer acetate)  Injection ",
  "date_of_approval": "April 16, 2015",
  "company": " Sandoz Inc.",
  "treatment": " Multiple Sclerosis",
  "drug_description": "Glatopa (glatiramer acetate) is a generic version of Copaxone, an immunomodulator drug for the treatment of patients with relapsing-forms of multiple sclerosis.",
  "previous application": "FDA Approves Glatopa (glatiramer acetate) as the First Generic Competitor to Copaxone Glatopa (glatiramer acetate) FDA Approval History"
},{
  "title": "Kybella (deoxycholic acid)  Injection  - formerly ATX-101",
  "date_of_approval": "April 29, 2015",
  "company": " Allergan, Inc.",
  "treatment": " Submental Fullness",
  "drug_description": "Kybella (deoxycholic acid) is a cytolytic drug indicated to improve the appearance of fullness associated with submental fat (double chin).",
  "previous application": "FDA Approves Kybella (deoxycholic acid) to Treat Submental Fullness, or 'Double Chin' Kybella (deoxycholic acid) FDA Approval History"
},{
  "title": "Ixinity (coagulation factor IX (recombinant)) ",
  "date_of_approval": "April 29, 2015",
  "company": " Emergent BioSolutions Inc.",
  "treatment": " Hemophilia B",
  "drug_description": "Ixinity (coagulation factor IX (recombinant)) is a clotting factor IX therapy indicated to prevent bleeding in patients with hemophilia B.",
  "previous application": "Emergent BioSolutions Announces FDA Approval of Ixinity [coagulation factor IX (recombinant)] for Hemophilia B Ixinity (coagulation factor IX (recombinant)) FDA Approval History"
},{
  "title": "Raplixa (fibrin sealant [human]) ",
  "date_of_approval": "April 30, 2015",
  "company": " ProFibrix BV",
  "treatment": " Hemostasis",
  "drug_description": "Raplixa (fibrin sealant [human]) is a spray-dried fibrin sealant used to help control bleeding during surgery.",
  "previous application": "FDA Approves Raplixa (fibrin sealant [human]) to Control Bleeding During Surgery Raplixa (fibrin sealant [human]) FDA Approval History"
},{
  "title": "Tuzistra XR (chlorpheniramine polistirex and codeine polistirex)  Extended Release Oral Suspension ",
  "date_of_approval": "April 30, 2015",
  "company": " Vernalis plc and Tris Pharma Inc.",
  "treatment": " Cold Symptoms, Cough",
  "drug_description": "Tuzistra XR (codeine polistirex and chlorpheniramine polistirex) is an extended-release opiate agonist \r antitussive and histamine-1 (H1) receptor antagonist combination indicated for the relief of cough and \r symptoms associated with upper respiratory allergies or the common cold.",
  "previous application": "Vernalis and Tris Pharma Receive FDA Approval for Tuzistra XR (codeine polistirex and chlorpheniramine polistirex) Tuzistra XR (chlorpheniramine polistirex and codeine polistirex) FDA Approval History"
},{
  "title": "Invega Trinza (paliperidone palmitate)  Extended-Release Injectable Suspension ",
  "date_of_approval": "May 18, 2015",
  "company": " Janssen Pharmaceuticals,  Inc.",
  "treatment": " Schizophrenia",
  "drug_description": "Invega Trinza (3-month paliperidone palmitate) is a  long-acting injectable atypical antipsychotic indicated for the treatment of schizophrenia.",
  "previous application": "FDA Approves Invega Trinza (paliperidone palmitate) Four-Times-A-Year Treatment for Schizophrenia Invega Trinza (paliperidone palmitate) FDA Approval History"
},{
  "title": "Stiolto Respimat (olodaterol and tiotropium)  Inhalation Spray ",
  "date_of_approval": "May 21, 2015",
  "company": " Boehringer Ingelheim Pharmaceuticals, Inc.",
  "treatment": " Chronic Obstructive Pulmonary Disease",
  "drug_description": "Stiolto Respimat (olodaterol and tiotropium bromide) is a long-acting beta agonist (LABA) and long-acting muscarinic antagonist (LAMA) fixed-dose combination for the treatment of chronic obstructive pulmonary disease (COPD).",
  "previous application": "FDA Approves Stiolto Respimat (tiotropium bromide and olodaterol) Inhalation Spray for COPD Stiolto Respimat (olodaterol and tiotropium) FDA Approval History"
},{
  "title": "Viberzi (eluxadoline)  Tablets ",
  "date_of_approval": "May 27, 2015",
  "company": " Allergan, Inc.",
  "treatment": " Irritable Bowel Syndrome",
  "drug_description": "Viberzi (eluxadoline) is a mu-opioid receptor agonist indicated for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.",
  "previous application": "FDA Approves Viberzi (eluxadoline) for Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults Viberzi (eluxadoline) FDA Approval History"
},{
  "title": "Kengreal (cangrelor)  for Injection ",
  "date_of_approval": "June 22, 2015",
  "company": " The Medicines Company",
  "treatment": " Percutaneous Coronary Intervention",
  "drug_description": "Kengreal (cangrelor) is an intravenous P2Y12 platelet inhibitor indicated for use in patients undergoing Percutaneous Coronary Intervention (PCI) to reduce the risk of periprocedural thrombotic events.",
  "previous application": "FDA Approves Antiplatelet Agent Kengreal (cangrelor) as Adjunct to Percutaneous Coronary Intervention Kengreal (cangrelor) FDA Approval History"
},{
  "title": "Tuxarin ER (chlorpheniramine and codeine)  Extended Release Tablets ",
  "date_of_approval": "June 22, 2015",
  "company": " Spriaso LLC",
  "treatment": " Cough, Cold Symptoms",
  "drug_description": "Tuxarin ER (codeine and chlorpheniramine) is a long acting narcotic antitussive and antihistamine combination for the treatment of cough and cold symptoms.",
  "previous application": "Spriaso Announces FDA Approval of Long Acting Tuxarin ER (codeine and chlorpheniramine) Tuxarin ER (chlorpheniramine and codeine) FDA Approval History"
},{
  "title": "Orkambi (ivacaftor and lumacaftor)  Tablets and Oral Granules ",
  "date_of_approval": "July 2, 2015",
  "company": " Vertex Pharmaceuticals Incorporated",
  "treatment": " Cystic Fibrosis",
  "drug_description": "Orkambi (ivacaftor and lumacaftor) is a CFTR potentiator and CFTR corrector combination for the treatment of the underlying cause of cystic fibrosis in patients 2 years and older with two copies of the F508del mutation in their CFTR gene.",
  "previous application": "FDA Approves Orkambi (lumacaftor/ivacaftor) for Cystic Fibrosis Orkambi (ivacaftor and lumacaftor) FDA Approval History"
},{
  "title": "Entresto (sacubitril and valsartan)  Tablets  - formerly LCZ696",
  "date_of_approval": "July 7, 2015",
  "company": " Novartis Pharmaceuticals Corporation",
  "treatment": " Heart Failure",
  "drug_description": "Entresto (sacubitril and valsartan) is a neprilysin inhibitor and angiotensin II receptor blocker combination indicated:",
  "previous application": "FDA Approves Entresto (sacubitril/valsartan) for Heart Failure Entresto (sacubitril and valsartan) FDA Approval History"
},{
  "title": "Rexulti (brexpiprazole)  Tablets ",
  "date_of_approval": "July 10, 2015",
  "company": " Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S",
  "treatment": " Schizophrenia; Major Depressive Disorder",
  "drug_description": "Rexulti (brexpiprazole) is a serotonin-dopamine activity modulator (SDAM) for the treatment of schizophrenia and the adjunctive treatment of major depressive disorder.",
  "previous application": "FDA Approves Rexulti (brexpiprazole) for Schizophrenia and Adjunctive Treatment for Major Depressive Disorder Rexulti (brexpiprazole) FDA Approval History"
},{
  "title": "Envarsus XR (tacrolimus)  Extended-Release Tablets ",
  "date_of_approval": "July 10, 2015",
  "company": " Veloxis Pharmaceuticals A/S",
  "treatment": " Organ Transplant -- Rejection Prophylaxis",
  "drug_description": "Envarsus XR (tacrolimus) is a once-daily extended-release immunosuppressant for the prophylaxis of organ rejection in kidney transplant patients.",
  "previous application": "FDA Approves Envarsus XR (tacrolimus) for Prevention of Organ Rejection in Kidney Transplant Patients Envarsus XR (tacrolimus) FDA Approval History"
},{
  "title": "Epiduo Forte (adapalene and benzoyl peroxide)  Topical Gel ",
  "date_of_approval": "July 15, 2015",
  "company": " Galderma Laboratories, L.P.",
  "treatment": " Acne",
  "drug_description": "Epiduo Forte (adapalene and benzoyl peroxide) gel is a topical retinoid and benzoyl peroxide combination indicated for the topical treatment of acne vulgaris.",
  "previous application": "Galderma Receives FDA Approval for Epiduo Forte (adapalene and benzoyl peroxide) for Acne  Epiduo Forte (adapalene and benzoyl peroxide) FDA Approval History"
},{
  "title": "Technivie (ombitasvir, paritaprevir and ritonavir)  Tablets ",
  "date_of_approval": "July 24, 2015",
  "company": " AbbVie Inc.",
  "treatment": " Chronic Hepatitis C",
  "drug_description": "",
  "previous application": "FDA Approves Technivie (ombitasvir, paritaprevir and ritonavir) for Chronic Hepatitis C Genotype 4 Infections Technivie (ombitasvir, paritaprevir and ritonavir) FDA Approval History"
},{
  "title": "Odomzo (sonidegib)  Capsules ",
  "date_of_approval": "July 24, 2015",
  "company": " Novartis Pharmaceuticals Corporation",
  "treatment": " Basal Cell Carcinoma",
  "drug_description": "Odomzo (sonidegib) is a hedgehog pathway inhibitor indicated for the treatment of locally advanced basal cell carcinoma (BCC).",
  "previous application": "FDA Approves Odomzo (sonidegib) for Locally Advanced Basal Cell Carcinoma Odomzo (sonidegib) FDA Approval History"
},{
  "title": "Praluent (alirocumab)  Injection ",
  "date_of_approval": "July 24, 2015",
  "company": " Sanofi and Regeneron Pharmaceuticals, Inc.",
  "treatment": " High Cholesterol",
  "drug_description": "Praluent (alirocumab) is a PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor monoclonal antibody indicated:",
  "previous application": "FDA Approves Praluent (alirocumab) to Treat Certain Patients with High Cholesterol Praluent (alirocumab) FDA Approval History"
},{
  "title": "Daklinza (daclatasvir)  Tablets ",
  "date_of_approval": "July 24, 2015",
  "company": " Bristol-Myers Squibb Company",
  "treatment": " Chronic Hepatitis C",
  "drug_description": "",
  "previous application": "FDA Approves Daklinza (daclatasvir) for Chronic Hepatitis C Genotype 3 Infections Daklinza (daclatasvir) FDA Approval History"
},{
  "title": "Spritam (levetiracetam)  Tablets ",
  "date_of_approval": "August 3, 2015",
  "company": " Aprecia Pharmaceuticals Company",
  "treatment": " Seizures, Epilepsy",
  "drug_description": "Spritam (levetiracetam) is a 3D printed drug product used as adjunctive therapy in the treatment of partial onset seizures, myoclonic seizures and primary generalized tonic-clonic seizures in adults and children with epilepsy.",
  "previous application": "FDA Approves Spritam (levetiracetam) as the First 3D Printed Drug Product Spritam (levetiracetam) FDA Approval History"
},{
  "title": "Keveyis (dichlorphenamide)  Tablets ",
  "date_of_approval": "August 7, 2015",
  "company": " Taro Pharmaceutical Industries Ltd.",
  "treatment": " Primary Hyperkalemic and Hypokalemic Periodic Paralysis",
  "drug_description": "Keveyis (dichlorphenamide) is an oral carbonic anhydrase inhibitor indicated for the treatment of primary hyperkalemic and hypokalemic periodic paralysis.",
  "previous application": "FDA Approves Keveyis (dichlorphenamide) for Primary Hyperkalemic and Hypokalemic Periodic Paralysis Keveyis (dichlorphenamide) FDA Approval History"
},{
  "title": "Addyi (flibanserin)  Tablets ",
  "date_of_approval": "August 18, 2015",
  "company": " Sprout Pharmaceuticals, Inc.",
  "treatment": " Hypoactive Sexual Desire Disorder",
  "drug_description": "Addyi (flibanserin) is a non-hormonal, multifunctional serotonin agonist antagonist (MSAA) for the treatment of hypoactive sexual desire disorder in premenopausal women.",
  "previous application": "FDA Approves Addyi (flibanserin) for Hypoactive Sexual Desire Disorder in Premenopausal Women Addyi (flibanserin) FDA Approval History"
},{
  "title": "Synjardy (empagliflozin and metformin)  Tablets ",
  "date_of_approval": "August 26, 2015",
  "company": " Eli Lilly and Company and Boehringer Ingelheim",
  "treatment": " Diabetes Type 2",
  "drug_description": "Synjardy (empagliflozin and metformin hydrochloride) is a sodium glucose co-transporter-2 (SGLT2) inhibitor and biguanide combination for the treatment of adults with type 2 diabetes.",
  "previous application": "FDA Approves Synjardy (empagliflozin/metformin hydrochloride) for Type 2 Diabetes Synjardy (empagliflozin and metformin) FDA Approval History"
},{
  "title": "Repatha (evolocumab)  Injection ",
  "date_of_approval": "August 27, 2015",
  "company": " Amgen Inc.",
  "treatment": " High Cholesterol; Prevention of Heart Attack and Stroke",
  "drug_description": "Repatha (evolocumab) is a monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9) indicated for the treatment of patients with heterozygous familial hypercholesterolemia; homozygous familial hypercholesterolemia; and to reduce the risk of myocardial infarction, stroke, and coronary revascularization in adults with established cardiovascular disease.",
  "previous application": "FDA Approves Repatha (evolocumab) to Treat Certain Patients with High Cholesterol Repatha (evolocumab) FDA Approval History"
},{
  "title": "Varubi (rolapitant)  Tablets and Injection ",
  "date_of_approval": "September 1, 2015",
  "company": " Tesaro Inc.",
  "treatment": " Nausea/Vomiting -- Chemotherapy Induced",
  "drug_description": "Varubi (rolapitant) is a substance P/neurokinin 1 (NK1) receptor antagonist indicated for use in the prevention of delayed nausea and vomiting associated with emetogenic chemotherapy.",
  "previous application": "FDA Approves Varubi (rolapitant) for Chemotherapy-Induced Nausea and Vomiting Varubi (rolapitant) FDA Approval History"
},{
  "title": "Xuriden (uridine triacetate)  Oral Granules ",
  "date_of_approval": "September 4, 2015",
  "company": " Wellstat Therapeutics Corporation",
  "treatment": " Hereditary Orotic Aciduria",
  "drug_description": "Xuriden (uridine triacetate) is an orally administered pyrimidine analog uridine replacement product for the treatment of patients with hereditary orotic aciduria.",
  "previous application": "FDA Approves Xuriden (uridine triacetate) to Treat Hereditary Orotic Aciduria Xuriden (uridine triacetate) FDA Approval History"
},{
  "title": "Durlaza (aspirin)  Extended Release Capsules  ",
  "date_of_approval": "September 4, 2015",
  "company": " New Haven Pharmaceuticals, Inc.",
  "treatment": " Ischemic Stroke -- Prophylaxis",
  "drug_description": "Durlaza (aspirin) is a 24-hour, extended release aspirin formulation for the secondary prevention of stroke and acute cardiac events, including myocardial infarction (heart attack).",
  "previous application": "FDA Approves Durlaza (aspirin) ER Capsules for Secondary Prevention of Stroke and Acute Cardiac Events Durlaza (aspirin) FDA Approval History"
},{
  "title": "Nuwiq (antihemophilic factor (recombinant))  for Injection ",
  "date_of_approval": "September 4, 2015",
  "company": " Octapharma USA, Inc.",
  "treatment": " Hemophilia A",
  "drug_description": "Nuwiq (antihemophilic factor [recombinant]) is recombinant blood coagulation factor VIII indicated for the control and prevention of bleeding episodes in patients with hemophilia A.",
  "previous application": "FDA Approves Nuwiq (Antihemophilic Factor [Recombinant]) for Hemophilia A Nuwiq (antihemophilic factor (recombinant)) FDA Approval History"
},{
  "title": "Vraylar (cariprazine)  Capsules ",
  "date_of_approval": "September 17, 2015",
  "company": " Allergan and Gedeon Richter plc",
  "treatment": " Schizophrenia, Bipolar Disorder",
  "drug_description": "Vraylar (cariprazine) is a dopamine D3/D2 receptor partial\r agonist atypical antipsychotic for the:",
  "previous application": "FDA Approves Vraylar (cariprazine) for Schizophrenia and Bipolar Disorder Vraylar (cariprazine) FDA Approval History"
},{
  "title": "Lonsurf (tipiracil hydrochloride and trifluridine)  Capsules ",
  "date_of_approval": "September 22, 2015",
  "company": " Taiho Oncology, Inc.",
  "treatment": " Colorectal Cancer, Gastric Cancer",
  "drug_description": "Lonsurf (tipiracil and trifluridine) is a thymidine phosphorylase inhibitor and nucleoside metabolic inhibitor combination indicated for the treatment of patients with previously treated metastatic colorectal cancer, and previously treated metastatic gastric or gastroesophageal junction adenocarcinoma.",
  "previous application": "FDA Approves Lonsurf (tipiracil and trifluridine) for Advanced Colorectal Cancer Lonsurf (tipiracil hydrochloride and trifluridine) FDA Approval History"
},{
  "title": "Ryzodeg 70/30 (insulin degludec and insulin aspart)  Injection ",
  "date_of_approval": "September 25, 2015",
  "company": " Novo Nordisk",
  "treatment": " Diabetes Type 1, Diabetes Type 2",
  "drug_description": "Ryzodeg 70/30 (insulin degludec and insulin aspart) is a long-acting insulin analog and rapid-acting human insulin analog combination indicated to improve glycemic control in adults with diabetes mellitus.",
  "previous application": "FDA Approves Ryzodeg 70/30 (insulin degludec/insulin aspart) for Diabetes Mellitus Ryzodeg 70/30 (insulin degludec and insulin aspart) FDA Approval History"
},{
  "title": "Tresiba (insulin degludec)  Injection ",
  "date_of_approval": "September 25, 2015",
  "company": " Novo Nordisk",
  "treatment": " Diabetes Type 1, Diabetes Type 2",
  "drug_description": "Tresiba (insulin degludec) is a long-acting basal insulin analogue indicated to improve glycemic control in patients one year of age and older with diabetes mellitus.",
  "previous application": "FDA Approves Tresiba (insulin degludec) for Diabetes Mellitus  Tresiba (insulin degludec) FDA Approval History"
},{
  "title": "MorphaBond ER (morphine sulfate)  Extended-Release Tablets ",
  "date_of_approval": "October 2, 2015",
  "company": " Inspirion Delivery Technologies, LLC",
  "treatment": " Pain",
  "drug_description": "MorphaBond ER (morphine sulfate) is an extended-release, abuse-deterrent, opioid analgesic for the treatment of pain severe enough to require daily, around-the-clock, long-term opioid treatment.",
  "previous application": "FDA Approves MorphaBond (morphine sulfate) Extended-Release Tablets with Abuse-Deterrent Properties  MorphaBond ER (morphine sulfate) FDA Approval History"
},{
  "title": "Aristada (aripiprazole lauroxil)  Injection ",
  "date_of_approval": "October 5, 2015",
  "company": " Alkermes plc ",
  "treatment": " Schizophrenia",
  "drug_description": "Aristada (aripiprazole lauroxil) is an extended-release injectable atypical antipsychotic with one-month, six-week, and two-month dosing options for the treatment of schizophrenia.",
  "previous application": "FDA Approves Aristada (aripiprazole lauroxil) for Schizophrenia Aristada (aripiprazole lauroxil) FDA Approval History"
},{
  "title": "Praxbind (idarucizumab)  Injection ",
  "date_of_approval": "October 16, 2015",
  "company": " Boehringer Ingelheim Pharmaceuticals, Inc.",
  "treatment": " Reversal Agent for Pradaxa",
  "drug_description": "Praxbind (idarucizumab) is a humanized monoclonal antibody fragment (Fab) indicated in patients treated with Pradaxa\u00ae (dabigatran) when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures; and in life-threatening or uncontrolled bleeding.",
  "previous application": "FDA Approves Praxbind (idarucizumab) as a Reversal Agent for the Anticoagulant Pradaxa Praxbind (idarucizumab) FDA Approval History"
},{
  "title": "Enstilar (betamethasone dipropionate and calcipotriene)  Foam ",
  "date_of_approval": "October 16, 2015",
  "company": " LEO Pharma",
  "treatment": " Plaque Psoriasis",
  "drug_description": "Enstilar (betamethasone dipropionate and calcipotriene) is a topical corticosteroid and vitamin D analogue foam formulation for the treatment of psoriasis vulgaris.",
  "previous application": "LEO Pharma Announces U.S. Approval of Enstilar Foam (calcipotriene/betamethasone dipropionate) for Plaque Psoriasis Enstilar (betamethasone dipropionate and calcipotriene) FDA Approval History"
},{
  "title": "Dyanavel XR (amphetamine)  Extended-Release Oral Suspension ",
  "date_of_approval": "October 19, 2015",
  "company": " Tris Pharma, Inc.",
  "treatment": " Attention Deficit Hyperactivity Disorder (ADHD)",
  "drug_description": "Dyanavel XR (amphetamine) is an extended-release central nervous system (CNS) stimulant in an oral suspension formulation for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).",
  "previous application": "Tris Pharma Receives FDA Approval of Dyanavel XR (amphetamine) Once-Daily Liquid for ADHD in Children Dyanavel XR (amphetamine) FDA Approval History"
},{
  "title": "Coagadex (coagulation factor X (human))  Injection ",
  "date_of_approval": "October 20, 2015",
  "company": " Bio Products Laboratory Limited",
  "treatment": " Hereditary Factor X Deficiency",
  "drug_description": "Coagadex (coagulation factor X (human)) is a human factor X concentrate for the treatment of hereditary factor X deficiency.",
  "previous application": "FDA Approves Coagadex (coagulation factor X (human)) for Hereditary Factor X Deficiency Coagadex (coagulation factor X (human)) FDA Approval History"
},{
  "title": "Veltassa (patiromer)  for Oral Suspension ",
  "date_of_approval": "October 21, 2015",
  "company": " Relypsa, Inc. ",
  "treatment": " Hyperkalemia",
  "drug_description": "Veltassa (patiromer) is an oral potassium binder for the treatment of hyperkalemia.",
  "previous application": "FDA Approves Veltassa (patiromer) for Hyperkalemia Veltassa (patiromer) FDA Approval History"
},{
  "title": "Onivyde (irinotecan liposomal)  Injection  - formerly MM-398",
  "date_of_approval": "October 22, 2015",
  "company": " Merrimack Pharmaceuticals, Inc.",
  "treatment": " Pancreatic Cancer",
  "drug_description": "Onivyde (irinotecan liposome injection) is a liposomal formulation of the topoisomerase I inhibitor irinotecan indicated for the treatment of post-gemcitabine metastatic adenocarcinoma of the pancreas.",
  "previous application": "FDA Approves Onivyde (irinotecan liposome injection) for Advanced Pancreatic Cancer Onivyde (irinotecan liposomal) FDA Approval History"
},{
  "title": "Yondelis (trabectedin)  for Injection ",
  "date_of_approval": "October 23, 2015",
  "company": " Janssen Biotech, Inc.",
  "treatment": " Soft Tissue Sarcoma",
  "drug_description": "Yondelis (trabectedin) is a cytotoxic antitumor agent for the treatment of unresectable or metastatic liposarcoma or leiomyosarcoma, two common subtypes of soft tissue sarcoma.",
  "previous application": "FDA Approves Yondelis (trabectedin) for the Treatment of Specific Soft Tissue Sarcomas Yondelis (trabectedin) FDA Approval History"
},{
  "title": "Strensiq (asfotase alfa)  Injection ",
  "date_of_approval": "October 23, 2015",
  "company": " Alexion Pharmaceuticals, Inc.",
  "treatment": " Hypophosphatasia",
  "drug_description": "Strensiq (asfotase alfa) is a tissue nonspecific alkaline phosphatase  enzyme replacement therapy indicated for the treatment of patients with perinatal, infantile and juvenile-onset hypophosphatasia (HPP).",
  "previous application": "FDA Approves Strensiq (asfotase alfa) for Perinatal, Infantile and Juvenile-Onset Hypophosphatasia Strensiq (asfotase alfa) FDA Approval History"
},{
  "title": "Vivlodex (meloxicam)  Capsules ",
  "date_of_approval": "October 22, 2015",
  "company": " Iroko Pharmaceuticals, LLC",
  "treatment": " Osteoarthritis",
  "drug_description": "Vivlodex (meloxicam) is a low dose nonsteroidal anti-inflammatory drug (NSAID) indicated for the management of osteoarthritis pain.",
  "previous application": "FDA Approves Vivlodex (meloxicam) for Osteoarthritis Pain Vivlodex (meloxicam) FDA Approval History"
},{
  "title": "Belbuca (buprenorphine hydrochloride)  Buccal Film ",
  "date_of_approval": "October 23, 2015",
  "company": " Endo Pharmaceuticals Inc.",
  "treatment": " Chronic Pain",
  "drug_description": "Belbuca (buprenorphine) is a partial opioid agonist analgesic in a buccal film formulation for the management of chronic pain.",
  "previous application": "FDA Approves Belbuca (buprenorphine) Buccal Film for Chronic Pain Management Belbuca (buprenorphine hydrochloride) FDA Approval History"
},{
  "title": "Imlygic (talimogene laherparepvec)  Injection ",
  "date_of_approval": "October 27, 2015",
  "company": " Amgen Inc.",
  "treatment": " Melanoma",
  "drug_description": "Imlygic (talimogene laherparepvec) is a genetically modified oncolytic viral therapy indicated for the local treatment of melanoma lesions in the skin and lymph nodes.",
  "previous application": "FDA Approves Imlygic (talimogene laherparepvec) for the Treatment of Melanoma Imlygic (talimogene laherparepvec) FDA Approval History"
},{
  "title": "Utibron Neohaler (glycopyrrolate and indacaterol)  Inhalation Powder ",
  "date_of_approval": "October 29, 2015",
  "company": " Novartis Pharmaceuticals Corporation",
  "treatment": " Chronic Obstructive Pulmonary Disease",
  "drug_description": "Utibron Neohaler (glycopyrrolate and indacaterol) is a long-acting muscarinic antagonist (LAMA) and long-acting beta2-adrenergic agonist (LABA) fixed-dose combination for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).",
  "previous application": "FDA Approves Utibron Neohaler (indacaterol/glycopyrrolate) for COPD Utibron Neohaler (glycopyrrolate and indacaterol) FDA Approval History"
},{
  "title": "Seebri Neohaler (glycopyrrolate)  Inhalation Powder ",
  "date_of_approval": "October 29, 2015",
  "company": " Novartis Pharmaceuticals Corporation",
  "treatment": " Chronic Obstructive Pulmonary Disease",
  "drug_description": "Seebri Neohaler (glycopyrrolate) is a long-acting muscarinic antagonist (LAMA) for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).",
  "previous application": "FDA Approves Seebri Neohaler (glycopyrrolate) for COPD Seebri Neohaler (glycopyrrolate) FDA Approval History"
},{
  "title": "Nucala (mepolizumab)  Injection ",
  "date_of_approval": "November 4, 2015",
  "company": " GlaxoSmithKline plc",
  "treatment": " Asthma, Churg-Strauss Allergic Angiitis, Hypereosinophilic Syndrome",
  "drug_description": "Nucala (mepolizumab) is an interleukin-5 antagonist monoclonal antibody (IgG1 kappa) indicated for the add-on maintenance treatment of patients \u22656 years with severe eosinophilic asthma, for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome), and for the treatment of patients \u226512 years with hypereosinophilic syndrome (HES).",
  "previous application": "FDA Approves Nucala (mepolizumab) to Treat Severe Asthma Nucala (mepolizumab) FDA Approval History"
},{
  "title": "Genvoya (cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide)  Tablets ",
  "date_of_approval": "November 5, 2015",
  "company": " Gilead Sciences, Inc.",
  "treatment": " HIV Infection",
  "drug_description": "Genvoya (elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide or E/C/F/TAF) is an antiretroviral combination for the treatment of HIV infection.",
  "previous application": "FDA Approves Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) for HIV Genvoya (cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide) FDA Approval History"
},{
  "title": "Cotellic (cobimetinib)  Tablets ",
  "date_of_approval": "November 10, 2015",
  "company": " Genentech, Inc.",
  "treatment": " Melanoma -- Metastatic",
  "drug_description": "Cotellic (cobimetinib) is a kinase inhibitor indicated for use in combination with vemurafenib for the treatment of advanced melanoma with a BRAF V600E or V600K mutation.",
  "previous application": "FDA Approves Cotellic (cobimetinib) for the Combination Treatment of Advanced Melanoma Cotellic (cobimetinib) FDA Approval History"
},{
  "title": "Tagrisso (osimertinib)  Tablets ",
  "date_of_approval": "November 13, 2015",
  "company": " AstraZeneca Pharmaceuticals",
  "treatment": " Non-Small Cell Lung Cancer",
  "drug_description": "",
  "previous application": "FDA Approves Tagrisso (osimertinib) for EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer Tagrisso (osimertinib) FDA Approval History"
},{
  "title": "Adynovate (antihemophilic factor (recombinant) pegylated) ",
  "date_of_approval": "November 13, 2015",
  "company": " Baxalta Incorporated",
  "treatment": " Hemophilia A",
  "drug_description": "Adynovate (antihemophilic factor (recombinant) pegylated) is a human antihemophilic factor indicated for the control and prevention of bleeding episodes in patients with hemophilia A.",
  "previous application": "FDA Approves Adynovate Modified Antihemophilic Factor for Hemophilia A Adynovate (antihemophilic factor (recombinant) pegylated) FDA Approval History"
},{
  "title": "Darzalex (daratumumab)  Injection ",
  "date_of_approval": "November 16, 2015",
  "company": " Janssen Biotech, Inc.",
  "treatment": " Multiple Myeloma",
  "drug_description": "Darzalex (daratumumab) is a human anti-CD38 monoclonal antibody indicated for the treatment of patients with multiple myeloma.",
  "previous application": "FDA Approves Darzalex (daratumumab) for Patients with Previously Treated Multiple Myeloma Darzalex (daratumumab) FDA Approval History"
},{
  "title": "Narcan (naloxone)  Nasal Spray ",
  "date_of_approval": "November 18, 2015",
  "company": " Adapt Pharma, Inc.",
  "treatment": " Opioid Overdose",
  "drug_description": "Narcan Nasal Spray (naloxone) is an intranasal opioid antagonist formulation indicated for the emergency treatment of known or \r suspected opioid overdose.",
  "previous application": "FDA Approves Narcan (naloxone) Nasal Spray to Treat Opioid Overdose Narcan (naloxone) FDA Approval History"
},{
  "title": "Ninlaro (ixazomib)  Capsules ",
  "date_of_approval": "November 20, 2015",
  "company": " Takeda Pharmaceutical Company Limited",
  "treatment": " Multiple Myeloma",
  "drug_description": "Ninlaro (ixazomib) is an oral proteasome inhibitor indicated for use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.",
  "previous application": "FDA Approves Ninlaro (ixazomib) for Multiple Myeloma Ninlaro (ixazomib) FDA Approval History"
},{
  "title": "Portrazza (necitumumab)  Injection ",
  "date_of_approval": "November 24, 2015",
  "company": " Eli Lilly and Company",
  "treatment": " Non-Small Cell Lung Cancer",
  "drug_description": "Portrazza (necitumumab) is an epidermal growth factor receptor (EGFR) antagonist indicated in combination with gemcitabine and cisplatin for the treatment of patients with metastatic squamous non-small cell lung cancer.",
  "previous application": "FDA Approves Portrazza (necitumumab) for Advanced Squamous Non-Small Cell Lung Cancer Portrazza (necitumumab) FDA Approval History"
},{
  "title": "Fluad (influenza vaccine, adjuvanted)  Injection ",
  "date_of_approval": "November 24, 2015",
  "company": " Seqirus",
  "treatment": " Influenza Prophylaxis",
  "drug_description": "Fluad (influenza vaccine, adjuvanted) is an inactivated influenza virus vaccine indicated for the prevention of seasonal influenza in people 65 years of age and older.",
  "previous application": "FDA Approves Fluad (influenza vaccine, adjuvanted) for Prevention of Seasonal Influenza Fluad (influenza vaccine, adjuvanted) FDA Approval History"
},{
  "title": "Empliciti (elotuzumab)  Injection ",
  "date_of_approval": "November 30, 2015",
  "company": " Bristol-Myers Squibb Company and AbbVie",
  "treatment": " Multiple Myeloma",
  "drug_description": "Empliciti (elotuzumab) is a Signaling Lymphocyte Activation Molecule (SLAMF7)-directed immunostimulatory antibody indicated for the combination treatment of patients with multiple myeloma.",
  "previous application": "FDA Approves Empliciti (elotuzumab) for Multiple Myeloma Empliciti (elotuzumab) FDA Approval History"
},{
  "title": "QuilliChew ER (methylphenidate hydrochloride)  Extended Release Chewable Tablets ",
  "date_of_approval": "December 7, 2015",
  "company": " Pfizer Inc.",
  "treatment": " Attention Deficit Hyperactivity Disorder",
  "drug_description": "QuilliChew ER (methylphenidate hydrochloride) is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).",
  "previous application": "Pfizer Receives FDA Approval for QuilliChew ER (methylphenidate hydrochloride) Extended-Release Chewable Tablets QuilliChew ER (methylphenidate hydrochloride) FDA Approval History"
},{
  "title": "Vonvendi (von willebrand factor (recombinant))  for Injection ",
  "date_of_approval": "December 8, 2015",
  "company": " Baxalta Incorporated",
  "treatment": " von Willebrand's Disease",
  "drug_description": "Vonvendi [von Willebrand factor (recombinant)] is a recombinant von Willebrand factor \r (VWF) indicated for on-demand treatment and control of bleeding episodes in adults \r diagnosed with von Willebrand disease.",
  "previous application": "FDA Approves Vonvendi (Von Willebrand Factor (Recombinant)) to Treat Bleeding Episodes in Patients with VWD Vonvendi (von willebrand factor (recombinant)) FDA Approval History"
},{
  "title": "Kanuma (sebelipase alfa)  Injection ",
  "date_of_approval": "December 8, 2015",
  "company": " Alexion Pharmaceuticals, Inc. ",
  "treatment": " Lysosomal Acid Lipase Deficiency",
  "drug_description": "Kanuma (sebelipase alfa) is an enzyme replacement therapy for the treatment of lysosomal acid lipase deficiency (LAL-D).",
  "previous application": "FDA Approves Kanuma (sebelipase alfa) for Lysosomal Acid Lipase Deficiency Kanuma (sebelipase alfa) FDA Approval History"
},{
  "title": "Bendeka (bendamustine hydrochloride)  Injection ",
  "date_of_approval": "December 7, 2015",
  "company": " Eagle Pharmaceuticals, Inc.",
  "treatment": " Chronic Lymphocytic Leukemia, non-Hodgkin's Lymphoma",
  "drug_description": "Bendeka (bendamustine hydrochloride) is an alkylating drug indicated for treatment of patients with chronic lymphocytic leukemia (CLL) and patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.",
  "previous application": "Teva Pharmaceuticals and Eagle Pharmaceuticals Announce FDA Approval of Bendeka (bendamustine hydrochloride) Injection Bendeka (bendamustine hydrochloride) FDA Approval History"
},{
  "title": "Otiprio (ciprofloxacin)  Otic Suspension  - formerly AuriPro",
  "date_of_approval": "December 10, 2015",
  "company": " Otonomy, Inc.",
  "treatment": " Tympanostomy Tube Placement Surgery; Acute Otitis Externa",
  "drug_description": "Otiprio (ciprofloxacin otic suspension) is a single-dose, physician-administered, sustained-exposure otic fluoroquinolone antibacterial for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement surgery, and for the treatment of acute otitis externa due to Pseudomonas aeruginosa and Staphylococcus aureus.",
  "previous application": "FDA Approves Otiprio (ciprofloxacin otic suspension) for the Treatment of Pediatric Patients Undergoing Tympanostomy Tube Placement Surgery Otiprio (ciprofloxacin) FDA Approval History"
},{
  "title": "Vistogard (uridine triacetate)  Oral Granules ",
  "date_of_approval": "December 11, 2015",
  "company": " Wellstat Therapeutics Corporation",
  "treatment": " Fluorouracil Overdose and Capecitabine Overdose",
  "drug_description": "Vistogard (uridine triacetate) is a pyrimidine analog indicated \r for the emergency treatment of adults and children who receive an overdose of the cancer treatments fluorouracil or capecitabine.",
  "previous application": "FDA Approves Vistogard (uridine triacetate) for Emergency Treatment for Overdose of Certain Types of Chemotherapy Vistogard (uridine triacetate) FDA Approval History"
},{
  "title": "Alecensa (alectinib)  Capsules ",
  "date_of_approval": "December 11, 2015",
  "company": " Genentech, Inc.",
  "treatment": " Non-Small Cell Lung Cancer",
  "drug_description": "Alecensa (alectinib) is an oral, anaplastic lymphoma kinase (ALK) inhibitor for the treatment of ALK-positive non-small cell lung cancer (NSCLC).",
  "previous application": "FDA Approves Alecensa (alectinib) for ALK-Positive Non-Small Cell Lung Cancer Alecensa (alectinib) FDA Approval History"
},{
  "title": "Bridion (sugammadex)  Injection ",
  "date_of_approval": "December 15, 2015",
  "company": " Merck &amp; Co., Inc.",
  "treatment": " Reversal of Nondepolarizing Muscle Relaxants",
  "drug_description": "Bridion (sugammadex) is a novel selective relaxant binding agent (SRBA) for the reversal of neuromuscular blockade induced by rocuronium or vecuronium.",
  "previous application": "FDA Approves Bridion (sugammadex) to Reverse Effects of Neuromuscular Blocking Drugs Bridion (sugammadex) FDA Approval History"
},{
  "title": "Basaglar (insulin glargine)  Injection ",
  "date_of_approval": "December 16, 2015",
  "company": " Eli Lilly and Company and Boehringer Ingelheim",
  "treatment": " Diabetes Type 1, Diabetes Type 2",
  "drug_description": "Basaglar (insulin glargine injection) is a long-acting human insulin analog indicated to improve glycemic control in patients with type 1 and  type 2 diabetes mellitus.",
  "previous application": "FDA Approves Basaglar (insulin glargine) for Type 1 and Type 2 Diabetes Basaglar (insulin glargine) FDA Approval History"
},{
  "title": "Zurampic (lesinurad)  Tablets ",
  "date_of_approval": "December 22, 2015",
  "company": " Ironwood Pharmaceuticals, Inc.",
  "treatment": " Hyperuricemia Associated with Gout",
  "drug_description": "",
  "previous application": "FDA Approves Zurampic (lesinurad) to Treat High Blood Uric Acid Levels Associated with Gout Zurampic (lesinurad) FDA Approval History"
},{
  "title": "Uptravi (selexipag)  Tablets ",
  "date_of_approval": "December 21, 2015",
  "company": " Actelion Pharmaceuticals US, Inc.",
  "treatment": " Pulmonary Arterial Hypertension",
  "drug_description": "Uptravi (selexipag) is an oral prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension.",
  "previous application": "FDA Approves Uptravi (selexipag) for Pulmonary Arterial Hypertension Uptravi (selexipag) FDA Approval History"
},{
  "title": "Docetaxel Non-Alcohol Formula ()   Injection ",
  "date_of_approval": "December 22, 2015",
  "company": " Eagle Pharmaceuticals, Inc.",
  "treatment": " Cancer",
  "drug_description": "Docetaxel Injection, Non-Alcohol Formula is an alcohol-free formulation of docetaxel for use in the treatment of patients with breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer.",
  "previous application": "Teikoku Pharma USA, Inc. Announces FDA Approval of Docetaxel Injection, Non-Alcohol Formula Docetaxel Non-Alcohol Formula FDA Approval History"
},{
  "title": "Emverm (mebendazole)  Chewable Tablets ",
  "date_of_approval": "January 15, 2016",
  "company": " Impax Laboratories, Inc.",
  "treatment": " Pinworm Infection (Enterobius vermicularis), Whipworm Infection (Trichuris trichiura), Hookworm Infection (Necator or Ancylostoma), Ascariasis",
  "drug_description": "Emverm (mebendazole) is a chewable tablet formulation of the approved anthelmintic mebendazole for the treatment of Enterobius vermicularis (pinworm), Trichuris trichiura (whipworm), Ascaris lumbricoides (common roundworm), Ancylostoma duodenale (common hookworm), Necator americanus (American hookworm) in single or mixed infections.",
  "previous application": "Impax Receives Approval of Emverm (mebendazole) Chewable Tablets Emverm (mebendazole) FDA Approval History"
},{
  "title": "Adzenys XR-ODT (amphetamine)  Extended-Release Orally Disintegrating Tablets ",
  "date_of_approval": "January 27, 2016",
  "company": " Neos Therapeutics, Inc.",
  "treatment": " Attention-Deficit Hyperactivity Disorder (ADHD)",
  "drug_description": "Adzenys XR-ODT (amphetamine) is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older.",
  "previous application": "Neos Therapeutics Announces FDA Approval of Adzenys XR-ODT (Amphetamine Extended-Release Orally Disintegrating Tablet) for ADHD Adzenys XR-ODT (amphetamine) FDA Approval History"
},{
  "title": "Onzetra Xsail (sumatriptan)  Inhalation Powder  - formerly AVP-825",
  "date_of_approval": "January 27, 2016",
  "company": " Avanir Pharmaceuticals, Inc.",
  "treatment": " Migraine",
  "drug_description": "Onzetra Xsail (sumatriptan) is a fast-acting, intranasal serotonin 5-HT1B/1D receptor agonist (triptan) indicated \r for the acute treatment of migraine with or without aura.",
  "previous application": "FDA Approves Onzetra Xsail (sumatriptan nasal powder) for the Acute Treatment of Migraine Onzetra Xsail (sumatriptan) FDA Approval History"
},{
  "title": "Zepatier (elbasvir and grazoprevir)  Tablets ",
  "date_of_approval": "January 28, 2016",
  "company": " Merck &amp; Co., Inc.",
  "treatment": " Chronic Hepatitis C",
  "drug_description": "Zepatier (elbasvir and grazoprevir) is a once-daily, single tablet, NS5A replication complex inhibitor and NS3/4A protease inhibitor combination for the treatment of chronic hepatitis C virus (HCV) genotypes 1 and 4 infections.",
  "previous application": "FDA Approves Zepatier (elbasvir and grazoprevir) for Chronic Hepatitis C Genotypes 1 and 4 Zepatier (elbasvir and grazoprevir) FDA Approval History"
},{
  "title": "Zembrace SymTouch (sumatriptan)  Injection ",
  "date_of_approval": "January 28, 2016",
  "company": " Dr. Reddy\u2019s Laboratories Ltd.",
  "treatment": " Migraine",
  "drug_description": "Zembrace SymTouch (sumatriptan) is a  selective 5-HT1B/ID receptor agonist in a prefilled, ready-to-use, single-dose disposable autoinjector for the treatment of acute migraine episodes, with or without aura.",
  "previous application": "Dr. Reddy\u2019s Laboratories Ltd. Receives FDA Approval for Zembrace SymTouch (sumatriptan succinate) Injection for the Acute Treatment of Migraines Zembrace SymTouch (sumatriptan) FDA Approval History"
},{
  "title": "Cetylev (acetylcysteine)  Effervescent Tablets for Oral Solution ",
  "date_of_approval": "January 29, 2016",
  "company": " Arbor Pharmaceuticals, LLC",
  "treatment": " Acetaminophen Overdose",
  "drug_description": "",
  "previous application": "Arbor Pharmaceuticals Announces FDA Approval of Cetylev Cetylev (acetylcysteine) FDA Approval History"
},{
  "title": "Sernivo (betamethasone dipropionate)  Topical Spray ",
  "date_of_approval": "February 5, 2016",
  "company": " Promius Pharma, LLC",
  "treatment": " Plaque Psoriasis",
  "drug_description": "Sernivo Spray (betamethasone dipropionate) is a topical corticosteroid indicated for the treatment of mild to moderate plaque psoriasis.",
  "previous application": "Promius Pharma Receives FDA Approval for Sernivo (betamethasone dipropionate) Spray Sernivo (betamethasone dipropionate) FDA Approval History"
},{
  "title": "Briviact (brivaracetam) ",
  "date_of_approval": "February 19, 2016",
  "company": " UCB, Inc.",
  "treatment": " Epilepsy",
  "drug_description": "Briviact (brivaracetam) is a selective, high-affinity synaptic vesicle protein 2A ligand and analog of levetiracetam indicated for the treatment of partial-onset seizures in patients with epilepsy.",
  "previous application": "FDA Approves Briviact (brivaracetam) to Treat Partial Onset Seizures Briviact (brivaracetam) FDA Approval History"
},{
  "title": "Xeljanz XR (tofacitinib)  Extended-Release Tablets ",
  "date_of_approval": "February 23, 2016",
  "company": " Pfizer Inc.",
  "treatment": " Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis",
  "drug_description": "Xeljanz XR (tofacitinib) is a Janus kinase (JAK) inhibitor indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.",
  "previous application": "Pfizer Announces FDA Approval of Xeljanz XR (tofacitinib citrate), the First and Only Once-Daily Oral JAK Inhibitor Treatment for Rheumatoid Arthritis Xeljanz XR (tofacitinib) FDA Approval History"
},{
  "title": "Odefsey (emtricitabine, rilpivirine and tenofovir alafenamide)  Tablets ",
  "date_of_approval": "March 1, 2016",
  "company": " Gilead Sciences, Inc.",
  "treatment": " HIV Infection",
  "drug_description": "Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide) is a fixed-dose combination of emtricitabine (FTC) and tenofovir alafenamide (TAF), both HIV nucleoside analog reverse transcriptase inhibitors (NRTIs), and rilpivirine (RPV), a non-nucleoside reverse transcriptase inhibitor (NNRTI), indicated as a complete regimen for the treatment of HIV-1 infection.",
  "previous application": "FDA Approves Odefsey (emtricitabine, rilpivirine and tenofovir alafenamide) for the Treatment of HIV-1 Infection Odefsey (emtricitabine, rilpivirine and tenofovir alafenamide) FDA Approval History"
},{
  "title": "Idelvion (coagulation factor IX (recombinant), albumin fusion protein)  Injection ",
  "date_of_approval": "March 4, 2016",
  "company": " CSL Behring",
  "treatment": " Hemophilia B",
  "drug_description": "Idelvion (coagulation factor IX (recombinant), albumin fusion protein) is a long-acting recombinant human blood coagulation factor indicated for the control and prevention of bleeding episodes in patients with hemophilia B.",
  "previous application": "FDA Approves Idelvion (coagulation factor IX (recombinant), albumin fusion protein) to Treat Patients with Hemophilia B  Idelvion (coagulation factor IX (recombinant), albumin fusion protein) FDA Approval History"
},{
  "title": "Evomela (melphalan)  for Injection ",
  "date_of_approval": "March 10, 2016",
  "company": " Spectrum Pharmaceuticals, Inc.",
  "treatment": " Multiple Myeloma",
  "drug_description": "Evomela (melphalan) is an alkylating agent used as a high-dose conditioning treatment prior to stem cell transplantation in patients with multiple myeloma (MM), and for the palliative treatment of patients with MM for whom oral therapy is not appropriate.",
  "previous application": "FDA Grants Spectrum Pharmaceuticals Approval of Evomela (melphalan) for Injection  Evomela (melphalan) FDA Approval History"
},{
  "title": "Kovaltry (antihemophilic factor (recombinant))  Injection ",
  "date_of_approval": "March 16, 2016",
  "company": " Bayer HealthCare Pharmaceuticals Inc.",
  "treatment": " Hemophilia A",
  "drug_description": "Kovaltry (antihemophilic factor (recombinant)) is a human DNA sequence derived, full length Factor VIII concentrate indicated for the control and prevention of bleeding episodes in adults and children with hemophilia A.",
  "previous application": "FDA Approves Bayer's Kovaltry (Antihemophilic Factor (Recombinant)) for the Treatment of Children and Adults with Hemophilia A Kovaltry (antihemophilic factor (recombinant)) FDA Approval History"
},{
  "title": "Anthim (obiltoxaximab)  Injection ",
  "date_of_approval": "March 18, 2016",
  "company": " Elusys Therapeutics, Inc.",
  "treatment": " Anthrax Prophylaxis, Inhalation Bacillus anthracis",
  "drug_description": "Anthim (obiltoxaximab) is a monoclonal antibody (mAb) anthrax antitoxin for the treatment and prevention of inhalational anthrax.",
  "previous application": "FDA Approves Anthim (obiltoxaximab) for Inhalation Anthrax Anthim (obiltoxaximab) FDA Approval History"
},{
  "title": "Taltz (ixekizumab)  Injection ",
  "date_of_approval": "March 22, 2016",
  "company": " Eli Lilly and Company",
  "treatment": " Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis",
  "drug_description": "Taltz (ixekizumab) is a humanized interleukin-17A antagonist indicated for the treatment of:",
  "previous application": "FDA Approves Taltz (ixekizumab) for Plaque Psoriasis Taltz (ixekizumab) FDA Approval History"
},{
  "title": "Cinqair (reslizumab)  Injection ",
  "date_of_approval": "March 23, 2016",
  "company": " Teva Pharmaceutical Industries Ltd.",
  "treatment": " Asthma",
  "drug_description": "Cinqair (reslizumab) is an interleukin 5 antagonist monoclonal antibody (IgG4 kappa) indicated for add-on maintenance treatment of patients with eosinophilic asthma.",
  "previous application": "FDA Approves Cinqair (reslizumab) to Treat Severe Asthma Cinqair (reslizumab) FDA Approval History"
},{
  "title": "Defitelio (defibrotide)  Injection ",
  "date_of_approval": "March 30, 2016",
  "company": " Jazz Pharmaceuticals plc",
  "treatment": " Hepatic Veno-Occlusive Disease",
  "drug_description": "Defitelio (defibrotide sodium) is a deoxyribonucleic acid derivative anticoagulant for the treatment of patients with hepatic veno-occlusive disease (VOD) with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT).",
  "previous application": "FDA Approves Defitelio (defibrotide sodium) for Hepatic Veno-Occlusive Disease Following Hematopoietic Stem-Cell Transplantation Defitelio (defibrotide) FDA Approval History"
},{
  "title": "Descovy (emtricitabine and tenofovir alafenamide)  Tablets ",
  "date_of_approval": "April 4, 2016",
  "company": " Gilead Sciences, Inc.",
  "treatment": " HIV Infection, Pre-Exposure Prophylaxis",
  "drug_description": "Descovy (emtricitabine and tenofovir alafenamide) is a nucleoside analog HIV-1 reverse transcriptase inhibitor (NRTI) and nucleotide reverse transcriptase inhibitor (NtRTI) fixed-dose combination for the treatment of HIV-1 infection, and for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection.",
  "previous application": "FDA Approves Descovy (emtricitabine and tenofovir alafenamide), Gilead\u2019s Third TAF-Based HIV Therapy  Descovy (emtricitabine and tenofovir alafenamide) FDA Approval History"
},{
  "title": "Inflectra (infliximab-dyyb)  Injection ",
  "date_of_approval": "April 5, 2016",
  "company": " Celltrion, Inc.",
  "treatment": " Crohn's Disease -- Maintenance, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Plaque Psoriasis",
  "drug_description": "Inflectra (infliximab-dyyb) is a tumor necrosis factor (TNF) blocker biosimilar to Remicade (infliximab) indicated for the treatment of Crohn\u2019s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis.",
  "previous application": "FDA Approves Inflectra (infliximab-dyyb) a Biosimilar to Remicade Inflectra (infliximab-dyyb) FDA Approval History"
},{
  "title": "BromSite (bromfenac)  Ophthalmic Solution ",
  "date_of_approval": "April 8, 2016",
  "company": " Sun Pharmaceutical Industries Ltd.",
  "treatment": " Postoperative Ocular Inflammation",
  "drug_description": "BromSite (bromfenac) is a low dose nonsteroidal anti-inflammatory drug (NSAID) ophthalmic solution for the treatment of inflammation and prevention of pain in patients undergoing cataract surgery.",
  "previous application": "Sun Pharma Receives FDA Approval For BromSite (bromfenac ophthalmic solution) BromSite (bromfenac) FDA Approval History"
},{
  "title": "Venclexta (venetoclax)  Tablets ",
  "date_of_approval": "April 11, 2016",
  "company": " AbbVie Inc.",
  "treatment": " Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia",
  "drug_description": "Venclexta (venetoclax) is an oral B-cell lymphoma-2 (BCL-2) inhibitor indicated:",
  "previous application": "FDA Approves Venclexta (venetoclax) for Chronic Lymphocytic Leukemia with 17p Deletion Venclexta (venetoclax) FDA Approval History"
},{
  "title": "Bevespi Aerosphere (formoterol fumarate and glycopyrrolate)  Inhalation Aerosol ",
  "date_of_approval": "April 25, 2016",
  "company": " AstraZeneca Pharmaceuticals LP",
  "treatment": " Chronic Obstructive Pulmonary Disease",
  "drug_description": "Bevespi Aerosphere (formoterol fumarate and glycopyrrolate) is a long\r -acting beta2-adrenergic agonist (LABA) and anticholinergic combination indicated for the long-term, maintenance treatment of airflow \r obstruction in patients with chronic obstructive pulmonary disease (COPD).",
  "previous application": "Bevespi Aerosphere Approved by the FDA for Patients with COPD Bevespi Aerosphere (formoterol fumarate and glycopyrrolate) FDA Approval History"
},{
  "title": "Cabometyx (cabozantinib)  Tablets ",
  "date_of_approval": "April 25, 2016",
  "company": " Exelixis, Inc.",
  "treatment": " Renal Cell Carcinoma, Hepatocellular Carcinoma",
  "drug_description": "Cabometyx (cabozantinib) is a tyrosine kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma (RCC), and patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.",
  "previous application": "Exelixis Announces FDA Approval of Cabometyx (cabozantinib) for Patients with Advanced Renal Cell Carcinoma Cabometyx (cabozantinib) FDA Approval History"
},{
  "title": "Xtampza ER (oxycodone)  Extended-Release Capsules ",
  "date_of_approval": "April 26, 2016",
  "company": " Collegium Pharmaceutical, Inc.",
  "treatment": " Chronic Pain",
  "drug_description": "Xtampza ER (oxycodone) is an extended-release, abuse-deterrent, narcotic analgesic for the treatment of chronic pain.",
  "previous application": "Collegium Receives FDA Approval for Xtampza ER, an Analgesic with Abuse-Deterrent Properties Xtampza ER (oxycodone) FDA Approval History"
},{
  "title": "Nuplazid (pimavanserin)  Tablets and Capsules ",
  "date_of_approval": "April 29, 2016",
  "company": " Acadia Pharmaceuticals Inc. ",
  "treatment": " Parkinson\u2019s Disease Psychosis",
  "drug_description": "Nuplazid (pimavanserin) is a non-dopaminergic, selective serotonin inverse agonist (SSIA) for the treatment of psychosis associated with Parkinson\u2019s disease.",
  "previous application": "FDA Approves Nuplazid (pimavanserin) for Parkinson\u2019s Disease Psychosis Nuplazid (pimavanserin) FDA Approval History"
},{
  "title": "Akovaz (ephedrine sulfate)  Injection ",
  "date_of_approval": "April 29, 2016",
  "company": " Flamel Technologies",
  "treatment": " Hypotension",
  "drug_description": "Akovaz (ephedrine sulfate) is a pressor agent administered parenterally to address clinically important hypotension in surgical settings.",
  "previous application": "Flamel Technologies Receives FDA Approval of Akovaz (ephedrine sulfate) for Surgical Hypotension Akovaz (ephedrine sulfate) FDA Approval History"
},{
  "title": "Otovel (ciprofloxacin and fluocinolone acetonide)  Otic Solution ",
  "date_of_approval": "April 29, 2016",
  "company": " Laboratorios Salvat S.A. and Arbor Pharmaceuticals, LLC",
  "treatment": " Acute Otitis Media with Tympanostomy Tubes",
  "drug_description": "Otovel otic solution (ciprofloxacin and fluocinolone acetonide) is a fluoroquinolone antibacterial and corticosteroid combination indicated for the treatment of acute otitis media with tympanostomy tubes (AOMT) in pediatric patients.",
  "previous application": "Laboratorios Salvat S.A. and Arbor Pharmaceuticals, LLC Announce the Launch of Otovel (ciprofloxacin 0.3 % and fluocinolone acetonide 0.025 %) Otic Solution Otovel (ciprofloxacin and fluocinolone acetonide) FDA Approval History"
},{
  "title": "Flucelvax Quadrivalent (influenza virus vaccine, inactivated) ",
  "date_of_approval": "May 23, 2016",
  "company": " Seqirus",
  "treatment": " Influenza Prophylaxis",
  "drug_description": "Flucelvax Quadrivalent is an inactivated influenza vaccine indicated for active immunization for active immunization against influenza disease in people 4 years of age and older.",
  "previous application": "FDA Approves Flucelvax - First Seasonal Influenza Vaccine Manufactured Using Cell Culture Technology Flucelvax Quadrivalent (influenza virus vaccine, inactivated) FDA Approval History"
},{
  "title": "Ameluz (aminolevulinic acid)  Gel  - formerly BF-200 ALA",
  "date_of_approval": "May 10, 2016",
  "company": " Biofrontera AG",
  "treatment": " Actinic Keratosis",
  "drug_description": "Ameluz (aminolevulinic acid) is a porphyrin precursor used in combination with the BF-RhodoLED lamp for photodynamic therapy (PDT) treatment of actinic keratoses on the face and scalp.",
  "previous application": "Biofrontera Announces U.S. FDA Approval of Ameluz and Activating BF-RhodoLED Device for Treatment of Actinic Keratosis Ameluz (aminolevulinic acid) FDA Approval History"
},{
  "title": "Tecentriq (atezolizumab)  Injection ",
  "date_of_approval": "May 18, 2016",
  "company": " Genentech, Inc.",
  "treatment": " Bladder Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Small Cell Lung Cancer, Hepatocellular Carcinoma, Melanoma -- Metastatic",
  "drug_description": "Tecentriq (atezolizumab) is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for use in the treatment of urothelial carcinoma, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), small cell lung cancer (SCLC), heptatocellular carcinoma and melanoma.",
  "previous application": "FDA Approves Tecentriq (atezolizumab) for Urothelial Carcinoma Tecentriq (atezolizumab) FDA Approval History"
},{
  "title": "Flucelvax Quadrivalent (influenza virus vaccine, inactivated) ",
  "date_of_approval": "May 23, 2016",
  "company": " Seqirus",
  "treatment": " Influenza Prophylaxis",
  "drug_description": "Flucelvax Quadrivalent is an inactivated influenza vaccine indicated for active immunization for active immunization against influenza disease in people 4 years of age and older.",
  "previous application": "Seqirus Receives FDA Approval for Flucelvax Quadrivalent (Influenza Vaccine) for People Four Years of Age and Older Flucelvax Quadrivalent (influenza virus vaccine, inactivated) FDA Approval History"
},{
  "title": "Afstyla (antihemophilic factor (recombinant), single chain)  for Injection ",
  "date_of_approval": "May 25, 2016",
  "company": " CSL Behring",
  "treatment": " Hemophilia A",
  "drug_description": "Afstyla (antihemophilic factor (recombinant), single chain, is a recombinant,\r antihemophilic factor indicated for the control and prevention of bleeding episodes in adults and children with hemophilia A.",
  "previous application": "FDA Approves Afstyla (Antihemophilic Factor (Recombinant), Single Chain) for Hemophilia A Afstyla (antihemophilic factor (recombinant), single chain) FDA Approval History"
},{
  "title": "Probuphine (buprenorphine)  Implant ",
  "date_of_approval": "May 26, 2016",
  "company": " Titan Pharmaceuticals, Inc.",
  "treatment": " Opiate Dependence",
  "drug_description": "Probuphine (buprenorphine) is an opioid partial agonist subdermal implant for the treatment of opioid dependence.",
  "previous application": "FDA Approves Probuphine (buprenorphine) Implant for Treatment of Opioid Dependence Probuphine (buprenorphine) FDA Approval History"
},{
  "title": "Ocaliva (obeticholic acid)  Tablets ",
  "date_of_approval": "May 27, 2016",
  "company": " Intercept Pharmaceuticals, Inc.",
  "treatment": " Biliary Cirrhosis",
  "drug_description": "Ocaliva (obeticholic acid) is a first-in-class farnesoid X receptor (FXR) agonist for the treatment of primary biliary cholangitis.",
  "previous application": "FDA Grants Accelerated Approval to Ocaliva (obeticholic acid) for Primary Biliary Cholangitis Ocaliva (obeticholic acid) FDA Approval History"
},{
  "title": "Axumin (fluciclovine F 18)  Injection ",
  "date_of_approval": "May 27, 2016",
  "company": " Blue Earth Diagnostics, Ltd.",
  "treatment": " Diagnostic",
  "drug_description": "Axumin (fluciclovine F 18) a radioactive diagnostic agent indicated for positron emission\r tomography (PET) imaging in men with suspected recurrent prostate cancer.",
  "previous application": "FDA Approves Axumin (fluciclovine F 18) Diagnostic Imaging Agent to Detect Recurrent Prostate Cancer Axumin (fluciclovine F 18) FDA Approval History"
},{
  "title": "Zinbryta (daclizumab)  Injection ",
  "date_of_approval": "May 27, 2016",
  "company": " AbbVie, Inc. and Biogen",
  "treatment": " Multiple Sclerosis",
  "drug_description": "Zinbryta (daclizumab) is an interleukin-2 receptor blocking antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS).",
  "previous application": "FDA Approves Zinbryta (daclizumab) to Treat Multiple Sclerosis Zinbryta (daclizumab) FDA Approval History"
},{
  "title": "Netspot (gallium Ga 68 dotatate)  Injection ",
  "date_of_approval": "June 1, 2016",
  "company": " Advanced Accelerator Applications USA, Inc.",
  "treatment": " Diagnostic",
  "drug_description": "Netspot (gallium Ga 68 dotatate) is a radioactive diagnostic\r agent indicated for use with positron emission tomography (PET) for\r localization of somatostatin receptor positive neuroendocrine tumors",
  "previous application": "FDA Approves Netspot (gallium Ga 68 dotatate) Imaging Agent to Detect Rare Neuroendocrine Tumors Netspot (gallium Ga 68 dotatate) FDA Approval History"
},{
  "title": "Byvalson (nebivolol and valsartan)  Tablets ",
  "date_of_approval": "June 3, 2016",
  "company": " Forest Laboratories, Inc.",
  "treatment": " Hypertension",
  "drug_description": "",
  "previous application": "Allergan Announces FDA Approval of Byvalson (nebivolol and valsartan) for Hypertension Byvalson (nebivolol and valsartan) FDA Approval History"
},{
  "title": "Vaxchora (cholera vaccine, live, oral)  Suspension for Oral Administration ",
  "date_of_approval": "June 10, 2016",
  "company": " PaxVax Bermuda Ltd.",
  "treatment": " Cholera Prophylaxis",
  "drug_description": "Vaxchora (cholera vaccine, live, oral) is a vaccine indicated for active immunization against disease caused by Vibrio cholerae serogroup O1 in adults traveling to cholera-affected areas.",
  "previous application": "FDA Approves Vaxchora (Cholera Vaccine, Live, Oral) to Prevent Cholera in Travelers Vaxchora (cholera vaccine, live, oral) FDA Approval History"
},{
  "title": "GoNitro (nitroglycerin)  Sublingual Powder ",
  "date_of_approval": "June 8, 2016",
  "company": " Espero Pharmaceuticals, Inc.",
  "treatment": " Angina Pectoris Prophylaxis",
  "drug_description": "GoNitro (nitroglycerin) is a nitrate vasodilator indicated for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease.",
  "previous application": "Espero Pharmaceuticals Receives FDA Approval for GoNitro (nitroglycerin) Sublingual Powder GoNitro (nitroglycerin) FDA Approval History"
},{
  "title": "Rayaldee (calcifediol)  Extended Release Capsules ",
  "date_of_approval": "June 17, 2016",
  "company": " OPKO Health, Inc.",
  "treatment": " Secondary Hyperparathyroidism",
  "drug_description": "Rayaldee (calcifediol) is a vitamin D3 analog indicated for the treatment of secondary hyperparathyroidism associated with vitamin D Insufficiency in stage 3-4 chronic kidney disease.",
  "previous application": "FDA Approves Rayaldee (calcifediol) to Treat Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease Rayaldee (calcifediol) FDA Approval History"
},{
  "title": "Epclusa (sofosbuvir and velpatasvir)  Tablets ",
  "date_of_approval": "June 28, 2016",
  "company": " Gilead Sciences, Inc.",
  "treatment": " Chronic Hepatitis C",
  "drug_description": "Epclusa (sofosbuvir and velpatasvir) is a nucleotide analog polymerase inhibitor and pan-genotypic NS5A inhibitor fixed-dose combination for the treatment of chronic genotype 1-6 hepatitis C virus (HCV) infection.",
  "previous application": "FDA Approves Epclusa (sofosbuvir and velpatasvir) for Treatment of all Major Forms of Chronic Hepatitis C Virus Infection Epclusa (sofosbuvir and velpatasvir) FDA Approval History"
},{
  "title": "Kovanaze (oxymetazoline hydrochloride and tetracaine hydrochloride)  Nasal Spray ",
  "date_of_approval": "June 29, 2016",
  "company": " St. Renatus, LLC",
  "treatment": " Dental Anesthesia",
  "drug_description": "Kovanaze (oxymetazoline hydrochloride and tetracaine hydrochloride) is a vasoconstrictor and local anesthetic combination administered intranasally as a topical anesthetic for use in restorative dental procedures.",
  "previous application": "St. Renatus, LLC Announces FDA Approval of Kovanaze (tetracaine HCl and oxymetazoline HCl) Nasal Spray for Use in Dentistry Kovanaze (oxymetazoline hydrochloride and tetracaine hydrochloride) FDA Approval History"
},{
  "title": "Syndros (dronabinol)  Oral Solution ",
  "date_of_approval": "July 1, 2016",
  "company": " Insys Therapeutics, Inc.",
  "treatment": " Anorexia -- AIDS Patients; Nausea/Vomiting -- Chemotherapy Induced",
  "drug_description": "Syndros (dronabinol) is an orally administered liquid formulation of the pharmaceutical cannabinoid dronabinol, a pharmaceutical version of tetrahydrocannabinol (THC) approved for use in treating anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.",
  "previous application": "Insys Therapeutics Announces FDA Approval of Syndros (dronabinol) Oral Solution Syndros (dronabinol) FDA Approval History"
},{
  "title": "Xiidra (lifitegrast)  Ophthalmic Solution ",
  "date_of_approval": "July 11, 2016",
  "company": " Shire US Inc.",
  "treatment": " Dry Eye Disease",
  "drug_description": "Xiidra (lifitegrast) is a lymphocyte function-associated antigen-1 (LFA-1) antagonist indicated for the treatment of the signs and symptoms of dry eye disease.",
  "previous application": "FDA Approves Xiidra (lifitegrast ophthalmic solution) for Dry Eye Disease Xiidra (lifitegrast) FDA Approval History"
},{
  "title": "Viekira XR (dasabuvir, ombitasvir, paritaprevir and ritonavir)  Extended-Release Tablets ",
  "date_of_approval": "July 22, 2016",
  "company": " Abbvie, Inc.",
  "treatment": " Chronic Hepatitis C",
  "drug_description": "",
  "previous application": "AbbVie Receives U.S. FDA Approval of Once-Daily Viekira XR (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the Treatment of Genotype 1 Chronic Hepatitis C Viekira XR (dasabuvir, ombitasvir, paritaprevir and ritonavir) FDA Approval History"
},{
  "title": "Adlyxin (lixisenatide)  Injection ",
  "date_of_approval": "July 27, 2016",
  "company": " Sanofi",
  "treatment": " Diabetes Type 2",
  "drug_description": "Adlyxin (lixisenatide) is a once-daily prandial GLP-1\r receptor agonist for the treatment of adults with type 2 diabetes\r mellitus.",
  "previous application": "Sanofi Receives FDA Approval of Adlyxin (lixisenatide) for Treatment of Adults With Type 2 Diabetes Adlyxin (lixisenatide) FDA Approval History"
},{
  "title": "Qbrelis (lisinopril)  Oral Solution ",
  "date_of_approval": "July 29, 2016",
  "company": " Silvergate Pharmaceuticals, Inc.",
  "treatment": " Hypertension, Congestive Heart Failure, Myocardial Infarction",
  "drug_description": "Qbrelis (lisinopril) is an oral solution formulation of the approved angiotensin converting enzyme (ACE) inhibitor lisinopril indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older, adjunct therapy for heart failure, and treatment of acute myocardial infarction in adults.",
  "previous application": "FDA Approves Qbrelis (lisinopril) Oral Solution for Pediatric Patients 6 Years of Age and Older Qbrelis (lisinopril) FDA Approval History"
},{
  "title": "Flonase Sensimist (fluticasone furoate)  Nasal Spray ",
  "date_of_approval": "August 2, 2016",
  "company": " GSK Consumer Healthcare",
  "treatment": " Allergic Rhinitis",
  "drug_description": "Flonase Sensimist (fluticasone furoate) is an over-the-counter corticosteroid nasal spray indicated for the treatment of symptoms associated with seasonal and perennial allergies in adults and children ages 2 years and older.",
  "previous application": "FDA Approves Flonase Sensimist Allergy Relief Flonase Sensimist (fluticasone furoate) FDA Approval History"
},{
  "title": "Sustol (granisetron)  Extended-Release Injection ",
  "date_of_approval": "August 9, 2016",
  "company": " Heron Therapeutics, Inc.",
  "treatment": " Nausea/Vomiting -- Chemotherapy Induced",
  "drug_description": "Sustol (granisetron) is a long-acting 5-HT3 antagonist indicated for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens.",
  "previous application": "Heron Therapeutics Announces FDA Approval of Sustol (granisetron) Extended-Release Injection for the Prevention of Chemotherapy-Induced Nausea and Vomiting Sustol (granisetron) FDA Approval History"
},{
  "title": "Troxyca ER (naltrexone and oxycodone)  Extended-Release Capsules ",
  "date_of_approval": "August 19, 2016",
  "company": " Pfizer Inc.",
  "treatment": " Pain",
  "drug_description": "",
  "previous application": "FDA Approves Troxyca ER (oxycodone hydrochloride and naltrexone hydrochloride) Capsules with Abuse-Deterrent Properties for the Management of Pain Troxyca ER (naltrexone and oxycodone) FDA Approval History"
},{
  "title": "Afluria Quadrivalent (influenza virus vaccine, inactivated)  Injection ",
  "date_of_approval": "August 26, 2016",
  "company": " Seqirus",
  "treatment": " Influenza Prophylaxis",
  "drug_description": "Afluria Quadrivalent is an inactivated influenza virus vaccine indicated for active immunization against influenza disease in persons 6 months of age and older.",
  "previous application": "Seqirus Receives FDA Approval for Afluria Quadrivalent (Influenza Vaccine) for People 18 Years of Age and Older Afluria Quadrivalent (influenza virus vaccine, inactivated) FDA Approval History"
},{
  "title": "Erelzi (etanercept-szzs)  Injection ",
  "date_of_approval": "August 30, 2016",
  "company": " Sandoz Inc.",
  "treatment": " Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis",
  "drug_description": "Erelzi (etanercept-szzs) is a tumor necrosis factor (TNF) blocker biosimilar to Enbrel indicated for the treatment of rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis (JIA), psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis.",
  "previous application": "FDA Approves Erelzi (etanercept-szzs), a Biosimilar to Enbrel Erelzi (etanercept-szzs) FDA Approval History"
},{
  "title": "Afluria Quadrivalent (influenza virus vaccine, inactivated)  Injection ",
  "date_of_approval": "August 26, 2016",
  "company": " Seqirus",
  "treatment": " Influenza Prophylaxis",
  "drug_description": "Afluria Quadrivalent is an inactivated influenza virus vaccine indicated for active immunization against influenza disease in persons 6 months of age and older.",
  "previous application": "Seqirus Receives FDA Approval of Afluria Quadrivalent (Influenza Vaccine) for People Five Years of Age and Older in the U.S. Afluria Quadrivalent (influenza virus vaccine, inactivated) FDA Approval History"
},{
  "title": "Cuvitru (immune globulin subcutaneous (human))  Injection ",
  "date_of_approval": "September 13, 2016",
  "company": " Shire plc",
  "treatment": " Primary Immunodeficiency Syndrome",
  "drug_description": "Cuvitru (immune globulin subcutaneous (human)) is indicated as replacement therapy in the treatment of primary humoral immunodeficiency (PI).",
  "previous application": "Shire Announces FDA Approval of Cuvitru [immune globulin subcutaneous (human)] for Primary Immunodeficiency Cuvitru (immune globulin subcutaneous (human)) FDA Approval History"
},{
  "title": "Yosprala (aspirin and omeprazole)  Delayed-Release Tablets ",
  "date_of_approval": "September 14, 2016",
  "company": " Aralez Pharmaceuticals Inc. ",
  "treatment": " Ischemic Stroke -- Prophylaxis, Gastric Ulcer Prophylaxis",
  "drug_description": "Yosprala (aspirin and omeprazole) is a platelet aggregation inhibitor and proton pump inhibitor combination indicated for patients who require aspirin for secondary prevention of cardiovascular (CV) and cerebrovascular events and who are at risk of developing aspirin associated gastric ulcers.",
  "previous application": "FDA Approves Yosprala (aspirin and omeprazole) for Secondary Prevention of Cardiovascular Disease in Patients at Risk for Aspirin-Associated Gastric Ulcers Yosprala (aspirin and omeprazole) FDA Approval History"
},{
  "title": "Exondys 51 (eteplirsen)  Injection ",
  "date_of_approval": "September 19, 2016",
  "company": " Sarepta Therapeutics",
  "treatment": " Duchenne Muscular Dystrophy",
  "drug_description": "Exondys 51 (eteplirsen) is an antisense oligonucleotide indicated for the treatment of\r Duchenne muscular dystrophy (DMD) in patients who have a confirmed\r mutation of the DMD gene that is amenable to exon 51 skipping.",
  "previous application": "FDA Approves Exondys 51 (eteplirsen) for Duchenne Muscular Dystrophy Exondys 51 (eteplirsen) FDA Approval History"
},{
  "title": "Kyleena (levonorgestrel)  Releasing Intrauterine System ",
  "date_of_approval": "September 16, 2016",
  "company": " Bayer",
  "treatment": " Contraception",
  "drug_description": "Kyleena (levonorgestrel-releasing intrauterine system) is a low-dose progestin-containing intrauterine system (IUS) indicated for the prevention of pregnancy for up to  five years.",
  "previous application": "FDA Approves Bayer's Kyleena (Levonorgestrel-Releasing Intrauterine System) for Prevention of Pregnancy for up to Five Years Kyleena (levonorgestrel) FDA Approval History"
},{
  "title": "Lomaira (phentermine hydrochloride)  Tablets ",
  "date_of_approval": "September 13, 2016",
  "company": " KVK Tech, Inc.",
  "treatment": " Weight Loss, Obesity",
  "drug_description": "Lomaira (phentermine hydrochloride) is a sympathomimetic amine anorectic used short-term for weight reduction in overweight or obese adults.",
  "previous application": "KVK Tech Announces FDA-Approval of Lomaira (phentermine hydrochloride USP) for Weight Reduction Lomaira (phentermine hydrochloride) FDA Approval History"
},{
  "title": "Amjevita (adalimumab-atto)  Injection  - formerly ABP 501",
  "date_of_approval": "September 23, 2016",
  "company": " Amgen Inc.",
  "treatment": " Plaque Psoriasis, Rheumatoid Arthritis, Ankylosing Spondylitis, Ulcerative Colitis, Crohn's Disease -- Maintenance, Psoriatic Arthritis, Juvenile Idiopathic Arthritis",
  "drug_description": "Amjevita (adalimumab-atto) an anti-TNF-\u03b1 monoclonal antibody biosimilar to Humira, approved for the treatment of various inflammatory diseases including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn\u2019s disease, ulcerative colitis, and plaque psoriasis.",
  "previous application": "FDA Approves Amjevita (adalimumab-atto), a Biosimilar to Humira Amjevita (adalimumab-atto) FDA Approval History"
},{
  "title": "Flublok Quadrivalent (influenza virus vaccine, inactivated)  Injection ",
  "date_of_approval": "October 7, 2016",
  "company": " Protein Sciences Corp.",
  "treatment": " Influenza Prophylaxis",
  "drug_description": "FluBlok Quadrivalent is an influenza virus vaccine indicated for active immunization against seasonal influenza in adults 18 years of age and older .",
  "previous application": "FDA Approves Flublok - New Seasonal Influenza Vaccine Made Using Novel Technology Flublok Quadrivalent (influenza virus vaccine, inactivated) FDA Approval History"
},{
  "title": "Carnexiv (carbamazepine)  Injection ",
  "date_of_approval": "October 7, 2016",
  "company": " Lundbeck Inc.",
  "treatment": " Seizures",
  "drug_description": "",
  "previous application": "FDA Approves Carnexiv (carbamazepine) injection as Intravenous Short-Term Replacement Therapy for Certain Seizure Types Carnexiv (carbamazepine) FDA Approval History"
},{
  "title": "Lartruvo (olaratumab)  Injection ",
  "date_of_approval": "October 19, 2016",
  "company": " Eli Lilly and Company",
  "treatment": " Soft Tissue Sarcoma",
  "drug_description": "Lartruvo (olaratumab) is a platelet-derived growth factor receptor alpha (PDGFR-\u03b1) blocking antibody indicated in combination with doxorubicin for the treatment of patients with advanced soft tissue sarcoma (STS).",
  "previous application": "FDA Grants Accelerated Approval to Lartruvo (olaratumab) for Advanced Soft Tissue Sarcoma Lartruvo (olaratumab) FDA Approval History"
},{
  "title": "Zinplava (bezlotoxumab)  Injection ",
  "date_of_approval": "October 21, 2016",
  "company": " Merck &amp; Co., Inc.",
  "treatment": " Prevention of <i>Clostridium Difficile</i> Infection Recurrence",
  "drug_description": "Zinplava (bezlotoxumab) is a selective, fully-human, monoclonal antibody that binds to Clostridium difficile toxin B, indicated to reduce recurrence of Clostridium difficile infection (CDI) in patients 18 years of age or older.",
  "previous application": "FDA Approves Merck\u2019s Zinplava (bezlotoxumab) to Reduce Recurrence of Clostridium difficile Infection Zinplava (bezlotoxumab) FDA Approval History"
},{
  "title": "Vemlidy (tenofovir alafenamide)  Tablets ",
  "date_of_approval": "November 10, 2016",
  "company": " Gilead Sciences, Inc.",
  "treatment": " Chronic Hepatitis B",
  "drug_description": "Vemlidy (tenofovir alafenamide) is a hepatitis B virus (HBV) nucleoside analog reverse transcriptase inhibitor indicated for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease.",
  "previous application": "FDA Approves Gilead\u2019s Vemlidy (tenofovir alafenamide) for the Treatment of Chronic Hepatitis B Virus Infection Vemlidy (tenofovir alafenamide) FDA Approval History"
},{
  "title": "Intrarosa (prasterone)  Vaginal Inserts ",
  "date_of_approval": "November 17, 2016",
  "company": " Endoceutics Inc.",
  "treatment": " Dyspareunia",
  "drug_description": "Intrarosa (prasterone) is a once-daily, vaginally administered steroid indicated to treat postmenopausal women experiencing moderate to severe pain during sexual intercourse (dyspareunia) as a symptom of vulvar and vaginal atrophy.",
  "previous application": "FDA Approves Intrarosa (prasterone) for Postmenopausal Women Experiencing Dyspareunia Intrarosa (prasterone) FDA Approval History"
},{
  "title": "Xultophy (insulin degludec and liraglutide)  Injection  - formerly IDegLira",
  "date_of_approval": "November 21, 2016",
  "company": " Novo Nordisk",
  "treatment": " Diabetes Type 2",
  "drug_description": "Xultophy 100/3.6 (insulin degludec and liraglutide) is a fixed-ratio combination of the long-acting basal insulin analog, insulin degludec (Tresiba), and the a glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide (Victoza), indicated as an adjunct to diet and exercise to improve  glycemic control in adults with type 2 diabetes.",
  "previous application": "Novo Nordisk Receives FDA Approval for Xultophy 100/3.6 (insulin degludec and liraglutide injection) for Type 2 Diabetes Xultophy (insulin degludec and liraglutide) FDA Approval History"
},{
  "title": "Soliqua 100/33 (insulin glargine and lixisenatide)  Injection ",
  "date_of_approval": "November 21, 2016",
  "company": " Sanofi",
  "treatment": " Diabetes Type 2",
  "drug_description": "Soliqua 100/33 (insulin glargine and lixisenatide) is fixed-ratio combination of the long-acting human insulin analog insulin glargine (Lantus) and the glucagon-like peptide-1 (GLP-1) receptor agonist lixisenatide (Adlyxin), indicated as an adjunct to diet and exercise to improve  glycemic control in adults with type 2 diabetes.",
  "previous application": "Sanofi Receives FDA Approval of Soliqua 100/33 (insulin glargine and lixisenatide) for the Treatment of Adults with Type 2 Diabetes Soliqua 100/33 (insulin glargine and lixisenatide) FDA Approval History"
},{
  "title": "Eucrisa (crisaborole)  Topical Ointment ",
  "date_of_approval": "December 14, 2016",
  "company": " Pfizer, Inc.",
  "treatment": " Atopic Dermatitis",
  "drug_description": "Eucrisa (crisaborole) is a phosphodiesterase 4 inhibitor indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.",
  "previous application": "FDA Approves Eucrisa (crisaborole) for Eczema Eucrisa (crisaborole) FDA Approval History"
},{
  "title": "Rubraca (rucaparib)  Tablets ",
  "date_of_approval": "December 19, 2016",
  "company": " Clovis Oncology, Inc.",
  "treatment": " Ovarian Cancer, Prostate Cancer",
  "drug_description": "Rubraca (rucaparib) is a poly (ADP-ribose) polymerase (PARP) inhibitor for the treatment of ovarian cancer and prostate cancer.",
  "previous application": "FDA Grants Accelerated Approval to Rubraca (rucaparib) for Advanced Ovarian Cancer Rubraca (rucaparib) FDA Approval History"
},{
  "title": "Spinraza (nusinersen)  Injection ",
  "date_of_approval": "December 23, 2016",
  "company": " Biogen",
  "treatment": " Spinal Muscular Atrophy",
  "drug_description": "Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense\r oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in  pediatric and adult patients.",
  "previous application": "FDA Approves Spinraza (nusinersen) for Spinal Muscular Atrophy Spinraza (nusinersen) FDA Approval History"
},{
  "title": "Arymo ER (morphine sulfate)  Extended-Release Tablets ",
  "date_of_approval": "January 9, 2017",
  "company": " Egalet Corporation",
  "treatment": " Pain",
  "drug_description": "",
  "previous application": "FDA Approves Arymo ER (morphine sulfate) Abuse-Deterrent Formulation for the Treatment of Chronic Pain Arymo ER (morphine sulfate) FDA Approval History"
},{
  "title": "Vantrela ER (hydrocodone bitartrate)  Extended-Release Tablets ",
  "date_of_approval": "January 17, 2017",
  "company": " Teva Pharmaceutical Industries Ltd.",
  "treatment": " Pain",
  "drug_description": "",
  "previous application": "Teva Receives FDA Approval for Vantrela ER (hydrocodone bitartrate) Extended-Release Tablets Formulated with Proprietary Abuse Deterrence Technology Vantrela ER (hydrocodone bitartrate) FDA Approval History"
},{
  "title": "Trulance (plecanatide)  Tablets ",
  "date_of_approval": "January 19, 2017",
  "company": " Synergy Pharmaceuticals Inc. ",
  "treatment": " Constipation -- Chronic, Irritable Bowel Syndrome",
  "drug_description": "Trulance (plecanatide) is a guanylate cyclase-C agonist for the treatment of chronic idiopathic constipation, and irritable bowel syndrome with constipation (IBS-C).",
  "previous application": "FDA Approves Trulance (plecanatide) for Chronic Idiopathic Constipation Trulance (plecanatide) FDA Approval History"
},{
  "title": "Rhofade (oxymetazoline hydrochloride)  Cream ",
  "date_of_approval": "January 18, 2017",
  "company": " Allergan plc",
  "treatment": " Acne Rosacea",
  "drug_description": "Rhofade (oxymetazoline hydrochloride) is a topical alpha1A adrenoceptor agonist vasoconstrictor for the treatment of persistent facial erythema associated with rosacea in adults.",
  "previous application": "Allergan Announces FDA Approval of Rhofade (oxymetazoline hydrochloride) Cream for Facial Erythema Associated with Rosacea Rhofade (oxymetazoline hydrochloride) FDA Approval History"
},{
  "title": "AirDuo RespiClick (fluticasone propionate and salmeterol)  Inhalation Powder ",
  "date_of_approval": "January 27, 2017",
  "company": " Teva Pharmaceutical Industries Ltd.",
  "treatment": " Asthma -- Maintenance",
  "drug_description": "AirDuo RespiClick (fluticasone propionate and salmeterol) is a corticosteroid and long-acting beta2-adrenergic agonist (LABA) combination in a breath-activated, multi-dose dry powder inhaler formulation for the treatment of asthma.",
  "previous application": "Teva Announces FDA Approval of AirDuo RespiClick (fluticasone propionate and salmeterol) for Maintenance Treatment of Asthma AirDuo RespiClick (fluticasone propionate and salmeterol) FDA Approval History"
},{
  "title": "ArmonAir RespiClick (fluticasone propionate)  Inhalation Powder ",
  "date_of_approval": "January 27, 2017",
  "company": " Teva Pharmaceutical Industries Ltd.",
  "treatment": " Asthma -- Maintenance",
  "drug_description": "ArmonAir RespiClick (fluticasone propionate) is an inhaled corticosteroid in a breath-activated, multi-dose dry powder inhaler formulation for the treatment of asthma.",
  "previous application": "Teva Announces FDA Approval of ArmonAir RespiClick (fluticasone propionate) for Maintenance Treatment of Asthma ArmonAir RespiClick (fluticasone propionate) FDA Approval History"
},{
  "title": "Parsabiv (etelcalcetide)  Injection ",
  "date_of_approval": "February 7, 2017",
  "company": " Amgen Inc.",
  "treatment": " Secondary Hyperparathyroidism",
  "drug_description": "Parsabiv (etelcalcetide) is a calcium-sensing receptor agonist indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.",
  "previous application": "FDA Approves Amgen's Parsabiv (etelcalcetide) for Secondary Hyperparathyroidism in Adult Patients on Hemodialysis Parsabiv (etelcalcetide) FDA Approval History"
},{
  "title": "Emflaza (deflazacort)  Tablets and Oral Suspension ",
  "date_of_approval": "February 9, 2017",
  "company": " PTC Therapeutics, Inc.",
  "treatment": " Duchenne Muscular Dystrophy",
  "drug_description": "Emflaza (deflazacort) is a glucocorticoid indicated for the treatment of Duchenne\r muscular dystrophy (DMD) in patients 2 years of age and older.",
  "previous application": "FDA Approves Emflaza (deflazacort) to treat Duchenne Muscular Dystrophy Emflaza (deflazacort) FDA Approval History"
},{
  "title": "Siliq (brodalumab)  Injection ",
  "date_of_approval": "February 15, 2017",
  "company": " Valeant Pharmaceuticals International, Inc.",
  "treatment": " Plaque Psoriasis",
  "drug_description": "Siliq (brodalumab) is a human anti-interleukin-17-receptor monoclonal antibody for the treatment of plaque psoriasis.",
  "previous application": "FDA Approves Siliq (brodalumab) for Plaque Psoriasis Siliq (brodalumab) FDA Approval History"
},{
  "title": "Qtern (dapagliflozin and saxagliptin)  Tablets ",
  "date_of_approval": "February 27, 2017",
  "company": " AstraZeneca",
  "treatment": " Diabetes Type 2",
  "drug_description": "Qtern (dapagliflozin and saxagliptin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor and dipeptidyl peptidase-4 (DPP4) inhibitor fixed-dose combination for the treatment of adult patients with type 2 diabetes.",
  "previous application": "FDA Approves Once-Daily Qtern (dapagliflozin and saxagliptin) Tablets for Adults with Type-2 Diabetes Qtern (dapagliflozin and saxagliptin) FDA Approval History"
},{
  "title": "Xermelo (telotristat ethyl)  Tablets ",
  "date_of_approval": "February 28, 2017",
  "company": " Lexicon Pharmaceuticals, Inc.",
  "treatment": " Carcinoid Syndrome Diarrhea",
  "drug_description": "Xermelo (telotristat ethyl) is an oral tryptophan hydroxylase inhibitor indicated for use in combination with somatostatin analog (SSA) therapy for the treatment of carcinoid syndrome diarrhea in patients with metastatic neuroendocrine tumors.",
  "previous application": "FDA Approves Xermelo (telotristat ethyl) as First and Only Oral Treatment for Carcinoid Syndrome Diarrhea in Cancer Patients with Metastatic Neuroendocrine Tumors Xermelo (telotristat ethyl) FDA Approval History"
},{
  "title": "Odactra (house dust mite allergen extract)  Sublingual Tablets ",
  "date_of_approval": "March 1, 2017",
  "company": " ALK-Abell\u00f3 A/S",
  "treatment": " House Dust Mite Allergies",
  "drug_description": "Odactra (house dust mite allergen extract) is a sublingual allergy immunotherapy (SLIT) tablet indicated as immunotherapy for house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis.",
  "previous application": "FDA Approves Odactra for House Dust Mite Allergies Odactra (house dust mite allergen extract) FDA Approval History"
},{
  "title": "Noctiva (desmopressin acetate)  Nasal Spray ",
  "date_of_approval": "March 3, 2017",
  "company": " Serenity Pharmaceuticals, LLC",
  "treatment": " Nocturia",
  "drug_description": "Noctiva (desmopressin acetate) is vasopressin analog nasal spray indicated for the treatment of nocturia due to nocturnal polyuria.",
  "previous application": "FDA Approves Noctiva (desmopressin acetate) Nasal Spray for Nocturia in Adults Noctiva (desmopressin acetate) FDA Approval History"
},{
  "title": "Kisqali (ribociclib)  Tablets  - formerly LEE011",
  "date_of_approval": "March 13, 2017",
  "company": " Novartis Pharmaceuticals Corporation",
  "treatment": " Breast Cancer",
  "drug_description": "Kisqali (ribociclib) is an inhibitor of cyclin-dependent kinase (CDK) 4 and 6 indicated for the combination treatment of pre/perimenopausal or postmenopausal women with HR+/HER2- metastatic breast cancer.",
  "previous application": "FDA Approves Kisqali (ribociclib) for HR+/HER2- Metastatic Breast Cancer Kisqali (ribociclib) FDA Approval History"
},{
  "title": "Xadago (safinamide)  Tablets ",
  "date_of_approval": "March 21, 2017",
  "company": " Newron Pharmaceuticals S.p.A.",
  "treatment": " Parkinson's Disease",
  "drug_description": "Xadago (safinamide) is a monoamine oxidase type B (MAO-B) inhibitor indicated as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson\u2019s\r disease (PD) experiencing \u201coff\u201d episodes.",
  "previous application": "FDA Approves Xadago (safinamide) as an Add-On Treatment for Patients with Parkinson\u2019s Disease Xadago (safinamide) FDA Approval History"
},{
  "title": "Bavencio (avelumab)  Injection ",
  "date_of_approval": "March 23, 2017",
  "company": " EMD Serono Inc.",
  "treatment": " Merkel Cell Carcinoma, Urothelial Carcinoma, Renal Cell Carcinoma",
  "drug_description": "Bavencio (avelumab) is a programmed death ligand-1 (PD-L1) blocking antibody\r indicated for the treatment of patients with metastatic Merkel cell carcinoma (MCC); patients with advanced or metastatic urothelial carcinoma; and in combination with axitinib for patients with advanced renal cell carcinoma.",
  "previous application": "FDA Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma Bavencio (avelumab) FDA Approval History"
},{
  "title": "Symproic (naldemedine)  Tablets ",
  "date_of_approval": "March 23, 2017",
  "company": " Shionogi Inc.",
  "treatment": " Opioid-Induced Constipation",
  "drug_description": "Symproic (naldemedine) is a peripherally-acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation.",
  "previous application": "FDA Approves Symproic (naldemedine) for the Treatment of Opioid-Induced Constipation Symproic (naldemedine) FDA Approval History"
},{
  "title": "Zejula (niraparib)  Capsules ",
  "date_of_approval": "March 27, 2017",
  "company": " GSK",
  "treatment": " Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer",
  "drug_description": "Zejula (niraparib) is an oral, poly ADP-ribose polymerase (PARP) inhibitor for the treatment of patients with ovarian, fallopian tube, or primary peritoneal cancer.",
  "previous application": "Tesaro Announces FDA Approval of Zejula (niraparib) for Women with Recurrent Ovarian Cancer Zejula (niraparib) FDA Approval History"
},{
  "title": "Dupixent (dupilumab)  Injection ",
  "date_of_approval": "March 28, 2017",
  "company": " Sanofi and Regeneron Pharmaceuticals, Inc.",
  "treatment": "Atopic Dermatitis,Asthma,Chronic Rhinosinusitis with Nasal Polyposis",
  "drug_description": "Dupixent (dupilumab) is an interleukin-4 receptor alpha antagonist indicated:",
  "previous application": "FDA Approves Dupixent (dupilumab) for Eczema Dupixent (dupilumab) FDA Approval History"
},{
  "title": "Ocrevus (ocrelizumab)  Injection ",
  "date_of_approval": "March 28, 2017",
  "company": " Genentech, Inc.",
  "treatment": " Multiple Sclerosis",
  "drug_description": "Ocrevus (ocrelizumab) is a humanized monoclonal antibody designed to selectively target CD20-positive B cells, a specific type of immune cell thought to be a key contributor to myelin and axonal nerve cell damage. Ocrevus is indicated as a treatment for both relapsing (RMS) and primary progressive (PPMS) forms of multiple sclerosis.",
  "previous application": "FDA Approves Ocrevus (ocrelizumab) for Relapsing and Primary Progressive Forms of Multiple Sclerosis Ocrevus (ocrelizumab) FDA Approval History"
},{
  "title": "Austedo (deutetrabenazine)  Tablets  - formerly SD-809",
  "date_of_approval": "April 3, 2017",
  "company": " Teva Pharmaceutical Industries Ltd.",
  "treatment": " Huntington Disease, Tardive Dyskinesia",
  "drug_description": "Austedo (deutetrabenazine) is a vesicular monoamine transporter 2 (VMAT2) inhibitor\r indicated for the treatment of chorea associated with Huntington\u2019s disease and the treatment of tardive dyskinesia.",
  "previous application": "Teva Announces FDA Approval of Austedo (deutetrabenazine) for the Treatment of Chorea Associated with Huntington\u2019s Disease Austedo (deutetrabenazine) FDA Approval History"
},{
  "title": "Ingrezza (valbenazine)  Capsules ",
  "date_of_approval": "April 11, 2017",
  "company": " Neurocrine Biosciences, Inc.",
  "treatment": " Tardive Dyskinesia",
  "drug_description": "Ingrezza (valbenazine) is a novel, highly-selective VMAT2 inhibitor for the treatment of tardive dyskinesia.",
  "previous application": "Neurocrine Announces FDA Approval of Ingrezza (valbenazine) as the First and Only Approved Treatment for Adults with Tardive Dyskinesia (TD) Ingrezza (valbenazine) FDA Approval History"
},{
  "title": "Renflexis (infliximab-abda)  Injection ",
  "date_of_approval": "April 21, 2017",
  "company": " Samsung Bioepis Co., Ltd.",
  "treatment": " Crohn's Disease -- Maintenance, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Plaque Psoriasis",
  "drug_description": "Renflexis (infliximab-abda) is a tumor necrosis factor (TNF) blocker biosimilar to Remicade (infliximab) indicated for the treatment of Crohn\u2019s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis.",
  "previous application": "FDA Approves Renflexis (infliximab-abda), a Biosimilar to Remicade Renflexis (infliximab-abda) FDA Approval History"
},{
  "title": "RoxyBond (oxycodone hydrochloride)  Tablets ",
  "date_of_approval": "April 20, 2017",
  "company": " Inspirion Delivery Sciences, LLC",
  "treatment": " Pain",
  "drug_description": "",
  "previous application": "Inspirion Delivery Sciences Receives FDA Approval for RoxyBond (oxycodone hydrochloride) Immediate Release Tablets with Abuse-Deterrent Label Claims RoxyBond (oxycodone hydrochloride) FDA Approval History"
},{
  "title": "Xatmep (methotrexate)  Oral Solution ",
  "date_of_approval": "April 25, 2017",
  "company": " Silvergate Pharmaceuticals, Inc.",
  "treatment": " Acute Lymphoblastic Leukemia, Juvenile Idiopathic Arthritis",
  "drug_description": "Xatmep (methotrexate) is a folate analog metabolic inhibitor in an oral solution formulation indicated for the treatment of pediatric patients with acute lymphoblastic leukemia (ALL) and for the management of pediatric patients with active polyarticular juvenile idiopathic arthritis.",
  "previous application": "FDA Approves Xatmep (methotrexate) Oral Solution Xatmep (methotrexate) FDA Approval History"
},{
  "title": "Brineura (cerliponase alfa)  Injection ",
  "date_of_approval": "April 27, 2017",
  "company": " BioMarin Pharmaceutical Inc.",
  "treatment": " CLN2 Disease",
  "drug_description": "Brineura (cerliponase alfa) is an enzyme replacement therapy for the restoration of tripeptidyl peptidase-1 (TPP1) enzyme activity in patients with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), or TPP1 deficiency, a form of Batten disease.",
  "previous application": "FDA Approves Brineura (cerliponase alfa) for CLN2 Disease, a Form of Batten Disease Brineura (cerliponase alfa) FDA Approval History"
},{
  "title": "Rydapt (midostaurin)  Capsules  - formerly PKC412",
  "date_of_approval": "April 28, 2017",
  "company": " Novartis",
  "treatment": " Acute Myeloid Leukemia, Mastocytosis",
  "drug_description": "Rydapt (midostaurin) is an oral, multi-targeted kinase inhibitor for the treatment of acute myeloid leukemia (AML) in newly-diagnosed adults with an FMS-like tyrosine kinase-3 (FLT3) mutation, and for the treatment of advanced systemic mastocytosis (SM), which includes aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN) and mast cell leukemia.",
  "previous application": "FDA Approves Rydapt (midostaurin) for FLT3-Mutated Acute Myeloid Leukemia and Systemic Mastocytosis Rydapt (midostaurin) FDA Approval History"
},{
  "title": "Tymlos (abaloparatide)  Injection ",
  "date_of_approval": "April 28, 2017",
  "company": " Radius Health, Inc.",
  "treatment": " Osteoporosis",
  "drug_description": "Tymlos (abaloparatide) is a synthetic peptide analog of hPTHrP (human parathyroid hormone-related protein) for the treatment of postmenopausal women with osteoporosis.",
  "previous application": "FDA Approves Tymlos (abaloparatide) for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture Tymlos (abaloparatide) FDA Approval History"
},{
  "title": "Alunbrig (brigatinib)  Tablets ",
  "date_of_approval": "April 28, 2017",
  "company": " Takeda Pharmaceutical Company Limited",
  "treatment": " Non-Small Cell Lung Cancer",
  "drug_description": "Alunbrig (brigatinib) is an anaplastic lymphoma kinase (ALK) inhibitor for the treatment of patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.",
  "previous application": "Takeda Announces FDA Accelerated Approval of Alunbrig (brigatinib) Alunbrig (brigatinib) FDA Approval History"
},{
  "title": "Imfinzi (durvalumab)  Injection ",
  "date_of_approval": "May 1, 2017",
  "company": " AstraZeneca",
  "treatment": " Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small Cell Lung Cancer",
  "drug_description": "Imfinzi (durvalumab) is a programmed death-ligand 1 (PD-L1) blocking antibody indicated:",
  "previous application": "AstraZeneca\u2019s Imfinzi (durvalumab) Receives FDA Accelerated Approval for Previously Treated Patients with Advanced Bladder Cancer Imfinzi (durvalumab) FDA Approval History"
},{
  "title": "Radicava (edaravone)  Injection ",
  "date_of_approval": "May 5, 2017",
  "company": " Mitsubishi Tanabe Pharma",
  "treatment": " Amyotrophic Lateral Sclerosis",
  "drug_description": "Radicava (edaravone) is a free radical scavenger that relieves the effects of oxidative stress, a likely factor in the onset and progression of amyotrophic lateral sclerosis.",
  "previous application": "FDA Approves Radicava (edaravone) to Treat Amyotrophic Lateral Sclerosis (ALS) Radicava (edaravone) FDA Approval History"
},{
  "title": "Kevzara (sarilumab)  Injection ",
  "date_of_approval": "May 22, 2017",
  "company": " Sanofi and Regeneron Pharmaceuticals, Inc.",
  "treatment": " Rheumatoid Arthritis",
  "drug_description": "Kevzara (sarilumab) is an interleukin-6 (IL-6) receptor antagonist indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs).",
  "previous application": "Sanofi and Regeneron Announce FDA Approval of Kevzara (sarilumab) for Rheumatoid Arthritis Kevzara (sarilumab) FDA Approval History"
},{
  "title": "Rebinyn (coagulation factor IX (recombinant), glycopegylated)  Injection ",
  "date_of_approval": "May 31, 2017",
  "company": " Novo Nordisk",
  "treatment": " Hemophilia B",
  "drug_description": "Rebinyn (coagulation factor IX (recombinant), glycopegylated is an extended-half-life recombinant DNA-derived coagulation factor IX concentrate for the treatment and control of bleeding episodes in patients with hemophilia B.",
  "previous application": "FDA Approves Rebinyn (Coagulation Factor IX (Recombinant), GlycoPEGylated) for Patients with Hemophilia B Rebinyn (coagulation factor IX (recombinant), glycopegylated) FDA Approval History"
},{
  "title": "Zerviate (cetirizine hydrochloride)  Ophthalmic Solution ",
  "date_of_approval": "May 30, 2017",
  "company": " Nicox S.A.",
  "treatment": " Allergic Conjunctivitis",
  "drug_description": "Zerviate (cetirizine hydrochloride) is a histamine-1 (H1) receptor antagonist ophthalmic formulation for the treatment of ocular itching associated with allergic conjunctivitis.",
  "previous application": "Nicox Receives FDA Approval of Zerviate (cetirizine ophthalmic solution) 0.24% Zerviate (cetirizine hydrochloride) FDA Approval History"
},{
  "title": "Gleolan (aminolevulinic acid hydrochloride)  Oral Solution ",
  "date_of_approval": "June 6, 2017",
  "company": " NX Development Corp.",
  "treatment": " Optical Imaging During Glioma Surgery",
  "drug_description": "Gleolan (aminolevulinic acid hydrochloride) is an optical imaging agent indicated for use in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.",
  "previous application": "FDA Approves Gleolan (aminolevulinic acid hydrochloride) as an Optical Imaging Agent in Patients with Gliomas Gleolan (aminolevulinic acid hydrochloride) FDA Approval History"
},{
  "title": "Symjepi (epinephrine)  Injection ",
  "date_of_approval": "June 15, 2017",
  "company": " Adamis Pharmaceuticals Corporation",
  "treatment": " Allergic Reaction",
  "drug_description": "Symjepi (epinephrine) is a non-selective alpha and betaadrenergic\r receptor agonist in a single-dose, pre-filled syringe for use the emergency\r treatment of allergic reactions (Type I) including anaphylaxis.",
  "previous application": "Adamis Pharmaceuticals Receives FDA Approval for Symjepi (epinephrine) Pre-Filled Syringe Symjepi (epinephrine) FDA Approval History"
},{
  "title": "Baxdela (delafloxacin)  Tablets and Injection ",
  "date_of_approval": "June 19, 2017",
  "company": " Melinta Therapeutics",
  "treatment": " Skin and Structure Infection, Pneumonia",
  "drug_description": "Baxdela (delafloxacin) is a fluoroquinolone antibacterial indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP) caused by designated susceptible bacteria.",
  "previous application": "Melinta Therapeutics Announces FDA Approval of Baxdela (delafloxacin) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Baxdela (delafloxacin) FDA Approval History"
},{
  "title": "Cotempla XR-ODT (methylphenidate)  Extended-Release Orally Disintegrating Tablets ",
  "date_of_approval": "June 19, 2017",
  "company": " Neos Therapeutics, Inc.",
  "treatment": " Attention-Deficit/Hyperactivity Disorder (ADHD)",
  "drug_description": "Cotempla XR-ODT (methylphenidate) is a once-daily, extended-release, orally disintegrating tablet formulation of the central nervous system (CNS) stimulant methylphenidate indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age.",
  "previous application": "Neos Therapeutics Announces FDA Approval of Cotempla XR-ODT (methylphenidate) Extended-Release Orally Disintegrating Tablets for the Treatment of ADHD in Patients 6 to 17 Years Old Cotempla XR-ODT (methylphenidate) FDA Approval History"
},{
  "title": "Mydayis (amphetamine mixed salts) ",
  "date_of_approval": "June 20, 2017",
  "company": " Shire plc",
  "treatment": " Attention Deficit Hyperactivity Disorder (ADHD)",
  "drug_description": "Mydayis (amphetamine mixed salts) is a central nervous system (CNS) stimulant indicated\r for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 13 years and older.",
  "previous application": "FDA Approves Mydayis (mixed salts of a single-entity amphetamine product) \u2013 A New Once-Daily Option for ADHD Mydayis (amphetamine mixed salts) FDA Approval History"
},{
  "title": "Rituxan Hycela (rituximab and hyaluronidase human)  Injection ",
  "date_of_approval": "June 22, 2017",
  "company": " Genentech, Inc.",
  "treatment": " Follicular Lymphoma; Diffuse Large B-Cell Lymphoma; Chronic Lymphocytic Leukemia",
  "drug_description": "Rituxan Hycela (rituximab and hyaluronidase human) is a subcutaneous monoclonal antibody and hyaluronidase human formulation for the treatment of adult patients with follicular lymphoma, diffuse large B-cell lymphoma (DLBCL), and chronic lymphocytic leukemia (CLL).",
  "previous application": "FDA Approves Rituxan Hycela (rituximab and hyaluronidase human) for Subcutaneous Injection in Certain Blood Cancers Rituxan Hycela (rituximab and hyaluronidase human) FDA Approval History"
},{
  "title": "Haegarda (C1 esterase inhibitor (human))  Subcutaneous Injection  - formerly CSL830",
  "date_of_approval": "June 22, 2017",
  "company": " CSL Behring",
  "treatment": " Hereditary Angioedema",
  "drug_description": "Haegarda (C1 esterase inhibitor (human)) is a low-volume subcutaneous (SC) C1-esterase inhibitor (C1-INH) replacement therapy to prevent Hereditary Angioedema (HAE) attacks.",
  "previous application": "FDA Approves Haegarda - First Subcutaneous C1 Esterase Inhibitor for Hereditary Angioedema Haegarda (C1 esterase inhibitor (human)) FDA Approval History"
},{
  "title": "Bevyxxa (betrixaban)  Capsules ",
  "date_of_approval": "June 23, 2017",
  "company": " Portola Pharmaceuticals Inc.",
  "treatment": " Prevention of Venous Thromboembolism",
  "drug_description": "Bevyxxa (betrixaban) is an oral, once-daily Factor Xa inhibitor anticoagulant for the extended-duration prophylaxis of venous thromboembolism (VTE) in at-risk adult patients hospitalized for an acute medical illness.",
  "previous application": "FDA Approves Bevyxxa (betrixaban) for Hospital and Extended Duration Prevention of Venous Thromboembolism (VTE) in Acutely Ill Medical Patients Bevyxxa (betrixaban) FDA Approval History"
},{
  "title": "Triptodur (triptorelin)  Injection ",
  "date_of_approval": "June 29, 2017",
  "company": " Arbor Pharmaceuticals, LLC",
  "treatment": " Precocious Puberty",
  "drug_description": "Triptodur (triptorelin) is a gonadotropin releasing hormone (GnRH) agonist\r indicated for the treatment of pediatric patients with\r central precocious puberty.",
  "previous application": "Arbor Pharmaceuticals, LLC Announces FDA Approval for Triptodur (triptorelin) Triptodur (triptorelin) FDA Approval History"
},{
  "title": "Endari (L-glutamine)  Oral Powder ",
  "date_of_approval": "July 7, 2017",
  "company": " Emmaus Life Sciences Inc.",
  "treatment": " Sickle Cell Anemia",
  "drug_description": "Endari (L-glutamine) is orally-administered pharmaceutical grade L-glutamine (PGLG), an amino acid formulation to relieve pain, swelling and other complications of sickle cell anemia.",
  "previous application": "FDA Approves Endari (L-glutamine oral powder) for Sickle Cell Disease Endari (L-glutamine) FDA Approval History"
},{
  "title": "Tremfya (guselkumab)  Injection ",
  "date_of_approval": "July 13, 2017",
  "company": " Janssen Biotech, Inc.",
  "treatment": " Plaque Psoriasis, Psoriatic Arthritis",
  "drug_description": "Tremfya (guselkumab) is an interleukin-23 blocker indicated for the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis in adults.",
  "previous application": "Janssen Announces FDA Approval of Tremfya (guselkumab) for the Treatment of Moderate to Severe Plaque Psoriasis Tremfya (guselkumab) FDA Approval History"
},{
  "title": "Nerlynx (neratinib)  Tablets ",
  "date_of_approval": "July 17, 2017",
  "company": " Puma Biotechnology, Inc.",
  "treatment": " Breast Cancer",
  "drug_description": "Nerlynx (neratinib) is a tyrosine kinase inhibitor indicated:",
  "previous application": "FDA Approves Nerlynx (neratinib) for Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer Nerlynx (neratinib) FDA Approval History"
},{
  "title": "Vosevi (sofosbuvir, velpatasvir and voxilaprevir)  Tablets ",
  "date_of_approval": "July 18, 2017",
  "company": " Gilead Sciences, Inc.",
  "treatment": " Chronic Hepatitis C",
  "drug_description": "Vosevi (sofosbuvir, velpatasvir and voxilaprevir or SOF/VEL/VOX) is a fixed-dose combination of a nucleotide analog NS5B polymerase inhibitor (SOF), a pangenotypic NS5A inhibitor (VEL), and a pangenotypic NS3/4A protease inhibitor (VOX) for the treatment of genotype 1-6 chronic hepatitis C virus (HCV) infection.",
  "previous application": "FDA Approves Vosevi (sofosbuvir/velpatasvir/voxilaprevir) for Re-Treatment of Adults with Chronic Hepatitis C Virus Vosevi (sofosbuvir, velpatasvir and voxilaprevir) FDA Approval History"
},{
  "title": "Idhifa (enasidenib)  Tablets ",
  "date_of_approval": "August 1, 2017",
  "company": " Celgene Corporation",
  "treatment": " Acute Myeloid Leukemia",
  "drug_description": "Idhifa (enasidenib) is a first-in-class, oral, targeted inhibitor of mutant isocitrate dehydrogenase 2 (IDH2) for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) with an IDH2 mutation.",
  "previous application": "FDA Approves Idhifa (enasidenib) for Relapsed or Refractory Acute Myeloid Leukemia with IDH2 Mutation Idhifa (enasidenib) FDA Approval History"
},{
  "title": "Vyxeos (cytarabine and daunorubicin)  Injection ",
  "date_of_approval": "August 3, 2017",
  "company": " Jazz Pharmaceuticals plc",
  "treatment": " Acute Myeloid Leukemia",
  "drug_description": "Vyxeos (cytarabine and daunorubicin liposome injection) is a liposomal combination of cytarabine, a nucleoside metabolic inhibitor, and daunorubicin, an anthracycline topoisomerase inhibitor, indicated for the treatment of adults with newly-diagnosed therapy-related\r acute myeloid leukemia (t-AML) or AML with myelodysplasia-related\r changes (AML-MRC).",
  "previous application": "FDA Approves Vyxeos (daunorubicin and cytarabine) Liposome for Injection for Certain Types of Poor-Prognosis Acute Myeloid Leukemia Vyxeos (cytarabine and daunorubicin) FDA Approval History"
},{
  "title": "Mavyret (glecaprevir and pibrentasvir)  Tablets ",
  "date_of_approval": "August 3, 2017",
  "company": " AbbVie Inc.",
  "treatment": " Chronic Hepatitis C",
  "drug_description": "Mavyret (glecaprevir/pibrentasvir) is a fixed-dose combination of glecaprevir, an NS3/4A protease inhibitor, and pibrentasvir, an NS5A inhibitor, indicated for the treatment of all major genotypes (GT1-6) of chronic hepatitis C.",
  "previous application": "FDA Approves Mavyret (glecaprevir and pibrentasvir) for Hepatitis C Mavyret (glecaprevir and pibrentasvir) FDA Approval History"
},{
  "title": "CaroSpir (spironolactone)  Oral Suspension ",
  "date_of_approval": "August 4, 2017",
  "company": " CMP Pharma, Inc.",
  "treatment": " Congestive Heart Failure, Edema, Hypertension",
  "drug_description": "CaroSpir (spironolactone) is an oral suspension formulation of the potassium-sparing diuretic spironolactone indicated for the treatment of heart failure, management of edema, and for use as an add-on therapy in the treatment of hypertension.",
  "previous application": "CMP Pharma, Inc. Announces FDA Approval of CaroSpir (spironolactone) Oral Suspension CaroSpir (spironolactone) FDA Approval History"
},{
  "title": "Besponsa (inotuzumab ozogamicin)  for Injection ",
  "date_of_approval": "August 17, 2017",
  "company": " Pfizer Inc.",
  "treatment": " Acute Lymphoblastic Leukemia",
  "drug_description": "Besponsa (inotuzumab ozogamicin) is a CD22 monoclonal antibody and calicheamicin cytotoxic agent conjugate for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).",
  "previous application": "FDA Approves Besponsa (inotuzumab ozogamicin) for Relapsed or Refractory Acute Lymphoblastic Leukemia Besponsa (inotuzumab ozogamicin) FDA Approval History"
},{
  "title": "Duzallo (allopurinol and lesinurad)  Tablets ",
  "date_of_approval": "August 18, 2017",
  "company": " Ironwood Pharmaceuticals, Inc.",
  "treatment": " Gout",
  "drug_description": "",
  "previous application": "FDA Approves Duzallo (lesinurad and allopurinol) for Hyperuricemia in Patients with Uncontrolled Gout Duzallo (allopurinol and lesinurad) FDA Approval History"
},{
  "title": "Gocovri (amantadine hydrochloride)  Extended-Release Capsules  - formerly ADS-5102",
  "date_of_approval": "August 24, 2017",
  "company": " Adamas Pharmaceuticals, Inc.",
  "treatment": " Levodopa-Induced Dyskinesia",
  "drug_description": "Gocovri (amantadine hydrochloride) is a chrono-synchronous amantadine therapy for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease.",
  "previous application": "FDA Approves Gocovri (amantadine) for the Treatment of Dyskinesia in Parkinson's Disease Patients Gocovri (amantadine hydrochloride) FDA Approval History"
},{
  "title": "KedRAB (rabies immunoglobulin human)  Injection ",
  "date_of_approval": "August 23, 2017",
  "company": " Kamada Ltd. and Kedrion S.p.A.",
  "treatment": " Rabies Prophylaxis",
  "drug_description": "KedRAB [rabies immunoglobulin (human)] is a human plasma derived anti-rabies immunoglobulin indicated for post-exposure prophylaxis (PEP) of rabies infection.",
  "previous application": "FDA Approves KedRAB [rabies immune globulin (Human)] for Post-Exposure Prophylaxis of Rabies Infection\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t KedRAB (rabies immunoglobulin human) FDA Approval History"
},{
  "title": "Cyltezo (adalimumab-adbm)  Injection ",
  "date_of_approval": "August 25, 2017",
  "company": " Boehringer Ingelheim Pharmaceuticals, Inc.",
  "treatment": " Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn's Disease -- Acute, Crohn's Disease -- Maintenance, Ulcerative Colitis, Plaque Psoriasis",
  "drug_description": "Cyltezo (adalimumab-adbm) is an anti-TNF-\u03b1 monoclonal antibody biosimilar to Humira, approved for the treatment of various inflammatory diseases including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn\u2019s disease, ulcerative colitis, and plaque psoriasis.",
  "previous application": "FDA Approves Cyltezo (adalimumab-adbm), a Biosimilar to Humira Cyltezo (adalimumab-adbm) FDA Approval History"
},{
  "title": " (benznidazole)  Tablets ",
  "date_of_approval": "August 29, 2017",
  "company": " Chemo Research, S. L.",
  "treatment": " Chagas Disease",
  "drug_description": "Benznidazole is an antiprotozoal indicated for the treatment of Chagas disease, or American trypanosomiasis, a parasitic infection caused by Trypanosoma cruzi.",
  "previous application": "FDA Approves Benznidazole as First U.S. Treatment for Chagas Disease benznidazole FDA Approval History"
},{
  "title": "Vabomere (meropenem and vaborbactam)  Injection  - formerly Carbavance",
  "date_of_approval": "August 29, 2017",
  "company": " The Medicines Company",
  "treatment": " Urinary Tract Infection",
  "drug_description": "Vabomere (meropenem and vaborbactam) is a carbapenem and beta-lactamase inhibitor combination for the treatment of complicated urinary tract infections (cUTIs).",
  "previous application": "FDA Approves Vabomere (meropenem and vaborbactam) for Complicated Urinary Tract Infections Vabomere (meropenem and vaborbactam) FDA Approval History"
},{
  "title": "Kymriah (tisagenlecleucel)  Suspension for Intravenous Infusion  - formerly CTL019",
  "date_of_approval": "August 30, 2017",
  "company": " Novartis Pharmaceuticals Corporation",
  "treatment": " Acute Lymphoblastic Leukemia; Large B-Cell Lymphoma",
  "drug_description": "Kymriah (tisagenlecleucel) is a chimeric antigen receptor T cell (CAR-T) therapy for use in patients with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL) and patients with relapsed or refractory (r/r) large B-cell lymphoma.",
  "previous application": "FDA Approves Kymriah (tisagenlecleucel) CAR-T Gene Therapy for Acute Lymphoblastic Leukemia Kymriah (tisagenlecleucel) FDA Approval History"
},{
  "title": "Mylotarg (gemtuzumab ozogamicin)  Injection ",
  "date_of_approval": "September 1, 2017",
  "company": " Pfizer Inc.",
  "treatment": " Acute Myeloid Leukemia",
  "drug_description": "Mylotarg (gemtuzumab ozogamicin) is a D33-directed antibody-drug conjugate indicated for:",
  "previous application": "FDA Approves Mylotarg (gemtuzumab ozogamicin) for the Treatment of Acute Myeloid Leukemia Mylotarg (gemtuzumab ozogamicin) FDA Approval History"
},{
  "title": "Aliqopa (copanlisib)  Injection ",
  "date_of_approval": "September 14, 2017",
  "company": " Bayer Healthcare Pharmaceuticals, Inc.",
  "treatment": " Follicular Lymphoma",
  "drug_description": "Aliqopa (copanlisib) is a phosphatidylinositol-3-kinase (PI3K) inhibitor indicated for the treatment of adult patients with relapsed follicular lymphoma (FL).",
  "previous application": "FDA Approves Aliqopa (copanlisib) for Adults with Relapsed Follicular Lymphoma Aliqopa (copanlisib) FDA Approval History"
},{
  "title": "Mvasi (bevacizumab-awwb)  Injection ",
  "date_of_approval": "September 14, 2017",
  "company": " Amgen Inc.",
  "treatment": " Non-Small Cell Lung Cancer, Colorectal Cancer, Glioblastoma Multiforme, Renal Cell Carcinoma, Cervical Cancer",
  "drug_description": "Mvasi (bevacizumab-awwb) is an anti-vascular endothelial growth factor A (anti-VEGF) monoclonal antibody biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer including metastatic colorectal cancer, non-small cell lung cancer, glioblastoma, metastatic renal cell carcinoma, and cervical cancer.",
  "previous application": "FDA Approves Mvasi (bevacizumab-awwb), a Biosimilar to Avastin Mvasi (bevacizumab-awwb) FDA Approval History"
},{
  "title": "Adzenys ER (amphetamine)  Extended-Release Liquid Suspension  - formerly NT-0201",
  "date_of_approval": "September 15, 2017",
  "company": " Neos Therapeutics, Inc.",
  "treatment": " Attention-Deficit Hyperactivity Disorder (ADHD)",
  "drug_description": "Adzenys ER (amphetamine) is an extended-release liquid suspension formulation of the central nervous system (CNS) stimulant amphetamine indicated for the treatment of ADHD  in patients 6 years and older.",
  "previous application": "Neos Therapeutics Receives U.S. FDA Approval of Adzenys ER (amphetamine) Extended-Release Oral Suspension for ADHD Adzenys ER (amphetamine) FDA Approval History"
},{
  "title": "Solosec (secnidazole)  Oral Granules ",
  "date_of_approval": "September 15, 2017",
  "company": " Symbiomix Therapeutics, LLC",
  "treatment": " Bacterial Vaginosis",
  "drug_description": "Solosec (secnidazole) is a nitroimidazole antimicrobial for use as a single-dose oral therapy in the treatment of bacterial vaginosis (BV).",
  "previous application": "FDA Approves Symbiomix Therapeutics\u2019 Solosec (secnidazole) Oral Granules for the Treatment of Bacterial Vaginosis in Adult Women Solosec (secnidazole) FDA Approval History"
},{
  "title": "Trelegy Ellipta (fluticasone furoate, umeclidinium and vilanterol)  Inhalation Powder ",
  "date_of_approval": "September 18, 2017",
  "company": " GlaxoSmithKline",
  "treatment": " Chronic Obstructive Pulmonary Disease, Asthma -- Maintenance",
  "drug_description": "Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) is an inhaled corticosteroid, long-acting muscarinic antagonist (LAMA), and long-acting beta2-adrenergic agonist (LABA) combination indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD), and the maintenance treatment of asthma in patients aged 18 years and older.",
  "previous application": "FDA Approves Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) for the Treatment of COPD Trelegy Ellipta (fluticasone furoate, umeclidinium and vilanterol) FDA Approval History"
},{
  "title": "Xhance (fluticasone propionate)  Nasal Spray  - formerly OPN-375",
  "date_of_approval": "September 18, 2017",
  "company": " OptiNose US Inc.",
  "treatment": " Nasal Polyps",
  "drug_description": "Xhance (fluticasone propionate) is a topical nasal corticosteroid indicated for the treatment of nasal polyps.",
  "previous application": "Optinose Announces FDA Approval of Xhance (fluticasone propionate) Nasal Spray for the Treatment of Nasal Polyps Xhance (fluticasone propionate) FDA Approval History"
},{
  "title": "Verzenio (abemaciclib)  Tablets ",
  "date_of_approval": "September 28, 2017",
  "company": " Eli Lilly and Company",
  "treatment": " Breast Cancer",
  "drug_description": "Verzenio (abemaciclib) is a selective ATP-competitive inhibitor of cyclin dependent kinases (CDK) 4 and 6 indicated for the treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer.",
  "previous application": "FDA Approves Verzenio (abemaciclib) for Certain Advanced or Metastatic Breast Cancers Verzenio (abemaciclib) FDA Approval History"
},{
  "title": "Fiasp (insulin aspart)  Injection ",
  "date_of_approval": "September 29, 2017",
  "company": " Novo Nordisk",
  "treatment": " Diabetes Type 1, Diabetes Type 2",
  "drug_description": "Fiasp (insulin aspart) is a rapid-acting human insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus. Fiasp is a newer formulation of NovoLog, in which the addition of niacinamide (vitamin B3) helps to increase the speed of initial insulin absorption.",
  "previous application": "Novo Nordisk Receives FDA Approval for Fiasp (insulin aspart injection), a New Fast-Acting Mealtime Insulin Fiasp (insulin aspart) FDA Approval History"
},{
  "title": "Trelegy Ellipta (fluticasone furoate, umeclidinium and vilanterol)  Inhalation Powder ",
  "date_of_approval": "September 18, 2017",
  "company": " GlaxoSmithKline",
  "treatment": " Chronic Obstructive Pulmonary Disease, Asthma -- Maintenance",
  "drug_description": "Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) is an inhaled corticosteroid, long-acting muscarinic antagonist (LAMA), and long-acting beta2-adrenergic agonist (LABA) combination indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD), and the maintenance treatment of asthma in patients aged 18 years and older.",
  "previous application": "Once-Daily Trelegy Ellipta Gains Expanded Indication in the US for the Treatment of Patients with COPD Trelegy Ellipta (fluticasone furoate, umeclidinium and vilanterol) FDA Approval History"
},{
  "title": "Ascor (ascorbic acid)  Injection ",
  "date_of_approval": "October 2, 2017",
  "company": " McGuff Pharmaceuticals, Inc.",
  "treatment": " Scurvy",
  "drug_description": "Ascor (ascorbic acid) is an intravenous vitamin C formulation indicated for the short term treatment of scurvy.",
  "previous application": "FDA Approves Ascor (Ascorbic Acid Injection, USP) for the Treatment of Scurvy Ascor (ascorbic acid) FDA Approval History"
},{
  "title": "Zilretta (triamcinolone acetonide)  Sustained-Release Intra-Articular Injection ",
  "date_of_approval": "October 6, 2017",
  "company": " Flexion Therapeutics, Inc.",
  "treatment": " Osteoarthritis",
  "drug_description": "Zilretta (triamcinolone acetonide extended-release injectable suspension) is a corticosteroid intra-articular injection indicated for the management of osteoarthritis pain of the knee.",
  "previous application": "Flexion Therapeutics Announces FDA Approval of Zilretta (triamcinolone acetonide extended-release injectable suspension) for Osteoarthritis Knee Pain Zilretta (triamcinolone acetonide) FDA Approval History"
},{
  "title": "Yescarta (axicabtagene ciloleucel)  Suspension for Intravenous Infusion  - formerly KTE-C19",
  "date_of_approval": "October 18, 2017",
  "company": " Kite Pharma, Inc.",
  "treatment": " Large B-Cell Lymphoma",
  "drug_description": "",
  "previous application": "FDA Approves Yescarta (axicabtagene ciloleucel) CAR-T Cell Therapy to Treat Adults with Certain Types of Large B-Cell Lymphoma Yescarta (axicabtagene ciloleucel) FDA Approval History"
},{
  "title": "Shingrix (zoster vaccine recombinant, adjuvanted)  Injection ",
  "date_of_approval": "October 20, 2017",
  "company": " GlaxoSmithKline",
  "treatment": " Herpes Zoster -- Prophylaxis",
  "drug_description": "Shingrix (zoster vaccine recombinant, adjuvanted) is a non-live, recombinant subunit vaccine for the prevention of herpes zoster (shingles) in adults aged 50 years and older.",
  "previous application": "Shingrix (zoster vaccine recombinant, adjuvanted) Approved in the U.S. for Prevention of Shingles Shingrix (zoster vaccine recombinant, adjuvanted) FDA Approval History"
},{
  "title": "Calquence (acalabrutinib)  Capsules ",
  "date_of_approval": "October 31, 2017",
  "company": " AstraZeneca",
  "treatment": " Mantle Cell Lymphoma; Chronic Lymphocytic Leukemia",
  "drug_description": "Calquence (acalabrutinib) is a highly selective, potent, Bruton tyrosine kinase (BTK) inhibitor for the treatment of mantle cell lymphoma (MCL), and chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma.",
  "previous application": "FDA Approves Calquence (acalabrutinib) for Adults with Mantle Cell Lymphoma Calquence (acalabrutinib) FDA Approval History"
},{
  "title": "Vyzulta (latanoprostene bunod)  Ophthalmic Solution  - formerly Vesneo",
  "date_of_approval": "November 2, 2017",
  "company": " Valeant Pharmaceuticals International, Inc.",
  "treatment": " Glaucoma (Open Angle), Intraocular Hypertension",
  "drug_description": "Vyzulta (latanoprostene bunod) is a nitric oxide donating prostaglandin receptor agonist for the treatment of patients with open angle glaucoma or ocular hypertension.",
  "previous application": "FDA Approves Vyzulta (latanoprostene bunod) Ophthalmic Solution for Open-Angle Glaucoma, Ocular Hypertension Vyzulta (latanoprostene bunod) FDA Approval History"
},{
  "title": "Prevymis (letermovir)  Tablets and Injection ",
  "date_of_approval": "November 8, 2017",
  "company": " Merck &amp; Co., Inc.",
  "treatment": " CMV Prophylaxis",
  "drug_description": "Prevymis (letermovir) is a CMV DNA terminase complex inhibitor indicated for the prophylaxis of cytomegalovirus (CMV) infection and disease in adult allogeneic hematopoietic stem cell transplant patients.",
  "previous application": "FDA Approves Prevymis (letermovir) for Prevention of Cytomegalovirus (CMV) Infection and Disease in Adult Allogeneic Stem Cell Transplant Patients Prevymis (letermovir) FDA Approval History"
},{
  "title": "Heplisav-B (hepatitis B vaccine, recombinant (adjuvanted))  Injection ",
  "date_of_approval": "November 10, 2017",
  "company": " Dynavax Technologies Corporation",
  "treatment": " Hepatitis B Prophylaxis",
  "drug_description": "Heplisav-B (hepatitis B vaccine, recombinant (adjuvanted)) is a vaccine for use in the immunization against infection caused by all known subtypes of hepatitis B virus.",
  "previous application": "Dynavax Announces FDA Approval of Heplisav-B for Prevention of Hepatitis B in Adults Heplisav-B (hepatitis B vaccine, recombinant (adjuvanted)) FDA Approval History"
},{
  "title": "Cinvanti (aprepitant)  Injection ",
  "date_of_approval": "November 9, 2017",
  "company": " Heron Therapeutics, Inc.",
  "treatment": " Nausea/Vomiting -- Chemotherapy Induced",
  "drug_description": "Cinvanti (aprepitant) is a polysorbate 80 free, intravenous formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist indicated for the prevention of chemotherapy-induced nausea and vomiting (CINV).",
  "previous application": "FDA Approves Cinvanti (aprepitant) Injectable Emulsion for the Prevention of Acute and Delayed Chemotherapy-Induced Nausea and Vomiting (CINV) Cinvanti (aprepitant) FDA Approval History"
},{
  "title": "Abilify MyCite (aripiprazole)  Tablets with Sensor ",
  "date_of_approval": "November 13, 2017",
  "company": " Otsuka Pharmaceutical Co., Ltd. and Proteus Digital Health",
  "treatment": " Schizophrenia, Bipolar Disorder, Depression",
  "drug_description": "Abilify MyCite (aripiprazole) is a tablet formulation of the approved atypical antipsychotic aripiprazole embedded with an ingestible Proteus\u00ae sensor that communicates with a wearable sensor patch and a medical software application to measure adherence in the treatment of adults with schizophrenia, bipolar I disorder, and major depressive disorder.",
  "previous application": "FDA Approves Abilify MyCite (aripiprazole) Pill with Sensor to Digitally Track if Patients Have Ingested Their Medication Abilify MyCite (aripiprazole) FDA Approval History"
},{
  "title": "Fasenra (benralizumab)  Injection ",
  "date_of_approval": "November 14, 2017",
  "company": " AstraZeneca",
  "treatment": " Asthma",
  "drug_description": "Fasenra (benralizumab) is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody indicated for the treatment of patients with severe eosinophilic asthma.",
  "previous application": "FDA Approves Fasenra (benralizumab) for Severe Eosinophilic Asthma Fasenra (benralizumab) FDA Approval History"
},{
  "title": "Mepsevii (vestronidase alfa)  Injection ",
  "date_of_approval": "November 15, 2017",
  "company": " Ultragenyx Pharmaceutical, Inc.",
  "treatment": " Mucopolysaccharidosis Type VII",
  "drug_description": "Mepsevii (vestronidase alfa) is a recombinant human lysosomal beta glucuronidase\r indicated for the treatment of Mucopolysaccharidosis VII (MPS VII, Sly syndrome).",
  "previous application": "FDA Approves Mepsevii (vestronidase alfa) for Mucopolysaccharidosis Type VII Mepsevii (vestronidase alfa) FDA Approval History"
},{
  "title": "Hemlibra (emicizumab-kxwh)  Injection ",
  "date_of_approval": "November 16, 2017",
  "company": " Genentech, Inc.",
  "treatment": " Hemophilia A with Inhibitors, Hemophilia A",
  "drug_description": "Hemlibra (emicizumab-kxwh) is a bispecific factor IXa- and factor X-directed antibody\r indicated to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors.",
  "previous application": "FDA Approves Hemlibra (emicizumab-kxwh) for Hemophilia A with Inhibitors Hemlibra (emicizumab-kxwh) FDA Approval History"
},{
  "title": "Juluca (dolutegravir and rilpivirine)  Tablets ",
  "date_of_approval": "November 21, 2017",
  "company": " ViiV Healthcare",
  "treatment": " HIV Infection",
  "drug_description": "Juluca (dolutegravir and rilpivirine) is a single-tablet, two-drug regimen of the approved drugs dolutegravir (Tivicay) and rilpivirine (Edurant) for the maintenance treatment of virologically suppressed HIV-1 infection.",
  "previous application": "FDA Approves Juluca (dolutegravir and rilpivirine) for the Maintenance Treatment of Virologically Suppressed HIV-1 Infection Juluca (dolutegravir and rilpivirine) FDA Approval History"
},{
  "title": "Clenpiq (sodium picosulfate, magnesium oxide, and anhydrous citric acid)  Oral Solution ",
  "date_of_approval": "November 28, 2017",
  "company": " Ferring Pharmaceuticals Inc.",
  "treatment": " Bowel Preparation",
  "drug_description": "Clenpiq (sodium picosulfate, magnesium oxide, and anhydrous citric acid) is a stimulant laxative and osmotic laxative combination indicated for cleansing of the colon as a preparation for colonoscopy.",
  "previous application": "FDA Approves Clenpiq (sodium picosulfate, magnesium oxide, and anhydrous citric acid) Oral Solution for Colonoscopy Prep Clenpiq (sodium picosulfate, magnesium oxide, and anhydrous citric acid) FDA Approval History"
},{
  "title": "Sublocade (buprenorphine)  Sustained-Release Injection  - formerly RBP-6000",
  "date_of_approval": "November 30, 2017",
  "company": " Indivior PLC",
  "treatment": " Opioid Use Disorder",
  "drug_description": "Sublocade (buprenorphine) is a once-monthly injectable partial opioid agonist formulation for the treatment of opioid use disorder (OUD).",
  "previous application": "FDA Approves Sublocade (buprenorphine) Once-Monthly Injection for Opioid Use Disorder Sublocade (buprenorphine) FDA Approval History"
},{
  "title": "Impoyz (clobetasol propionate)  Cream ",
  "date_of_approval": "November 28, 2017",
  "company": " Dr. Reddy\u2019s Laboratories Ltd.",
  "treatment": " Plaque Psoriasis",
  "drug_description": "Impoyz (clobetasol propionate) is a high potency topical corticosteroid indicated for the treatment of moderate to severe plaque psoriasis.",
  "previous application": "Dr. Reddy\u2019s Announces Approval of Impoyz (clobetasol propionate) Cream for Plaque Psoriasis Impoyz (clobetasol propionate) FDA Approval History"
},{
  "title": "Ogivri (trastuzumab-dkst)  for Injection ",
  "date_of_approval": "December 1, 2017",
  "company": " Mylan GmbH",
  "treatment": " Breast Cancer, Gastric Cancer",
  "drug_description": "Ogivri (trastuzumab-dkst) is a HER2/neu receptor antagonist biosimilar to Herceptin  indicated for the treatment of HER2-overexpressing breast cancer and the treatment of HER2-overexpressing stomach cancer.",
  "previous application": "FDA Approves Ogivri (trastuzumab-dkst), a Biosimilar to Herceptin Ogivri (trastuzumab-dkst) FDA Approval History"
},{
  "title": "Lonhala Magnair (glycopyrrolate)  Inhalation Solution ",
  "date_of_approval": "December 5, 2017",
  "company": " Sunovion Pharmaceuticals Inc.",
  "treatment": " Chronic Obstructive Pulmonary Disease",
  "drug_description": "Lonhala Magnair (glycopyrrolate) is a long-acting muscarinic antagonist (LAMA) bronchodilator for the long-term, maintenance treatment of airflow obstruction in people with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.",
  "previous application": "Sunovion Receives FDA Approval for Lonhala Magnair (glycopyrrolate) Inhalation Solution to Treat COPD Lonhala Magnair (glycopyrrolate) FDA Approval History"
},{
  "title": "Ozempic (semaglutide)  Injection ",
  "date_of_approval": "December 5, 2017",
  "company": " Novo Nordisk",
  "treatment": " Diabetes Type 2, Cardiovascular Risk Reduction",
  "drug_description": "Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) analog indicated:",
  "previous application": "Novo Nordisk Receives FDA Approval of Ozempic (semaglutide) Injection For the Treatment of Adults with Type 2 Diabetes Ozempic (semaglutide) FDA Approval History"
},{
  "title": "Admelog (insulin lispro)  Injection ",
  "date_of_approval": "December 11, 2017",
  "company": " Sanofi",
  "treatment": " Diabetes Type 1, Diabetes Type 2",
  "drug_description": "Admelog (insulin lispro) is a follow-on rapid-acting human insulin analog (referenced to Humalog) for the treatment of patients with type 1 and type 2 diabetes.",
  "previous application": "FDA Approves Admelog (insulin lispro) Rapid-Acting \"Follow-On\" Insulin Product to Treat Diabetes Admelog (insulin lispro) FDA Approval History"
},{
  "title": "Sinuva (mometasone furoate)  Sinus Implant ",
  "date_of_approval": "December 8, 2017",
  "company": " Intersect ENT, Inc.",
  "treatment": " Nasal Polyps",
  "drug_description": "Sinuva (mometasone furoate) is a corticosteroid-eluting sinus implant indicated for the treatment of recurrent nasal polyp disease.",
  "previous application": "Intersect ENT Announces FDA Approval of Sinuva (mometasone furoate) Sinus Implant, a New In-Office Treatment Option for Recurrent Nasal Polyps Sinuva (mometasone furoate) FDA Approval History"
},{
  "title": "Ixifi (infliximab-qbtx)  Injection ",
  "date_of_approval": "December 13, 2017",
  "company": " Pfizer Inc.",
  "treatment": " Crohn's Disease -- Maintenance, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Plaque Psoriasis",
  "drug_description": "Ixifi (infliximab-qbtx) is a tumor necrosis factor (TNF) blocker biosimilar to Remicade (infliximab) indicated for the treatment of Crohn\u2019s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis.",
  "previous application": "FDA Approves Ixifi (infliximab-qbtx), a Biosimilar to Remicade Ixifi (infliximab-qbtx) FDA Approval History"
},{
  "title": "Xepi (ozenoxacin)  Cream ",
  "date_of_approval": "December 11, 2017",
  "company": " Medimetriks Pharmaceuticals, Inc.",
  "treatment": " Impetigo",
  "drug_description": "Xepi (ozenoxacin) is a topical non-fluorinated quinolone for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes.",
  "previous application": "Medimetriks Pharmaceuticals, Inc. Receives FDA Approval for Xepi (ozenoxacin) Cream 1%, a Novel Topical Antibiotic for Impetigo Xepi (ozenoxacin) FDA Approval History"
},{
  "title": "Eskata (hydrogen peroxide)  Topical Solution ",
  "date_of_approval": "December 14, 2017",
  "company": " Aclaris Therapeutics, Inc.",
  "treatment": " Seborrheic Keratoses",
  "drug_description": "Eskata (hydrogen peroxide) 40% (w/w) topical solution is a high-concentration hydrogen peroxide formulation for the treatment of raised seborrheic keratoses.",
  "previous application": "Aclaris Therapeutics Receives FDA Approval for Eskata (hydrogen peroxide) Topical Solution, 40% (w/w) for the Treatment of Raised Seborrheic Keratoses Eskata (hydrogen peroxide) FDA Approval History"
},{
  "title": "Prexxartan (valsartan)  Oral Solution ",
  "date_of_approval": "December 19, 2017",
  "company": " Medicure Inc.",
  "treatment": " Hypertension, Congestive Heart Failure, Left Ventricular Dysfunction",
  "drug_description": "",
  "previous application": "Medicure Announces FDA Approval Received for Prexxartan (valsartan) Oral Solution Prexxartan (valsartan) FDA Approval History"
},{
  "title": "Rhopressa (netarsudil)  Ophthalmic Solution ",
  "date_of_approval": "December 18, 2017",
  "company": " Aerie Pharmaceuticals, Inc.",
  "treatment": " Glaucoma",
  "drug_description": "Rhopressa (netarsudil ophthalmic solution) is a Rho kinase inhibitor for the treatment of open-angle glaucoma or ocular hypertension.",
  "previous application": "Aerie Pharmaceuticals Announces U.S. FDA Approval of Rhopressa (netarsudil ophthalmic solution) 0.02% for Patients with Open-Angle Glaucoma or Ocular Hypertension Rhopressa (netarsudil) FDA Approval History"
},{
  "title": "Luxturna (voretigene neparvovec)  Intraocular Suspension for Subretinal Injection ",
  "date_of_approval": "December 19, 2017",
  "company": " Spark Therapeutics",
  "treatment": " Biallelic RPE65-Mediated Inherited Retinal Disease",
  "drug_description": "Luxturna (voretigene neparvovec) is an adeno-associated viral (AAV) vector gene therapy for the treatment of patients with vision loss due to confirmed biallelic RPE65-mediated inherited retinal disease (IRD).",
  "previous application": "FDA Approves Luxturna (voretigene neparvovec-rzyl) Gene Therapy to Treat Patients with a Rare Form of Inherited Vision Loss Luxturna (voretigene neparvovec) FDA Approval History"
},{
  "title": "Macrilen (macimorelin)   for Oral Solution ",
  "date_of_approval": "December 20, 2017",
  "company": " Aeterna Zentaris Inc.",
  "treatment": " Diagnosis of Adult Growth Hormone Deficiency",
  "drug_description": "Macrilen (macimorelin) is a growth hormone (GH) secretagogue receptor agonist indicated for the diagnosis of adult growth hormone deficiency.",
  "previous application": "Aeterna Zentaris Announces FDA Approval of Macrilen (macimorelin) for Diagnosis of Adult Growth Hormone Deficiency Macrilen (macimorelin) FDA Approval History"
},{
  "title": "Giapreza (angiotensin II)  Injection  - formerly LJPC-501",
  "date_of_approval": "December 21, 2017",
  "company": " La Jolla Pharmaceutical Company",
  "treatment": " Hypotension, Shock",
  "drug_description": "Giapreza (angiotensin II) is a synthetic human angiotensin II vasoconstrictor indicated for the treatment of hypotension in adults with septic or other distributive shock.",
  "previous application": "FDA Approves Giapreza (angiotensin II) to Treat Dangerously Low Blood Pressure Giapreza (angiotensin II) FDA Approval History"
},{
  "title": "Steglatro (ertugliflozin)  Tablets ",
  "date_of_approval": "December 19, 2017",
  "company": " Merck",
  "treatment": " Diabetes Type 2",
  "drug_description": "Steglatro (ertugliflozin) is a sodium-glucose co-transporter-2 (SGLT2) inhibitor used to help improve glycemic control in adults with type 2 diabetes.",
  "previous application": "FDA Approves Steglatro (ertugliflozin) for Type 2 Diabetes Steglatro (ertugliflozin) FDA Approval History"
},{
  "title": "Steglujan (ertugliflozin and sitagliptin)  Tablets ",
  "date_of_approval": "December 19, 2017",
  "company": " Merck &amp; Co., Inc.",
  "treatment": " Diabetes Type 2",
  "drug_description": "Steglujan (ertugliflozin and sitagliptin) is a sodium glucose co-transporter 2 (SGLT2) inhibitor, and dipeptidyl peptidase-4 (DPP-4) inhibitor combination used to improve glycemic control in adults with type 2 diabetes.",
  "previous application": "FDA Approves Steglujan (ertugliflozin and sitagliptin) for Type 2 Diabetes Steglujan (ertugliflozin and sitagliptin) FDA Approval History"
},{
  "title": "Segluromet (ertugliflozin and metformin hydrochloride)  Tablets ",
  "date_of_approval": "December 19, 2017",
  "company": " Merck &amp; Co., Inc.",
  "treatment": " Diabetes Type 2",
  "drug_description": "Segluromet (ertugliflozin and metformin hydrochloride) is a sodium glucose co-transporter 2 (SGLT2) inhibitor and biguanide combination used to improve glycemic control in adults with type 2 diabetes.",
  "previous application": "FDA Approves Segluromet (ertugliflozin and metformin hydrochloride) for Type 2 Diabetes Segluromet (ertugliflozin and metformin hydrochloride) FDA Approval History"
},{
  "title": "Lumify (brimonidine tartrate)  Ophthalmic Solution ",
  "date_of_approval": "December 22, 2017",
  "company": " Bausch + Lomb",
  "treatment": " Ocular Redness",
  "drug_description": "Lumify (brimonidine tartrate) is an over-the-counter (OTC) formulation of the  alpha-adrenergic agonist brimonidine indicated for use in the treatment of ocular redness.",
  "previous application": "Bausch + Lomb Receives FDA Approval of Lumify (brimonidine tartrate) Over-the-Counter Eye Drop for the Treatment of Eye Redness Lumify (brimonidine tartrate) FDA Approval History"
},{
  "title": "Balcoltra (ethinyl estradiol/levonorgestrel and ferrous bisglycinate)  Tablets ",
  "date_of_approval": "January 9, 2018",
  "company": " Avion Pharmaceuticals, LLC",
  "treatment": " Prevention of Pregnancy",
  "drug_description": "Balcoltra (levonorgestrel and ethinyl estradiol tablets and ferrous bisglycinate tablets)  is a progestin/estrogen combination oral contraceptive (COC) indicated for use by females of reproductive potential to prevent pregnancy.",
  "previous application": "Avion Pharmaceuticals Announces FDA Approval of Balcoltra (levonorgestrel and ethinyl estradiol tablets and ferrous bisglycinate tablets) Oral Contraceptive Balcoltra (ethinyl estradiol/levonorgestrel and ferrous bisglycinate) FDA Approval History"
},{
  "title": "Lutathera (lutetium Lu 177 dotatate)  Injection ",
  "date_of_approval": "January 26, 2018",
  "company": " Advanced Accelerator Applications S.A.",
  "treatment": " Gastroenteropancreatic Neuroendocrine Tumors",
  "drug_description": "Lutathera (lutetium Lu 177 dotatate) is a Lu-177-labeled somatostatin analogue indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.",
  "previous application": "FDA Approves Lutathera (lutetium Lu 177 dotatate) for Gastroenteropancreatic Neuroendocrine Tumors Lutathera (lutetium Lu 177 dotatate) FDA Approval History"
},{
  "title": "Firvanq (vancomycin hydrochloride)  for Oral Solution ",
  "date_of_approval": "January 26, 2018",
  "company": " CutisPharma",
  "treatment": " Clostridium Difficile Associated Diarrhea; Enterocolitis",
  "drug_description": "Firvanq (vancomycin hydrochloride) is an oral solution formulation of an approved tricyclic glycopeptide antibiotic for the treatment of Clostridium difficile associated diarrhea and Staphylococcus aureus enterocolitis.",
  "previous application": "CutisPharma Announces FDA Approval of Firvanq (vancomycin) for Treatment of Clostridium Difficile Associated Diarrhea and Staphylococcus Aureus Colitis Firvanq (vancomycin hydrochloride) FDA Approval History"
},{
  "title": "Biktarvy (bictegravir, emtricitabine and tenofovir alafenamide)  Tablets ",
  "date_of_approval": "February 7, 2018",
  "company": " Gilead Sciences, Inc.",
  "treatment": " HIV Infection",
  "drug_description": "Biktarvy (bictegravir, emtricitabine and tenofovir alafenamide) is an integrase strand transfer inhibitor and emtricitabine/tenofovir alafenamide (Descovy) combination for the treatment of HIV-1 infection in adults.",
  "previous application": "FDA Approves Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) for Treatment of HIV-1 Infection Biktarvy (bictegravir, emtricitabine and tenofovir alafenamide) FDA Approval History"
},{
  "title": "Dexycu (dexamethasone)  Intraocular Suspension ",
  "date_of_approval": "February 9, 2018",
  "company": " EyePoint Pharmaceuticals, Inc.",
  "treatment": " Postoperative Ocular Inflammation",
  "drug_description": "Dexycu (dexamethasone) is a long-acting, injectable corticosteroid formulation administered intraocularly into the posterior chamber of the eye for the treatment of postoperative inflammation associated with cataract surgery.",
  "previous application": "Icon Bioscience Receives FDA Approval for Dexycu (dexamethasone intraocular suspension) for Treating Inflammation Associated With Cataract Surgery Dexycu (dexamethasone) FDA Approval History"
},{
  "title": "Symdeko (ivacaftor/tezacaftor and ivacaftor)  Tablets ",
  "date_of_approval": "February 12, 2018",
  "company": " Vertex Pharmaceuticals Incorporated",
  "treatment": " Cystic Fibrosis",
  "drug_description": "Symdeko (ivacaftor/tezacaftor tablets and ivacaftor tablets) is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator and CFTR corrector combination for the treatment of cystic fibrosis in patients aged 6 years and older who are homozygous for the F508del mutation or who have at least one mutation in the CFTR) gene that is responsive to Symdeko.",
  "previous application": "FDA Approves Symdeko (tezacaftor/ivacaftor and ivacaftor) to Treat Cystic Fibrosis in People Ages 12 and Older with Certain Mutations in the CFTR Gene Symdeko (ivacaftor/tezacaftor and ivacaftor) FDA Approval History"
},{
  "title": "Erleada (apalutamide)  Tablets ",
  "date_of_approval": "February 14, 2018",
  "company": " Janssen Pharmaceuticals, Inc.",
  "treatment": " Prostate Cancer",
  "drug_description": "Erleada (apalutamide) is an oral androgen receptor inhibitor for the treatment of metastatic castration-sensitive prostate cancer, and non-metastatic castration-resistant prostate cancer.",
  "previous application": "FDA Approves Erleada (apalutamide) for Non-Metastatic Castration-Resistant Prostate Cancer Erleada (apalutamide) FDA Approval History"
},{
  "title": "Osmolex ER (amantadine hydrochloride)  Extended-Release Tablets ",
  "date_of_approval": "February 20, 2018",
  "company": " Osmotica Pharmaceutical US LLC",
  "treatment": " Parkinson's Disease, Extrapyramidal Reaction",
  "drug_description": "Osmolex ER (amantadine hydrochloride) is a proprietary formulation of immediate release and extended release amantadine for the once-a-day treatment of Parkinson\u2019s disease and drug-induced extrapyramidal reactions.",
  "previous application": "FDA Approves Osmolex ER (amantadine) for the treatment of Parkinson\u2019s Disease and Drug-Induced Extrapyramidal Reactions Osmolex ER (amantadine hydrochloride) FDA Approval History"
},{
  "title": "Apadaz (acetaminophen and benzhydrocodone hydrochloride)  Tablets  - formerly KP201",
  "date_of_approval": "February 23, 2018",
  "company": " KemPharm, Inc.",
  "treatment": " Pain",
  "drug_description": "Apadaz (acetaminophen and benzhydrocodone hydrochloride) is an immediate release combination of acetaminophen and  benzhydrocodone, a prodrug of the opioid agonist hydrocodone, indicated for the short-term management of acute pain.",
  "previous application": "FDA Approves Apadaz (benzhydrocodone and acetaminophen) for the Short-Term Management of Acute Pain Apadaz (acetaminophen and benzhydrocodone hydrochloride) FDA Approval History"
},{
  "title": "ZTlido (lidocaine)  Patch  - formerly Ztilido",
  "date_of_approval": "February 28, 2018",
  "company": " Scilex Pharmaceuticals, Inc.",
  "treatment": " Postherpetic Neuralgia",
  "drug_description": "ZTlido (lidocaine topical system 1.8%) is a transdermal anesthetic formulation for the treatment of pain associated with postherpetic neuralgia.",
  "previous application": "Sorrento Therapeutics Subsidiary, Scilex, Receives FDA Approval for Non-Opioid ZTlido (lidocaine topical system) 1.8% for Post-Herpetic Neuralgia Pain ZTlido (lidocaine) FDA Approval History"
},{
  "title": "Symfi Lo (efavirenz, lamivudine and tenofovir disoproxil fumarate)  Tablets ",
  "date_of_approval": "February 5, 2018",
  "company": " Mylan N.V.",
  "treatment": " HIV Infection",
  "drug_description": "Symfi Lo (efavirenz, lamivudine and tenofovir disoproxil fumarate) is a three-drug combination of a non-nucleoside reverse transcriptase inhibitor (efavirenz), and two nucleo(t)side reverse transcriptase inhibitors (lamivudine and tenofovir disoproxil fumarate) indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.",
  "previous application": "Mylan to Introduce Symfi Lo (efavirenz, lamivudine and tenofovir disoproxil fumarate) as a New Cost-Saving HIV Combination Treatment in the U.S. Symfi Lo (efavirenz, lamivudine and tenofovir disoproxil fumarate) FDA Approval History"
},{
  "title": "Cimduo (lamivudine and tenofovir disoproxil fumarate)  Tablets ",
  "date_of_approval": "February 28, 2018",
  "company": " Mylan N.V.",
  "treatment": " HIV Infection",
  "drug_description": "Cimduo (lamivudine and tenofovir disoproxil fumarate) is a combination of two nucleo(t)side reverse transcriptase inhibitors indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.",
  "previous application": "Mylan to Introduce Cimduo (lamivudine and tenofovir disoproxil fumarate) as a New Cost-Saving HIV Combination Treatment in the U.S. Cimduo (lamivudine and tenofovir disoproxil fumarate) FDA Approval History"
},{
  "title": "Trogarzo (ibalizumab-uiyk)  Injection ",
  "date_of_approval": "March 6, 2018",
  "company": " TaiMed Biologics USA Corp.",
  "treatment": " HIV Infection",
  "drug_description": "Trogarzo (ibalizumab-uiyk) is a CD4-directed post-attachment HIV-1 inhibitor for the treatment of multidrug resistant human immunodeficiency virus-1 (HIV-1) infection in heavily treatment-experienced adults.",
  "previous application": "FDA Approves Trogarzo (ibalizumab-uiyk) for Treatment-Experienced Patients with Multidrug Resistant HIV Trogarzo (ibalizumab-uiyk) FDA Approval History"
},{
  "title": "Ilumya (tildrakizumab-asmn)  Injection ",
  "date_of_approval": "March 20, 2018",
  "company": " Sun Pharmaceutical Industries Ltd.",
  "treatment": " Plaque Psoriasis",
  "drug_description": "Ilumya (tildrakizumab-asmn) is a humanized, anti-IL-23p19 monoclonal antibody for the treatment of moderate-to-severe plaque psoriasis.",
  "previous application": "FDA Approves Ilumya (tildrakizumab-asmn) for the Treatment of Moderate-to-Severe Plaque Psoriasis Ilumya (tildrakizumab-asmn) FDA Approval History"
},{
  "title": "Symfi (efavirenz, lamivudine and tenofovir disoproxil fumarate)  Tablets ",
  "date_of_approval": "March 22, 2018",
  "company": " Mylan N.V.",
  "treatment": " HIV Infection",
  "drug_description": "Symfi (efavirenz, lamivudine and tenofovir disoproxil fumarate) is a three-drug combination of a non-nucleoside reverse transcriptase inhibitor (efavirenz), and two nucleo(t)side reverse transcriptase inhibitors (lamivudine and tenofovir disoproxil fumarate) indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.",
  "previous application": "Mylan Introduces Symfi (efavirenz, lamivudine and tenofovir disoproxil fumarate) Triple Combo Once-Daily HIV Treatment in the U.S. Symfi (efavirenz, lamivudine and tenofovir disoproxil fumarate) FDA Approval History"
},{
  "title": "Tavalisse (fostamatinib)  Tablets ",
  "date_of_approval": "April 17, 2018",
  "company": " Rigel Pharmaceuticals, Inc.",
  "treatment": " Idiopathic (Immune) Thrombocytopenic Purpura",
  "drug_description": "Tavalisse (fostamatinib) is an oral spleen tyrosine kinase (SYK) inhibitor for the treatment of patients with chronic immune thrombocytopenia (ITP).",
  "previous application": "FDA Approves Tavalisse (fostamatinib disodium hexahydrate) for Chronic Immune Thrombocytopenia Tavalisse (fostamatinib) FDA Approval History"
},{
  "title": "Crysvita (burosumab-twza)  Injection ",
  "date_of_approval": "April 17, 2018",
  "company": " Ultragenyx Pharmaceutical Inc.",
  "treatment": " X-Linked Hypophosphatemia; Tumor-Induced Osteomalacia",
  "drug_description": "Crysvita (burosumab-twza) is a fibroblast growth factor 23 (FGF23) blocking antibody for the treatment of x-linked hypophosphatemia (XLH) and FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO).",
  "previous application": "FDA Approves Crysvita (burosumab-twza) for X-Linked Hypophosphatemia Crysvita (burosumab-twza) FDA Approval History"
},{
  "title": "Akynzeo for Injection (fosnetupitant and palonosetron) ",
  "date_of_approval": "April 19, 2018",
  "company": " Helsinn",
  "treatment": " Nausea/Vomiting -- Chemotherapy Induced",
  "drug_description": "Akynzeo for Injection (fosnetupitant and palonosetron) is a substance\r P/neurokinin-1 (NK-1) receptor antagonist and serotonin-3 (5-HT3) receptor antagonist combination indicated for use with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV).",
  "previous application": "FDA Approves Intravenous Formulation of Akynzeo (fosnetupitant/palonosetron) for Chemotherapy-Induced Nausea and Vomiting Akynzeo for Injection (fosnetupitant and palonosetron) FDA Approval History"
},{
  "title": "Jynarque (tolvaptan)  Tablets ",
  "date_of_approval": "April 23, 2018",
  "company": " Otsuka Pharmaceutical Co., Ltd.",
  "treatment": " Adults at Risk of Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease",
  "drug_description": "Jynarque (tolvaptan) is a selective vasopressin V2-receptor antagonist indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD).",
  "previous application": "FDA Approves Jynarque (tolvaptan) to Slow Kidney Function Decline in Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease Jynarque (tolvaptan) FDA Approval History"
},{
  "title": "Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo) ",
  "date_of_approval": "May 3, 2018",
  "company": " Portola Pharmaceuticals, Inc.",
  "treatment": " Reversal of Anticoagulant Activity of Factor Xa Inhibitors",
  "drug_description": "Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo) is a recombinant modified human Factor Xa (FXa) protein indicated for patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is\r needed due to life-threatening or uncontrolled bleeding.",
  "previous application": "FDA Approves Portola Pharmaceuticals\u2019 Andexxa, First and Only Antidote for the Reversal of Factor Xa Inhibitors Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo) FDA Approval History"
},{
  "title": "Plenvu (polyethylene glycol 3350 with electrolytes)  for Oral Solution ",
  "date_of_approval": "May 4, 2018",
  "company": " Salix Pharmaceuticals, Inc.",
  "treatment": " Bowel Preparation",
  "drug_description": "Plenvu (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride) is a lower-volume, polyethylene glycol based osmotic laxative indicated for cleansing of the colon (bowel preparation) prior to colonoscopy.",
  "previous application": "Salix Receives FDA Approval for Plenvu, Next Generation 1-Liter Bowel Cleansing Preparation for Colonoscopies Plenvu (polyethylene glycol 3350 with electrolytes) FDA Approval History"
},{
  "title": "Retacrit (epoetin alfa-epbx)  for Injection ",
  "date_of_approval": "May 15, 2018",
  "company": " Hospira Inc.",
  "treatment": " Anemia",
  "drug_description": "Retacrit (epoetin alfa-epbx) is an erythropoiesis-stimulating agent (ESA) biosimilar to Epogen/Procrit (epoetin alfa) indicated for treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in patients with HIV infection. Retacrit is also approved for use before and after surgery to reduce the chance that red blood cell transfusions will be needed because of blood loss during surgery.",
  "previous application": "FDA Approves Retacrit (epoetin alfa-epbx) as First Epoetin Alfa Biosimilar for the Treatment of Anemia Retacrit (epoetin alfa-epbx) FDA Approval History"
},{
  "title": "Lucemyra (lofexidine hydrochloride)  Tablets ",
  "date_of_approval": "May 16, 2018",
  "company": " US WorldMeds",
  "treatment": " Opiate Withdrawal",
  "drug_description": "Lucemyra (lofexidine hydrochloride) is a selective alpha 2-adrenergic receptor agonist indicated for reducing the severity of withdrawal symptoms in patients experiencing opioid withdrawal.",
  "previous application": "FDA Approves Lucemyra (lofexidine hydrochloride) as the First Non-Opioid Treatment for Management of Opioid Withdrawal Symptoms Lucemyra (lofexidine hydrochloride) FDA Approval History"
},{
  "title": "Aimovig (erenumab-aooe)  Injection ",
  "date_of_approval": "May 17, 2018",
  "company": " Amgen Inc.",
  "treatment": " Migraine Prophylaxis",
  "drug_description": "Aimovig (erenumab-aooe) is a calcitonin gene-related peptide (CGRP) receptor antagonist indicated for the preventive treatment of migraine.",
  "previous application": "FDA Approves Aimovig (erenumab-aooe) as a Preventive Treatment for Migraine Aimovig (erenumab-aooe) FDA Approval History"
},{
  "title": "Lokelma (sodium zirconium cyclosilicate)  for Oral Suspension ",
  "date_of_approval": "May 18, 2018",
  "company": " AstraZeneca",
  "treatment": " Hyperkalemia",
  "drug_description": "Lokelma (sodium zirconium cyclosilicate) is a potassium binder indicated for the treatment of hyperkalemia in adults.",
  "previous application": "FDA Approves Lokelma (sodium zirconium cyclosilicate) for the Treatment of Adults with Hyperkalemia Lokelma (sodium zirconium cyclosilicate) FDA Approval History"
},{
  "title": "Doptelet (avatrombopag)  Tablets ",
  "date_of_approval": "May 21, 2018",
  "company": " Dova Pharmaceuticals, Inc.",
  "treatment": " Thrombocytopenia, Idiopathic (Immune) Thrombocytopenic Purpura",
  "drug_description": "Doptelet (avatrombopag) is a second generation, orally administered thrombopoietin receptor agonist (TPO-RA) indicated for the treatment of:",
  "previous application": "FDA Approves Doptelet (avatrombopag) for Chronic Liver Disease Patients with Thrombocytopenia who are Undergoing a Medical Procedure Doptelet (avatrombopag) FDA Approval History"
},{
  "title": "Yonsa (abiraterone acetate)  Tablets ",
  "date_of_approval": "May 22, 2018",
  "company": " Sun Pharmaceutical Industries Ltd.",
  "treatment": " Prostate Cancer",
  "drug_description": "Yonsa (abiraterone acetate) is an ultramicrosize formulation of the oral CYP17 inhibitor abiraterone acetate (approved as Zytiga) used in combination with methylprednisolone for the treatment of metastatic castration-resistant prostate cancer.",
  "previous application": "Sun Pharma Announces FDA Approval of Yonsa (abiraterone acetate) to Treat Metastatic Castration-Resistant Prostate Cancer Yonsa (abiraterone acetate) FDA Approval History"
},{
  "title": "Palynziq (pegvaliase-pqpz)  Injection ",
  "date_of_approval": "May 24, 2018",
  "company": " BioMarin Pharmaceutical Inc.",
  "treatment": " Phenylketonuria",
  "drug_description": "Palynziq (pegvaliase-pqpz) is a phenylalanine-metabolizing enzyme indicated to reduce blood phenylalanine concentrations in adult patients with phenylketonuria.",
  "previous application": "FDA Approves Palynziq (pegvaliase-pqpz) for the Treatment of Adults with Phenylketonuria Palynziq (pegvaliase-pqpz) FDA Approval History"
},{
  "title": "Imvexxy (estradiol)  Vaginal Inserts  - formerly TX-004HR",
  "date_of_approval": "May 29, 2018",
  "company": " TherapeuticsMD, Inc.",
  "treatment": " Dyspareunia",
  "drug_description": "Imvexxy (estradiol) is a bio-identical 17\u03b2-estradiol vaginal insert for the treatment of dyspareunia (vaginal pain during sexual intercourse) due to menopause.",
  "previous application": "TherapeuticsMD Announces FDA Approval of Imvexxy (estradiol vaginal inserts) for the Treatment of Dyspareunia Due to Menopause Imvexxy (estradiol) FDA Approval History"
},{
  "title": "Consensi (amlodipine and celecoxib)  Tablets ",
  "date_of_approval": "May 31, 2018",
  "company": " Kitov Pharma Ltd.",
  "treatment": " Hypertension, Osteoarthritis",
  "drug_description": "Consensi (amlodipine and celecoxib) is a calcium channel blocker and nonsteroidal anti-inflammatory drug combination for the treatment of both hypertension and pain associated with osteoarthritis.",
  "previous application": "FDA Approves Consensi (amlodipine and celecoxib) for Treatment of Hypertension and Osteoarthritis Pain Consensi (amlodipine and celecoxib) FDA Approval History"
},{
  "title": "Olumiant (baricitinib)  Tablets ",
  "date_of_approval": "May 31, 2018",
  "company": " Eli Lilly and Company and Incyte Corporation ",
  "treatment": " Rheumatoid Arthritis",
  "drug_description": "Olumiant (baricitinib) is a Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.",
  "previous application": "FDA Approves Olumiant (baricitinib) 2 mg Tablets for the Treatment of Adults with Moderately-to-Severely Active Rheumatoid Arthritis Olumiant (baricitinib) FDA Approval History"
},{
  "title": "Fulphila (pegfilgrastim-jmdb)  Injection ",
  "date_of_approval": "June 4, 2018",
  "company": " Mylan N.V.",
  "treatment": " Neutropenia Associated with Chemotherapy",
  "drug_description": "Fulphila (pegfilgrastim-jmbd) is a leukocyte growth factor biosimilar to Neulasta (pegfilgrastim) indicated to reduce the incidence of febrile neutropenia in patients treated with chemotherapy.",
  "previous application": "FDA Approves Fulphila (pegfilgrastim-jmdb), the First Biosimilar to Neulasta Fulphila (pegfilgrastim-jmdb) FDA Approval History"
},{
  "title": " (moxidectin)  Tablets ",
  "date_of_approval": "June 13, 2018",
  "company": " Medicines Development for Global Health",
  "treatment": " Onchocerciasis",
  "drug_description": "Moxidectin is a macrocyclic lactone anthelmintic medicine indicated for the treatment of river blindness (onchocerciasis) in patients aged 12 years and older.",
  "previous application": "FDA Approves Moxidectin for the Treatment of River Blindness moxidectin FDA Approval History"
},{
  "title": "Nocdurna (desmopressin acetate)  Sublingual Tablets ",
  "date_of_approval": "June 21, 2018",
  "company": " Ferring Pharmaceuticals Inc.",
  "treatment": " Nocturia",
  "drug_description": "Nocdurna (desmopressin acetate) is a vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults.",
  "previous application": "Nocdurna (desmopressin acetate) Approved by FDA as First Sublingual Tablet to Treat Nocturia due to Nocturnal Polyuria Nocdurna (desmopressin acetate) FDA Approval History"
},{
  "title": "Epidiolex (cannabidiol)  Oral Solution ",
  "date_of_approval": "June 25, 2018",
  "company": " GW Pharmaceuticals plc",
  "treatment": " Seizures associated with Lennox-Gastaut Syndrome, Dravet syndrome, or Tuberous Sclerosis Complex",
  "drug_description": "Epidiolex (cannabidiol) is a prescription pharmaceutical formulation of highly-purified, marijuana plant-derived cannabidiol (CBD) indicated for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex.",
  "previous application": "FDA Approves Epidiolex (cannabidiol) to Treat Lennox-Gastaut Syndrome and Dravet Syndrome Epidiolex (cannabidiol) FDA Approval History"
},{
  "title": "Zemdri (plazomicin)  Injection ",
  "date_of_approval": "June 25, 2018",
  "company": " Achaogen, Inc.",
  "treatment": " Urinary Tract Infection",
  "drug_description": "Zemdri (plazomicin) is an aminoglycoside antibacterial for the treatment of complicated urinary tract infections.",
  "previous application": "Zemdri (plazomicin) Approved by FDA for the Treatment of Adults with Complicated Urinary Tract Infections (cUTI) Zemdri (plazomicin) FDA Approval History"
},{
  "title": "Braftovi (encorafenib)  Capsules ",
  "date_of_approval": "June 27, 2018",
  "company": " Pfizer, Inc.",
  "treatment": " Melanoma -- Metastatic, Colorectal Cancer",
  "drug_description": "Braftovi (encorafenib) is a kinase inhibitor indicated:",
  "previous application": "Array BioPharma Announces FDA Approval of Braftovi (encorafenib) in Combination with Mektovi (binimetinib) for Unresectable or Metastatic Melanoma with BRAF Mutations Braftovi (encorafenib) FDA Approval History"
},{
  "title": "Mektovi (binimetinib)  Tablets ",
  "date_of_approval": "June 27, 2018",
  "company": " Array BioPharma Inc.",
  "treatment": " Melanoma -- Metastatic",
  "drug_description": "Mektovi (binimetinib)  is a kinase inhibitor indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.",
  "previous application": "FDA Approves Mektovi (binimetinib) and Braftovi (encorafenib) in Combination for Unresectable or Metastatic Melanoma with BRAF Mutations Mektovi (binimetinib) FDA Approval History"
},{
  "title": "Qbrexza (glycopyrronium)  Cloth for Topical Use ",
  "date_of_approval": "June 28, 2018",
  "company": " Dermira, Inc.",
  "treatment": " Hyperhidrosis",
  "drug_description": "Qbrexza (glycopyrronium) is a topical anticholinergic contained in a single-use, pre-moistened, medicated cloth for the treatment of primary axillary hyperhidrosis (excessive underarm sweating) in adults and children 9 years of age and older.",
  "previous application": "Dermira Receives FDA Approval for Qbrexza (glycopyrronium) Cloth to Treat Excessive Underarm Sweating Qbrexza (glycopyrronium) FDA Approval History"
},{
  "title": "TPOXX (tecovirimat)  Capsules ",
  "date_of_approval": "July 13, 2018",
  "company": " SIGA Technologies, Inc.",
  "treatment": " Smallpox",
  "drug_description": "TPOXX (tecovirimat) is an orthopoxvirus-specific antiviral indicated for the treatment of human smallpox disease.",
  "previous application": "FDA Approves TPOXX (tecovirimat) as the First Drug for the Treatment of Smallpox TPOXX (tecovirimat) FDA Approval History"
},{
  "title": "Symtuza (cobicistat, darunavir, emtricitabine and tenofovir alafenamide)  Tablets ",
  "date_of_approval": "July 17, 2018",
  "company": " Janssen Pharmaceuticals, Inc.",
  "treatment": " HIV Infection",
  "drug_description": "Symtuza (darunavir, cobicistat, emtricitabine and tenofovir alafenamide) is a once daily, single-tablet regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) in treatment-na\u00efve and certain virologically suppressed adults.",
  "previous application": "FDA Approves Symtuza (D/C/F/TAF), the First and Only Complete Darunavir-Based Single-Tablet Regimen for the Treatment of HIV-1 Infection Symtuza (cobicistat, darunavir, emtricitabine and tenofovir alafenamide) FDA Approval History"
},{
  "title": "Tibsovo (ivosidenib)  Tablets ",
  "date_of_approval": "July 20, 2018",
  "company": " Agios Pharmaceuticals, Inc.",
  "treatment": " Acute Myeloid Leukemia",
  "drug_description": "Tibsovo (ivosidenib) is an isocitrate dehydrogenase-1 (IDH1) inhibitor for the treatment of patients with acute myeloid leukemia who have an IDH1 mutation.",
  "previous application": "FDA Approves Tibsovo (ivosidenib) for Relapsed or Refractory Acute Myeloid Leukemia with an IDH1 Mutation Tibsovo (ivosidenib) FDA Approval History"
},{
  "title": "Nivestym (filgrastim-aafi)  Injection ",
  "date_of_approval": "July 20, 2018",
  "company": " Pfizer Inc.",
  "treatment": " Neutropenia Associated with Chemotherapy, Febrile Neutropenia",
  "drug_description": "Nivestym (filgrastim-aafi) is a recombinant human granulocyte colony-stimulating factor biosimilar to Neupogen indicated for the treatment of neutropenia associated with chemotherapy and related conditions.",
  "previous application": "FDA Approves Nivestym (filgrastim-aafi), a Biosimilar to Neupogen Nivestym (filgrastim-aafi) FDA Approval History"
},{
  "title": "Krintafel (tafenoquine)  Tablets ",
  "date_of_approval": "July 20, 2018",
  "company": " GlaxoSmithKline",
  "treatment": " Malaria",
  "drug_description": "Krintafel (tafenoquine) is an 8-aminoquinoline derivative antimalarial for the radical cure (prevention of relapse) of Plasmodium vivax malaria.",
  "previous application": "FDA Approves Krintafel (tafenoquine) for the Radical Cure of Plasmodium vivax Malaria Krintafel (tafenoquine) FDA Approval History"
},{
  "title": "Orilissa (elagolix)  Tablets ",
  "date_of_approval": "July 23, 2018",
  "company": " AbbVie, Inc.",
  "treatment": " Endometriosis",
  "drug_description": "Orilissa (elagolix) is an orally administered gonadotropin-releasing hormone (GnRH) antagonist for the management of moderate to severe pain associated with endometriosis.",
  "previous application": "FDA Approves Orilissa (elagolix) for the Management of Moderate to Severe Pain Associated with Endometriosis Orilissa (elagolix) FDA Approval History"
},{
  "title": "Perseris (risperidone)  for Extended-Release Injectable Suspension ",
  "date_of_approval": "July 27, 2018",
  "company": " Indivior PLC",
  "treatment": " Schizophrenia",
  "drug_description": "Perseris (risperidone) is a once-monthly, subcutaneous formulation of the approved atypical antipsychotic risperidone indicated for the treatment of schizophrenia in adults.",
  "previous application": "FDA Approves Perseris (risperidone) for Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults Perseris (risperidone) FDA Approval History"
},{
  "title": "Azedra (iobenguane I 131)  Injection ",
  "date_of_approval": "July 30, 2018",
  "company": " Progenics Pharmaceuticals Inc.",
  "treatment": " Pheochromocytoma; Paraganglioma",
  "drug_description": "Azedra (iobenguane I 131) is a  radioactive therapeutic agent for the treatment of locally advanced or metastatic pheochromocytoma and paraganglioma.",
  "previous application": "FDA Approves Azedra (iobenguane I 131) for Rare Adrenal Tumors  Azedra (iobenguane I 131) FDA Approval History"
},{
  "title": "Mulpleta (lusutrombopag)  Tablets ",
  "date_of_approval": "July 31, 2018",
  "company": " Shionogi Inc.",
  "treatment": " Thrombocytopenia",
  "drug_description": "Mulpleta (lusutrombopag) is a once-daily, orally administered, thrombopoietin (TPO) receptor agonist for the treatment of thrombocytopenia in patients with chronic liver disease who are scheduled to undergo a medical or dental procedure.",
  "previous application": "FDA Approves Mulpleta (lusutrombopag) for Thrombocytopenia in Adults with Chronic Liver Disease Mulpleta (lusutrombopag) FDA Approval History"
},{
  "title": "Poteligeo (mogamulizumab-kpkc)  Injection ",
  "date_of_approval": "August 8, 2018",
  "company": " Kyowa Hakko Kirin Co., Ltd.",
  "treatment": " Mycosis Fungoides; S\u00e9zary Syndrome",
  "drug_description": "Poteligeo (mogamulizumab-kpkc) is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and S\u00e9zary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma (CTCL).",
  "previous application": "FDA Approves Poteligeo (mogamulizumab-kpkc) for Mycosis Fungoides and S\u00e9zary Syndrome Poteligeo (mogamulizumab-kpkc) FDA Approval History"
},{
  "title": "Arakoda (tafenoquine)  Tablets ",
  "date_of_approval": "August 8, 2018",
  "company": " 60 Degrees Pharmaceuticals",
  "treatment": " Malaria Prophylaxis",
  "drug_description": "Arakoda (tafenoquine) is an 8-aminoquinoline antimalarial drug indicated for the prophylaxis of malaria in patients aged 18 years and older.",
  "previous application": "FDA Approves Arakoda (tafenoquine) for the Prevention of Malaria Arakoda (tafenoquine) FDA Approval History"
},{
  "title": "Jornay PM (methylphenidate hydrochloride)  Extended-Release Capsules ",
  "date_of_approval": "August 8, 2018",
  "company": " Ironshore Pharmaceuticals &amp; Development, Inc.",
  "treatment": " Attention Deficit Hyperactivity Disorder (ADHD)",
  "drug_description": "Jornay PM (methylphenidate hydrochloride) is a once-daily formulation of the approved central nervous system (CNS) stimulant methylphenidate indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older.",
  "previous application": "FDA Approves Jornay PM (methylphenidate) Extended-Release Capsules for Attention Deficit Hyperactivity Disorder (ADHD) Jornay PM (methylphenidate hydrochloride) FDA Approval History"
},{
  "title": "Onpattro (patisiran)  Injection ",
  "date_of_approval": "August 10, 2018",
  "company": " Alnylam Pharmaceuticals, Inc.",
  "treatment": " Hereditary Transthyretin-Mediated Amyloidosis (hATTR)",
  "drug_description": "Onpattro (patisiran) is a small interfering ribonucleic acid (siRNA) therapeutic  for the treatment of polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR).",
  "previous application": "FDA Approves Onpattro (patisiran) Targeted RNA-based Therapy for Polyneuropathy Caused by hATTR Onpattro (patisiran) FDA Approval History"
},{
  "title": "Annovera (ethinyl estradiol and segesterone acetate)  Vaginal System ",
  "date_of_approval": "August 10, 2018",
  "company": " The Population Council",
  "treatment": " Contraception",
  "drug_description": "Annovera (ethinyl estradiol and segesterone acetate) is an estrogen and progestin vaginal contraceptive system indicated to prevent pregnancy for up to a year.",
  "previous application": "FDA Approves Annovera (segesterone acetate and ethinyl estradiol) Vaginal Contraceptive System Annovera (ethinyl estradiol and segesterone acetate) FDA Approval History"
},{
  "title": "Galafold (migalastat)  Capsules ",
  "date_of_approval": "August 10, 2018",
  "company": " Amicus Therapeutics",
  "treatment": " Fabry Disease",
  "drug_description": "Galafold (migalastat) is an alpha-galactosidase A (alpha-Gal A) pharmacological\r chaperone indicated for the treatment of adults with a confirmed diagnosis of\r Fabry disease and an amenable galactosidase alpha gene variant.",
  "previous application": "FDA Approves Galafold (migalastat) for the Treatment of Fabry Disease Galafold (migalastat) FDA Approval History"
},{
  "title": "Cequa (cyclosporine)  Ophthalmic Solution ",
  "date_of_approval": "August 14, 2018",
  "company": " Sun Pharmaceutical Industries Ltd.",
  "treatment": " Keratoconjunctivitis Sicca",
  "drug_description": "Cequa (cyclosporine) ophthalmic solution is a calcineurin inhibitor immunosuppressant indicated to increase tear production in patients with dry eye disease (keratoconjunctivitis sicca).",
  "previous application": "Sun Pharma Announces FDA Approval of Cequa (cyclosporine) Ophthalmic Solution to Treat Dry Eye Disease Cequa (cyclosporine) FDA Approval History"
},{
  "title": "Diacomit (stiripentol)  Capsules and Powder for Oral Suspension ",
  "date_of_approval": "August 20, 2018",
  "company": " Biocodex",
  "treatment": " Dravet Syndrome",
  "drug_description": "Diacomit (stiripentol) is an anticonvulsant indicated for the treatment of seizures associated with Dravet syndrome in patients 2 years of age and older taking clobazam.",
  "previous application": "FDA Approves Diacomit (stiripentol) for Seizures Associated with Dravet Syndrome Diacomit (stiripentol) FDA Approval History"
},{
  "title": "Oxervate (cenegermin-bkbj)  Ophthalmic Solution ",
  "date_of_approval": "August 22, 2018",
  "company": " Domp\u00e9 farmaceutici SpA",
  "treatment": " Neurotrophic Keratitis",
  "drug_description": "Oxervate (cenegermin) is a recombinant human nerve growth factor (rhNGF) ophthalmic solution indicated for the treatment of neurotrophic keratitis.",
  "previous application": "FDA Approves Oxervate (cenegermin) for Neurotrophic Keratitis Oxervate (cenegermin-bkbj) FDA Approval History"
},{
  "title": "Inveltys (loteprednol etabonate)  Ophthalmic Suspension ",
  "date_of_approval": "August 22, 2018",
  "company": " Kala Pharmaceuticals, Inc.",
  "treatment": " Postoperative Ocular Inflammation",
  "drug_description": "Inveltys (loteprednol etabonate) is a nanoparticle ocular corticosteroid formulation for the treatment of post-operative ocular inflammation and pain.",
  "previous application": "FDA Approves Inveltys (loteprednol etabonate) for Post-Operative Inflammation and Pain Following Ocular Surgery Inveltys (loteprednol etabonate) FDA Approval History"
},{
  "title": "Takhzyro (lanadelumab-flyo)  Injection ",
  "date_of_approval": "August 23, 2018",
  "company": " Shire plc",
  "treatment": " Hereditary Angioedema",
  "drug_description": "Takhzyro (lanadelumab-flyo) is a plasma kallikrein inhibitor (monoclonal antibody) for the prevention of angioedema attacks in patients with hereditary angioedema.",
  "previous application": "FDA Approves Takhzyro (lanadelumab-flyo) for Hereditary Angioedema Takhzyro (lanadelumab-flyo) FDA Approval History"
},{
  "title": "Altreno (tretinoin)  Lotion ",
  "date_of_approval": "August 23, 2018",
  "company": " Ortho Dermatologics",
  "treatment": " Acne",
  "drug_description": "Altreno (tretinoin) is a topical retinoid for the treatment of acne.",
  "previous application": "Ortho Dermatologics Receives FDA Approval for Altreno (tretinoin 0.05%) Lotion For Acne Altreno (tretinoin) FDA Approval History"
},{
  "title": "Xerava (eravacycline)  Injection ",
  "date_of_approval": "August 27, 2018",
  "company": " Tetraphase Pharmaceuticals, Inc.",
  "treatment": " Complicated Intra-Abdominal Infections",
  "drug_description": "Xerava (eravacycline) is a fluorocycline antibiotic indicated for the treatment of complicated intra-abdominal infections.",
  "previous application": "Tetraphase Pharmaceuticals Announces FDA Approval of Xerava (eravacycline) for Complicated Intra-Abdominal Infections (cIAI) Xerava (eravacycline) FDA Approval History"
},{
  "title": "Jivi (antihemophilic factor [recombinant] PEGylated-aucl)  Injection ",
  "date_of_approval": "August 30, 2018",
  "company": " Bayer HealthCare LLC",
  "treatment": " Hemophilia A",
  "drug_description": "Jivi (antihemophilic factor (recombinant), PEGylated-aucl) is a recombinant DNA-derived, Factor VIII concentrate indicated to treat and control bleeding in patients with hemophilia A.",
  "previous application": "Bayer Receives FDA Approval for Jivi (antihemophilic factor (recombinant), PEGylated-aucl) for Prophylactic Treatment of Hemophilia A Jivi (antihemophilic factor [recombinant] PEGylated-aucl) FDA Approval History"
},{
  "title": "Pifeltro (doravirine)  Tablets ",
  "date_of_approval": "August 30, 2018",
  "company": " Merck",
  "treatment": " HIV Infection",
  "drug_description": "Pifeltro (doravirine) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) indicated for the treatment of HIV-1 infection.",
  "previous application": "FDA Approves Merck\u2019s Pifeltro (doravirine) for the Treatment of HIV-1 in Appropriate Patients Pifeltro (doravirine) FDA Approval History"
},{
  "title": "Delstrigo (doravirine, lamivudine and tenofovir disoproxil fumarate)  Tablets ",
  "date_of_approval": "August 30, 2018",
  "company": " Merck",
  "treatment": " HIV Infection",
  "drug_description": "Delstrigo (doravirine, lamivudine and tenofovir disoproxil fumarate) a non-nucleoside reverse transcriptase inhibitor (NNRTI) and nucleoside analogue reverse transcriptase inhibitors combination indicated for the treatment of HIV-1 infection.",
  "previous application": "FDA Approves Merck\u2019s Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) for the Treatment of HIV-1 in Appropriate Patients Delstrigo (doravirine, lamivudine and tenofovir disoproxil fumarate) FDA Approval History"
},{
  "title": "Tiglutik (riluzole)  Oral Suspension ",
  "date_of_approval": "September 5, 2018",
  "company": " ITF Pharma",
  "treatment": " Amyotrophic Lateral Sclerosis",
  "drug_description": "Tiglutik (riluzole) is an easy-to-swallow, thickened, oral suspension formulation of the approved drug riluzole for the treatment of amyotrophic lateral sclerosis (ALS).",
  "previous application": "ITF Pharma Announces FDA Approval of Tiglutik (riluzole) Oral Suspension for the Treatment of Amyotrophic Lateral Sclerosis (ALS) Tiglutik (riluzole) FDA Approval History"
},{
  "title": "Cassipa (buprenorphine and naloxone)  Sublingual Film ",
  "date_of_approval": "September 7, 2018",
  "company": " Teva Pharmaceuticals USA Inc.",
  "treatment": " Opiate Dependence - Maintenance",
  "drug_description": "",
  "previous application": "FDA Approves Cassipa (buprenorphine and naloxone) Sublingual Film as Maintenance Treatment for Opioid Dependence Cassipa (buprenorphine and naloxone) FDA Approval History"
},{
  "title": "Lumoxiti (moxetumomab pasudotox-tdfk)  Injection ",
  "date_of_approval": "September 13, 2018",
  "company": " AstraZeneca and MedImmune",
  "treatment": " Hairy Cell Leukemia",
  "drug_description": "Lumoxiti  (moxetumomab pasudotox-tdfk) is an anti-CD22 recombinant immunotoxin for the treatment of adult patients with hairy cell leukemia.",
  "previous application": "FDA Approves Lumoxiti (moxetumomab pasudotox-tdfk) for Hairy Cell Leukemia  Lumoxiti (moxetumomab pasudotox-tdfk) FDA Approval History"
},{
  "title": "Xelpros (latanoprost)  Ophthalmic Emulsion ",
  "date_of_approval": "September 12, 2018",
  "company": " Sun Pharmaceutical Industries Ltd.",
  "treatment": " Glaucoma (Open Angle), Intraocular Hypertension",
  "drug_description": "Xelpros (latanoprost) is a prostaglandin F2\u03b1 analog indicated for reduction of elevated intraocular pressure in patients with open-angle glaucoma, or ocular hypertension.",
  "previous application": "FDA Approves Xelpros (latanoprost ophthalmic emulsion) to Treat Open-angle Glaucoma or Ocular Hypertension Xelpros (latanoprost) FDA Approval History"
},{
  "title": "Ajovy (fremanezumab-vfrm)  Injection ",
  "date_of_approval": "September 14, 2018",
  "company": " Teva Pharmaceutical Industries Ltd.",
  "treatment": " Migraine Prophylaxis",
  "drug_description": "Ajovy (fremanezumab) is a fully-humanized monoclonal antibody targeting the calcitonin gene-related peptide (CGRP) ligand indicated for the preventive treatment of migraine.",
  "previous application": "FDA Approves Ajovy (fremanezumab-vfrm) for Preventive Treatment of Migraine Ajovy (fremanezumab-vfrm) FDA Approval History"
},{
  "title": "Copiktra (duvelisib)  Capsules ",
  "date_of_approval": "September 24, 2018",
  "company": " Verastem, Inc.",
  "treatment": " Chronic Lymphocytic Leukemia, Follicular Lymphoma",
  "drug_description": "Copiktra (duvelisib) is a first-in-class, oral, dual phosphoinositide-3-kinase (PI3K)-delta/PI3K-gamma inhibitor for the treatment relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and relapsed or refractory follicular lymphoma (FL).",
  "previous application": "FDA Approves Copiktra (duvelisib) Capsules for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma Copiktra (duvelisib) FDA Approval History"
},{
  "title": "Emgality (galcanezumab-gnlm)  Injection ",
  "date_of_approval": "September 27, 2018",
  "company": " Eli Lilly and Company",
  "treatment": " Migraine Prophylaxis, Cluster Headache",
  "drug_description": "Emgality (galcanezumab-gnlm) is a calcitonin gene-related peptide (CGRP) antagonist indicated for the preventive treatment of migraine, and for the treatment of episodic cluster headache.",
  "previous application": "FDA Approves Emgality (galcanezumab-gnlm) for the Preventive Treatment of Migraine in Adults Emgality (galcanezumab-gnlm) FDA Approval History"
},{
  "title": "Vizimpro (dacomitinib)  Tablets ",
  "date_of_approval": "September 27, 2018",
  "company": " Pfizer Inc.",
  "treatment": " Non-Small Cell Lung Cancer",
  "drug_description": "Vizimpro (dacomitinib) is an oral, once-daily, irreversible pan-human epidermal growth factor receptor tyrosine kinase inhibitor (TKI) indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R\r substitution mutations as detected by an FDA-approved test.",
  "previous application": "FDA Approves Vizimpro (dacomitinib) for the First-Line Treatment of Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer Vizimpro (dacomitinib) FDA Approval History"
},{
  "title": "Libtayo (cemiplimab-rwlc)  Injection ",
  "date_of_approval": "September 28, 2018",
  "company": " Sanofi",
  "treatment": " Squamous Cell Carcinoma",
  "drug_description": "Libtayo (cemiplimab-rwlc) is a programmed death receptor-1 (PD-1) blocking antibody\r indicated for the treatment of patients with metastatic cutaneous squamous\r cell carcinoma (CSCC).",
  "previous application": "FDA Approves Libtayo (cemiplimab-rwlc) for Advanced Cutaneous Squamous Cell Carcinoma Libtayo (cemiplimab-rwlc) FDA Approval History"
},{
  "title": "Arikayce (amikacin liposome)  Inhalation Suspension ",
  "date_of_approval": "September 28, 2018",
  "company": " Insmed, Inc.",
  "treatment": " Mycobacterium Avium Complex (MAC) Lung Disease",
  "drug_description": "Arikayce (amikacin liposome inhalation suspension) is an aminoglycoside antibacterial\r indicated for the treatment of Mycobacterium avium complex (MAC) lung disease in adults who have limited or no alternative treatment options.",
  "previous application": "FDA Approves Arikayce (amikacin liposome inhalation suspension) to treat Mycobacterium Avium Complex (MAC) Lung Disease  Arikayce (amikacin liposome) FDA Approval History"
},{
  "title": "Xyosted (testosterone enanthate)  Subcutaneous Injection ",
  "date_of_approval": "September 28, 2018",
  "company": " Antares Pharma, Inc.",
  "treatment": " Hypogonadism -- Male",
  "drug_description": "Xyosted (testosterone enanthate) is a self-administered, subcutaneous injection formulation of the androgen testosterone for the treatment of male hypogonadism, also known as testosterone deficiency or Low T.",
  "previous application": "FDA Approves Xyosted (testosterone enanthate) Injection for Testosterone Replacement Therapy in Adult Males Xyosted (testosterone enanthate) FDA Approval History"
},{
  "title": "Seysara (sarecycline)  Tablets ",
  "date_of_approval": "October 1, 2018",
  "company": " Almirall, S.A.",
  "treatment": " Acne",
  "drug_description": "Seysara (sarecycline) is an oral, narrow spectrum tetracycline-derived antibiotic for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.",
  "previous application": "FDA Approves Seysara (sarecycline) for the Treatment of Moderate to Severe Acne Seysara (sarecycline) FDA Approval History"
},{
  "title": "Nuzyra (omadacycline)  for Injection and Tablets ",
  "date_of_approval": "October 2, 2018",
  "company": " Paratek Pharmaceuticals, Inc.",
  "treatment": " Skin and Structure Infection, Pneumonia",
  "drug_description": "Nuzyra (omadacycline) is an aminomethylcycline tetracycline antibiotic for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).",
  "previous application": "FDA Approves Nuzyra (omadacycline) for Community-Acquired Bacterial Pneumonia and Acute Skin and Skin Structure Infections Nuzyra (omadacycline) FDA Approval History"
},{
  "title": "Revcovi (elapegademase-lvlr)  Injection ",
  "date_of_approval": "October 5, 2018",
  "company": " Leadiant Biosciences, Inc.",
  "treatment": " Adenosine Deaminase Severe Combined Immune\r Deficiency (ADA-SCID)",
  "drug_description": "Revcovi (elapegademase-lvlr) is a recombinant adenosine deaminase indicated for the\r treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID).",
  "previous application": "FDA Approves Revcovi (elapegademase-lvlr) for Adenosine Deaminase Severe Combined Immune Deficiency (ADA-SCID)  Revcovi (elapegademase-lvlr) FDA Approval History"
},{
  "title": "Tegsedi (inotersen)  Injection ",
  "date_of_approval": "October 5, 2018",
  "company": " Ionis Pharmaceuticals, Inc.",
  "treatment": " Amyloidogenic Transthyretin Amyloidosis",
  "drug_description": "Tegsedi (inotersen) is an antisense oligonucleotide inhibitor of the transthyretin (TTR) protein for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.",
  "previous application": "FDA Approves Tegsedi (inotersen) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis Tegsedi (inotersen) FDA Approval History"
},{
  "title": "Yutiq (fluocinolone acetonide)  Intravitreal Implant ",
  "date_of_approval": "October 12, 2018",
  "company": " EyePoint Pharmaceuticals, Inc.",
  "treatment": " Non-Infectious Posterior Segment Uveitis",
  "drug_description": "Yutiq (fluocinolone acetonide) is a corticosteroid intravitreal implant indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.",
  "previous application": "FDA Approves Yutiq (fluocinolone acetonide intravitreal implant) for Chronic Non-Infectious Posterior Segment Uveitis Yutiq (fluocinolone acetonide) FDA Approval History"
},{
  "title": "Talzenna (talazoparib)  Capsules ",
  "date_of_approval": "October 16, 2018",
  "company": " Pfizer Inc.",
  "treatment": " Breast Cancer",
  "drug_description": "Talzenna (talazoparib) is an oral poly ADP ribose polymerase (PARP) inhibitor indicated for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer.",
  "previous application": "FDA Approves Talzenna (talazoparib) for gBRCAm HER2-Negative Locally Advanced or Metastatic Breast Cancer Talzenna (talazoparib) FDA Approval History"
},{
  "title": "Khapzory (levoleucovorin)  for Injection ",
  "date_of_approval": "October 19, 2018",
  "company": " Spectrum Pharmaceuticals, Inc.",
  "treatment": " Methotrexate Rescue, Folic Acid Antagonist Overdose, Colorectal Cancer",
  "drug_description": "Khapzory (levoleucovorin) is a folate analog indicated for:",
  "previous application": "Spectrum Pharmaceuticals Receives FDA Approval of Khapzory (levoleucovorin) for Injection Khapzory (levoleucovorin) FDA Approval History"
},{
  "title": "Xofluza (baloxavir marboxil)  Tablets and Granules for Oral Suspension ",
  "date_of_approval": "October 24, 2018",
  "company": " Genentech, Inc.",
  "treatment": " Influenza",
  "drug_description": "Xofluza (baloxavir marboxil) is a polymerase acidic (PA) endonuclease inhibitor for the treatment of influenza, and for the post-exposure prophylaxis of influenza in people 12 years of age and older.",
  "previous application": "FDA Approves Xofluza (baloxavir marboxil) for the Treatment of Acute Uncomplicated Influenza Xofluza (baloxavir marboxil) FDA Approval History"
},{
  "title": "Bijuva (estradiol and progesterone)  Capsules  - formerly TX-001HR",
  "date_of_approval": "October 28, 2018",
  "company": " TherapeuticsMD, Inc.",
  "treatment": " Menopausal Vasomotor Symptoms",
  "drug_description": "Bijuva (estradiol and progesterone) is a bio-identical hormone combination for the treatment of moderate-to-severe vasomotor symptoms (hot flashes) due to menopause.",
  "previous application": "FDA Approves Bijuva (estradiol and progesterone) Capsules for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause Bijuva (estradiol and progesterone) FDA Approval History"
},{
  "title": "Hyrimoz (adalimumab-adaz)  Injection ",
  "date_of_approval": "October 30, 2018",
  "company": " Sandoz Inc.",
  "treatment": " Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn's Disease -- Maintenance, Ulcerative Colitis, Plaque Psoriasis",
  "drug_description": "Hyrimoz (adalimumab-adaz) is an anti-TNF-\u03b1 monoclonal antibody biosimilar to Humira, approved for the treatment of various inflammatory diseases including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn\u2019s disease, ulcerative colitis, and plaque psoriasis.",
  "previous application": "FDA Approves Hyrimoz (adalimumab-adaz), a Biosimilar to Humira Hyrimoz (adalimumab-adaz) FDA Approval History"
},{
  "title": "Sympazan (clobazam)  Oral Film ",
  "date_of_approval": "November 1, 2018",
  "company": " Aquestive Therapeutics, Inc.",
  "treatment": " Lennox-Gastaut Syndrome",
  "drug_description": "Sympazan (clobazam) is an oral film benzodiazepine formulation indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome.",
  "previous application": "FDA Approves Sympazan (clobazam) Oral Film for Adjunctive Treatment of Seizures Associated with Lennox-Gastaut Syndrome Sympazan (clobazam) FDA Approval History"
},{
  "title": "Dsuvia (sufentanil)  Sublingual Tablets ",
  "date_of_approval": "November 2, 2018",
  "company": " AcelRx Pharmaceuticals, Inc.",
  "treatment": " Pain",
  "drug_description": "Dsuvia (sufentanil) is a synthetic opioid analgesic formulation for the management of acute pain that is severe enough to require an opioid analgesic, and for which alternative treatments are inadequate.",
  "previous application": "FDA Approves Dsuvia (sufentanil) Sublingual Tablets for Severe Pain Dsuvia (sufentanil) FDA Approval History"
},{
  "title": "Lorbrena (lorlatinib)  Tablets ",
  "date_of_approval": "November 2, 2018",
  "company": " Pfizer Inc.",
  "treatment": " Non-Small Cell Lung Cancer",
  "drug_description": "Lorbrena (lorlatinib) is an anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) for the treatment of patients with ALK-positive metastatic non-small cell lung cancer (NSCLC).",
  "previous application": "FDA Approves Lorbrena (lorlatinib) for Previously-Treated ALK-Positive Metastatic Non-Small Cell Lung Cancer Lorbrena (lorlatinib) FDA Approval History"
},{
  "title": "Udenyca (pegfilgrastim-cbqv)  Injection ",
  "date_of_approval": "November 2, 2018",
  "company": " Coherus BioSciences, Inc.",
  "treatment": " Neutropenia Associated with Chemotherapy",
  "drug_description": "Udenyca (pegfilgrastim-cbqv) is a PEGylated growth colony-stimulating factor biosimilar to Neulasta (pegfilgrastim) indicated to reduce the duration of febrile neutropenia in patients treated with chemotherapy.",
  "previous application": "FDA Approves Udenyca (pegfilgrastim-cbqv), a Biosimilar to Neulasta Udenyca (pegfilgrastim-cbqv) FDA Approval History"
},{
  "title": "Bryhali (halobetasol propionate)  Lotion  - formerly Jemdel",
  "date_of_approval": "November 6, 2018",
  "company": " Ortho Dermatologics",
  "treatment": " Plaque Psoriasis",
  "drug_description": "Bryhali (halobetasol propionate) is a high-potency topical corticosteroid formulation for the treatment of plaque psoriasis in adults.",
  "previous application": "Bausch Health Announces U.S. Launch of Bryhali (halobetasol propionate) Lotion, 0.01%, for Plaque Psoriasis In Adults Bryhali (halobetasol propionate) FDA Approval History"
},{
  "title": "Primatene Mist (epinephrine)  Inhalation Aerosol ",
  "date_of_approval": "November 8, 2018",
  "company": " Amphastar Pharmaceuticals, Inc.",
  "treatment": " Asthma",
  "drug_description": "Primatene Mist (epinephrine) is an over-the-counter (OTC) bronchodilator used for the temporary relief of the symptoms of mild asthma. The new formulation of Primatene Mist approved November 2018 is a CFC-free metered dose inhaler (MDI) containing hydrofluoroalkane (HFA) propellants.",
  "previous application": "FDA Approves Newly Formulated OTC Primatene Mist (epinephrine) to Treat Mild Asthma Primatene Mist (epinephrine) FDA Approval History"
},{
  "title": "Yupelri (revefenacin)  Inhalation Solution ",
  "date_of_approval": "November 9, 2018",
  "company": " Theravance Biopharma, Inc.",
  "treatment": " Chronic Obstructive Pulmonary Disease",
  "drug_description": "Yupelri (revefenacin) is a long-acting muscarinic antagonist (LAMA) for the treatment of chronic obstructive pulmonary disease (COPD).",
  "previous application": "FDA Approves Yupelri (revefenacin) for Chronic Obstructive Pulmonary Disease (COPD) Yupelri (revefenacin) FDA Approval History"
},{
  "title": "Aemcolo (rifamycin)  Delayed-Release Tablets ",
  "date_of_approval": "November 16, 2018",
  "company": " Cosmo Technologies, Ltd.",
  "treatment": " Traveler's Diarrhea",
  "drug_description": "Aemcolo (rifamycin) is a broad spectrum, orally non-absorbable antibiotic for the treatment of traveler\u2019s diarrhea caused by noninvasive strains of Escherichia coli.",
  "previous application": "FDA Approves Aemcolo (rifamycin) to Treat Travelers\u2019 Diarrhea Aemcolo (rifamycin) FDA Approval History"
},{
  "title": "Gamifant (emapalumab-lzsg)  Injection ",
  "date_of_approval": "November 20, 2018",
  "company": " Novimmune SA",
  "treatment": " Hemophagocytic Lymphohistiocytosis",
  "drug_description": "Gamifant (emapalumab-lzsg) is an interferon gamma (IFN\u03b3) blocking antibody for the treatment of patients with primary hemophagocytic lymphohistiocytosis (HLH).",
  "previous application": "FDA Approves Gamifant (emapalumab-lzsg) for Primary Hemophagocytic Lymphohistiocytosis Gamifant (emapalumab-lzsg) FDA Approval History"
},{
  "title": "Daurismo (glasdegib)  Tablets ",
  "date_of_approval": "November 21, 2018",
  "company": " Pfizer Inc.",
  "treatment": " Acute Myeloid Leukemia",
  "drug_description": "Daurismo (glasdegib) is a hedgehog pathway inhibitor indicated for the combination treatment of adult patients \u226575 years with newly-diagnosed acute myeloid leukemia (AML).",
  "previous application": "FDA Approves Daurismo (glasdegib) for Patients with Acute Myeloid Leukemia Daurismo (glasdegib) FDA Approval History"
},{
  "title": "Vitrakvi (larotrectinib)  Capsules and Oral Solution ",
  "date_of_approval": "November 26, 2018",
  "company": " Loxo Oncology, Inc.",
  "treatment": " TRK Fusion Cancers",
  "drug_description": "Vitrakvi (larotrectinib) is an oral selective tropomyosin receptor kinase (TRK) inhibitor for the treatment solid tumors harboring NTRK-fusion proteins.",
  "previous application": "FDA Approves Vitrakvi (larotrectinib) for TRK Fusion Cancers Vitrakvi (larotrectinib) FDA Approval History"
},{
  "title": "Truxima (rituximab-abbs)  Injection ",
  "date_of_approval": "November 28, 2018",
  "company": " Celltrion, Inc.",
  "treatment": " non-Hodgkin's Lymphoma",
  "drug_description": "Truxima (rituximab-abbs) is a  CD20-directed cytolytic antibody biosimilar to Rituxan indicated for\r the treatment of adult patients with non-Hodgkin\u2019s lymphoma.",
  "previous application": "FDA Approves Truxima (rituximab-abbs), a Biosimilar to Rituxan Truxima (rituximab-abbs) FDA Approval History"
},{
  "title": "Xospata (gilteritinib)  Tablets ",
  "date_of_approval": "November 28, 2018",
  "company": " Astellas Pharma Inc.",
  "treatment": " Acute Myeloid Leukemia",
  "drug_description": "Xospata (gilteritinib) is a FLT3/AXL kinase inhibitor indicated for the treatment of patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.",
  "previous application": "FDA Approves Xospata (gilteritinib) for Acute Myeloid Leukemia (AML) with a FLT3 Mutation Xospata (gilteritinib) FDA Approval History"
},{
  "title": "Firdapse (amifampridine phosphate)  Tablets ",
  "date_of_approval": "November 28, 2018",
  "company": " Catalyst Pharmaceuticals, Inc.",
  "treatment": " Lambert Eaton Myasthenic Syndrome",
  "drug_description": "Firdapse (amifampridine phosphate) is a nonspecific, voltage-dependent, potassium (K+) channel blocker for the treatment of Lambert Eaton myasthenic syndrome (LEMS) in adults.",
  "previous application": "FDA Approves Firdapse (amifampridine) for Lambert-Eaton Myasthenic Syndrome Firdapse (amifampridine phosphate) FDA Approval History"
},{
  "title": "Dextenza (dexamethasone)  Ophthalmic Insert ",
  "date_of_approval": "November 30, 2018",
  "company": " Ocular Therapeutix, Inc.",
  "treatment": " Post-Surgical Ocular Inflammation and Pain",
  "drug_description": "Dextenza (dexamethasone ophthalmic insert) is a corticosteroid intracanalicular insert for the treatment of post-surgical ocular inflammation and pain.",
  "previous application": "FDA Approves Dextenza (dexamethasone ophthalmic insert) for the Treatment of Ocular Pain Following Ophthalmic Surgery Dextenza (dexamethasone) FDA Approval History"
},{
  "title": "Elepsia XR (levetiracetam)  Extended-Release Tablets ",
  "date_of_approval": "December 20, 2018",
  "company": " Sun Pharma Global",
  "treatment": " Epilepsy",
  "drug_description": "Elepsia XR (levetiracetam) is an extended-release formulation of the antiepileptic drug levetiracetam  designed to reduce pill burden in patients receiving high doses for the treatment of partial onset seizures.",
  "previous application": "Sun Pharma Announces FDA Approval of Elepsia XR (levetiracetam) Extended-Release Tablets Elepsia XR (levetiracetam) FDA Approval History"
},{
  "title": "Elepsia XR (levetiracetam)  Extended-Release Tablets ",
  "date_of_approval": "December 20, 2018",
  "company": " Sun Pharma Global",
  "treatment": " Epilepsy",
  "drug_description": "Elepsia XR (levetiracetam) is an extended-release formulation of the antiepileptic drug levetiracetam  designed to reduce pill burden in patients receiving high doses for the treatment of partial onset seizures.",
  "previous application": "Sun Pharma Advanced Research Company Ltd. Receives Complete Response Letter for Elepsia XR Elepsia XR (levetiracetam) FDA Approval History"
},{
  "title": "Tolsura (itraconazole)  Capsules ",
  "date_of_approval": "December 11, 2018",
  "company": " Mayne Pharma",
  "treatment": " Blastomycosis; Histoplasmosis; Aspergillosis",
  "drug_description": "Tolsura (itraconazole) is an azole antifungal indicated for the treatment of certain fungal infections including blastomycosis, histoplasmosis and aspergillosis.",
  "previous application": "FDA Approves Tolsura (SUBA\u00ae-itraconazole capsules) for the Treatment of Certain Fungal Infections Tolsura (itraconazole) FDA Approval History"
},{
  "title": "Herzuma (trastuzumab-pkrb)  for Injection ",
  "date_of_approval": "December 14, 2018",
  "company": " Celltrion, Inc. and Teva Pharmaceutical Industries Ltd.",
  "treatment": " Breast Cancer",
  "drug_description": "Herzuma (trastuzumab-pkrb) is a HER2/neu receptor antagonist biosimilar to Herceptin indicated for the treatment of HER2-overexpressing breast cancer.",
  "previous application": "FDA Approves Herzuma (trastuzumab-pkrb), a Biosimilar to Herceptin Herzuma (trastuzumab-pkrb) FDA Approval History"
},{
  "title": "Motegrity (prucalopride)  Tablets ",
  "date_of_approval": "December 14, 2018",
  "company": " Shire plc",
  "treatment": " Chronic Idiopathic Constipation",
  "drug_description": "Motegrity (prucalopride) is a selective serotonin type 4 (5\u2011HT4) receptor agonist for the treatment of chronic idiopathic constipation (CIC) in adults.",
  "previous application": "FDA Approves Motegrity (prucalopride) for Adults with Chronic Idiopathic Constipation (CIC) Motegrity (prucalopride) FDA Approval History"
},{
  "title": "Asparlas (calaspargase pegol-mknl)  Injection ",
  "date_of_approval": "December 20, 2018",
  "company": " Servier Pharmaceuticals LLC",
  "treatment": " Acute Lymphoblastic Leukemia",
  "drug_description": "Asparlas (calaspargase pegol-mknl) is an asparagine specific enzyme indicated as a component\r of a multi-agent chemotherapy regimen for the treatment of acute lymphoblastic leukemia.",
  "previous application": "FDA Approves Asparlas (calaspargase pegol-mknl) for Acute Lymphoblastic Leukemia (ALL) Asparlas (calaspargase pegol-mknl) FDA Approval History"
},{
  "title": "Ultomiris (ravulizumab-cwvz)  Injection ",
  "date_of_approval": "December 21, 2018",
  "company": " Alexion Pharmaceuticals, Inc.",
  "treatment": " Paroxysmal Nocturnal Hemoglobinuria, Hemolytic Uremic Syndrome",
  "drug_description": "Ultomiris (ravulizumab-cwvz) is a long-acting C5 complement inhibitor for:",
  "previous application": "FDA Approves Ultomiris (ravulizumab-cwvz) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH) Ultomiris (ravulizumab-cwvz) FDA Approval History"
},{
  "title": "Elzonris (tagraxofusp-erzs)  Injection ",
  "date_of_approval": "December 21, 2018",
  "company": " Stemline Therapeutics, Inc.",
  "treatment": " Blastic Plasmacytoid Dendritic Cell Neoplasm",
  "drug_description": "Elzonris (tagraxofusp-erzs) is a CD123-directed cytotoxin for the treatment of blastic\r plasmacytoid dendritic cell neoplasm (BPDCN).",
  "previous application": "FDA Approves Elzonris (tagraxofusp-erzs), the First Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm and First CD123-Targeted Therapy Elzonris (tagraxofusp-erzs) FDA Approval History"
},{
  "title": "Inbrija (levodopa)  Inhalation Powder ",
  "date_of_approval": "December 21, 2018",
  "company": " Acorda Therapeutics, Inc.",
  "treatment": " Parkinson's Disease",
  "drug_description": "Inbrija (levodopa) is an oral inhalation formulation of the approved drug levodopa for the treatment of OFF episodes in people with Parkinson\u2019s disease taking a carbidopa/levodopa regimen.",
  "previous application": "FDA Approves Inbrija (levodopa inhalation powder) for Intermittent Treatment of OFF Episodes in People with Parkinson\u2019s Disease Inbrija (levodopa) FDA Approval History"
},{
  "title": "ProAir Digihaler (albuterol sulfate)  Inhalation Powder ",
  "date_of_approval": "December 21, 2018",
  "company": " Teva Pharmaceutical Industries Ltd.",
  "treatment": " Bronchospasm Prophylaxis, Asthma, Chronic Obstructive Pulmonary Disease",
  "drug_description": "ProAir Digihaler (albuterol sulfate) is a beta2-adrenergic agonist indicated for the treatment or prevention of bronchospasm in patients with reversible obstructive airway disease, and the prevention of exercise-induced bronchospasm.",
  "previous application": "FDA Approves ProAir Digihaler (albuterol sulfate) as the First and Only Digital Inhaler with Built-In Sensors ProAir Digihaler (albuterol sulfate) FDA Approval History"
},{
  "title": "Vaxelis (diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus, haemophilus b conjugate [meningococcal protein conjugate] and hepatitis B [recombinant] vaccine)  Suspension for Intramuscular Injection ",
  "date_of_approval": "December 21, 2018",
  "company": " Merck and Sanofi",
  "treatment": " Diphtheria Prophylaxis, Tetanus Prophylaxis, Pertussis Prophylaxis, Poliomyelitis Prophylaxis, Hepatitis B Prophylaxis, Haemophilus influenzae Prophylaxis",
  "drug_description": "Vaxelis is a hexavalent combination vaccine indicated for active immunization to prevent\r diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease\r due to Haemophilus influenzae type b in children from 6 weeks through 4 years of age (prior to the 5th birthday).",
  "previous application": "FDA Approves Vaxelis Pediatric Hexavalent Combination Vaccine Vaxelis (diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus, haemophilus b conjugate [meningococcal protein conjugate] and hepatitis B [recombinant] vaccine) FDA Approval History"
},{
  "title": "Ontruzant (trastuzumab-dttb)  for Injection ",
  "date_of_approval": "January 18, 2019",
  "company": " Samsung Bioepis Co., Ltd.",
  "treatment": " Breast Cancer, Gastric Cancer",
  "drug_description": "Ontruzant (trastuzumab-dttb) is a HER2/neu receptor antagonist biosimilar to Herceptin indicated for the treatment of HER2-overexpressing breast cancer, and the treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.",
  "previous application": "FDA Approves Ontruzant (trastuzumab-dttb), a Biosimilar to Herceptin Ontruzant (trastuzumab-dttb) FDA Approval History"
},{
  "title": "Tosymra (sumatriptan)  Nasal Spray ",
  "date_of_approval": "January 25, 2019",
  "company": " Dr. Reddy's Laboratories, Inc.",
  "treatment": " Migraine",
  "drug_description": "Tosymra (sumatriptan) is a serotonin (5-HT1B/1D) receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults.",
  "previous application": "FDA Approves Tosymra (sumatriptan) Nasal Spray for Acute Treatment of Migraine Tosymra (sumatriptan) FDA Approval History"
},{
  "title": "Wixela Inhub (fluticasone propionate and salmeterol)  Inhalation Powder ",
  "date_of_approval": "January 30, 2019",
  "company": " Mylan N.V.",
  "treatment": " Asthma, Chronic Obstructive Pulmonary Disease",
  "drug_description": "Wixela Inhub is the first approved generic version of Advair Diskus.",
  "previous application": "FDA Approves Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP), First Generic of Advair Diskus Wixela Inhub (fluticasone propionate and salmeterol) FDA Approval History"
},{
  "title": "Gloperba (colchicine)  Oral Solution ",
  "date_of_approval": "January 30, 2019",
  "company": " Romeg Therapeutics, LLC",
  "treatment": " Gout",
  "drug_description": "Gloperba (colchicine) is an oral solution formulation of the approved drug colchicine indicated for prophylaxis of gout flares in adults.",
  "previous application": "FDA Approves Gloperba (colchicine) for Prophylaxis of Adult Gout Flares Gloperba (colchicine) FDA Approval History"
},{
  "title": "Jeuveau (prabotulinumtoxinA-xvfs)  Injection ",
  "date_of_approval": "February 1, 2019",
  "company": " Evolus, Inc.",
  "treatment": " Glabellar Lines",
  "drug_description": "Jeuveau (prabotulinumtoxinA) is a proprietary 900 kDa purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar (frown) lines.",
  "previous application": "FDA Approves Jeuveau (prabotulinumtoxinA-xvfs) for Temporary Improvement in the Appearance of Frown Lines Jeuveau (prabotulinumtoxinA-xvfs) FDA Approval History"
},{
  "title": "Cablivi (caplacizumab-yhdp)  Injection ",
  "date_of_approval": "February 6, 2019",
  "company": " Ablynx NV",
  "treatment": " Acquired Thrombotic Thrombocytopenic Purpura",
  "drug_description": "Cablivi (caplacizumab-yhdp) is a von Willebrand factor (vWF)-directed antibody fragment\r indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.",
  "previous application": "FDA Approves Cablivi (caplacizumab-yhdp) for Acquired Thrombotic Thrombocytopenic Purpura (aTTP) in Adults Cablivi (caplacizumab-yhdp) FDA Approval History"
},{
  "title": "Egaten (triclabendazole)  Tablets ",
  "date_of_approval": "February 13, 2019",
  "company": " Novartis",
  "treatment": " Fascioliasis",
  "drug_description": "Egaten (triclabendazole) is a benzimidazole anthelmintic indicated for the treatment of fascioliasis,  a neglected tropical disease (NTD) caused by liver flukes Fasciola hepatica and Fasciola gigantica.",
  "previous application": "FDA Approves Egaten (triclabendazole) for the Treatment of Fascioliasis, a Neglected Tropical Disease Egaten (triclabendazole) FDA Approval History"
},{
  "title": "Esperoct (turoctocog alfa pegol)  Injection ",
  "date_of_approval": "February 19, 2019",
  "company": " Novo Nordisk",
  "treatment": " Hemophilia A",
  "drug_description": "Esperoct (turoctocog alfa pegol, N8-GP) is an extended half-life factor VIII molecule for the treatment of adults and children with hemophilia A.",
  "previous application": "FDA Approves Esperoct (turoctocog alfa pegol, N8-GP) for Hemophilia A Esperoct (turoctocog alfa pegol) FDA Approval History"
},{
  "title": "Herceptin Hylecta (trastuzumab and hyaluronidase-oysk)  for Subcutaneous Injection ",
  "date_of_approval": "February 28, 2019",
  "company": " Genentech, Inc.",
  "treatment": " Breast Cancer",
  "drug_description": "Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) is a combination of the approved HER2/neu receptor antagonist trastuzumab (Herceptin) and recombinant human hyaluronidase PH20 (an enzyme that helps to deliver trastuzumab under the skin) indicated for the treatment of HER2-overexpressing breast cancer.",
  "previous application": "FDA Approves Herceptin Hylecta for Subcutaneous Injection in Certain HER2-Positive Breast Cancers Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) FDA Approval History"
},{
  "title": "Adhansia XR (methylphenidate hydrochloride)  Extended-Release Capsules ",
  "date_of_approval": "February 27, 2019",
  "company": " Adlon Therapeutics L.P.",
  "treatment": " Attention-Deficit / Hyperactivity Disorder",
  "drug_description": "Adhansia XR (methylphenidate hydrochloride) is an extended-release capsule formulation of the approved central nervous system (CNS) stimulant methylphenidate indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in patients six years and older.",
  "previous application": "FDA Approves Adhansia XR (methylphenidate hydrochloride) Extended-Release Capsules for the Treatment of ADHD Adhansia XR (methylphenidate hydrochloride) FDA Approval History"
},{
  "title": "Spravato (esketamine)  Nasal Spray ",
  "date_of_approval": "March 5, 2019",
  "company": " Janssen Pharmaceuticals, Inc.",
  "treatment": " Depression",
  "drug_description": "Spravato (esketamine) is a rapid acting, nasal spray formulation of a non-competitive N-methyl D-aspartate (NMDA) receptor antagonist indicated, in conjunction with an oral antidepressant, for the treatment of treatment-resistant depression (TRD) in adults, and depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior.",
  "previous application": "FDA Approves Spravato (esketamine) Nasal Spray for Treatment-Resistant Depression Spravato (esketamine) FDA Approval History"
},{
  "title": "Trazimera (trastuzumab-qyyp)  for Injection ",
  "date_of_approval": "March 11, 2019",
  "company": " Pfizer Inc.",
  "treatment": " Breast Cancer, Gastric Cancer",
  "drug_description": "Trazimera (trastuzumab-qyyp) is a HER2/neu receptor antagonist biosimilar to Herceptin indicated for the treatment of HER2-overexpressing breast cancer, and the treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.",
  "previous application": "FDA Approves Trazimera (trastuzumab-qyyp), a Biosimilar to Herceptin Trazimera (trastuzumab-qyyp) FDA Approval History"
},{
  "title": "Rocklatan (netarsudil and latanoprost)  Ophthalmic Solution ",
  "date_of_approval": "March 12, 2019",
  "company": " Aerie Pharmaceuticals, Inc.",
  "treatment": " Glaucoma (Open Angle), Intraocular Hypertension",
  "drug_description": "Rocklatan (netarsudil and latanoprost ophthalmic solution) is a fixed dose combination of the Rho kinase inhibitor netarsudil (Rhopressa) and the prostaglandin F2\u03b1 analogue latanoprost (Xalatan), indicated to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.",
  "previous application": "FDA Approves Rocklatan (netarsudil and latanoprost ophthalmic solution) for the Reduction of Intraocular Pressure in Open-Angle Glaucoma or Ocular Hypertension Rocklatan (netarsudil and latanoprost) FDA Approval History"
},{
  "title": "Zulresso (brexanolone)  Injection ",
  "date_of_approval": "March 19, 2019",
  "company": " Sage Therapeutics",
  "treatment": " Postpartum Depression",
  "drug_description": "Zulresso (brexanolone) is a gamma-aminobutyric acid A (GABAA)\r receptor positive allosteric modulator indicated for the treatment of postpartum depression (PPD).",
  "previous application": "FDA Approves Zulresso (brexanolone) for the Treatment of Postpartum Depression Zulresso (brexanolone) FDA Approval History"
},{
  "title": "Sunosi (solriamfetol)  Tablets ",
  "date_of_approval": "March 20, 2019",
  "company": " Jazz Pharmaceuticals plc",
  "treatment": " Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome",
  "drug_description": "Sunosi (solriamfetol) is a selective dopamine and norepinephrine reuptake inhibitor (DNRI) for the treatment of excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea (OSA).",
  "previous application": "FDA Approves Sunosi (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea Sunosi (solriamfetol) FDA Approval History"
},{
  "title": "Mayzent (siponimod)  Tablets ",
  "date_of_approval": "March 26, 2019",
  "company": " Novartis",
  "treatment": " Multiple Sclerosis",
  "drug_description": "Mayzent (siponimod) is a sphingosine-1-phosphate receptor modulator for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.",
  "previous application": "FDA Approves Mayzent (siponimod) for Secondary Progressive Multiple Sclerosis Mayzent (siponimod) FDA Approval History"
},{
  "title": "Jatenzo (testosterone undecanoate)  Capsules ",
  "date_of_approval": "March 27, 2019",
  "company": " Clarus Therapeutics, Inc.",
  "treatment": " Hypogonadism -- Male",
  "drug_description": "Jatenzo (testosterone undecanoate) is an oral testosterone replacement therapy for the treatment of low testosterone in hypogonadal men.",
  "previous application": "FDA Approves Jatenzo (testosterone undecanoate) for Certain Forms of Hypogonadism Jatenzo (testosterone undecanoate) FDA Approval History"
},{
  "title": "Mavenclad (cladribine)  Tablets ",
  "date_of_approval": "March 29, 2019",
  "company": " EMD Serono, Inc.",
  "treatment": " Multiple Sclerosis",
  "drug_description": "Mavenclad (cladribine) is a purine antimetabolite indicated for the treatment of\r relapsing forms of multiple sclerosis (MS).",
  "previous application": "FDA Approves Mavenclad (cladribine) Tablets for Multiple Sclerosis Mavenclad (cladribine) FDA Approval History"
},{
  "title": "Duaklir Pressair (aclidinium bromide and formoterol fumarate)  Inhalation Powder ",
  "date_of_approval": "March 29, 2019",
  "company": " Circassia Pharmaceuticals plc",
  "treatment": " Chronic Obstructive Pulmonary Disease",
  "drug_description": "Duaklir Pressair (aclidinium bromide and formoterol fumarate) is a long-acting muscarinic antagonist (LAMA) and long-acting beta2 agonist (LABA) fixed dose combination maintenance bronchodilator for the treatment of COPD.",
  "previous application": "FDA Approves Duaklir Pressair (aclidinium bromide and formoterol fumarate) for Maintenance Treatment of Chronic Obstructive Pulmonary Disease Duaklir Pressair (aclidinium bromide and formoterol fumarate) FDA Approval History"
},{
  "title": "Avaclyr (acyclovir)  Ophthalmic Ointment ",
  "date_of_approval": "March 29, 2019",
  "company": " Fera Pharmaceuticals",
  "treatment": " Herpes Simplex Dendritic Keratitis",
  "drug_description": "Avaclyr (acyclovir ophthalmic ointment) is a herpes simplex virus nucleoside analog DNA polymerase inhibitor indicated for the treatment of acute herpetic keratitis (dendritic ulcers) in patients with herpes simplex (HSV-1 and HSV-2) virus.",
  "previous application": "FDA Approves Avaclyr (acyclovir ophthalmic ointment) for the Treatment of Herpetic Keratitis Avaclyr (acyclovir) FDA Approval History"
},{
  "title": "Asceniv (immune globulin intravenous, human \u2013 slra)  Injection ",
  "date_of_approval": "April 1, 2019",
  "company": " ADMA Biologics, Inc.",
  "treatment": " Primary Immunodeficiency Syndrome",
  "drug_description": "Asceniv (immune globulin intravenous, human \u2013 slra) is a 10% immune globulin liquid for intravenous injection, indicated for the treatment of primary humoral immunodeficiency (PI).",
  "previous application": "FDA Approves Asceniv (immune globulin intravenous, human) for Primary Humoral Immunodeficiency Asceniv (immune globulin intravenous, human \u2013 slra) FDA Approval History"
},{
  "title": "Dovato (dolutegravir and lamivudine)  Tablets ",
  "date_of_approval": "April 8, 2019",
  "company": " ViiV Healthcare",
  "treatment": " HIV Infection",
  "drug_description": "Dovato (dolutegravir and lamivudine) is a combination of the integrase strand transfer inhibitor dolutegravir (Tivicay) and the nucleoside analogue reverse transcriptase inhibitor lamivudine (Epivir) used for the treatment of HIV-1 infection in adults.",
  "previous application": "FDA Approves Dovato (dolutegravir/lamivudine) for HIV-1 Infection in Adults with No Antiretroviral (ARV) Treatment History Dovato (dolutegravir and lamivudine) FDA Approval History"
},{
  "title": "Evenity (romosozumab-aqqg)  Injection ",
  "date_of_approval": "April 9, 2019",
  "company": " Amgen Inc.",
  "treatment": " Osteoporosis",
  "drug_description": "Evenity (romosozumab) is an anti-sclerostin monoclonal antibody for the treatment of osteoporosis in postmenopausal women at increased risk of fracture.",
  "previous application": "FDA Approves Evenity (romosozumab-aqqg) for the Treatment of Osteoporosis in Postmenopausal Women at High Risk of Fracture Evenity (romosozumab-aqqg) FDA Approval History"
},{
  "title": "Balversa (erdafitinib)  Tablets ",
  "date_of_approval": "April 12, 2019",
  "company": " Janssen Pharmaceuticals, Inc.",
  "treatment": " Urothelial Carcinoma",
  "drug_description": "Balversa (erdafitinib) is a once-daily, oral, pan-fibroblast growth factor receptor for the treatment of patients with locally advanced or metastatic urothelial cancer.",
  "previous application": "FDA Approves Balversa (erdafitinib) for the Treatment of Metastatic Bladder Cancer Balversa (erdafitinib) FDA Approval History"
},{
  "title": "Plenity (cellulose and citric acid)  Capsules ",
  "date_of_approval": "April 12, 2019",
  "company": " Gelesis",
  "treatment": " Obesity",
  "drug_description": "Plenity (cellulose and citric acid) is an oral, non-systemic, superabsorbent hydrogel used in conjunction with diet and exercise to aid weight management in adults who are overweight or obese. It works by inducing a feeling of fullness so that patients eat less and lose weight.",
  "previous application": "Gelesis Granted FDA Clearance to Market Plenity - a New Prescription Aid in Weight Management Plenity (cellulose and citric acid) FDA Approval History"
},{
  "title": "Skyrizi (risankizumab-rzaa)  Injection ",
  "date_of_approval": "April 23, 2019",
  "company": " AbbVie Inc.",
  "treatment": " Plaque Psoriasis",
  "drug_description": "Skyrizi (risankizumab-rzaa) is an interleukin-23 (IL-23) inhibitor for the treatment of plaque psoriasis.",
  "previous application": "FDA Approves Skyrizi (risankizumab-rzaa) for Moderate to Severe Plaque Psoriasis Skyrizi (risankizumab-rzaa) FDA Approval History"
},{
  "title": "Duobrii (halobetasol propionate and tazarotene)  Lotion ",
  "date_of_approval": "April 25, 2019",
  "company": " Ortho Dermatologics",
  "treatment": " Plaque Psoriasis",
  "drug_description": "Duobrii (halobetasol propionate and tazarotene) is a corticosteroid and retinoid combination indicated for the topical treatment of plaque psoriasis.",
  "previous application": "FDA Approves Duobrii (halobetasol propionate and tazarotene) Lotion 0.01%/0.045% for Plaque Psoriasis In Adults Duobrii (halobetasol propionate and tazarotene) FDA Approval History"
},{
  "title": "Eticovo (etanercept-ykro)  Injection ",
  "date_of_approval": "April 25, 2019",
  "company": " Samsung Bioepis Co., Ltd.",
  "treatment": "NONE",
  "drug_description": "Eticovo (etanercept-ykro) is a tumor necrosis factor (TNF) blocker biosimilar to Enbrel indicated for the treatment of rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis (JIA), psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis.",
  "previous application": "FDA Approves Eticovo (etanercept-ykro), a Biosimilar to Enbrel Eticovo (etanercept-ykro) FDA Approval History"
},{
  "title": "Dengvaxia (dengue tetravalent vaccine, live)  Injection ",
  "date_of_approval": "May 1, 2019",
  "company": " Sanofi Pasteur, Inc.",
  "treatment": " Prevention of Dengue Disease",
  "drug_description": "Dengvaxia (dengue tetravalent vaccine, live) is a vaccine indicated for the prevention of dengue caused by dengue virus serotypes 1, 2, 3 and 4 in people 9 years through 16 years of age living in endemic areas who have laboratory-confirmed previous dengue infection.",
  "previous application": "FDA Approves Dengvaxia (dengue vaccine) for the Prevention of Dengue Disease in Endemic Regions Dengvaxia (dengue tetravalent vaccine, live) FDA Approval History"
},{
  "title": "Qternmet XR (dapagliflozin, metformin hydrochloride and saxagliptin)  Extended-Release Tablets ",
  "date_of_approval": "May 2, 2019",
  "company": " AstraZeneca",
  "treatment": " Diabetes Type 2",
  "drug_description": "Qternmet XR (dapagliflozin, metformin hydrochloride and saxagliptin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, biguanide and dipeptidyl peptidase-4 (DPP-4) inhibitor combination indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.",
  "previous application": "FDA Approves Qternmet XR (dapagliflozin, saxagliptin and metformin hydrochloride) for Type 2 Diabetes Qternmet XR (dapagliflozin, metformin hydrochloride and saxagliptin) FDA Approval History"
},{
  "title": "Vyndaqel (tafamidis meglumine)  Capsules ",
  "date_of_approval": "May 3, 2019",
  "company": " Pfizer Inc.",
  "treatment": " Cardiomyopathy of Transthyretin-Mediated Amyloidosis",
  "drug_description": "Vyndaqel (tafamidis meglumine) is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis.",
  "previous application": "FDA Approves New Treatments Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) for Heart Disease Caused by Transthyretin Mediated Amyloidosis Vyndaqel (tafamidis meglumine) FDA Approval History"
},{
  "title": "Ruzurgi (amifampridine)  Tablets ",
  "date_of_approval": "May 6, 2019",
  "company": " Jacobus Pharmaceutical Company, Inc.",
  "treatment": " Lambert-Eaton Myasthenic Syndrome",
  "drug_description": "Ruzurgi (amifampridine) is a potassium-channel blocker indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 years to less than 17 years of age.",
  "previous application": "FDA Approves Ruzurgi (amifampridine) for Children with Lambert-Eaton Myasthenic Syndrome Ruzurgi (amifampridine) FDA Approval History"
},{
  "title": "Nayzilam (midazolam)  Nasal Spray ",
  "date_of_approval": "May 17, 2019",
  "company": " UCB",
  "treatment": " Seizure Clusters",
  "drug_description": "Nayzilam (midazolam) is a nasally administered benzodiazepine indicated for the acute treatment of seizure clusters.",
  "previous application": "FDA Approves Nayzilam (midazolam) Nasal Spray to Treat Seizure Clusters Nayzilam (midazolam) FDA Approval History"
},{
  "title": "Piqray (alpelisib)  Tablets ",
  "date_of_approval": "May 24, 2019",
  "company": " Novartis",
  "treatment": " Breast Cancer",
  "drug_description": "Piqray (alpelisib) is a kinase inhibitor indicated in combination with fulvestrant for the\r treatment of postmenopausal women, and men, with HR positive, HER2-negative,\r PIK3CA-mutated breast cancer.",
  "previous application": "FDA Approves Piqray (alpelisib) as First PI3K Inhibitor for Breast Cancer Piqray (alpelisib) FDA Approval History"
},{
  "title": "Zolgensma (onasemnogene abeparvovec-xioi)  Suspension for Intravenous Infusion ",
  "date_of_approval": "May 24, 2019",
  "company": " Novartis",
  "treatment": " Spinal Muscular Atrophy",
  "drug_description": "Zolgensma (onasemnogene abeparvovec-xioi) is an adeno-associated virus vector-based gene therapy indicated for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA).",
  "previous application": "FDA Approves Zolgensma (onasemnogene abeparvovec-xioi) Gene Therapy to Treat Pediatric Patients with Spinal Muscular Atrophy Zolgensma (onasemnogene abeparvovec-xioi) FDA Approval History"
},{
  "title": "Slynd (drospirenone)  Tablets ",
  "date_of_approval": "May 23, 2019",
  "company": " Exeltis",
  "treatment": " Contraception",
  "drug_description": "Slynd (drospirenone) is a progestin oral contraceptive for birth control.",
  "previous application": "Exeltis USA, Inc. Announces the Approval of Slynd (drospirenone), the First and Only Progestin-Only Pill Providing Pregnancy Prevention with a 24/4 Dosing Regimen and 24-hour Missed Pill Window Slynd (drospirenone) FDA Approval History"
},{
  "title": "Polivy (polatuzumab vedotin-piiq)  Injection ",
  "date_of_approval": "June 10, 2019",
  "company": " Genentech, Inc.",
  "treatment": " Diffuse Large B-Cell Lymphoma",
  "drug_description": "Polivy (polatuzumab vedotin-piiq) is a CD79b-directed antibody\u2013drug conjugate indicated in\r combination with bendamustine and rituximab for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma, who have received at least two prior therapies.",
  "previous application": "FDA Grants Genentech\u2019s Polivy (polatuzumab vedotin-piiq) Accelerated Approval for Adults With Previously Treated Aggressive Lymphoma Polivy (polatuzumab vedotin-piiq) FDA Approval History"
},{
  "title": "Kanjinti (trastuzumab-anns)  Injection ",
  "date_of_approval": "June 13, 2019",
  "company": " Amgen Inc.",
  "treatment": " Breast Cancer, Gastric Cancer",
  "drug_description": "Kanjinti (trastuzumab-anns) is a HER2/neu receptor antagonist biosimilar to Herceptin indicated for the treatment of HER2 overexpressing breast cancer, and the treatment of HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.",
  "previous application": "FDA Approves Kanjinti (trastuzumab-anns), a Biosimilar to Herceptin Kanjinti (trastuzumab-anns) FDA Approval History"
},{
  "title": "Vyleesi (bremelanotide)  Injection ",
  "date_of_approval": "June 21, 2019",
  "company": " AMAG Pharmaceuticals, Inc.",
  "treatment": " Hypoactive Sexual Desire Disorder",
  "drug_description": "Vyleesi  (bremelanotide) is a melanocortin receptor agonist for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.",
  "previous application": "AMAG Pharmaceuticals Announces FDA Approval of Vyleesi (bremelanotide injection) for Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women Vyleesi (bremelanotide) FDA Approval History"
},{
  "title": "Zirabev (bevacizumab-bvzr)  Injection ",
  "date_of_approval": "June 27, 2019",
  "company": " Pfizer Inc.",
  "treatment": " Colorectal Cancer, Non-Small Cell Lung Cancer, Glioblastoma Multiforme, Renal Cell Carcinoma, Cervical Cancer",
  "drug_description": "Zirabev (bevacizumab-bvzr) is a vascular endothelial growth factor (VEGF) inhibitor biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer including metastatic colorectal cancer, non-small cell lung cancer, glioblastoma, metastatic renal cell carcinoma, and cervical cancer.",
  "previous application": "FDA Approves Zirabev (bevacizumab-bvzr), a Biosimilar to Avastin  Zirabev (bevacizumab-bvzr) FDA Approval History"
},{
  "title": "Thiola EC (tiopronin)  Delayed-Release Tablets ",
  "date_of_approval": "June 28, 2019",
  "company": " Retrophin, Inc.",
  "treatment": " Cystinuria",
  "drug_description": "Thiola EC (tiopronin) is a reducing and complexing thiol indicated for the prevention of cystine stone formation in patients with cystinuria.",
  "previous application": "FDA Approves Thiola EC (tiopronin) for the Treatment of Cystinuria Thiola EC (tiopronin) FDA Approval History"
},{
  "title": "Myxredlin (insulin human in sodium chloride)  Injection ",
  "date_of_approval": "June 20, 2019",
  "company": " Baxter International Inc.",
  "treatment": " Diabetes Type 1, Diabetes Type 2",
  "drug_description": "Myxredlin (insulin human in sodium chloride) is a short-acting human insulin indicated to\r improve glycemic control in adults and pediatric patients with diabetes mellitus.",
  "previous application": "Baxter Announces U.S FDA Approval of Myxredlin, the First and Only Ready-To-Use Insulin for IV Infusion Myxredlin (insulin human in sodium chloride) FDA Approval History"
},{
  "title": "Ortikos (budesonide)  Extended-Release Capsules ",
  "date_of_approval": "June 13, 2019",
  "company": " Ferring Pharmaceuticals Inc.",
  "treatment": " Crohn's Disease -- Acute, Crohn's Disease -- Maintenance",
  "drug_description": "Ortikos (budesonide) is an oral corticosteroid indicated for the treatment of mild to moderate active Crohn\u2019s disease.",
  "previous application": "Ortikos (budesonide), the First and Only Once-Daily Dose for Treatment of Mild to Moderate Crohn\u2019s Disease, Now Available in the U.S. Ortikos (budesonide) FDA Approval History"
},{
  "title": "Xpovio (selinexor)  Tablets ",
  "date_of_approval": "July 3, 2019",
  "company": " Karyopharm Therapeutics Inc.",
  "treatment": " Multiple Myeloma; Diffuse Large B-cell Lymphoma",
  "drug_description": "Xpovio (selinexor) is a first in class Selective Inhibitor of Nuclear Export (SINE) XPO1 antagonist for the treatment of patients adult patients with multiple myeloma (RRMM) and relapsed or refractory diffuse large B-cell lymphoma (DLBCL).",
  "previous application": "FDA Approves Xpovio (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Xpovio (selinexor) FDA Approval History"
},{
  "title": "Xembify (immune globulin subcutaneous, human - klhw)  Injection ",
  "date_of_approval": "July 3, 2019",
  "company": " Grifols",
  "treatment": " Primary Immunodeficiency Syndrome",
  "drug_description": "Xembify (immune globulin subcutaneous, human- klhw) is a 20% immune globulin solution for subcutaneous injection indicated for treatment of Primary Humoral Immunodeficiency (PI).",
  "previous application": "FDA Approves Xembify (immune globulin subcutaneous) for Primary Immunodeficiencies Xembify (immune globulin subcutaneous, human - klhw) FDA Approval History"
},{
  "title": "Katerzia (amlodipine benzoate)  Oral Suspension ",
  "date_of_approval": "July 8, 2019",
  "company": " Silvergate Pharmaceuticals, Inc.",
  "treatment": " Hypertension, Coronary Artery Disease",
  "drug_description": "Katerzia (amlodipine benzoate) is a calcium channel blocker in an oral suspension formulation indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, and coronary artery disease in adults.",
  "previous application": "FDA Approves Katerzia (amlodipine) Oral Suspension for Pediatric Patients 6 Years of Age and Older Katerzia (amlodipine benzoate) FDA Approval History"
},{
  "title": "AirDuo Digihaler (fluticasone propionate and salmeterol)  Inhalation Powder ",
  "date_of_approval": "July 15, 2019",
  "company": "NONE",
  "treatment": " Asthma",
  "drug_description": "AirDuo Digihaler (fluticasone propionate and salmeterol) is a corticosteroid and a long-acting beta2-adrenergic agonist (LABA) combination therapy for the treatment of asthma in patients aged 12 years and older.",
  "previous application": "FDA Approves AirDuo Digihaler (fluticasone propionate and salmeterol) Inhalation Powder for Asthma AirDuo Digihaler (fluticasone propionate and salmeterol) FDA Approval History"
},{
  "title": "Recarbrio (imipenem, cilastatin, and relebactam)  for Injection ",
  "date_of_approval": "July 16, 2019",
  "company": " Merck",
  "treatment": " Urinary Tract Infection, Intraabdominal Infection, Nosocomial Pneumonia",
  "drug_description": "Recarbrio (imipenem, cilastatin, and relebactam) is a combination of imipenem, a penem antibacterial, cilastatin, a renal dehydropeptidase inhibitor, and relebactam, a betalactamase inhibitor, indicated for the treatment of complicated urinary tract infections (cUTI), complicated intra-abdominal infections (cIAI), and hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in adults.",
  "previous application": "FDA Approves Recarbrio (imipenem, cilastatin, and relebactam) for the Treatment of Complicated Urinary Tract and Complicated Intra-Abdominal Bacterial Infections  Recarbrio (imipenem, cilastatin, and relebactam) FDA Approval History"
},{
  "title": "Ruxience (rituximab-pvvr)  Injection ",
  "date_of_approval": "July 23, 2019",
  "company": " Pfizer Inc.",
  "treatment": " non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Wegener's Granulomatosis, Microscopic Polyangiitis",
  "drug_description": "Ruxience (rituximab-pvvr) is a CD20-directed cytolytic antibody biosimilar to Rituxan indicated for the treatment of adult patients with non-Hodgkin\u2019s lymphoma (NHL), chronic lymphocytic leukemia (CLL), and granulomatosis with polyangiitis (GPA) (Wegener\u2019s Granulomatosis) and microscopic polyangiitis (MPA).",
  "previous application": "FDA Approves Ruxience (rituximab-pvvr), a Biosimilar to Rituxan Ruxience (rituximab-pvvr) FDA Approval History"
},{
  "title": "Hadlima (adalimumab-bwwd)  Injection ",
  "date_of_approval": "July 23, 2019",
  "company": " Samsung Bioepis Co., Ltd.",
  "treatment": " Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn's Disease -- Maintenance, Ulcerative Colitis, Plaque Psoriasis",
  "drug_description": "Hadlima (adalimumab-bwwd) is a tumor necrosis factor (TNF) blocker biosimilar to Humira indicated for the treatment of rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), Crohn\u2019s disease (CD), ulcerative colitis (UC), and plaque psoriasis (Ps).",
  "previous application": "FDA Approves Hadlima (adalimumab-bwwd), a Biosimilar to Humira Hadlima (adalimumab-bwwd) FDA Approval History"
},{
  "title": "Baqsimi (glucagon)  Nasal Powder ",
  "date_of_approval": "July 24, 2019",
  "company": " Eli Lilly and Company",
  "treatment": " Hypoglycemia",
  "drug_description": "Baqsimi (glucagon) is a nasally administered antihypoglycemic agent indicated for the treatment of\r severe hypoglycemia in diabetes patients ages 4 years and older.",
  "previous application": "FDA Approves Baqsimi (glucagon) Nasal Powder for the Treatment of Severe Hypoglycemia Baqsimi (glucagon) FDA Approval History"
},{
  "title": "Accrufer (ferric maltol)  Capsules  - formerly Feraccru",
  "date_of_approval": "July 25, 2019",
  "company": " Shield Therapeutics plc",
  "treatment": " Iron Deficiency",
  "drug_description": "Accrufer (ferric maltol) is a non-salt formulation of ferric iron for the treatment of iron deficiency in adults.",
  "previous application": "FDA Approves Accrufer (ferric maltol) for the Treatment of Iron Deficiency in Adults Accrufer (ferric maltol) FDA Approval History"
},{
  "title": "Nubeqa (darolutamide)  Tablets ",
  "date_of_approval": "July 30, 2019",
  "company": " Bayer",
  "treatment": " Prostate Cancer",
  "drug_description": "Nubeqa (darolutamide) is an androgen receptor inhibitor (ARi) indicated for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC).",
  "previous application": "FDA Approves Nubeqa (darolutamide) for Men with Non-Metastatic Castration-Resistant Prostate Cancer Nubeqa (darolutamide) FDA Approval History"
},{
  "title": "Turalio (pexidartinib)  Capsules ",
  "date_of_approval": "August 2, 2019",
  "company": " Daiichi Sankyo Company, Limited",
  "treatment": " Tenosynovial Giant Cell Tumor",
  "drug_description": "Turalio (pexidartinib) is a kinase inhibitor indicated for the treatment of symptomatic tenosynovial giant cell tumor (TGCT) in adults.",
  "previous application": "FDA Approves Turalio (pexidartinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumors (TGCT) in Adults Turalio (pexidartinib) FDA Approval History"
},{
  "title": " (pretomanid)  Tablets ",
  "date_of_approval": "August 14, 2019",
  "company": " TB Alliance",
  "treatment": " Tuberculosis -- Resistant",
  "drug_description": "Pretomanid is a nitroimidazooxazine antimycobacterial indicated for use in combination with bedaquiline and linezolid (the BPaL regimen) for the treatment of adults with pulmonary extensively drug resistant (XDR), treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB).",
  "previous application": "FDA Approves Pretomanid for Highly Drug-Resistant Forms of Tuberculosis pretomanid FDA Approval History"
},{
  "title": "Rozlytrek (entrectinib)  Capsules ",
  "date_of_approval": "August 15, 2019",
  "company": " Genentech, Inc.",
  "treatment": " Solid Tumors, Non-Small Cell Lung Cancer",
  "drug_description": "Rozlytrek (entrectinib) is a selective tyrosine kinase inhibitor for the treatment of patients with ROS1-positive, metastatic non-small cell lung cancer and neurotrophic tyrosine receptor kinase (NTRK) gene fusion-positive solid tumors.",
  "previous application": "FDA Approves Rozlytrek (entrectinib) for People With ROS1-Positive, Metastatic Non-Small Cell Lung Cancer and NTRK Gene Fusion-Positive Solid Tumors Rozlytrek (entrectinib) FDA Approval History"
},{
  "title": "Wakix (pitolisant)  Tablets ",
  "date_of_approval": "August 14, 2019",
  "company": " Harmony Biosciences, LLC",
  "treatment": " Narcolepsy",
  "drug_description": "Wakix (pitolisant) is a histamine-3 (H\u2083) receptor antagonist/inverse agonist for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy.",
  "previous application": "FDA Approves Wakix (pitolisant), a First-in-Class Medication for the Treatment of Excessive Daytime Sleepiness in Adult Patients with Narcolepsy Wakix (pitolisant) FDA Approval History"
},{
  "title": "Inrebic (fedratinib)  Capsules ",
  "date_of_approval": "August 16, 2019",
  "company": " Celgene Corporation",
  "treatment": " Myelofibrosis",
  "drug_description": "Inrebic (fedratinib) is a highly selective JAK2 inhibitor for the treatment of patients with myelofibrosis.",
  "previous application": "FDA Approves Inrebic (fedratinib) for the Treatment of Patients With Myelofibrosis Inrebic (fedratinib) FDA Approval History"
},{
  "title": "Rinvoq (upadacitinib)  Extended-Release Tablets ",
  "date_of_approval": "August 16, 2019",
  "company": " AbbVie Inc.",
  "treatment": " Rheumatoid Arthritis",
  "drug_description": "Rinvoq (upadacitinib) is a Janus kinase (JAK) inhibitor for the treatment of adult patients with moderate to severe rheumatoid arthritis.",
  "previous application": "FDA Approves Rinvoq (upadacitinib), an Oral JAK Inhibitor for the Treatment of Moderate to Severe Rheumatoid Arthritis Rinvoq (upadacitinib) FDA Approval History"
},{
  "title": "Xenleta (lefamulin)  Tablets and Injection ",
  "date_of_approval": "August 19, 2019",
  "company": " Nabriva Therapeutics plc",
  "treatment": " Pneumonia",
  "drug_description": "Xenleta (lefamulin) is a first-in-class, semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia (CABP).",
  "previous application": "FDA Approves Xenleta (lefamulin) to Treat Community-Acquired Bacterial Pneumonia (CABP) Xenleta (lefamulin) FDA Approval History"
},{
  "title": "Nourianz (istradefylline)  Tablets ",
  "date_of_approval": "August 27, 2019",
  "company": " Kyowa Kirin, Inc.",
  "treatment": " Parkinson's Disease",
  "drug_description": "Nourianz (istradefylline) is an adenosine A2A receptor antagonist indicated for use as an adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson\u2019s disease (PD) experiencing \u201cOFF\u201d episodes.",
  "previous application": "FDA Approves Nourianz (istradefylline) as an Add-On Drug to Treat Off Episodes in Adults with Parkinson\u2019s Disease Nourianz (istradefylline) FDA Approval History"
},{
  "title": "Gvoke (glucagon)  Ready-to-Use Injection ",
  "date_of_approval": "September 10, 2019",
  "company": " Xeris Pharmaceuticals, Inc.",
  "treatment": " Hypoglycemia",
  "drug_description": "Gvoke (glucagon injection) is a ready-to-use, room-temperature stable, liquid glucagon for the treatment of severe hypoglycemia in diabetes patients ages 2 years and older.",
  "previous application": "FDA Approves Gvoke (glucagon), the First Ready-to-use Stable Liquid Glucagon for Severe Hypoglycemia Gvoke (glucagon) FDA Approval History"
},{
  "title": "Ibsrela (tenapanor)  Tablets ",
  "date_of_approval": "September 12, 2019",
  "company": " Ardelyx, Inc",
  "treatment": " Irritable Bowel Syndrome",
  "drug_description": "Ibsrela (tenapanor) is a first-in-class, sodium/hydrogen exchanger 3 (NHE3) inhibitor indicated for the treatment of adults with irritable bowel syndrome with constipation (IBS-C).",
  "previous application": "FDA Approves Ibsrela (tenapanor) for the Treatment of Irritable Bowel Syndrome with Constipation Ibsrela (tenapanor) FDA Approval History"
},{
  "title": "Rybelsus (semaglutide)  Tablets ",
  "date_of_approval": "September 20, 2019",
  "company": " Novo Nordisk",
  "treatment": " Diabetes Type 2",
  "drug_description": "Rybelsus (semaglutide) is an oral glucagon-like peptide-1 (GLP-1) receptor agonist indicated for the treatment of adults with type 2 diabetes mellitus.",
  "previous application": "FDA Approves Rybelsus (semaglutide), the First Oral GLP-1 Analog Treatment for Adults with Type 2 Diabetes Rybelsus (semaglutide) FDA Approval History"
},{
  "title": "Jynneos (smallpox and monkeypox vaccine)  Injection ",
  "date_of_approval": "September 24, 2019",
  "company": " Bavarian Nordic",
  "treatment": " Prevention of Smallpox; Prevention of Monkeypox",
  "drug_description": "Jynneos (smallpox and monkeypox vaccine, live, nonreplicating) is a vaccine indicated for the prevention of smallpox and monkeypox in adults.",
  "previous application": "FDA Approves Jynneos (Smallpox and Monkeypox Vaccine, Live, Non-replicating) for Prevention of Smallpox and Monkeypox Disease in Adults Jynneos (smallpox and monkeypox vaccine) FDA Approval History"
},{
  "title": "Aklief (trifarotene)  Topical Cream ",
  "date_of_approval": "October 4, 2019",
  "company": " Galderma",
  "treatment": " Acne",
  "drug_description": "Aklief (trifarotene) is a topical retinoid indicated for the treatment of acne vulgaris in patients 9 years of age and older.",
  "previous application": "FDA Approves Aklief (trifarotene) Cream, a New Topical Retinoid for the Treatment of Acne Aklief (trifarotene) FDA Approval History"
},{
  "title": "Bonsity (teriparatide)  Injection  - formerly PF708",
  "date_of_approval": "October 4, 2019",
  "company": " Pfenex Inc.",
  "treatment": " Osteoporosis",
  "drug_description": "Bonsity (teriparatide) is a parathyroid hormone analog (PTH 1-34) indicated for the treatment of osteoporosis in certain patients at high risk for fracture.",
  "previous application": "FDA Approves Bonsity (teriparatide injection) to Treat Osteoporosis Bonsity (teriparatide) FDA Approval History"
},{
  "title": "Scenesse (afamelanotide)  Implant ",
  "date_of_approval": "October 8, 2019",
  "company": " Clinuvel Pharmaceuticals Ltd.",
  "treatment": " Prevention of Phototoxicity in Erythropoietic Protoporphyria",
  "drug_description": "Scenesse (afamelanotide) is a selective agonist of the melanocortin 1 receptor (MC1R) indicated for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).",
  "previous application": "FDA Approves Scenesse (afamelanotide) for Prevention of Phototoxicity in Erythropoietic Protoporphyria Scenesse (afamelanotide) FDA Approval History"
},{
  "title": "Beovu (brolucizumab-dbll)  Injection ",
  "date_of_approval": "October 7, 2019",
  "company": " Novartis",
  "treatment": " Macular Degeneration",
  "drug_description": "Beovu (brolucizumab-dbll) is a human vascular endothelial growth factor (VEGF) inhibitor\r indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD).",
  "previous application": "FDA Approves Beovu (brolucizumab-dbll) for the Treatment of Wet Age-Related Macular Degeneration (AMD) Beovu (brolucizumab-dbll) FDA Approval History"
},{
  "title": "Quzyttir (cetirizine hydrochloride)  Injection ",
  "date_of_approval": "October 4, 2019",
  "company": " TerSera Therapeutics LLC",
  "treatment": " Urticaria",
  "drug_description": "Quzyttir (cetirizine hydrochloride) is a histamine-1 (H1) receptor antagonist indicated for the treatment of acute urticaria in adults and children 6 months of age and older.",
  "previous application": "FDA Approves Quzyttir (cetirizine) Injection for the Treatment of Acute Urticaria Quzyttir (cetirizine hydrochloride) FDA Approval History"
},{
  "title": "Reyvow (lasmiditan)  Tablets ",
  "date_of_approval": "October 11, 2019",
  "company": " Eli Lilly and Company",
  "treatment": " Migraine",
  "drug_description": "Reyvow (lasmiditan) is a serotonin (5-HT)1F receptor agonist indicated for the acute treatment of migraine with or without aura in adults.",
  "previous application": "FDA Approves Reyvow (lasmiditan), the First Serotonin (5-HT) 1F Receptor Agonist for the Acute Treatment for Migraine Reyvow (lasmiditan) FDA Approval History"
},{
  "title": "Secuado (asenapine)  Transdermal System ",
  "date_of_approval": "October 11, 2019",
  "company": " Noven Pharmaceuticals, Inc.",
  "treatment": " Schizophrenia",
  "drug_description": "Secuado (asenapine) is a transdermal atypical antipsychotic formulation indicated for the treatment of adults with schizophrenia.",
  "previous application": "FDA Approves Secuado (asenapine) Transdermal System for the Treatment of Adults with Schizophrenia Secuado (asenapine) FDA Approval History"
},{
  "title": "Amzeeq (minocycline)  Topical Foam ",
  "date_of_approval": "October 18, 2019",
  "company": " Foamix Pharmaceuticals",
  "treatment": " Acne",
  "drug_description": "Amzeeq (minocycline) is a topical foam formulation of the approved tetracycline drug minocycline indicated for the treatment of moderate to severe acne vulgaris in patients 9 years of age and\r older.",
  "previous application": "FDA Approves Amzeeq (minocycline) Topical Foam for the Treatment of Moderate to Severe Acne Amzeeq (minocycline) FDA Approval History"
},{
  "title": "Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor)  Tablets ",
  "date_of_approval": "October 21, 2019",
  "company": " Vertex Pharmaceuticals Incorporated",
  "treatment": " Cystic Fibrosis",
  "drug_description": "Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) is a triple combination regimen for the treatment of cystic fibrosis (CF) in patients ages 12 years and older who have at least one copy of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.",
  "previous application": "FDA Approves Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for Cystic Fibrosis Patients Ages 12 and Older Who Have at Least One F508del Mutation Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) FDA Approval History"
},{
  "title": "Biorphen (phenylephrine hydrochloride)  Injection ",
  "date_of_approval": "October 21, 2019",
  "company": " Eton Pharmaceuticals, Inc.",
  "treatment": " Hypotension",
  "drug_description": "Biorphen (phenylephrine hydrochloride) injection is an alpha-1 adrenergic receptor agonist indicated for the treatment of hypotension during anesthesia.",
  "previous application": "FDA Approves Biorphen (phenylephrine hydrochloride) Ready-to-Use Injection for Hypotension During Anesthesia  Biorphen (phenylephrine hydrochloride) FDA Approval History"
},{
  "title": "Vumerity (diroximel fumarate)  Delayed-Release Capsules ",
  "date_of_approval": "October 29, 2019",
  "company": " Alkermes plc and Biogen",
  "treatment": " Multiple Sclerosis",
  "drug_description": "Vumerity (diroximel fumarate) is a novel oral fumarate for the treatment of relapsing forms of multiple sclerosis (MS).",
  "previous application": "FDA Approves Vumerity (diroximel fumarate) for Multiple Sclerosis Vumerity (diroximel fumarate) FDA Approval History"
},{
  "title": "Talicia (amoxicillin, omeprazole and rifabutin)  Delayed-Release Capsules ",
  "date_of_approval": "November 4, 2019",
  "company": " RedHill Biopharma Ltd.",
  "treatment": " Helicobacter pylori Infection",
  "drug_description": "Talicia (omeprazole magnesium, amoxicillin and rifabutin) is a fixed-dose combination of two antibiotics, (amoxicillin and rifabutin) and a proton pump inhibitor (omeprazole) for the treatment of Helicobacter pylori (H. pylori) infection.",
  "previous application": "FDA Approves Talicia (omeprazole magnesium, amoxicillin and rifabutin) for the Treatment of H. pylori Infection in Adults Talicia (amoxicillin, omeprazole and rifabutin) FDA Approval History"
},{
  "title": "Ziextenzo (pegfilgrastim-bmez)  Injection ",
  "date_of_approval": "November 4, 2019",
  "company": " Sandoz",
  "treatment": " Neutropenia Associated with Chemotherapy",
  "drug_description": "Ziextenzo (pegfilgrastim-bmez) is a PEGylated growth colony-stimulating factor biosimilar to Neulasta (pegfilgrastim) used to reduce the incidence of febrile neutropenia in patients treated with chemotherapy.",
  "previous application": "FDA Approves Ziextenzo (pegfilgrastim-bmez), a Biosimilar to Neulasta Ziextenzo (pegfilgrastim-bmez) FDA Approval History"
},{
  "title": "Reblozyl (luspatercept-aamt)  for Injection ",
  "date_of_approval": "November 8, 2019",
  "company": " Celgene Corporation",
  "treatment": " Anemia in Beta-Thalassemia; Anemia in Lower-Risk Myelodysplastic Syndromes",
  "drug_description": "Reblozyl (luspatercept-aamt) is a first-in-class erythroid maturation agent (EMA) for the treatment of:",
  "previous application": "FDA Approves Reblozyl (luspatercept-aamt) for the Treatment of Anemia in Adults With Beta Thalassemia Who Require Regular Red Blood Cell Transfusions Reblozyl (luspatercept-aamt) FDA Approval History"
},{
  "title": "Brukinsa (zanubrutinib)  Capsules ",
  "date_of_approval": "November 14, 2019",
  "company": " BeiGene, Ltd.",
  "treatment": " Mantle Cell Lymphoma",
  "drug_description": "Brukinsa (zanubrutinib) is a Bruton\u2019s tyrosine kinase (BTK) inhibitor indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.",
  "previous application": "FDA Approves Brukinsa (zanubrutinib) for the Treatment of Mantle Cell Lymphoma Brukinsa (zanubrutinib) FDA Approval History"
},{
  "title": "Fetroja (cefiderocol)  Injection ",
  "date_of_approval": "November 14, 2019",
  "company": " Shionogi &amp; Co., Ltd.",
  "treatment": " Complicated Urinary Tract Infections; Hospital-acquired Bacterial Pneumonia; Ventilator-associated Bacterial Pneumonia",
  "drug_description": "Fetroja (cefiderocol) is a siderophore cephalosporin indicated for the treatment of complicated urinary tract infections (cUTI), hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible Gram-negative microorganisms.",
  "previous application": "FDA Approves Fetroja (cefiderocol) for the Treatment of Complicated Urinary Tract Infections Fetroja (cefiderocol) FDA Approval History"
},{
  "title": "Adakveo (crizanlizumab-tmca)  Injection ",
  "date_of_approval": "November 15, 2019",
  "company": " Novartis",
  "treatment": " Prevention of Vaso-Occlusive Crises (VOCs) in Sickle Cell Disease",
  "drug_description": "Adakveo (crizanlizumab-tmca) is a P-selectin inhibitor for the prevention of vaso-occlusive crises (VOCs) in patients with sickle cell disease (SCD).",
  "previous application": "FDA Approves Adakveo (crizanlizumab-tmca) to Reduce Frequency of Pain Crises in Individuals Living with Sickle Cell Disease Adakveo (crizanlizumab-tmca) FDA Approval History"
},{
  "title": "Abrilada (adalimumab-afzb)  Injection ",
  "date_of_approval": "November 15, 2019",
  "company": " Pfizer Inc.",
  "treatment": " Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn's Disease -- Maintenance, Ulcerative Colitis, Plaque Psoriasis",
  "drug_description": "Abrilada (adalimumab-afzb) is a tumor necrosis factor (TNF) blocker biosimilar to Humira indicated for the treatment of rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), Crohn\u2019s disease (CD), ulcerative colitis (UC), and plaque psoriasis (Ps).",
  "previous application": "FDA Approves Abrilada (adalimumab-afzb), a Biosimilar to Humira Abrilada (adalimumab-afzb) FDA Approval History"
},{
  "title": "Givlaari (givosiran)  Injection ",
  "date_of_approval": "November 20, 2019",
  "company": " Alnylam Pharmaceuticals, Inc.",
  "treatment": " Acute Hepatic Porphyria",
  "drug_description": "Givlaari (givosiran) is an aminolevulinate synthase 1-directed small interfering RNA (siRNA) indicated for the treatment of adults with acute hepatic porphyria (AHP).",
  "previous application": "FDA Approves Givlaari (givosiran) for Acute Hepatic Porphyria Givlaari (givosiran) FDA Approval History"
},{
  "title": "Xcopri (cenobamate)  Tablets ",
  "date_of_approval": "November 21, 2019",
  "company": " SK Life Science, Inc.",
  "treatment": " Seizures",
  "drug_description": "Xcopri (cenobamate) is an antiepileptic drug for the treatment of partial-onset seizures in adult patients.",
  "previous application": "FDA Approves Xcopri (cenobamate) for the Treatment of Partial-Onset Seizures in Adults Xcopri (cenobamate) FDA Approval History"
},{
  "title": "Exservan (riluzole)  Oral Film ",
  "date_of_approval": "November 22, 2019",
  "company": " Aquestive Therapeutics, Inc.",
  "treatment": " Amyotrophic Lateral Sclerosis",
  "drug_description": "Exservan (riluzole) an oral film formulation of the approved glutamate Inhibitor riluzole for the treatment of patients with amyotrophic lateral sclerosis (ALS) patients who have difficulty swallowing.",
  "previous application": "FDA Approves Exservan (riluzole) Oral Film for the Treatment of Amyotrophic Lateral Sclerosis Exservan (riluzole) FDA Approval History"
},{
  "title": "Oxbryta (voxelotor)  Tablets ",
  "date_of_approval": "November 25, 2019",
  "company": " Global Blood Therapeutics, Inc.",
  "treatment": " Sickle Cell Anemia",
  "drug_description": "Oxbryta (voxelotor) is an oral, HbS (sickle hemoglobin) polymerization inhibitor for the treatment of patients with sickle cell disease (SCD).",
  "previous application": "FDA Approves Oxbryta (voxelotor) for the Treatment of Sickle Cell Disease Oxbryta (voxelotor) FDA Approval History"
},{
  "title": "RediTrex (methotrexate)  /pro/reditrex-injection.html ",
  "date_of_approval": "November 27, 2019",
  "company": " Cumberland Pharmaceuticals Inc.",
  "treatment": " Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriasis",
  "drug_description": "RediTrex (methotrexate) is a folate analog metabolic inhibitor indicated for the management of rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis (pJIA), and psoriasis.",
  "previous application": "FDA Approves RediTrex (methotrexate) for Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, and Psoriasis RediTrex (methotrexate) FDA Approval History"
},{
  "title": "Avsola (infliximab-axxq)  Injection ",
  "date_of_approval": "December 6, 2019",
  "company": " Amgen Inc.",
  "treatment": " Crohn's Disease -- Maintenance, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Plaque Psoriasis",
  "drug_description": "Avsola (infliximab-axxq) is a tumor necrosis factor (TNF) blocker biosimilar to Remicade indicated  for the treatment of Crohn\u2019s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.",
  "previous application": "FDA Approves Avsola (infliximab-axxq), a Biosimilar to Remicade Avsola (infliximab-axxq) FDA Approval History"
},{
  "title": "Vyondys 53 (golodirsen)  Injection ",
  "date_of_approval": "December 12, 2019",
  "company": " Sarepta Therapeutics, Inc.",
  "treatment": " Duchenne Muscular Dystrophy",
  "drug_description": "Vyondys 53 (golodirsen) is a phosphordiamidate morpholino oligimer for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation amenable to exon 53 skipping.",
  "previous application": "FDA Approves Vyondys 53 (golodirsen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 53 Vyondys 53 (golodirsen) FDA Approval History"
},{
  "title": "EluRyng (ethinyl estradiol and etonogestrel)  Vaginal Ring ",
  "date_of_approval": "December 11, 2019",
  "company": " Amneal Pharmaceuticals, Inc.",
  "treatment": " Contraception",
  "drug_description": "",
  "previous application": "FDA Approves EluRyng (etonogestrel/ethinyl estradiol vaginal ring), the First Generic NuvaRing EluRyng (ethinyl estradiol and etonogestrel) FDA Approval History"
},{
  "title": "Nouress (cysteine hydrochloride)  Injection ",
  "date_of_approval": "December 13, 2019",
  "company": " Avadel Pharmaceuticals plc",
  "treatment": " Total Parenteral Nutrition",
  "drug_description": "Nouress (cysteine hydrochloride) is a sulfur-containing amino acid indicated for use as an additive\r to amino acid solutions to meet nutritional requirements of neonates requiring total parenteral\r nutrition.",
  "previous application": "FDA Approves Nouress (cysteine hydrochloride) Injection for Treating Neonate Patients Requiring Total Parenteral Nutrition (TPN) Nouress (cysteine hydrochloride) FDA Approval History"
},{
  "title": "Padcev (enfortumab vedotin-ejfv)  for Injection ",
  "date_of_approval": "December 18, 2019",
  "company": " Astellas and Seattle Genetics",
  "treatment": " Urothelial Carcinoma",
  "drug_description": "Padcev (enfortumab vedotin-ejfv) is a Nectin-4 targeted antibody-drug conjugate (ADC) for the treatment of patients with locally advanced or metastatic urothelial cancer.",
  "previous application": "FDA Approves Padcev (enfortumab vedotin-ejfv) for Locally Advanced or Metastatic Urothelial Cancer, the Most Common Type of Bladder Cancer Padcev (enfortumab vedotin-ejfv) FDA Approval History"
},{
  "title": "Arazlo (tazarotene)  Lotion ",
  "date_of_approval": "December 18, 2019",
  "company": " Bausch Health Companies Inc.",
  "treatment": " Acne",
  "drug_description": "Arazlo (tazarotene) is a lotion formulation of the approved retinoid tazarotene for the topical treatment of acne vulgaris in patients 9 years of age and older.",
  "previous application": "FDA Approves Arazlo (tazarotene) Lotion for the Topical Treatment of Acne Vulgaris Arazlo (tazarotene) FDA Approval History"
},{
  "title": "Ervebo (ebola zaire vaccine, live)  Injection  - formerly V920",
  "date_of_approval": "December 19, 2019",
  "company": " Merck",
  "treatment": " Prevention of Ebola Zaire Disease",
  "drug_description": "Ervebo (ebola zaire vaccine, live) is a vaccine indicated for the prevention of disease caused\r by Zaire ebolavirus in individuals 18 years of age and older.",
  "previous application": "FDA Approves Ervebo (Ebola Zaire Vaccine, Live) for the Prevention of Disease Caused by Zaire Ebolavirus Ervebo (ebola zaire vaccine, live) FDA Approval History"
},{
  "title": "Conjupri (levamlodipine maleate)  Tablets ",
  "date_of_approval": "December 19, 2019",
  "company": " CSPC Pharmaceutical Group Limited",
  "treatment": " Hypertension",
  "drug_description": "Conjupri (levamlodipine maleate) is a calcium channel blocker indicated for the treatment of hypertension.",
  "previous application": "FDA Approves Conjupri (levamlodipine maleate) for the Treatment of Hypertension Conjupri (levamlodipine maleate) FDA Approval History"
},{
  "title": "Enhertu (fam-trastuzumab deruxtecan-nxki)  Injection ",
  "date_of_approval": "December 20, 2019",
  "company": " AstraZeneca and Daiichi Sankyo Company, Limited",
  "treatment": " Breast Cancer",
  "drug_description": "Enhertu (fam-trastuzumab deruxtecan-nxki) is a HER2-directed antibody and topoisomerase inhibitor\r conjugate indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.",
  "previous application": "FDA Approves Enhertu (fam-trastuzumab deruxtecan-nxki) for HER2-Positive Unresectable or Metastatic Breast Cancer Following Two or More Prior Anti-HER2 Based Regimens Enhertu (fam-trastuzumab deruxtecan-nxki) FDA Approval History"
},{
  "title": "Ubrelvy (ubrogepant)  Tablets ",
  "date_of_approval": "December 23, 2019",
  "company": " Allergan plc",
  "treatment": " Migraine",
  "drug_description": "Ubrelvy (ubrogepant) is a potent, orally-administered CGRP receptor antagonist for the acute treatment of migraine with or without aura in adults.",
  "previous application": "FDA Approves Ubrelvy (ubrogepant) for the Acute Treatment of Migraine Ubrelvy (ubrogepant) FDA Approval History"
},{
  "title": "Caplyta (lumateperone)  Capsules ",
  "date_of_approval": "December 20, 2019",
  "company": " Intra-Cellular Therapies, Inc.",
  "treatment": " Schizophrenia",
  "drug_description": "Caplyta (lumateperone) is an atypical antipsychotic for the treatment of schizophrenia.",
  "previous application": "FDA Approves Caplyta (lumateperone) for the Treatment of Schizophrenia in Adults Caplyta (lumateperone) FDA Approval History"
},{
  "title": "Dayvigo (lemborexant)  Tablets ",
  "date_of_approval": "December 20, 2019",
  "company": " Eisai Co., Ltd.",
  "treatment": " Insomnia",
  "drug_description": "Dayvigo (lemborexant) is dual orexin receptor antagonist (DORA) for the treatment of insomnia.",
  "previous application": "FDA Approves Dayvigo (lemborexant) for the Treatment of Insomnia in Adult Patients Dayvigo (lemborexant) FDA Approval History"
},{
  "title": "Ayvakit (avapritinib)  Tablets ",
  "date_of_approval": "January 9, 2020",
  "company": " Blueprint Medicines Corporation",
  "treatment": " Gastrointestinal Stromal Tumor",
  "drug_description": "Ayvakit (avapritinib) is a kinase inhibitor for the treatment of PDGFR\u03b1 exon 18 mutant gastrointestinal stromal tumors (GIST).",
  "previous application": "FDA Approves Ayvakit (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor Ayvakit (avapritinib) FDA Approval History"
},{
  "title": "Valtoco (diazepam)  Nasal Spray ",
  "date_of_approval": "January 10, 2020",
  "company": " Neurelis, Inc.",
  "treatment": " Epilepsy",
  "drug_description": "Valtoco (diazepam) is a benzodiazepine nasal spray for the short-term treatment of epilepsy cluster seizures.",
  "previous application": "FDA Approves Valtoco (diazepam nasal spray) as a Seizure Rescue Treatment Valtoco (diazepam) FDA Approval History"
},{
  "title": "Numbrino (cocaine hydrochloride)  Nasal Solution ",
  "date_of_approval": "January 10, 2020",
  "company": " Lannett Company, Inc.",
  "treatment": " Nasal Anesthesia",
  "drug_description": "Numbrino (cocaine hydrochloride) nasal solution is a local anesthetic indicated for the introduction of local anesthesia of the mucous membranes for diagnostic procedures and surgeries on or\r through the nasal cavities of adults.",
  "previous application": "FDA Approves Numbrino (cocaine hydrochloride) Nasal Solution for Nasal Anesthesia Numbrino (cocaine hydrochloride) FDA Approval History"
},{
  "title": "Tepezza (teprotumumab-trbw)  Injection ",
  "date_of_approval": "January 21, 2020",
  "company": " Horizon Therapeutics plc",
  "treatment": " Thyroid Eye Disease",
  "drug_description": "Tepezza (teprotumumab-trbw) is a fully human monoclonal antibody (mAb) and a targeted inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) for the treatment of active thyroid eye disease (TED).",
  "previous application": "FDA Approves Tepezza (teprotumumab-trbw) for the Treatment of Thyroid Eye Disease (TED) Tepezza (teprotumumab-trbw) FDA Approval History"
},{
  "title": "Tazverik (tazemetostat)  Tablets ",
  "date_of_approval": "January 23, 2020",
  "company": " Epizyme, Inc.",
  "treatment": " Epithelioid Sarcoma; Follicular Lymphoma",
  "drug_description": "",
  "previous application": "FDA Approves Tazverik (tazemetostat) for the Treatment of Patients with Epithelioid Sarcoma Tazverik (tazemetostat) FDA Approval History"
},{
  "title": "Trijardy XR (empagliflozin, linagliptin and metformin hydrochloride)  Extended-Release Tablets ",
  "date_of_approval": "January 27, 2020",
  "company": " Boehringer Ingelheim and Eli Lilly and Company",
  "treatment": " Diabetes Type 2",
  "drug_description": "Trijardy XR (empagliflozin/linagliptin/metformin hydrochloride) is a fixed-dose combination of the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (Jardiance), the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin (Tradjenta) and the biguanide metformin hydrochloride indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.",
  "previous application": "FDA Approves Trijardy XR (empagliflozin/linagliptin/metformin) for Type 2 Diabetes in Adults Trijardy XR (empagliflozin, linagliptin and metformin hydrochloride) FDA Approval History"
},{
  "title": "Monoferric (ferric derisomaltose)  Injection ",
  "date_of_approval": "January 16, 2020",
  "company": " Pharmacosmos Therapeutics Inc.",
  "treatment": " Iron Deficiency Anemia",
  "drug_description": "Monoferric (ferric derisomaltose) is an intravenous iron replacement product indicated for the treatment of iron deficiency anemia.",
  "previous application": "FDA Approves Monoferric (ferric derisomaltose) Injection for the Treatment of Iron Deficiency Anemia Monoferric (ferric derisomaltose) FDA Approval History"
},{
  "title": "Palforzia (Peanut (Arachis hypogaea) Allergen Powder-dnfp)  - formerly AR101",
  "date_of_approval": "January 31, 2020",
  "company": " Aimmune Therapeutics, Inc.",
  "treatment": " Peanut Allergy",
  "drug_description": "Palforzia (Peanut (Arachis hypogaea) Allergen Powder-dnfp) is an oral immunotherapy indicated to help reduce the severity of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut.",
  "previous application": "FDA Approves Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] as First Treatment for Peanut Allergy Palforzia (Peanut (Arachis hypogaea) Allergen Powder-dnfp) FDA Approval History"
},{
  "title": "Audenz (influenza A (H5N1) monovalent vaccine, adjuvanted)  Injection ",
  "date_of_approval": "January 31, 2020",
  "company": " Seqirus",
  "treatment": " Influenza Prophylaxis",
  "drug_description": "Audenz (influenza A (H5N1) monovalent vaccine, adjuvanted) is a cell-based influenza vaccine designed to protect against influenza A (H5N1) in the event of a pandemic.",
  "previous application": "FDA Approves Audenz (Influenza A (H5N1) Monovalent Vaccine, Adjuvanted) as First-Ever Adjuvanted, Cell-Based Pandemic Influenza A (H5N1) Vaccine Audenz (influenza A (H5N1) monovalent vaccine, adjuvanted) FDA Approval History"
},{
  "title": "Pemfexy (pemetrexed)  Injection ",
  "date_of_approval": "February 8, 2020",
  "company": " Eagle Pharmaceuticals, Inc.",
  "treatment": " Non-Small Cell Lung Cancer, Malignant Pleural Mesothelioma",
  "drug_description": "Pemfexy (pemetrexed for injection) is a branded alternative to Alimta for the treatment of nonsquamous non-small cell lung cancer and malignant pleural mesothelioma.",
  "previous application": "FDA Approves Pemfexy (pemetrexed for injection) as a Branded Alternative to Alimta Pemfexy (pemetrexed) FDA Approval History"
},{
  "title": "Pizensy (lactitol)  Powder for Oral Solution ",
  "date_of_approval": "February 12, 2020",
  "company": " Braintree Laboratories, Inc.",
  "treatment": " Chronic Idiopathic Constipation",
  "drug_description": "Pizensy (lactitol) is an osmotic laxative indicated for the treatment of chronic idiopathic constipation (CIC) in adults.",
  "previous application": "FDA Approves Pizensy (lactitol) for the Treatment of Chronic Idiopathic Constipation (CIC) Pizensy (lactitol) FDA Approval History"
},{
  "title": "Twirla (ethinyl estradiol and levonorgestrel)  Transdermal System ",
  "date_of_approval": "February 14, 2020",
  "company": " Agile Therapeutics, Inc.",
  "treatment": " Contraception",
  "drug_description": "Twirla (ethinyl estradiol and levonorgestrel transdermal system) is a low-dose combined hormonal contraceptive patch for birth control.",
  "previous application": "FDA Approves Twirla (levonorgestrel and ethinyl estradiol) Contraceptive Patch Twirla (ethinyl estradiol and levonorgestrel) FDA Approval History"
},{
  "title": "Anjeso (meloxicam)  Injection ",
  "date_of_approval": "February 20, 2020",
  "company": " Baudax Bio, Inc.",
  "treatment": " Pain",
  "drug_description": "Anjeso (meloxicam) is a non-steroidal anti-inflammatory drug (NSAID) injection indicated for use in adults for the management of moderate-to-severe pain, alone or in combination with non-NSAID analgesics.",
  "previous application": "FDA Approves Anjeso (meloxicam injection) for the Management of Moderate to Severe Pain Anjeso (meloxicam) FDA Approval History"
},{
  "title": "Nexletol (bempedoic acid)  Tablets ",
  "date_of_approval": "February 21, 2020",
  "company": " Esperion Therapeutics, Inc.",
  "treatment": " Heterozygous Familial Hypercholesterolemia",
  "drug_description": "Nexletol (bempedoic acid) is a first-in-class, adenosine triphosphate-citrate lyase (ACL) inhibitor for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-Cholesterol.",
  "previous application": "FDA Approves Nexletol (bempedoic acid) to Lower LDL-Cholesterol Nexletol (bempedoic acid) FDA Approval History"
},{
  "title": "Vyepti (eptinezumab-jjmr)  Injection ",
  "date_of_approval": "February 21, 2020",
  "company": " Lundbeck",
  "treatment": " Migraine Prophylaxis",
  "drug_description": "Vyepti (eptinezumab-jjmr) is a calcitonin gene-related peptide antagonist indicated for the prevention of migraine in adults.",
  "previous application": "FDA Approves Vyepti (eptinezumab-jjmr) Intravenous Injection for the Preventive Treatment of Migraine Vyepti (eptinezumab-jjmr) FDA Approval History"
},{
  "title": "Fluad Quadrivalent (influenza vaccine, adjuvanted)  Injection ",
  "date_of_approval": "February 21, 2020",
  "company": " Seqirus",
  "treatment": " Influenza Prophylaxis",
  "drug_description": "Fluad Quadrivalent (influenza vaccine, adjuvanted) is an inactivated influenza virus vaccine approved for the prevention of seasonal influenza in adults 65 years and older.",
  "previous application": "FDA Approves Fluad Quadrivalent (influenza vaccine, adjuvanted) for Influenza Prophylaxis in Adults 65 Years and Older Fluad Quadrivalent (influenza vaccine, adjuvanted) FDA Approval History"
},{
  "title": "Nexlizet (bempedoic acid and ezetimibe)  Tablets ",
  "date_of_approval": "February 26, 2020",
  "company": " Esperion Therapeutics",
  "treatment": " Heterozygous Familial Hypercholesterolemia",
  "drug_description": "Nexlizet (bempedoic acid and ezetimibe) is an adenosine triphosphate-citrate lyase (ACL) inhibitor and a cholesterol absorption inhibitor combination indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C.",
  "previous application": "FDA Approves Nexlizet (bempedoic acid and ezetimibe) to Lower LDL-Cholesterol Nexlizet (bempedoic acid and ezetimibe) FDA Approval History"
},{
  "title": "Barhemsys (amisulpride)  Injection ",
  "date_of_approval": "February 26, 2020",
  "company": " Acacia Pharma",
  "treatment": " Nausea/Vomiting -- Postoperative",
  "drug_description": "Barhemsys (amisulpride) is a dopamine-2 (D2) antagonist for the management of post-operative nausea and vomiting (PONV).",
  "previous application": "FDA Approves Barhemsys (amisulpride) for the Treatment and Prevention of Postoperative Nausea and Vomiting Barhemsys (amisulpride) FDA Approval History"
},{
  "title": "Nurtec ODT (rimegepant)  Orally Disintegrating Tablets (ODT) ",
  "date_of_approval": "February 27, 2020",
  "company": " Biohaven Pharmaceutical Holding Company Ltd.",
  "treatment": " Migraine",
  "drug_description": "Nurtec ODT (rimegepant) is an orally-dosed calcitonin gene-related peptide (CGRP) receptor antagonist for the acute treatment of migraine.",
  "previous application": "FDA Approves Nurtec ODT (rimegepant) for the Acute Treatment of Migraine in Adults Nurtec ODT (rimegepant) FDA Approval History"
},{
  "title": "Advil Dual Action (ibuprofen and acetaminophen)  Tablets ",
  "date_of_approval": "February 28, 2020",
  "company": " GSK Consumer Healthcare",
  "treatment": " Pain",
  "drug_description": "Advil Dual Action (ibuprofen with acetaminophen) is an over-the-counter (OTC) fixed-dose combination of ibuprofen (the nonsteroidal anti-inflammatory drug (NSAID) contained in Advil) and acetaminophen (the active ingredient in Tylenol) for the relief of pain.",
  "previous application": "FDA Approves Advil Dual Action (ibuprofen and acetaminophen) as an Over-the-Counter Pain Treatment Advil Dual Action (ibuprofen and acetaminophen) FDA Approval History"
},{
  "title": "Pizensy (lactitol)  Powder for Oral Solution ",
  "date_of_approval": "February 12, 2020",
  "company": " Braintree Laboratories, Inc.",
  "treatment": " Chronic Idiopathic Constipation",
  "drug_description": "Pizensy (lactitol) is an osmotic laxative indicated for the treatment of chronic idiopathic constipation (CIC) in adults.",
  "previous application": "FDA Approves Pizensy (lactitol) for the Treatment of Chronic Idiopathic Constipation in Adults Pizensy (lactitol) FDA Approval History"
},{
  "title": "Sarclisa (isatuximab-irfc)  Injection ",
  "date_of_approval": "March 2, 2020",
  "company": " Sanofi",
  "treatment": " Multiple Myeloma",
  "drug_description": "Sarclisa (isatuximab-irfc) is a CD38-directed cytolytic antibody indicated in combination\r with pomalidomide and dexamethasone for the treatment of adult patients multiple myeloma.",
  "previous application": "FDA Approves Sarclisa (isatuximab-irfc) for Patients with Relapsed Refractory Multiple Myeloma Sarclisa (isatuximab-irfc) FDA Approval History"
},{
  "title": "Durysta (bimatoprost)  Implant ",
  "date_of_approval": "March 3, 2020",
  "company": " Allergan plc",
  "treatment": " Glaucoma (Open Angle), Intraocular Hypertension",
  "drug_description": "Durysta (bimatoprost implant) is a prostaglandin analog indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension (OHT).",
  "previous application": "FDA Approves Durysta (bimatoprost implant) to Lower Intraocular Pressure In Open-Angle Glaucoma or Ocular Hypertension Patients Durysta (bimatoprost) FDA Approval History"
},{
  "title": "Isturisa (osilodrostat)  Tablets ",
  "date_of_approval": "March 6, 2020",
  "company": " Novartis Pharmaceuticals Corporation",
  "treatment": " Cushing's Syndrome",
  "drug_description": "Isturisa (osilodrostat) is a cortisol synthesis inhibitor indicated for the treatment of adult patients with Cushing\u2019s disease.",
  "previous application": "FDA Approves Isturisa (osilodrostat) for the Treatment of Cushing\u2019s Disease Isturisa (osilodrostat) FDA Approval History"
},{
  "title": "Zeposia (ozanimod)  Capsules ",
  "date_of_approval": "March 25, 2020",
  "company": " Bristol-Myers Squibb Company",
  "treatment": " Multiple Sclerosis",
  "drug_description": "Zeposia (ozanimod) is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS).",
  "previous application": "FDA Approves Zeposia (ozanimod) for Relapsing Forms of Multiple Sclerosis Zeposia (ozanimod) FDA Approval History"
},{
  "title": "Sevenfact (coagulation factor VIIa (recombinant)-jncw)  Injection ",
  "date_of_approval": "April 1, 2020",
  "company": " HEMA Biologics, LLC",
  "treatment": " Hemophilia A or B with Inhibitors",
  "drug_description": "Sevenfact (coagulation factor VIIa [recombinant]-jncw) is a coagulation factor VIIa concentrate indicated for the treatment and control of bleeding episodes occurring in adults and adolescents 12 years of age and older with hemophilia A or B with inhibitors (neutralizing antibodies).",
  "previous application": "FDA Approves Sevenfact [coagulation factor VIIa (recombinant)-jncw] for Treatment and Control of Bleeding Episodes Occurring in Adult and Adolescent Hemophilia A and B Patients with Inhibitors Sevenfact (coagulation factor VIIa (recombinant)-jncw) FDA Approval History"
},{
  "title": "Koselugo (selumetinib)  Capsules ",
  "date_of_approval": "April 10, 2020",
  "company": " AstraZeneca and Merck",
  "treatment": " Neurofibromatosis Type 1",
  "drug_description": "Koselugo (selumetinib) is an inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK1/2) indicated for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).",
  "previous application": "FDA Approves Koselugo (selumetinib) for Pediatric Patients with Neurofibromatosis Type 1 Plexiform Neurofibromas Koselugo (selumetinib) FDA Approval History"
},{
  "title": "Jelmyto (mitomycin)  for Pyelocalyceal Solution ",
  "date_of_approval": "April 15, 2020",
  "company": " UroGen Pharma Ltd.",
  "treatment": " Urothelial Carcinoma",
  "drug_description": "Jelmyto (mitomycin) is a novel formulation of the approved alkylating drug mitomycin for the treatment of patients with low-grade upper tract urothelial cancer (LG-UTUC).",
  "previous application": "FDA Approves Jelmyto (mitomycin) for Treatment of Low-Grade Upper Tract Urothelial Cancer Jelmyto (mitomycin) FDA Approval History"
},{
  "title": "Tukysa (tucatinib)  Tablets ",
  "date_of_approval": "April 17, 2020",
  "company": " Seattle Genetics, Inc.",
  "treatment": " Breast Cancer",
  "drug_description": "Tukysa (tucatinib) is a kinase inhibitor indicated in combination with trastuzumab and capecitabine for the treatment of patients with advanced unresectable or metastatic HER2-positive breast cancer.",
  "previous application": "FDA Approves Tukysa (tucatinib) for People with Advanced Unresectable or Metastatic HER2-Positive Breast Cancer Tukysa (tucatinib) FDA Approval History"
},{
  "title": "Pemazyre (pemigatinib)  Tablets ",
  "date_of_approval": "April 17, 2020",
  "company": " Incyte Corporation",
  "treatment": " Cholangiocarcinoma",
  "drug_description": "Pemazyre (pemigatinib) is a selective fibroblast growth factor receptor (FGFR) inhibitor for the treatment of locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements, as detected by an FDA-approved test.",
  "previous application": "FDA Approves Pemazyre (pemigatinib) as First Targeted Treatment for Adults with Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma Pemazyre (pemigatinib) FDA Approval History"
},{
  "title": "Emerphed (ephedrine sulfate)  Injection ",
  "date_of_approval": "April 17, 2020",
  "company": " Nexus Pharmaceuticals, Inc.",
  "treatment": " Hypotension",
  "drug_description": "Emerphed (ephedrine sulfate) is a ready-to-use formulation of the approved pressor agent ephedrine indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.",
  "previous application": "FDA Approves Emerphed (ephedrine sulfate) Ready-to-Use Injection for Hypotension During Anesthesia Emerphed (ephedrine sulfate) FDA Approval History"
},{
  "title": "Trodelvy (sacituzumab govitecan-hziy)  Injection ",
  "date_of_approval": "April 22, 2020",
  "company": " Immunomedics, Inc.",
  "treatment": " Breast Cancer",
  "drug_description": "Trodelvy (sacituzumab govitecan-hziy) is a Trop-2-directed antibody and topoisomerase inhibitor conjugate for the treatment of patients with previously-treated metastatic triple-negative breast cancer (mTNBC).",
  "previous application": "FDA Approves Trodelvy (sacituzumab govitecan-hziy) for Previously-Treated Metastatic Triple Negative Breast Cancer Trodelvy (sacituzumab govitecan-hziy) FDA Approval History"
},{
  "title": "MenQuadfi (meningococcal (groups A, C, Y, W) conjugate vaccine)  Injection ",
  "date_of_approval": "April 23, 2020",
  "company": " Sanofi",
  "treatment": " Meningococcal Meningitis Prophylaxis",
  "drug_description": "MenQuadfi (meningococcal (groups A, C, Y, W) conjugate vaccine) is a MenACWY vaccine indicated for active immunization for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y in individuals 2 years of age and older.",
  "previous application": "FDA Approves MenQuadfi (Meningococcal (Groups A, C, Y, W) Conjugate Vaccine) for Meningococcal (MenACWY) Vaccination MenQuadfi (meningococcal (groups A, C, Y, W) conjugate vaccine) FDA Approval History"
},{
  "title": "Ongentys (opicapone)  Capsules ",
  "date_of_approval": "April 24, 2020",
  "company": " Neurocrine Biosciences, Inc.",
  "treatment": " Parkinson's Disease",
  "drug_description": "Ongentys (opicapone) is a catechol-O-methyltransferase (COMT) inhibitor indicated as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson\u2019s disease (PD) experiencing \u201coff\u201d episodes.",
  "previous application": "FDA Approves Ongentys (opicapone) as an Add-On Treatment for Patients with Parkinson\u2019s Disease Experiencing \u201cOff\u201d Episodes Ongentys (opicapone) FDA Approval History"
},{
  "title": "Bafiertam (monomethyl fumarate)  Delayed-Release Capsules ",
  "date_of_approval": "April 28, 2020",
  "company": " Banner Life Sciences LLC",
  "treatment": " Multiple Sclerosis",
  "drug_description": "Bafiertam (monomethyl fumarate) is a novel fumarate indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.",
  "previous application": "FDA Approves Bafiertam (monomethyl fumarate) for Multiple Sclerosis Bafiertam (monomethyl fumarate) FDA Approval History"
},{
  "title": "Darzalex\u00a0Faspro (daratumumab and hyaluronidase-fihj)  Injection ",
  "date_of_approval": "May 1, 2020",
  "company": " The Janssen Pharmaceutical Companies of Johnson &amp; Johnson",
  "treatment": " Multiple Myeloma",
  "drug_description": "Darzalex\u00a0Faspro (daratumumab and hyaluronidase-fihj) is a combination of daratumumab, a CD38-directed cytolytic antibody, and hyaluronidase, an endoglycosidase indicated for the treatment of adult patients with multiple myeloma.",
  "previous application": "FDA Approves Darzalex\u00a0Faspro (daratumumab and hyaluronidase-fihj) for the Treatment of Patients with Multiple Myeloma Darzalex\u00a0Faspro (daratumumab and hyaluronidase-fihj) FDA Approval History"
},{
  "title": "Fensolvi (leuprolide acetate)  Injection ",
  "date_of_approval": "May 1, 2020",
  "company": " Tolmar Pharmaceuticals, Inc.",
  "treatment": " Precocious Puberty",
  "drug_description": "Fensolvi (leuprolide acetate) is a gonadotropin releasing hormone (GnRH) agonist indicated for the treatment of pediatric patients 2 years of age and older with central precocious puberty.",
  "previous application": "FDA Approves Fensolvi (leuprolide acetate) for Injectable Suspension for Pediatric Patients with Central Precocious Puberty Fensolvi (leuprolide acetate) FDA Approval History"
},{
  "title": "Elyxyb (celecoxib)  Oral Solution ",
  "date_of_approval": "May 5, 2020",
  "company": " Dr. Reddy\u2019s Laboratories Limited",
  "treatment": " Migraine",
  "drug_description": "Elyxyb (celecoxib) is an oral solution formulation of the nonsteroidal anti-inflammatory drug celecoxib (first approved under the brand name Celebrex) indicated for the acute treatment of migraine with or without aura in adults.",
  "previous application": "FDA Approves Elyxyb (celecoxib) Oral Solution For Acute Treatment Of Migraine With Or Without Aura In Adults Elyxyb (celecoxib) FDA Approval History"
},{
  "title": "Tabrecta (capmatinib)  Tablets ",
  "date_of_approval": "May 6, 2020",
  "company": " Novartis",
  "treatment": " Non-Small Cell Lung Cancer",
  "drug_description": "Tabrecta (capmatinib) is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.",
  "previous application": "FDA Approves Tabrecta (capmatinib) for Metastatic Non-Small Cell Lung Cancer with METex14 Tabrecta (capmatinib) FDA Approval History"
},{
  "title": "Retevmo (selpercatinib)  Capsules ",
  "date_of_approval": "May 8, 2020",
  "company": " Eli Lilly and Company",
  "treatment": " Non-Small Cell Lung Cancer, Thyroid Cancer",
  "drug_description": "Retevmo (selpercatinib) is a kinase inhibitor for the treatment of patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer.",
  "previous application": "FDA Approves Retevmo (selpercatinib) for Patients with Advanced RET-Driven Lung and Thyroid Cancers Retevmo (selpercatinib) FDA Approval History"
},{
  "title": "Qinlock (ripretinib)  Tablets ",
  "date_of_approval": "May 15, 2020",
  "company": " Deciphera Pharmaceuticals, Inc.",
  "treatment": " Gastrointestinal Stromal Tumor",
  "drug_description": "Qinlock (ripretinib) is a broad-spectrum KIT and PDGFR\u03b1 inhibitor for the treatment of patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.",
  "previous application": "FDA Approves Qinlock (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor Qinlock (ripretinib) FDA Approval History"
},{
  "title": "Kynmobi (apomorphine hydrochloride)  Sublingual Film ",
  "date_of_approval": "May 21, 2020",
  "company": " Sunovion Pharmaceuticals Inc.",
  "treatment": " Parkinson's Disease",
  "drug_description": "Kynmobi (apomorphine sublingual film) is a novel formulation of the approved dopamine agonist apomorphine for the on-demand management of OFF episodes associated with Parkinson\u2019s disease (PD).",
  "previous application": "FDA Approves Kynmobi (apomorphine hydrochloride) Sublingual Film for the Treatment of Parkinson\u2019s Disease OFF Episodes Kynmobi (apomorphine hydrochloride) FDA Approval History"
},{
  "title": "Phexxi (lactic acid, citric acid and potassium bitartrate)  Vaginal Gel  - formerly Amphora",
  "date_of_approval": "May 22, 2020",
  "company": " Evofem, Inc.",
  "treatment": " Contraception",
  "drug_description": "Phexxi (lactic acid, citric acid and potassium bitartrate) is a non-hormonal vaginal gel indicated for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception.",
  "previous application": "FDA Approves Phexxi (lactic acid, citric acid and potassium bitartrate) Non-Hormonal Prescription Gel for the Prevention of Pregnancy Phexxi (lactic acid, citric acid and potassium bitartrate) FDA Approval History"
},{
  "title": "Cerianna (fluoroestradiol F18)  Injection ",
  "date_of_approval": "May 20, 2020",
  "company": " Zionexa USA",
  "treatment": " Diagnostic",
  "drug_description": "Cerianna (fluoroestradiol F18) is a radioactive diagnostic agent indicated for use with positron emission tomography (PET) imaging for the detection of estrogen receptor (ER)-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer.",
  "previous application": "FDA Approves Cerianna (fluoroestradiol F18) PET Imaging Agent for Use in Patients with Recurrent or Metastatic Breast Cancer Cerianna (fluoroestradiol F18) FDA Approval History"
},{
  "title": " (artesunate)  for Injection ",
  "date_of_approval": "May 26, 2020",
  "company": " Amivas (US), LLC",
  "treatment": " Malaria",
  "drug_description": "Artesunate for Injection is an antimalarial indicated for the initial treatment of severe malaria in adult and pediatric patients.",
  "previous application": "FDA Approves Artesunate for Injection for the Treatment of Severe Malaria artesunate FDA Approval History"
},{
  "title": "Tauvid (flortaucipir F 18)  Injection ",
  "date_of_approval": "May 28, 2020",
  "company": " Eli Lilly and Company",
  "treatment": " Diagnostic",
  "drug_description": "Tauvid (flortaucipir F 18) is a radioactive diagnostic agent indicated for positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer\u2019s disease (AD).",
  "previous application": "FDA Approves Tauvid (flortaucipir F 18 injection) for Use in Patients Being Evaluated for Alzheimer's Disease Tauvid (flortaucipir F 18) FDA Approval History"
},{
  "title": "Zilxi (minocycline)  Topical Foam  - formerly FMX103",
  "date_of_approval": "May 28, 2020",
  "company": " Foamix Pharmaceuticals Ltd.",
  "treatment": " Acne Rosacea",
  "drug_description": "Zilxi (minocycline) is a topical tetracycline formulation indicated for the treatment of inflammatory lesions of rosacea in adults.",
  "previous application": "FDA Approves Zilxi (minocycline) Topical Foam for the Treatment of Rosacea Zilxi (minocycline) FDA Approval History"
},{
  "title": "Oriahnn (elagolix/estradiol/norethindrone acetate and elagolix)  Capsules ",
  "date_of_approval": "May 29, 2020",
  "company": " AbbVie Inc.",
  "treatment": " Uterine Leiomyomata",
  "drug_description": "Oriahnn (elagolix/estradiol/norethindrone acetate and elagolix) is a gonadotropin-releasing hormone (GnRH) receptor antagonist, estrogen and progestin co-formulation indicated for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women.",
  "previous application": "FDA Approves Oriahnn (elagolix/estradiol/norethindrone acetate and elagolix) for the Management of Heavy Menstrual Bleeding Due to Uterine Fibroids in Pre-Menopausal Women Oriahnn (elagolix/estradiol/norethindrone acetate and elagolix) FDA Approval History"
},{
  "title": "Nyvepria (pegfilgrastim-apgf)  Injection ",
  "date_of_approval": "June 10, 2020",
  "company": " Pfizer Inc.",
  "treatment": " Neutropenia Associated with Chemotherapy",
  "drug_description": "Nyvepria (pegfilgrastim-apgf) is a PEGylated growth colony-stimulating factor biosimilar to Neulasta (pegfilgrastim) used to reduce the incidence of febrile neutropenia in patients treated with chemotherapy.",
  "previous application": "FDA Approves Nyvepria (pegfilgrastim-apgf), a Biosimilar to Neulasta Nyvepria (pegfilgrastim-apgf) FDA Approval History"
},{
  "title": "Semglee (insulin glargine)  Injection ",
  "date_of_approval": "June 11, 2020",
  "company": " Mylan N.V. and Biocon Ltd.",
  "treatment": " Diabetes Type 1, Diabetes Type 2",
  "drug_description": "Semglee (insulin glargine) is a long-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.",
  "previous application": "FDA Approves Semglee (insulin glargine injection) for Type 1 and Type 2 Diabetes Semglee (insulin glargine) FDA Approval History"
},{
  "title": "Uplizna (inebilizumab-cdon)  Injection ",
  "date_of_approval": "June 11, 2020",
  "company": " Viela Bio",
  "treatment": " Neuromyelitis Optica Spectrum Disorder (NMOSD)",
  "drug_description": "Uplizna (inebilizumab-cdon) is a CD19-directed cytolytic antibody indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.",
  "previous application": "FDA Approves Uplizna (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) Uplizna (inebilizumab-cdon) FDA Approval History"
},{
  "title": "Lyumjev (insulin lispro-aabc)  Injection ",
  "date_of_approval": "June 15, 2020",
  "company": " Eli Lilly and Company",
  "treatment": " Diabetes Type 1, Diabetes Type 2",
  "drug_description": "Lyumjev (insulin lispro-aabc) is a rapid-acting human insulin analog indicated to improve glycemic control in adults with diabetes mellitus.",
  "previous application": "FDA Approves Lyumjev (insulin lispro-aabc injection) for Type 1 and Type 2 Diabetes Lyumjev (insulin lispro-aabc) FDA Approval History"
},{
  "title": "Zepzelca (lurbinectedin)  Injection ",
  "date_of_approval": "June 15, 2020",
  "company": " PharmaMar and Jazz Pharmaceuticals plc",
  "treatment": " Small Cell Lung Cancer",
  "drug_description": "Zepzelca (lurbinectedin) is a selective oncogenic transcription inhibitor indicated for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.",
  "previous application": "FDA Approves Zepzelca (lurbinectedin) for the Treatment of Metastatic Small Cell Lung Cancer Zepzelca (lurbinectedin) FDA Approval History"
},{
  "title": "Gimoti (metoclopramide)  Nasal Spray ",
  "date_of_approval": "June 19, 2020",
  "company": " Evoke Pharma, Inc.",
  "treatment": " Gastroparesis",
  "drug_description": "Gimoti (metoclopramide) is an intranasal formulation of the approved drug metoclopramide for the relief of symptoms of acute and recurrent diabetic gastroparesis in adults.",
  "previous application": "FDA Approves Gimoti (metoclopramide) Nasal Spray for Diabetic Gastroparesis Gimoti (metoclopramide) FDA Approval History"
},{
  "title": "Fintepla (fenfluramine)  Oral Solution ",
  "date_of_approval": "June 25, 2020",
  "company": " Zogenix, Inc.",
  "treatment": " Dravet Syndrome",
  "drug_description": "Fintepla (fenfluramine) is an amphetamine derivative indicated for the treatment of seizures associated with Dravet syndrome in patients 2 years of age and older.",
  "previous application": "FDA Approves Fintepla (fenfluramine) for the Treatment of Seizures Associated with Dravet Syndrome Fintepla (fenfluramine) FDA Approval History"
},{
  "title": "Mycapssa (octreotide)  Delayed-Release Capsules ",
  "date_of_approval": "June 26, 2020",
  "company": " Chiasma, Inc.",
  "treatment": " Acromegaly",
  "drug_description": "Mycapssa (octreotide) is an oral formulation of the approved somatostatin analog octreotide for the treatment of acromegaly.",
  "previous application": "FDA Approves Mycapssa (octreotide) Oral Somatostatin Analog for Acromegaly Mycapssa (octreotide) FDA Approval History"
},{
  "title": "Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf)  Injection ",
  "date_of_approval": "June 29, 2020",
  "company": " Genentech",
  "treatment": " Breast Cancer",
  "drug_description": "Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is a combination of two HER2/neu receptor antagonists and the endoglycosidase hyaluronidase indicated for the treatment of early and metastatic HER2-positive breast cancer, as detected by an FDA-approved companion diagnostic test.",
  "previous application": "FDA Approves Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) for HER2-Positive Breast Cancer Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) FDA Approval History"
},{
  "title": "Dojolvi (triheptanoin)  Oral Liquid ",
  "date_of_approval": "June 30, 2020",
  "company": " Ultragenyx Pharmaceutical Inc.",
  "treatment": " Long-Chain Fatty Acid Oxidation Disorders",
  "drug_description": "Dojolvi (triheptanoin) is a medium-chain triglyceride indicated as a source of calories and fatty acids for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).",
  "previous application": "FDA Approves Dojolvi (triheptanoin) for the Treatment of Long-Chain Fatty Acid Oxidation Disorders Dojolvi (triheptanoin) FDA Approval History"
},{
  "title": "Byfavo (remimazolam)  Injection ",
  "date_of_approval": "July 2, 2020",
  "company": " Cosmo Pharmaceuticals NV",
  "treatment": " Sedation",
  "drug_description": "Byfavo (remimazolam) is an ultra-short-acting, intravenous benzodiazepine sedative/anesthetic for the induction and maintenance of procedural sedation in adults.",
  "previous application": "FDA Approves Byfavo (remimazolam injection) for the Induction and Maintenance of Procedural Sedation Byfavo (remimazolam) FDA Approval History"
},{
  "title": "Rukobia (fostemsavir)  Extended-Release Tablets ",
  "date_of_approval": "July 2, 2020",
  "company": " ViiV Healthcare",
  "treatment": " HIV Infection",
  "drug_description": "Rukobia (fostemsavir) is a first-in-class, human immunodeficiency virus type 1 (HIV-1) gp120-directed attachment inhibitor indicated for use in combination with other antiretroviral(s) for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection.",
  "previous application": "FDA Approves Rukobia (fostemsavir) for HIV in Adults with Few Treatment Options Available Rukobia (fostemsavir) FDA Approval History"
},{
  "title": "Qwo (collagenase clostridium histolyticum-aaes)  for Injection ",
  "date_of_approval": "July 6, 2020",
  "company": " Endo International plc",
  "treatment": " Cellulite",
  "drug_description": "Qwo (collagenase clostridium histolyticum-aaes) is a combination of bacterial collagenases indicated for the treatment of moderate to severe cellulite in the buttocks of adult women.",
  "previous application": "FDA Approves Qwo (collagenase clostridium histolyticum-aaes) as the First Injectable Treatment for Cellulite Qwo (collagenase clostridium histolyticum-aaes) FDA Approval History"
},{
  "title": "Inqovi (decitabine and cedazuridine)  Tablets ",
  "date_of_approval": "July 7, 2020",
  "company": " Astex Pharmaceuticals, Taiho Oncology, and Otsuka Pharmaceutical",
  "treatment": " Myelodysplastic Syndrome",
  "drug_description": "Inqovi (decitabine and cedazuridine) is a nucleoside metabolic inhibitor and\r cytidine deaminase inhibitor combination indicated for the treatment of adults with intermediate and high-risk myelodysplastic syndromes (MDS) including chronic myelomonocytic leukemia (CMML).",
  "previous application": "FDA Approves Inqovi (decitabine and cedazuridine) for Myelodysplastic Syndromes (MDS) including Chronic Myelomonocytic Leukemia (CMML) Inqovi (decitabine and cedazuridine) FDA Approval History"
},{
  "title": "Hulio (adalimumab-fkjp)  Injection ",
  "date_of_approval": "July 6, 2020",
  "company": " Mylan Pharmaceuticals Inc.",
  "treatment": " Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn's Disease -- Maintenance, Ulcerative Colitis, Plaque Psoriasis",
  "drug_description": "Hulio (adalimumab-fkjp) is a tumor necrosis factor (TNF) blocker biosimilar to Humira indicated for the treatment of rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), Crohn\u2019s disease (CD), ulcerative colitis (UC), and plaque psoriasis (Ps).",
  "previous application": "FDA Approves Hulio (adalimumab-fkjp), a Biosimilar to Humira Hulio (adalimumab-fkjp) FDA Approval History"
},{
  "title": "Upneeq (oxymetazoline hydrochloride)  Ophthalmic Solution ",
  "date_of_approval": "July 8, 2020",
  "company": " Osmotica Pharmaceuticals plc",
  "treatment": " Blepharoptosis",
  "drug_description": "Upneeq (oxymetazoline hydrochloride ophthalmic solution, 0.1%) is a once-daily ophthalmic formulation of the direct-acting alpha-adrenergic receptor agonist oxymetazoline indicated for the treatment of acquired blepharoptosis, or ptosis, a condition characterized by the abnormal drooping of the upper eyelid.",
  "previous application": "FDA Approves Upneeq (oxymetazoline hydrochloride ophthalmic solution) for Acquired Blepharoptosis (Droopy Eyelid) in Adults Upneeq (oxymetazoline hydrochloride) FDA Approval History"
},{
  "title": "Wynzora (calcipotriene and betamethasone dipropionate)  Cream ",
  "date_of_approval": "July 20, 2020",
  "company": " MC2 Therapeutics",
  "treatment": " Plaque Psoriasis",
  "drug_description": "Wynzora (calcipotriene and betamethasone dipropionate) is a PAD\u2122 Cream formulation of the  vitamin D analog calcipotriene, and the corticosteroid betamethasone dipropionate, indicated for the topical treatment of plaque psoriasis in patients 18 years of age and older.",
  "previous application": "FDA Approves Wynzora Cream (calcipotriene and betamethasone dipropionate) for Adults with Plaque Psoriasis Wynzora (calcipotriene and betamethasone dipropionate) FDA Approval History"
},{
  "title": "Xywav (calcium, magnesium, potassium, and sodium oxybates)  Oral Solution ",
  "date_of_approval": "July 21, 2020",
  "company": " Jazz Pharmaceuticals plc",
  "treatment": " Narcolepsy",
  "drug_description": "Xywav (calcium, magnesium, potassium, and sodium oxybates) is a low-sodium oxybate product for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.",
  "previous application": "FDA Approves Xywav (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy Xywav (calcium, magnesium, potassium, and sodium oxybates) FDA Approval History"
},{
  "title": "Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate)  Metered Dose Inhalation ",
  "date_of_approval": "July 23, 2020",
  "company": " AstraZeneca",
  "treatment": " Chronic Obstructive Pulmonary Disease",
  "drug_description": "Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) is a fixed dose triple-combination of the inhaled corticosteroid budesonide, the  long-acting muscarinic antagonist (LAMA) glycopyrrolate, and the long-acting beta2-agonist (LABA) formoterol fumarate, delivered in a pressurized metered-dose inhaler for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).",
  "previous application": "FDA Approves Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) for the Maintenance Treatment of COPD Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) FDA Approval History"
},{
  "title": "Tecartus (brexucabtagene autoleucel)  Suspension for Intravenous Infusion  - formerly KTE-X19",
  "date_of_approval": "July 24, 2020",
  "company": " Kite, a\u00a0Gilead Company",
  "treatment": " Mantle Cell Lymphoma",
  "drug_description": "Tecartus (brexucabtagene autoleucel) is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).",
  "previous application": "FDA Approves Tecartus (brexucabtagene autoleucel) as the First and Only CAR T Treatment for Relapsed or Refractory Mantle Cell Lymphoma Tecartus (brexucabtagene autoleucel) FDA Approval History"
},{
  "title": "Xeglyze (abametapir)  Topical Lotion ",
  "date_of_approval": "July 24, 2020",
  "company": " Dr. Reddy\u2019s Laboratories Ltd.",
  "treatment": " Head Lice",
  "drug_description": "Xeglyze (abametapir) is a pediculicide indicated for the topical treatment of head lice infestation in patients 6 months of age and older.",
  "previous application": "FDA Approves Xeglyze (abametapir) Lotion for the Treatment of Head Lice Xeglyze (abametapir) FDA Approval History"
},{
  "title": "Monjuvi (tafasitamab-cxix)  for Injection ",
  "date_of_approval": "July 31, 2020",
  "company": " MorphoSys AG",
  "treatment": " Diffuse Large B-Cell Lymphoma",
  "drug_description": "Monjuvi (tafasitamab-cxix) is a CD19-directed cytolytic antibody indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).",
  "previous application": "FDA Approves Monjuvi (tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) Monjuvi (tafasitamab-cxix) FDA Approval History"
},{
  "title": "Blenrep (belantamab mafodotin-blmf)  Injection ",
  "date_of_approval": "August 5, 2020",
  "company": " GlaxoSmithKline plc",
  "treatment": " Multiple Myeloma",
  "drug_description": "Blenrep (belantamab mafodotin-blmf) is a B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with relapsed or refractory multiple myeloma.",
  "previous application": "FDA Approves Blenrep (belantamab mafodotin-blmf) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Blenrep (belantamab mafodotin-blmf) FDA Approval History"
},{
  "title": "Lampit (nifurtimox)  Tablets ",
  "date_of_approval": "August 6, 2020",
  "company": " Bayer",
  "treatment": " Chagas Disease",
  "drug_description": "Lampit (nifurtimox) is a nitrofuran antiprotozoal used for the treatment of Chagas disease (American Trypanosomiasis) in pediatric patients.",
  "previous application": "FDA Approves Lampit (nifurtimox) for the Treatment of Chagas Disease in Children Lampit (nifurtimox) FDA Approval History"
},{
  "title": "Evrysdi (risdiplam)  for Oral Solution ",
  "date_of_approval": "August 7, 2020",
  "company": " Genentech",
  "treatment": " Spinal Muscular Atrophy",
  "drug_description": "Evrysdi (risdiplam) is a survival of motor neuron 2 (SMN2) splicing modifier\r indicated for the treatment of spinal muscular atrophy (SMA) in patients 2\r months of age and older.",
  "previous application": "FDA Approves Evrysdi (risdiplam) for Treatment of Spinal Muscular Atrophy (SMA) in Adults and Children 2 Months and Older Evrysdi (risdiplam) FDA Approval History"
},{
  "title": "Olinvyk (oliceridine)  Injection  - formerly Olinvo",
  "date_of_approval": "August 7, 2020",
  "company": " Trevena, Inc.",
  "treatment": " Pain",
  "drug_description": "Olinvyk (oliceridine) is an opioid agonist for the management of moderate to severe acute pain in adults.",
  "previous application": "FDA Approves Olinvyk (oliceridine) Injection for the Management of Severe Acute Pain Olinvyk (oliceridine) FDA Approval History"
},{
  "title": "Viltepso (viltolarsen)  Injection ",
  "date_of_approval": "August 12, 2020",
  "company": " NS Pharma, Inc.",
  "treatment": " Duchenne Muscular Dystrophy",
  "drug_description": "Viltepso (viltolarsen) is an antisense oliogonucleotide indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.",
  "previous application": "FDA Approves Viltepso (viltolarsen) for the Treatment of Duchenne Muscular Dystrophy in Patients Amenable to Exon 53 Skipping Therapy Viltepso (viltolarsen) FDA Approval History"
},{
  "title": "Enspryng (satralizumab-mwge)  Injection ",
  "date_of_approval": "August 14, 2020",
  "company": " Genentech",
  "treatment": " Neuromyelitis Optica Spectrum Disorder",
  "drug_description": "Enspryng (satralizumab-mwge) is an interleukin-6 (IL-6) receptor antagonist indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.",
  "previous application": "FDA Approves Enspryng (satralizumab-mwge) for Neuromyelitis Optica Spectrum Disorder Enspryng (satralizumab-mwge) FDA Approval History"
},{
  "title": "Kesimpta (ofatumumab)  Injection ",
  "date_of_approval": "August 20, 2020",
  "company": " Novartis",
  "treatment": " Multiple Sclerosis",
  "drug_description": "Kesimpta (ofatumumab) is a CD20-directed cytolytic antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.",
  "previous application": "FDA Approves Kesimpta (ofatumumab) Targeted B-cell Therapy for Patients with Relapsing Multiple Sclerosis Kesimpta (ofatumumab) FDA Approval History"
},{
  "title": "Cystadrops (cysteamine hydrochloride)  Ophthalmic Solution ",
  "date_of_approval": "August 19, 2020",
  "company": " Recordati Rare Diseases Inc.",
  "treatment": " Corneal Cystine Crystal Accumulation",
  "drug_description": "Cystadrops (cysteamine hydrochloride) is a cystine-depleting agent indicated for the treatment of corneal cystine crystal deposits in adults and children with cystinosis.",
  "previous application": "FDA Approves Cystadrops (cysteamine) Ophthalmic Solution for the Ocular Manifestations of Cystinosis Cystadrops (cysteamine hydrochloride) FDA Approval History"
},{
  "title": "Winlevi (clascoterone)  Cream ",
  "date_of_approval": "August 26, 2020",
  "company": " Cassiopea SpA",
  "treatment": " Acne",
  "drug_description": "Winlevi (clascoterone) cream is a first-in-class topical androgen receptor inhibitor indicated for the topical treatment of acne vulgaris in patients 12\r years of age and older.",
  "previous application": "FDA Approves Winlevi (clascoterone) Cream for the Treatment of Acne Winlevi (clascoterone) FDA Approval History"
},{
  "title": "Sogroya (somapacitan-beco)  Injection ",
  "date_of_approval": "August 28, 2020",
  "company": " Novo Nordisk",
  "treatment": " Adult Human Growth Hormone Deficiency",
  "drug_description": "Sogroya (somapacitan-beco) is a human growth hormone analog indicated for the replacement of endogenous growth hormone in adults with growth hormone deficiency.",
  "previous application": "FDA Approves Sogroya (somapacitan-beco) a Once-Weekly Treatment for Adult Growth Hormone Deficiency Sogroya (somapacitan-beco) FDA Approval History"
},{
  "title": "Xaracoll (bupivacaine hydrochloride)  Implant ",
  "date_of_approval": "August 28, 2020",
  "company": " Innocoll Holdings Limited",
  "treatment": " Postsurgical Pain Relief Following Open Inguinal Hernia",
  "drug_description": "Xaracoll (bupivacaine hydrochloride) is a fully bioresorbable collagen implant containing the local anesthetic bupivacaine indicated for acute postsurgical pain relief for up to 24 hours in adults following open inguinal hernia repair.",
  "previous application": "FDA Approves Xaracoll (bupivacaine hydrochloride) Implant for Acute Postsurgical Pain Relief Following Open Inguinal Hernia Repair Xaracoll (bupivacaine hydrochloride) FDA Approval History"
},{
  "title": "Onureg (azacitidine)  Tablets ",
  "date_of_approval": "September 1, 2020",
  "company": " Bristol Myers Squibb",
  "treatment": " Acute Myeloid Leukemia",
  "drug_description": "Onureg (azacitidine) is a nucleoside metabolic inhibitor indicated for the continued treatment of adult patients with acute myeloid leukemia.",
  "previous application": "FDA Approves Onureg (azacitidine tablets) as Continued Treatment for Adults in First Remission with Acute Myeloid Leukemia Onureg (azacitidine) FDA Approval History"
},{
  "title": "Gavreto (pralsetinib)  Capsules ",
  "date_of_approval": "September 4, 2020",
  "company": " Genentech, Inc.",
  "treatment": " Non-Small Cell Lung Cancer",
  "drug_description": "Gavreto (pralsetinib) is an oral selective RET kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion- positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test.",
  "previous application": "FDA Approves Gavreto (pralsetinib) for the Treatment of Adults With Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer Gavreto (pralsetinib) FDA Approval History"
},{
  "title": "Detectnet (copper Cu 64 dotatate)  Injection ",
  "date_of_approval": "September 3, 2020",
  "company": " RadioMedix Inc.",
  "treatment": " Positron Emission Tomography Imaging",
  "drug_description": "Detectnet (copper Cu 64 dotatate) is a radioactive diagnostic agent indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients.",
  "previous application": "FDA Approves Detectnet (copper Cu 64 dotatate injection) Positron Emission Tomography (PET) Agent Detectnet (copper Cu 64 dotatate) FDA Approval History"
},{
  "title": "Qdolo (tramadol hydrochloride)  Oral Solution ",
  "date_of_approval": "September 1, 2020",
  "company": " Athena Bioscience, LLC",
  "treatment": " Pain",
  "drug_description": "Qdolo (tramadol hydrochloride) is an opioid agonist indicated in adults for  the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.",
  "previous application": "FDA Approves Qdolo (tramadol hydrochloride) Oral Solution for the Management of Severe Pain Qdolo (tramadol hydrochloride) FDA Approval History"
},{
  "title": "Alkindi Sprinkle (hydrocortisone)  Oral Granules ",
  "date_of_approval": "September 29, 2020",
  "company": " Eton Pharmaceuticals, Inc.",
  "treatment": " Adrenocortical Insufficiency",
  "drug_description": "Alkindi Sprinkle (hydrocortisone granules in capsules for opening) is an immediate-release pediatric formulation of the approved glucocorticoid hydrocortisone for the treatment of adrenocortical insufficiency in infants, children and adolescents.",
  "previous application": "FDA Approves Alkindi Sprinkle (hydrocortisone oral granules) for Pediatric Adrenocortical Insufficiency Alkindi Sprinkle (hydrocortisone) FDA Approval History"
},{
  "title": "Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn)  Injection ",
  "date_of_approval": "October 14, 2020",
  "company": " Regeneron Pharmaceuticals, Inc.",
  "treatment": "Zaire Ebolavirus Infection",
  "drug_description": "Inmazeb is (atoltivimab, maftivimab, and odesivimab) is a monoclonal antibody combination indicated for the treatment of Zaire ebolavirus infection in adults and children, including newborns of mothers who have tested positive for the virus.",
  "previous application": "FDA Approves Inmazeb (atoltivimab, maftivimab and odesivimab-ebgn) Antibody Cocktail for Ebola (Zaire Ebolavirus) Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) FDA Approval History"
},{
  "title": "Veklury (remdesivir)  Injection ",
  "date_of_approval": "October 22, 2020",
  "company": " Gilead Sciences, Inc.",
  "treatment": "COVID-19",
  "drug_description": "Veklury (remdesivir) is a SARS-CoV-2 nucleotide analog RNA polymerase inhibitor indicated for the treatment of COVID-19 patients who require hospitalization.",
  "previous application": "FDA Approves Veklury (remdesivir) for the Treatment of COVID-19 Veklury (remdesivir) FDA Approval History"
},{
  "title": "Eysuvis (loteprednol etabonate)  Ophthalmic Suspension ",
  "date_of_approval": "October 26, 2020",
  "company": " Kala Pharmaceuticals, Inc.",
  "treatment": " Dry Eye Disease",
  "drug_description": "Eysuvis (loteprednol etabonate) is an ophthalmic corticosteroid formulation for the temporary relief of signs and symptoms of dry eye disease.",
  "previous application": "FDA Approves Eysuvis (loteprednol etabonate) Ophthalmic Suspension for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease Eysuvis (loteprednol etabonate) FDA Approval History"
},{
  "title": "Bronchitol (mannitol)  Inhalation Powder ",
  "date_of_approval": "October 30, 2020",
  "company": " Chiesi USA, Inc.",
  "treatment": " Cystic Fibrosis",
  "drug_description": "Bronchitol (mannitol) is an inhaled dry powder formulation of the sugar alcohol mannitol indicated as add-on maintenance therapy to improve pulmonary function in adult patients 18 years of age and older with cystic fibrosis.",
  "previous application": "FDA Approves Bronchitol (mannitol) Inhalation Powder to Improve Pulmonary Function in Adult Patients with Cystic Fibrosis Bronchitol (mannitol) FDA Approval History"
},{
  "title": "Sesquient (fosphenytoin sodium)  for Injection ",
  "date_of_approval": "November 5, 2020",
  "company": " Sedor Pharmaceuticals, LLC",
  "treatment": " Status Epilepticus",
  "drug_description": "Sesquient (fosphenytoin sodium for injection) is a Captisol-enabled\u2122, room-temperature stable formulation of fosphenytoin sodium indicated for the treatment of status epilepticus in adults and children.",
  "previous application": "FDA Approves Sesquient (fosphenytoin sodium) for the Treatment of Status Epilepticus in Adult and Pediatric Patients Sesquient (fosphenytoin sodium) FDA Approval History"
},{
  "title": "Sutab (sodium sulfate, magnesium sulfate, and potassium chloride)  Tablets ",
  "date_of_approval": "November 10, 2020",
  "company": " Sebela Pharmaceuticals, Inc.",
  "treatment": " Bowel Preparation",
  "drug_description": "Sutab (sodium sulfate, magnesium sulfate, and potassium chloride) is an osmotic laxative in a tablet formulation indicated for cleansing the colon in preparation for colonoscopy in adults.",
  "previous application": "FDA Approves Sutab (sodium sulfate, magnesium sulfate, and potassium chloride) Tablets for Colonoscopy Preparation Sutab (sodium sulfate, magnesium sulfate, and potassium chloride) FDA Approval History"
},{
  "title": "Zokinvy (lonafarnib)  Capsules ",
  "date_of_approval": "November 20, 2020",
  "company": " Eiger BioPharmaceuticals, Inc.",
  "treatment": " Progeria and Progeroid Laminopathies",
  "drug_description": "Zokinvy (lonafarnib) is an oral farnesyltransferase inhibitor (FTI) for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and processing-deficient Progeroid Laminopathies (PL).",
  "previous application": "FDA Approves Zokinvy (lonafarnib) for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies Zokinvy (lonafarnib) FDA Approval History"
},{
  "title": "Oxlumo (lumasiran)  Injection ",
  "date_of_approval": "November 23, 2020",
  "company": " Alnylam Pharmaceuticals, Inc.",
  "treatment": " Primary Hyperoxaluria Type 1 (PH1)",
  "drug_description": "Oxlumo (lumasiran) is a HAO1-directed small interfering ribonucleic acid (siRNA) indicated for the treatment of primary hyperoxaluria type 1 (PH1) to\r lower urinary oxalate levels in pediatric and adult patients.",
  "previous application": "FDA Approves Oxlumo (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1 Oxlumo (lumasiran) FDA Approval History"
},{
  "title": "Danyelza (naxitamab-gqgk)  Injection ",
  "date_of_approval": "November 25, 2020",
  "company": " Y-mAbs Therapeutics, Inc.",
  "treatment": " Neuroblastoma",
  "drug_description": "Danyelza (naxitamab-gqgk) is a GD2-binding monoclonal antibody indicated, in\r combination with granulocyte-macrophage colony-stimulating factor (GMCSF), for the treatment of patients with relapsed or refractory high-risk neuroblastoma.",
  "previous application": "FDA Approves Danyelza (naxitamab-gqgk) for the Treatment of Neuroblastoma Danyelza (naxitamab-gqgk) FDA Approval History"
},{
  "title": "Imcivree (setmelanotide)  Injection ",
  "date_of_approval": "November 25, 2020",
  "company": " Rhythm Pharmaceuticals, Inc.",
  "treatment": " Obesity",
  "drug_description": "Imcivree (setmelanotide) is a melanocortin 4 (MC4) receptor agonist for chronic weight management of obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency.",
  "previous application": "FDA Approves Imcivree (setmelanotide) for Chronic Weight Management in Patients with Obesity Due to POMC, PCSK1 or LEPR Deficiency Imcivree (setmelanotide) FDA Approval History"
},{
  "title": "Ga 68 PSMA-11 ()  Injection ",
  "date_of_approval": "December 1, 2020",
  "company": " University of California, San Francisco",
  "treatment": " Diagnostic",
  "drug_description": "Ga 68 PSMA-11 Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer.",
  "previous application": "FDA Approves Gallium 68 PSMA-11 as the First PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer Ga 68 PSMA-11 FDA Approval History"
},{
  "title": "Orladeyo (berotralstat)  Capsules ",
  "date_of_approval": "December 3, 2020",
  "company": " BioCryst Pharmaceuticals, Inc.",
  "treatment": " Hereditary Angioedema",
  "drug_description": "Orladeyo (berotralstat) is a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and\r pediatric patients 12 years and older.",
  "previous application": "FDA Approves Orladeyo (berotralstat) as the First Oral, Once-Daily Therapy to Prevent Attacks in Hereditary Angioedema Patients Orladeyo (berotralstat) FDA Approval History"
},{
  "title": "Klisyri (tirbanibulin)  Ointment ",
  "date_of_approval": "December 14, 2020",
  "company": " Athenex, Inc.",
  "treatment": " Actinic Keratosis",
  "drug_description": "Klisyri (tirbanibulin) is a first-in-class dual Src Kinase and tubulin polymerization inhibitor for the topical treatment of actinic keratosis on the face or scalp.",
  "previous application": "FDA Approves Klisyri (tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp Klisyri (tirbanibulin) FDA Approval History"
},{
  "title": "Margenza (margetuximab-cmkb)  Injection ",
  "date_of_approval": "December 16, 2020",
  "company": " MacroGenics, Inc.",
  "treatment": " Breast Cancer",
  "drug_description": "Margenza (margetuximab-cmkb) is a HER2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2- positive breast cancer.",
  "previous application": "FDA Approves Margenza (margetuximab-cmkb) for Patients with Pretreated Metastatic HER2-Positive Breast Cancer Margenza (margetuximab-cmkb) FDA Approval History"
},{
  "title": "Riabni (rituximab-arrx)  Injection ",
  "date_of_approval": "December 17, 2020",
  "company": " Amgen",
  "treatment": " non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Wegener's Granulomatosis, Microscopic Polyangiitis",
  "drug_description": "Riabni (rituximab-arrx) is a CD20-directed cytolytic antibody biosimilar to Rituxan indicated for the treatment of adult patients with non-Hodgkin\u2019s Lymphoma (NHL), chronic lymphocytic leukemia (CLL), and granulomatosis with polyangiitis (GPA) (Wegener\u2019s Granulomatosis) and microscopic polyangiitis (MPA).",
  "previous application": "FDA Approves Riabni (rituximab-arrx), a Biosimilar to Rituxan Riabni (rituximab-arrx) FDA Approval History"
},{
  "title": "Orgovyx (relugolix)  Tablets ",
  "date_of_approval": "December 18, 2020",
  "company": " Myovant Sciences",
  "treatment": " Prostate Cancer",
  "drug_description": "Orgovyx (relugolix) is an oral gonadotropin-releasing hormone (GnRH) receptor\r antagonist indicated for the treatment of adult patients with advanced\r prostate cancer.",
  "previous application": "FDA Approves Orgovyx (relugolix) as the First Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer Orgovyx (relugolix) FDA Approval History"
},{
  "title": "Ebanga (ansuvimab-zykl)  Injection ",
  "date_of_approval": "December 21, 2020",
  "company": " Ridgeback Biotherapeutics, LP.",
  "treatment": " Zaire Ebolavirus Infection",
  "drug_description": "Ebanga (ansuvimab-zykl) is a monoclonal antibody for the treatment of Zaire ebolavirus (Ebolavirus) infection in adults and children.",
  "previous application": "FDA Approves Ebanga (ansuvimab-zykl) for the Treatment of Zaire Ebolavirus Infection Ebanga (ansuvimab-zykl) FDA Approval History"
},{
  "title": "Gemtesa (vibegron)  Tablets ",
  "date_of_approval": "December 23, 2020",
  "company": " Urovant Sciences",
  "treatment": " Overactive Bladder Syndrome",
  "drug_description": "Gemtesa (vibegron) is a once-daily beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults.",
  "previous application": "FDA Approves Gemtesa (vibegron) Tablets for the Treatment of Patients with Overactive Bladder (OAB) Gemtesa (vibegron) FDA Approval History"
}]}
